HEALTHQUAL INTERNATIONAL

A PUBLIC HEALTH APPROACH TO QUALITY MANAGEMENT

Performance Measurement Data Report

February 2015

HEALTHQUAL International Country Teams and Contributors

HIVQUAL-UGANDA

Godfrey Kayita, MD, MPH
MOH, Coordinator - HIV/AIDS Quality of Care

Julius Ssendiwala, MPHS
MOH, Data Systems Analyst

Prosper Behumbiize, MPH
CDC, Health Information Management Systems Specialist

Joshua Musinguzi, MD, MPH
MOH, Program Manager - STD/AIDS Control Programme

Sarah Byakika, MD, MSc
MOH, Assistant Commissioner - Quality Assurance Department

Edson Niwamanya
MOH, Data Manager

CLINIQUAL-MOZAMBIQUE

Ussene Hilario Isse, MD
MOH, National Director, Medical Assistance

António Assane, MD
MOH, Deputy National Director, Medical Assistance

Aleny Couto, MD
MOH, Chief of STI/HIV/AIDS National Program

Armando Bucuane, MD
MOH, Quality Program

Joseph Lara, MPH
MOH ,M&E Technical Advisor

Mussa Calu, MD
CLINIQUAL, Program Chief

Carlos de Sousa
CLINIQUAL, Data Manager

Kebba Jobarteh, MD
CDC, Care and Treatment Branch Chief

Isabel Pereira, MD
CDC, Quality of Care and Treatment Advisor

HIVQUAL-NAMIBIA

Ndapewa Hamunime, MD
MOHSS Chief Medical Officer
National HIV/AIDS and STI Control Programme

Francina Kaindjee-Tjituka
MOHSS, Chief Health Program Administrator,
National HIV/AIDS and STI Control Programme

Salomo Natanael, RN/A
MOHSS, Senior Health Administrator-ART Program

Apollo Basenero, MD
MOHSS, Quality Assurance Medical Officer

Patience Luphahla
MOHSS, National Clinical Quality Improvement Officer

Sara Tobias
MOHSS, Senior Health Program Administrator-STI and Condom Promotion

Marytha Neo
MOHSS, Senior Health Program Administrator- IMAI

Gram Mutandi, MD
CDC, Medical Advisor, HIV Care and Treatment

Eliphas Hatutale
CDC, HIV Field Officer

Toubed Mbwale
CDC, HIV Field Officer

Linea Hans
CDC, HIV Field Officer

HEALTHQUAL-HAITI

George Dubuche, MD
MSPP, General Director

Nicasky Celestin
CDC, Health Information Specialist

Pavel C. Desrosiers, MD, MSc, Ph.D(C)
LMG. Healthcare organization Analyst

Nirva Duval
MSPP, Monitoring and Evaluation PNLS

Jean Paul Joseph, MD, MPH
Zanmi Lasante, M&E Officer and QI Coordinator

Adias Marcelin
Les Centres GHESKIO, IT Specialist

Nika-Nola Lamothe, MD
MSPP, Technical Director, Unite de Gestion Projet PEPFAR

Daniel Lauture, MD, MPH
MSPP, Technical Coordinator, Unite de Gestion Projet PEPFAR

Réginald Jean-Louis, MD
CDC, Maternal and Child Health Specialist

HEALTHQUAL-GUYANA

Shanti Singh, MD, MPH
MOH, NAPS Manager

Janice Woolford, MBBS, MPH
MOH, MCH Officer

Collene Hicks
CDC, Public Health Specialist, Infection Control

HIVQUAL-KENYA

Martin W. Sirengo, MD, MMed
MOH, NASCOP, Head

Irene Mukui, MD
MOH, NASCOP ART Program Manager

Rose Wafula, MD
MOH, NASCOP, PMTCT Program Manager

Caroline Olwande, PharmD
MOH, NASCOP, Commodities and Logistics Manager

Joyce Wamicwe, MD
MOH, NASCOP, Strategic Information Team Lead

Shobha N. Vakil, MD
MOH, NASCOP, Technical Advisor, HIV Care and Treatment

Evelyne Ngugi, MD
CDC, Care and Treatment Technical Advisor

Mary Schmitz, MPH
CDC, Care and Treatment Technical Advisor

John Wanyungu, MCommH
MOH, NASCOP, Quality Improvement Team Lead

Mohamed Abass, Bachelor of Business Information Technology
MOH, NASCOP, Quality Improvement Data Manager

Maureen Inimah, Dip. Clinical Medicine
MoH, NASCOP, Quality Improvement Team Member

HIVQUAL-VIETNAM

Bui Duc Duong, PhD
Deputy Director, Vietnam Authority of HIV/AIDS Control, MOH

Nguyen Thanh Long, PhD
Deputy Minister of Health, MOH

Nguyen Hoang Long, PhD
Director of Vietnam Authority of HIV/AIDS Control, MOH

Do Thi Nhan
Head of Care and Treatment Department, Vietnam Authority of HIV/AIDS Control, MOH

Nguyen Huu Hai, MPH
Deputy Head of Care and Treatment, Vietnam Authority of HIV/AIDS Control, MOH

Doan Thi Thuy Linh, MHM
Technical Officer, Vietnam Authority of HIV/AIDS Control, MOH

Nguyen Thanh Binh, BSc
Technical Officer, Vietnam Authority of HIV/AIDS Control, MOH

Le Ngoc Yen, PhD
Lead of HIV Treatment Team, CDC Vietnam

Nguyen Nguyet Phuong, MPH
Lead of M&E Team, CDC Vietnam

FHI 360

Do Thi Phuong, BPH
Project Officer, HAIVN

Nguyen Duc Duat, BE
Project Officer, HAIVN

Dinh Quoc Thong
Deputy Head of M&E, Provinces AIDS Center in Ho Chi Minh City

Hanoi School of Public Health

Todd Pollack, MD
Country Medical Director, HAIVN

HIVQUAL-ZIMBABWE

Josephine Z. Chiware, PhD
Director QA/QI, MOHCC

Joseph Murungu, MBChB
Deputy National ART Coordinator, AIDS and TB Unit, MOHCC

Bekezela B. Khabo, MBChB
Healthcare QI Specialist, AIDS and TB Unit, MOHCC

Lydia K. Madyira, MSTC
Data Quality Officer, AIDS and TB Unit, MOHCC

Blessing R. Mutede, MBChB, MPH
Technical Advisor- Quality Improvement, EGPAF

New York State Department of Health-AIDS Institute-HEALTHQUAL International

Bruce D. Agins, MD, MPH
Director, New York State Department of Health AIDS Institute, HEALTHQUAL International

Richard E. Birchard, MS
Administrative Director

Michelle Geis, MHA
Quality Manager

Clemens Steinböck, MBA
Quality Improvement Specialist

Joshua Bardfield, MPH
Knowledge Management Director

Elizabeth Eckel, MPH
Administrative Manager

Daniel Tietz
Consumer Involvement Specialist

Jearlene "Pat" Hunter
Senior Administrative Assistant

Emily Knudsen-Strong, MSc
Project Coordinator

Saskia Guerrier
Program Assistant

Alexander Martin
Program Assistant

Elvin Geng, MD, MPH
Consultant
UCSF, Division of Infectious Diseases

Margareth Jasmin, MD
HEALTHQUAL, QI Consultant

Special Acknowledgements

Jose Rafael Morales, MD
HIV/AIDS Officer, HRSA

George Tidwell, MBA
Global Health Systems Branch Chief, HRSA

Megan Lincoln, MSW
Public Health Analyst, HRSA

Elliot Raizes, MD
CDC, GAP Adult Care and Treatment Medical Officer

Carla Johnson
CDC, GAP Adult Care and Treatment Nurse Consultant and QI Specialist

John Hannay
Public Health Analyst, HRSA

Margaret Palumbo, MPH
Former Deputy Director, HEALTHQUAL International

Please address any questions to:
First Contact: Emily Knudsen-Strong, emily.knudsen-strong@health.ny.gov
Second Contact: Joshua Bardfield, joshua.bardfield@health.ny.gov; Richard E. Birchard, richard.birchard@health.ny.gov; Dr. Bruce Agins, bruce.agins@health.ny.gov

Table of Contents

Executive Summary

Routine performance measurement based on national indicators of care has empowered health care personnel to make important decisions about care delivery. The immediate use of data to guide improvement and inform decision making has enabled changes to local systems, a critical component of building capacity for a national quality management program that is responsive to contextual factors and patient needs.

Successful performance measurement has been most evident where programs are directed by local staff with attention to the following objectives:

- Data capture on selected indicators from clinical providers nationwide, including outcomes measures
- Harmonization/compatibility with other public health reporting systems
- Processes that are linked directly to a defined set of national goals and priorities
- Routine analysis and evaluation of data to prioritize areas for improvement at the local and national levels
- Inclusion of analysis based on geographic regions and key population groups
- Systematic review of results through a formal Data Quality Assurance (DQA) unit or program using defined DQA process steps
- Transparency of results for public and widespread dissemination through PM data reports as part of a written data communication and dissemination plan
- Integration into routine program activities, addressed through regular QI team review of PM data flow and processes as a system to discuss improvement at the national level
- Annual assessment and refinement

Although variation exists in the methodology used to measure clinical performance on indicators related to quality of care, each country's program follows the same general procedure for data collection. Case lists are developed based on country-specific eligibility criteria and ineligible patients are eliminated. For programs that conduct sampling, a statistical table is used to arrive at the sample size, which is calculated to achieve a 90 or 95% confidence interval (CI) with a spread of ± 8% in each participating clinic (based on country preference). Charts are then randomly sampled from the case list and the corresponding medical records are reviewed by the clinic team. When an electronic medical record (EMR) is available, as in Haiti, all patients are included in the review. For countries using paper records, individual patient-level data are entered on a medical record abstraction form, tailored to reflect the country's particular indicators. Data are then entered into the HEALTHQUAL software or other country-specific databases. When all values are entered into the HEALTHQUAL software, a clinic can generate its own data report directly from the software, allowing the clinic to identify its own areas for improvement.

Facility-level data are submitted to the Ministry of Health in each country, where data are aggregated and further validated by trained data personnel. Reports are produced to facilitate use of data for decision-making and prioritization of quality improvement activities.

Performance measurement data collection coincides with national- and clinic-level uptake and implementation of improvement methods, with the goal of scaling up implementation at all health facilities and using data at the national and facility levels to inform priorities.

In 8 countries implementing performance measurement, improvement has been demonstrated between baseline and most recent follow-up mean clinic scores in 100 of 133 indicators across adult and pediatric HIV programs and in Guyana's Well Child program for HIV-negative children. Improvement has been most consistent across implementing countries in the areas of ART initiation, ART adherence assessment and TB clinical screening for both adult and pediatric indicators. Improvement in the area of cotrimoxazole preventive therapy is notable among adult indicators.

For 14 of these 133 indicators, only baseline data are reported. Among 124 indicators with more than one round of data reported, performance between the baseline and most recent follow-up round has been lower for 16 indicators, including CD4 Monitoring in two countries. Other indicators for which performance has been lower between the baseline and most recent follow-up scores vary between countries.

Additional details including baseline and follow-up adult and pediatric results are summarized in the following tables by technical area and by country.

SUMMARY OF RESULTS FOR ADULTS:
Clinical Visits and Retention and **ARV Therapy**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Clinical Visits and Retention	Clinical Visits	Uganda	Percentage of patients with at a clinical visit in the last 3 months of the review period (for rounds 1-8, percentage of patients with a clinical visit in each 3-month quarter)	10	Mar - Aug 06 **70**	Jul - Dec 13 **92**
		Mozambique[1]	Percentage of patients (ART and pre-ART) with a clinical visit during the first 6 months of the review period	4	Jul 07 - Jun 08 **49**	Jul - Dec 12 **92**
		Namibia[2]	Percentage of patients on ART with a clinical visit during the last 3 months of the review period	9	Jan - Jun 08 **79**	Oct 12 - Mar 13 **85**
		Haiti	Percentage of patients on ART with a clinical visit within 3 months of their last visit during the review period	13	Jan - Jun 08 **76**	Oct 13 - Mar 14 **80**
		Guyana[3]	Percentage of patients (all ages) with at least 2 clinical visits during the review period	4	Jan - Jun 08 **85**	Jan - Jun 12 **79**
		Vietnam	Percentage of patients (pre-ART) with a clinical visit in the last 3 months of the review period	4	Jul - Dec 11 **55**	Apr - Sept 13 **75**
		Kenya	Percentage of patients on ART with at least 2 clinical visits at least 3 months apart during the review period	4	Jul - Dec 09 **67**	Jul - Dec 11 **73**
	Retention	Haiti	Percentage of patients (pre-ART) with at least one visit in the last 6 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **57**	Oct 13 - Mar 14 **58**
		Zimbabwe[4]	Percentage of patients who visited clinic in the 6 months prior to the review period who had a clinical visit during the review period	1	Jan - Jun 13 **71**	N/A
	Appointment Keeping	Uganda	Percentage of patients who missed their scheduled appointment and did not show up to clinic within seven days after the scheduled appointment date	3	Jul - Dec 11 **16**	Jul - Dec 13 **87**
ARV Therapy (ART)	ART	Uganda	Percentage of patients who are eligible for ART who have initiated ART within the past month (for rounds 1-8, percentage of patients who are eligible and receiving ART during the review period or at time of death)	11	Mar - Aug 06 **76**	Jul - Dec 13 **96**
		Mozambique[1]	Percentage of patients eligible for ART who received ART during the review period	5	Jan - Jun 07 **80**	Jul - Dec 12 **85**
		Namibia[2]	Percentage of patients eligible for ART who received ART during the review period	9	Jan - Jun 08 **83**	Oct 12 - Mar 13 **92**
		Haiti	Percentage of patients eligible for ART who were enrolled on ART during the review period	13	Jan - Jun 08 **45**	Oct 13 - Mar 14 **71**
		Guyana[3]	Percentage of patients (all ages) prescribed HAART during the review period	4	Jan - Jun 08 **71**	Jan - Jun 12 **84**
		Vietnam	Percentage of patients eligible for ART who initiated ART within 30 days	4	Jul - Dec 11 **58**	Apr - Sept 13 **72**
		Kenya	Percentage of patients eligible for ART who received ART during the review period	4	Jul - Dec 09 **86**	Jul - Dec 11 **90**

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline scores reported in the table above correspond to the first round in which ART and pre-ART patients were combined for a given indicator.
[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.
[3]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.
[4]Clinics implementing HQ-Zimbabwe have collected a baseline round of data. Although data are insufficient to assess whether improvement has occurred, the initial round of data collection identifies opportunities for improvement in the data collection process.

SUMMARY OF RESULTS FOR ADULTS:
CD4/Viral Load Monitoring and **ART Adherence**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
CD4/Viral Load Monitoring	CD4 Monitoring	Uganda	Percentage of patients with a CD4 test (percent or count) during the review period	10	Mar - Aug 06 **31**	Jul - Dec 13 **43**
		Mozambique[1]	Percentage of patients on ART with a CD4 count test during the review period	4	Jul 07 - Jun 08 **40**	Jul - Dec 12 **89**
		Namibia[2]	Percentage of patients on ART with a CD4 count test during the review period	9	Jan - Jun 08 **74**	Oct 12 - Mar 13 **66**
		Haiti	**CD4 Monitoring:** Percentage of newly enrolled patients (within 6-12 months prior to the review period) with a CD4 count test within 2 months of enrollment and between 2 and 8 months after enrollment	10	Jan - Jun 08 **31**	Oct 13 - Mar 14 **30**
			CD4 Monitoring (new): Percentage of patients (on ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **18**	Oct 13 - Mar 14 **46**
		Guyana[3]	Percentage of patients (all ages) with a CD4 test during the review period	4	Jan - Jun 08 **83**	Jan - Jun 12 **66**
		Vietnam	Percentage of patients with a CD4 count test during the review period	4	Jul - Dec 11 **74**	Apr - Sept 13 **75**
		Kenya	Percentage of patients with a CD4 count test during the review period	4	Jul - Dec 09 **63**	Jul - Dec 11 **66**
		Zimbabwe[4]	Percentage of patients on ART with a CD4 test during the review period	1	Jan - Jun 13 **17**	N/A
	CD4 Test at Enrollment	Haiti	Percentage of patients newly enrolled during the review period who received a CD4 test within 60 days of enrollment, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **62**	Oct 13 - Mar 14 **66**
		Vietnam	Percentage of patients newly registered who are tested for CD4 count within 15 days of enrollment (Initial CD4 Count indicator)	4	Jul - Dec 11 **65**	Apr - Sept 13 **79**
	Virology Monitoring	Uganda	Percentage of patients on ART who received a viral load test during the review period	1	Jul - Dec 13 **1**	N/A
ART Adherence	ART Adherence Assessment	Uganda	Percentage of patients on ART with an adherence assessment in the last 3 months (for rounds 1-8, percentage of patients who had an adherence assessment during the review period or at time of death)	11	Mar - Aug 06 **63**	Jul - Dec 13 **86**
		Mozambique[1]	Percentage of patients on ART who had an adherence assessment during the review period	5	Jan - Jun 07 **66**	Jul - Dec 12 **83**
		Namibia[2]	Percentage of patients on ART who had an adherence assessment during the review period	9	Jan - Jun 08 **90**	Oct 12 - Mar 13 **98**
		Haiti	Percentage of patients on ART who had an adherence assessment (pill count or questionnaire) during the last 3 months of the review period	13	Jan - Jun 08 **29**	Oct 13 - Mar 14 **79**
		Guyana[3]	Percentage of patients (all ages) on ART who had an adherence assessment at each clinical visit during the review period	4	Jan - Jun 08 **56**	Jan - Jun 12 **82**
		Vietnam	Percentage of patients on ART who had an adherence assessment at the last clinical visit	4	Jul - Dec 11 **97**	Apr - Sept 13 **96**
		Kenya	Percentage of patients on ART with an adherence assessment in the last 3 months of the review period	4	Jul - Dec 09 **96**	Jul - Dec 11 **89**
		Zimbabwe[4]	Percentage of patients on ART with an adherence assessment at the most recent clinical visit	1	Jan - Jun 13 **55**	N/A
	Adherence Rate	Haiti	Percentage of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%	3	Oct 12 - Mar 13 **67**	Oct 13 - Mar 14 **72**
	ART Medication Pick-up	Vietnam	Percentage of patients on ART visiting the health facility to pick up medication as scheduled at the last clinical visit	4	Jul - Dec 11 **68**	Apr - Sept 13 **89**

SUMMARY OF RESULTS FOR ADULTS:
ART for Pregnant Women (PMTCT) and **Tuberculosis Prevention and Treatment**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
ART for Pregnant Women (PMTCT)	ART for Pregnant Women	Haiti	Percentage of HIV+ pregnant women who were eligible for and received ARV prophylaxis during the review period (eligibility was changed from 28th to 14th week of pregnancy for the 7th round of data collection onward)	13	Jan - Jun 08 **32**	Oct 13 - Mar 14 **91**
ART for Pregnant Women (PMTCT)	ART for Pregnant Women	Kenya	Percentage of HIV+ pregnant women receiving preventive ART, either HAART or more efficacious short course prophylactic ARV regimens (AZT + sdNVP) during the review period	1	Jul - Dec 11 **90**	N/A
ART for Pregnant Women (PMTCT)	ART for Pregnant Women	Zimbabwe[4]	Percentage of HIV+ pregnant women with CD4 count < or = 350 or WHO stage 3/4 who initiated ART within one month of eligibility	1	Jan - Jun 13 **41**	N/A
ART for Pregnant Women (PMTCT)	ART Eligibility Assessment	Kenya	Percentage of HIV+ pregnant women assessed for ART eligibility by CD4 count during the review period	1	Jul - Dec 11 **73**	N/A
ART for Pregnant Women (PMTCT)	ART Eligibility Assessment	Zimbabwe[4]	Percentage of HIV+ pregnant women who had a CD4 test performed and received results within one week of diagnosis	1	Jan - Jun 13 **60**	N/A
ART for Pregnant Women (PMTCT)	PMTCT Counseling on Partner Testing	Kenya	Percentage of HIV+ pregnant women enrolled in PMTCT who were counseled on partner testing during the review period	1	Jul - Dec 11 **76**	N/A
Tuberculosis Prevention and Treatment	TB Clinical Screening	Uganda	Percentage of patients (in general care or on ART) seen in the clinic within the past month who were assessed for active TB at each clinical visit (for rounds 1-8, percentage of patients who were assessed for clinical symptoms of TB during the review period)	11	Mar - Aug 06 **55**	Jul - Dec 13 **94**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Mozambique[1]	Percentage of patients who were screened for TB during the review period	4	Jul 07 - Jun 08 **25**	Jul - Dec 12 **89**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Namibia[2]	Percentage of patients who were screened for signs and symptoms of active TB during the review period	9	Jan - Jun 08 **81**	Oct 12 - Mar 13 **92**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Haiti	Percentage of patients screened for TB by TST or for symptoms of cough, fever and weight loss during the review period (for rounds 1-6, percentage of patients screened for TB done by TST at enrollment)	13	Jan - Jun 08 **29**	Oct 13 - Mar 14 **93**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Guyana[3]	Percentage of patients (all ages) who were screened for TB by TST during the past 12 months	4	Jan - Jun 08 **89**	Jan - Jun 12 **85**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Vietnam	Percentage of patients who were screened for TB at the last clinical visit	4	Jul - Dec 11 **58**	Apr - Sept 13 **72**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Kenya	Percentage of patients screened for TB at each clinical visit during the review period	4	Jul - Dec 09 **51**	Jul - Dec 11 **95**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Zimbabwe[4]	Percentage of patients on ART who had a standard TB screening (all 5 components) performed at their last visit during the review period	1	Jan - Jun 13 **53**	N/A
Tuberculosis Prevention and Treatment	Isoniazid Prophylactic Therapy	Haiti	Percentage of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months, excluding deceased and transferred patients and those with active TB	3	Oct 12 - Mar 13 **42**	Oct 13 - Mar 14 **52**
Tuberculosis Prevention and Treatment	Isoniazid Prophylactic Therapy	Namibia[2]	Percentage of patients with no documented contraindication to IPT and who are not on TB treatment who are currently receiving IPT	9	Jan - Jun 08 **16**	Oct 12 - Mar 13 **25**
Tuberculosis Prevention and Treatment	TB Diagnostic Evaluation	Uganda	Percentage of patients with signs and symptoms of TB who have been evaluated for TB during the review period using sputum smear and/or CXR or gene Xpert	10	Mar - Aug 06 **23**	Jul - Dec 13 **47**
Tuberculosis Prevention and Treatment	TB Treatment	Uganda	Percentage of patients diagnosed with TB who were started on treatment during the review period	1	Jul - Dec 13 **93**	N/A

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline scores reported in the table above correspond to the first round in which ART and pre-ART patients were combined for a given indicator.

[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.

[3]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.

[4]Clinics implementing HQ-Zimbabwe have collected a baseline round of data. Although data are insufficient to assess whether improvement has occurred, the initial round of data collection identifies opportunities for improvement in the data collection process.

SUMMARY OF RESULTS FOR ADULTS: **Cotrimoxazole Preventive Therapy, Women's Health, Partner Testing, Prevention Education, Family Planning** and **Nutrition**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Cotrimoxazole Preventive Therapy (CPT)	CPT	Uganda	Percentage of patients who have been prescribed cotrimoxazole during the review period and are still receiving it at the end of the review period or at time of death	8	Mar - Aug 06 **88**	Jul - Dec 10 **90**
		Mozambique[1]	Percentage of patients eligible for cotrimoxazole who received cotrimoxazole during the last 6 months of the review period	4	Jul 07 - Jun 08 **65**	Jul - Dec 12 **79**
		Namibia[2]	Percentage of patients with CD4<300 or WHO stage 3/4 who have been prescribed cotrimoxazole prophylaxis during the review period and are still receiving it at the end of the review period or at time of death or transfer-out	9	Jan - Jun 08 **86**	Oct 12 - Mar 13 **92**
		Haiti	Percentage of patients who have received cotrimoxazole prophylaxis during the review period	13	Jan - Jun 08 **62**	Oct 13 - Mar 14 **94**
		Guyana[3]	Percentage of HIV+ patients (all ages) receiving cotrimoxazole during the review period (for HIV-exposed infants, percentage of exposed infants starting cotrimoxazole by two months of age)	4	Jan - Jun 08 **78**	Jan - Jun 12 **84**
		Vietnam	Percentage of patients who were prescribed cotrimoxazole or dapsone in the last clinical visit	4	Jul - Dec 11 **40**	Apr - Sept 13 **84**
		Kenya	Percentage of patients on cotrimoxazole during the review period	4	Jul - Dec 09 **97**	Jul - Dec 11 **98**
Women's Health	Syphilis Treatment	Haiti	Percentage of HIV+ women who tested positive for syphilis who completed treatment during the review period, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **10**	Oct 13 - Mar 14 **41**
	Cervical Cancer Screening		Percentage of HIV+ women aged 25-64 years who were screened for cervical cancer (visual inspection of the cervix with acetic acid [VIA] or a cervical cytology) during the review period, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **8**	Oct 13 - Mar 14 **6**
Partner Testing	Counseling on Partner Testing	Kenya	Percentage of HIV+ patients who have been counseled about partner testing during the review period	4	Jul - Dec 09 **36**	Jul - Dec 11 **48**
Prevention Education (PE)	PE	Namibia[2]	Percentage of patients who received prevention education during the last 3 months of the review period	9	Jan - Jun 08 **37**	Oct 12 - Mar 13 **41**
		Mozambique[1]	Percentage of patients who received prevention education in the last 6 months of the review period	4	Jul 07 - Jun 08 **66**	Jul - Dec 12 **84**
Family Planning (FP)	FP	Haiti	Percentage of HIV+ women of childbearing age who accepted a family planning method during the review period	13	Jan - Jun 08 **6**	Oct 13 - Mar 14 **51**
		Kenya	Percentage of non-pregnant women aged 15-49 years, not already on family planning, who initiated modern contraception during the review period	3	Jul - Dec 10 **30**	Jul - Dec 11 **36**
Nutrition	Nutrition Evaluation	Haiti	Percentage of patients who had a nutritional evaluation during the review period (BMI calculated at enrollment and weight measured at each visit)	13	Jan - Jun 08 **77**	Oct 13 - Mar 14 **86**
		Kenya	Percentage of patients who had at least one nutritional assessment (MUAC, BMI or weight for height during the 6-month review period)	2	Jan - Jun 11 **4**	Jul - Dec 11 **18**
	Nutritional Counseling	Kenya	Percentage of patients who received nutritional counseling during the review period	2	Jan - Jun 11 **42**	Jul - Dec 11 **51**
	Malnutrition Status	Haiti	Percentage of patients who received a BMI assessment during the last 6 months (excluding deceased and transferred patients) who had a BMI of 16 or lower (severe malnutrition)	3	Oct 12 - Mar 13 **2**	Oct 13 - Mar 14 **2**
	Weight Monitoring	Namibia[2]	Percentage of patients whose weight has been recorded during the review period	9	Jan - Jun 08 **84**	Oct 12 - Mar 13 **96**
	Food Security		Percentage of patients assessed for food security (hunger) during the review period	9	Jan - Jun 08 **24**	Oct 12 - Mar 13 **47**

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline scores reported in the table above correspond to the first round in which ART and pre-ART patients were combined for a given indicator.
[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.
[3]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.

SUMMARY OF RESULTS FOR ADULTS:
Alcohol Use and Mental Health Screening and **Vital Signs**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Alcohol Use and Mental Health Screening	Alcohol Screening	Namibia[2]	Percentage of patients who have been screened for alcohol use during the review period	9	Jan - Jun 08 **24**	Oct 12 - Mar 13 **47**
	Mental Health Assessment	Haiti	Percentage of patients who received a mental health evaluation during the past 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation, and assessment of sleep and appetite)	3	Oct 12 - Mar 13 **45**	Oct 13 - Mar 14 **53**
Vital Signs	Temperature	Guyana[3]	Percentage of patients (ages 16+) with temperature documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **39**	Jan - Jun 12 **86**
	Pulse		Percentage of patients (ages 16+) with pulse documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **48**	Jan - Jun 12 **90**
	Blood Pressure		Percentage of patients (ages 16+) with blood pressure documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **69**	Jan - Jun 12 **89**

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline scores reported in the table above correspond to the first round in which ART and pre-ART patients were combined for a given indicator.

[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.

[3]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.

SUMMARY OF RESULTS FOR ADULTS: **Uganda** and **Mozambique**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Clinical Visits and Retention	Clinical Visits	Percentage of patients with at a clinical visit in the last 3 months of the review period (for rounds 1-8, percentage of patients with a clinical visit in each 3-month quarter)	10	Mar - Aug 06 **70**	Jul - Dec 13 **92**
		Appointment Keeping	Percentage of patients who missed their scheduled appointment and did not show up to clinic within seven days after the scheduled appointment date	3	Jul - Dec 11 **16**	Jul - Dec 13 **87**
	ARV Therapy (ART)	ART	Percentage of patients who are eligible for ART who have initiated ART within the past month (for rounds 1-8, percentage of patients who are eligible and receiving ART during the review period or at time of death)	11	Mar - Aug 06 **76**	Jul - Dec 13 **96**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients with a CD4 test (percent or count) during the review period	10	Mar - Aug 06 **31**	Jul - Dec 13 **43**
		Virology Monitoring	Percentage of patients on ART who received a viral load test during the review period	1	Jul - Dec 13 **1**	N/A
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART with an adherence assessment in the last 3 months (for rounds 1-8, percentage of patients who had an adherence assessment during the review period or at time of death)	11	Mar - Aug 06 **63**	Jul - Dec 13 **86**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients (in general care or on ART) seen in the clinic within the past month who were assessed for active TB at each clinical visit (for rounds 1-8, percentage of patients who were assessed for clinical symptoms of TB during the review period)	11	Mar - Aug 06 **55**	Jul - Dec 13 **94**
		TB Diagnostic Evaluation	Percentage of patients with signs and symptoms of TB who have been evaluated for TB during the review period using sputum smear and/or CXR or gene Xpert	10	Mar - Aug 06 **23**	Jul - Dec 13 **47**
		TB Treatment	Percentage of patients diagnosed with TB who were started on treatment during the review period	1	Jul - Dec 13 **93**	N/A
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients who have been prescribed cotrimoxazole during the review period and are still receiving it at the end of the review period or at time of death	8	Mar - Aug 06 **88**	Jul - Dec 10 **90**
Mozambique[1]	Clinical Visits and Retention	Clinical Visits	Percentage of patients (ART and pre-ART) with a clinical visit during the first 6 months of the review period	4	Jul 07 - Jun 08 **49**	Jul - Dec 12 **92**
	ARV Therapy (ART)	ART	Percentage of patients eligible for ART who received ART during the review period	5	Jan - Jun 07 **80**	Jul - Dec 12 **85**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients on ART with a CD4 count test during the review period	4	Jul 07 - Jun 08 **40**	Jul - Dec 12 **89**
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART who had an adherence assessment during the review period	5	Jan - Jun 07 **66**	Jul - Dec 12 **83**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients who were screened for TB during the review period	4	Jul 07 - Jun 08 **25**	Jul - Dec 12 **89**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients eligible for cotrimoxazole who received cotrimoxazole during the last 6 months of the review period	4	Jul 07 - Jun 08 **65**	Jul - Dec 12 **79**
	Prevention Education (PE)	PE	Percentage of patients who received prevention education in the last 6 months of the review period	4	Jul 07 - Jun 08 **66**	Jul - Dec 12 **84**

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline scores reported in the table above correspond to the first round in which ART and pre-ART patients were combined for a given indicator.

SUMMARY OF RESULTS FOR ADULTS: **Namibia** and **Guyana**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Namibia[1]	Clinical Visits and Retention	Clinical Visits	Percentage of patients on ART with a clinical visit during the last 3 months of the review period	9	Jan - Jun 08 **79**	Oct 12 - Mar 13 **85**
	ARV Therapy (ART)	ART	Percentage of patients eligible for ART who received ART during the review period	9	Jan - Jun 08 **83**	Oct 12 - Mar 13 **92**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients on ART with a CD4 count test during the review period	9	Jan - Jun 08 **74**	Oct 12 - Mar 13 **66**
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART who had an adherence assessment during the review period	9	Jan - Jun 08 **90**	Oct 12 - Mar 13 **98**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients who were screened for signs and symptoms of active TB during the review period	9	Jan - Jun 08 **81**	Oct 12 - Mar 13 **92**
		Isoniazid Prophylactic Therapy	Percentage of patients with no documented contraindication to IPT and who are not on TB treatment who are currently receiving IPT	9	Jan - Jun 08 **16**	Oct 12 - Mar 13 **25**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients with CD4<300 or WHO stage 3/4 who have been prescribed cotrimoxazole prophylaxis during the review period and are still receiving it at the end of the review period or at time of death or transfer-out	9	Jan - Jun 08 **86**	Oct 12 - Mar 13 **92**
	Prevention Education (PE)	PE	Percentage of patients who received prevention education during the last 3 months of the review period	9	Jan - Jun 08 **37**	Oct 12 - Mar 13 **41**
	Nutrition	Weight Monitoring	Percentage of patients whose weight has been recorded during the review period	9	Jan - Jun 08 **84**	Oct 12 - Mar 13 **96**
		Food Security	Percentage of patients assessed for food security (hunger) during the review period	9	Jan - Jun 08 **24**	Oct 12 - Mar 13 **47**
	Alcohol Use and Mental Health Screening	Alcohol Screening	Percentage of patients who have been screened for alcohol use during the review period	9	Jan - Jun 08 **24**	Oct 12 - Mar 13 **47**
Guyana[2]	Clinical Visits and Retention	Clinical Visits	Percentage of patients (all ages) with at least 2 clinical visits during the review period	4	Jan - Jun 08 **85**	Jan - Jun 12 **79**
	ARV Therapy (ART)	ART	Percentage of patients (all ages) prescribed HAART during the review period	4	Jan - Jun 08 **71**	Jan - Jun 12 **84**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients (all ages) with a CD4 test during the review period	4	Jan - Jun 08 **83**	Jan - Jun 12 **66**
	ART Adherence	ART Adherence Assessment	Percentage of patients (all ages) on ART who had an adherence assessment at each clinical visit during the review period	4	Jan - Jun 08 **56**	Jan - Jun 12 **82**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients (all ages) who were screened for TB by TST during the past 12 months	4	Jan - Jun 08 **89**	Jan - Jun 12 **85**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of HIV+ patients (all ages) receiving cotrimoxazole during the review period (for HIV-exposed infants, percentage of exposed infants starting cotrimoxazole by two months of age)	4	Jan - Jun 08 **78**	Jan - Jun 12 **84**
	Vital Signs	Temperature	Percentage of patients (ages 16+) with temperature documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **39**	Jan - Jun 12 **86**
		Pulse	Percentage of patients (ages 16+) with pulse documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **48**	Jan - Jun 12 **90**
		Blood Pressure	Percentage of patients (ages 16+) with blood pressure documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **69**	Jan - Jun 12 **89**

[1] The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.

[2] Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.

SUMMARY OF RESULTS FOR ADULTS: **Haiti**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Clinical Visits and Retention	Clinical Visits	Percentage of patients on ART with a clinical visit within 3 months of their last visit during the review period	13	Jan - Jun 08 **76**	Oct 13 - Mar 14 **80**
		Retention	Percentage of patients (pre-ART) with at least one visit in the last 6 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **57**	Oct 13 - Mar 14 **58**
	ARV Therapy (ART)	ART	Percentage of patients eligible for ART who were enrolled on ART during the review period	13	Jan - Jun 08 **45**	Oct 13 - Mar 14 **71**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of newly enrolled patients (within 6-12 months prior to the review period) with a CD4 count test within 2 months of enrollment and between 2 and 8 months after enrollment	10	Jan - Jun 08 **31**	Oct 13 - Mar 14 **30**
		CD4 Monitoring (new)	Percentage of patients (on ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **18**	Oct 13 - Mar 14 **46**
		CD4 Test at Enrollment	Percentage of patients newly enrolled during the review period who received a CD4 test within 60 days of enrollment, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **62**	Oct 13 - Mar 14 **66**
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART who had an adherence assessment (pill count or questionnaire) during the last 3 months of the review period	13	Jan - Jun 08 **29**	Oct 13 - Mar 14 **79**
		Adherence Rate	Percentage of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%	3	Oct 12 - Mar 13 **67**	Oct 13 - Mar 14 **72**
	ART for Pregnant Women (PMTCT)	ART for Pregnant Women	Percentage of HIV+ pregnant women who were eligible for and received ARV prophylaxis during the review period (eligibility was changed from 28th to 14th week of pregnancy for the 7th round of data collection onward)	13	Jan - Jun 08 **32**	Oct 13 - Mar 14 **91**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients screened for TB by TST or for symptoms of cough, fever and weight loss during the review period (for rounds 1-6, percentage of patients screened for TB done by TST at enrollment)	13	Jan - Jun 08 **29**	Oct 13 - Mar 14 **93**
		Isoniazid Prophylactic Therapy	Percentage of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months, excluding deceased and transferred patients and those with active TB	3	Oct 12 - Mar 13 **42**	Oct 13 - Mar 14 **52**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients who have received cotrimoxazole prophylaxis during the review period	13	Jan - Jun 08 **62**	Oct 13 - Mar 14 **94**
	Women's Health	Syphilis Treatment	Percentage of HIV+ women who tested positive for syphilis who completed treatment during the review period, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **10**	Oct 13 - Mar 14 **41**
		Cervical Cancer Screening	Percentage of HIV+ women aged 25-64 years who were screened for cervical cancer (visual inspection of the cervix with acetic acid [VIA] or a cervical cytology) during the review period, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **8**	Oct 13 - Mar 14 **6**
	Family Planning (FP)	FP	Percentage of HIV+ women of childbearing age who accepted a family planning method during the review period	13	Jan - Jun 08 **6**	Oct 13 - Mar 14 **51**
	Nutrition	Nutrition Evaluation	Percentage of patients who had a nutritional evaluation during the review period (BMI calculated at enrollment and weight measured at each visit)	13	Jan - Jun 08 **77**	Oct 13 - Mar 14 **86**
		Malnutrition Status	Percentage of patients who received a BMI assessment during the last 6 months (excluding deceased and transferred patients) who had a BMI of 16 or lower (severe malnutrition)	3	Oct 12 - Mar 13 **2**	Oct 13 - Mar 14 **2**
	Alcohol Use and Mental Health Screening	Mental Health Assessment	Percentage of patients who received a mental health evaluation during the past 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation, and assessment of sleep and appetite)	3	Oct 12 - Mar 13 **45**	Oct 13 - Mar 14 **53**

SUMMARY OF RESULTS FOR ADULTS: **Vietnam** and **Kenya**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Vietnam	Clinical Visits and Retention	Clinical Visits	Percentage of patients (pre-ART) with a clinical visit in the last 3 months of the review period	4	Jul - Dec 11 **55**	Apr - Sept 13 **75**
	ARV Therapy (ART)	ART	Percentage of patients eligible for ART who initiated ART within 30 days	4	Jul - Dec 11 **58**	Apr - Sept 13 **72**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients with a CD4 count test during the review period	4	Jul - Dec 11 **74**	Apr - Sept 13 **75**
		CD4 Test at Enrollment	Percentage of patients newly registered who are tested for CD4 count within 15 days of enrollment (Initial CD4 Count indicator)	4	Jul - Dec 11 **65**	Apr - Sept 13 **79**
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART who had an adherence assessment at the last clinical visit	4	Jul - Dec 11 **97**	Apr - Sept 13 **96**
		ART Medication Pick-up	Percentage of patients on ART visiting the health facility to pick up medication as scheduled at the last clinical visit	4	Jul - Dec 11 **68**	Apr - Sept 13 **89**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients who were screened for TB at the last clinical visit	4	Jul - Dec 11 **58**	Apr - Sept 13 **72**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients who were prescribed cotrimoxazole or dapsone in the last clinical visit	4	Jul - Dec 11 **40**	Apr - Sept 13 **84**
Kenya	Clinical Visits and Retention	Clinical Visits	Percentage of patients on ART with at least 2 clinical visits at least 3 months apart during the review period	4	Jul - Dec 09 **67**	Jul - Dec 11 **73**
	ARV Therapy (ART)	ART	Percentage of patients eligible for ART who received ART during the review period	4	Jul - Dec 09 **86**	Jul - Dec 11 **90**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients with a CD4 count test during the review period	4	Jul - Dec 09 **63**	Jul - Dec 11 **66**
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART with an adherence assessment in the last 3 months of the review period	4	Jul - Dec 09 **96**	Jul - Dec 11 **89**
	ART for Pregnant Women (PMTCT)	ART for Pregnant Women	Percentage of HIV+ pregnant women receiving preventive ART, either HAART or more efficacious short course prophylactic ARV regimens (AZT + sdNVP) during the review period	1	Jul - Dec 11 **90**	N/A
		ART Eligibility Assessment	Percentage of HIV+ pregnant women assessed for ART eligibility by CD4 count during the review period	1	Jul - Dec 11 **73**	N/A
		PMTCT Counseling on Partner Testing	Percentage of HIV+ pregnant women enrolled in PMTCT who were counseled on partner testing during the review period	1	Jul - Dec 11 **76**	N/A
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients screened for TB at each clinical visit during the review period	4	Jul - Dec 09 **51**	Jul - Dec 11 **95**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients on cotrimoxazole during the review period	4	Jul - Dec 09 **97**	Jul - Dec 11 **98**
	Partner Testing	Counseling on Partner Testing	Percentage of HIV+ patients who have been counseled about partner testing during the review period	4	Jul - Dec 09 **36**	Jul - Dec 11 **48**
	Family Planning (FP)	FP	Percentage of non-pregnant women aged 15-49 years, not already on family planning, who initiated modern contraception during the review period	3	Jul - Dec 10 **30**	Jul - Dec 11 **36**
	Nutrition	Nutrition Evaluation	Percentage of patients who had at least one nutritional assessment (MUAC, BMI or weight for height during the 6-month review period)	2	Jan - Jun 11 **4**	Jul - Dec 11 **18**
		Nutritional Counseling	Percentage of patients who received nutritional counseling during the review period	2	Jan - Jun 11 **42**	Jul - Dec 11 **51**

SUMMARY OF RESULTS FOR ADULTS: **Zimbabwe**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Zimbabwe	Clinical Visits and Retention	Retention	Percentage of patients who visited clinic in the 6 months prior to the review period who had a clinical visit during the review period	1	Jan - Jun 13 **71**	N/A
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients on ART with a CD4 test during the review period	1	Jan - Jun 13 **17**	N/A
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART with an adherence assessment at the most recent clinical visit	1	Jan - Jun 13 **55**	N/A
	ART for Pregnant Women (PMTCT)	ART for Pregnant Women	Percentage of HIV+ pregnant women with CD4 count < or = 350 or WHO stage 3/4 who initiated ART within one month of eligibility	1	Jan - Jun 13 **41**	N/A
		ART Eligibility Assessment	Percentage of HIV+ pregnant women who had a CD4 test performed and received results within one week of diagnosis	1	Jan - Jun 13 **60**	N/A
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients on ART who had a standard TB screening (all 5 components) performed at their last visit during the review period	1	Jan - Jun 13 **53**	N/A

[1] Clinics implementing HQ-Zimbabwe have collected a baseline round of data. Although data are insufficient to assess whether improvement has occurred, the initial round of data collection identifies opportunities for improvement in the data collection process.

SUMMARY OF RESULTS FOR CHILDREN: **Clinical Visits and Retention, ARV Therapy, HIV Testing** and **WHO Clinical Staging**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Clinical Visits and Retention	Clinical Visits	Uganda	Percentage of patients with at least one clinical visit in the last 3 months of the review period (for rounds 1-8, percentage of patients with at least one clinical visit in each 3-month quarter)	10	Apr - Sept 07 **83**	Jul - Dec 13 **92**
		Mozambique	Percentage of pre-ART patients in WHO stages 2-4 who had one clinical visit in each month during the last 6 months or in WHO stage 1 (or unknown stage) who had one clinical visit in each 3-month interval. Percentage of ART patients on first year of treatment who had one visit in each month during the last 6 months Percentage of ART patients on treatment for more than a year who had one visit in each 2-month interval	3	Jul 08 - Jun 09 **7**	Jul - Dec 12 **5**
		Haiti	Percentage of patients on ART with a clinical visit within 3 months of their last visit during the review period	13	Jan - Jun 08 **69**	Oct 13 - Mar 14 **88**
		Guyana[1]	Percentage of HIV-negative patients < 5 years with at least 2 clinical visits during the review period	4	Jan - Jun 08 **67**	Jan - Jun 12 **75**
		Kenya[2]	Percentage of patients on ART with at least 2 clinical visits at least 3 months apart during the review period	2	Jan - Jun 11 **74**	Jul - Dec 11 **74**
	Retention	Haiti	Percentage of patients (pre-ART) with at least one visit in the last 6 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **55**	Oct 13 - Mar 14 **56**
	Appointment Keeping	Uganda	Percentage of patients on ART who kept the last scheduled clinical appointment in the last 3 months of the review period	1	Jul - Dec 13 **68**	N/A
ARV Therapy (ART)	ART	Uganda	Percentage of patients who were eligible and started on ART during the review period	10	Apr - Sept 07 **26**	Jul - Dec 13 **73**
		Mozambique	Percentage of patients eligible for ART receiving ART during the last 6 months of the review period	3	Jul 08 - Jun 09 **59**	Jul - Dec 12 **81**
		Haiti	Percentage of patients eligible for ART who were enrolled on ART during the review period	13	Jan - Jun 08 **44**	Oct 13 - Mar 14 **73**
		Kenya[1]	Percentage of patients eligible for ART who received ART during the review period	2	Jan - Jun 11 **54**	Jul - Dec 11 **83**
		Zimbabwe	Percentage of newly diagnosed HIV+ children (<15 years old by end of review period) who initiated ART within one month of diagnosis	1	Jan - Jun 13 **79**	N/A
	ART Initiation in HIV+ Infants	Zimbabwe	Percentage of HIV+ children <12 months of age who have been initiated on ART	1	Jan - Jun 13 **68**	N/A
	Infant Referral from PMTCT	Uganda	Percentage of newly HIV-infected or HIV-exposed pediatric patients who were referred for HIV care from PMTCT based on reviews in pediatric clinics	7	Apr - Sept 07 **6**	Jul - Dec 10 **12**
HIV Testing	Early HIV Detection	Haiti	Percentage of children exposed to HIV aged 4 weeks to 1 year who have received early screening by PCR during the last 3 months, excluding those out of care	3	Oct 12 - Mar 13 **22**	Oct 13 - Mar 14 **63**
	HIV-exposed Infant Management	Zimbabwe[3]	Percentage of HIV-exposed infants 12 months of age or younger who had a DBS test performed and received results within one month	1	Jan - Jun 13 **15**	N/A
WHO Clinical Staging	WHO Clinical Staging	Mozambique	Percentage of HIV+ children for whom a WHO clinical stage was documented at each clinical visit during the review period (for rounds 1-2, percentage of HIV+ children for whom a WHO clinical stage was documented at the last clinical visit)	3	Jul 08 - Jun 09 **69**	Jul - Dec 12 **94**

[1]Guyana Well Child data include HIV-negative patients < 5 years of age. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.
[2]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.
[3]During the baseline round of data collection, a group of sites misinterpreted the definition of the HIV-exposed infant management (DBS test) indicator. Because of errors in data collection, the mean clinic score reported for this indicator may not reflect actual clinical performance during the first round of data collection.

SUMMARY OF RESULTS FOR CHILDREN: **CD4 Monitoring, ART Adherence, Tuberculosis Prevention and Treatment** and **Cotrimoxazole Preventive Therapy**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
CD4 Monitoring	CD4 Monitoring	Uganda	Percentage of patients with a CD4 test during the review period	10	Apr - Sept 07 **15**	Jul - Dec 13 **35**
CD4 Monitoring	CD4 Monitoring	Mozambique	Percentage of patients who had a CD4 test in the last 6 months of the review period	3	Jul 08 - Jun 09 **36**	Jul - Dec 12 **46**
CD4 Monitoring	CD4 Monitoring	Haiti	**CD4 Monitoring:** Percentage of newly enrolled patients (within 6-12 months prior to the review period) with a CD4 count test within 2 months of enrollment and between 2 and 8 months after enrollment	10	Jan - Jun 08 **35**	Oct 13 - Mar 14 **20**
CD4 Monitoring	CD4 Monitoring	Haiti	**CD4 Monitoring (new):** Percentage of patients (on ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **14**	Oct 13 - Mar 14 **49**
CD4 Monitoring	CD4 Monitoring	Kenya[1]	Percentage of patients with a CD4 count test during the review period	2	Jan - Jun 11 **54**	Jul - Dec 11 **63**
CD4 Monitoring	CD4 Test at Enrollment	Haiti	Percentage of patients enrolled during the review period who received a CD4 count within 60 days of enrollment	3	Oct 12 - Mar 13 **20**	Oct 13 - Mar 14 **41**
ART Adherence	ART Adherence Assessment	Uganda	Percentage of patients on ART with an adherence assessment in the last 3 months (for rounds 1-8, % of patients who had an adherence assessment during the review period or at time of death)	10	Apr - Sept 07 **43**	Jul - Dec 13 **75**
ART Adherence	ART Adherence Assessment	Mozambique	Percentage of patients on ART who had an adherence assessment during the review period	3	Jul 08 - Jun 09 **81**	Jul - Dec 12 **72**
ART Adherence	ART Adherence Assessment	Haiti	Percentage of patients on ART who had an adherence assessment (pill count or questionnaire) during the last 3 months of the review period	13	Jan - Jun 08 **30**	Oct 13 - Mar 14 **76**
ART Adherence	Adherence Rate	Haiti	Percentage of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%	3	Oct 12 - Mar 13 **63**	Oct 13 - Mar 14 **73**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Uganda	Percentage of patients who have been screened for TB during the last 3 months (for rounds 1-8, percentage of patients who were assessed for clinical symptoms of TB during the review period)	10	Apr - Sept 07 **57**	Jul - Dec 13 **90**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Mozambique	Percentage of patients who were screened for pulmonary TB during the last 6 months of the review period	3	Jul 08 - Jun 09 **34**	Jul - Dec 12 **84**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Haiti	Percentage of patients screened for TB by TST or for symptoms of cough, fever and weight loss during the review period (for rounds 1-6, percentage of patients screened for TB done by TST at enrollment)	13	Jan - Jun 08 **17**	Oct 13 - Mar 14 **91**
Tuberculosis Prevention and Treatment	TB Clinical Screening	Kenya[1]	Percentage of patients screened for TB at each clinical visit during the review period	2	Jan - Jun 11 **82**	Jul - Dec 11 **78**
Tuberculosis Prevention and Treatment	TB Diagnostic Evaluation	Uganda	Percentage of patients with signs and symptoms of TB who have been evaluated for TB during the review period using sputum smear and/or CXR or gene Xpert	10	Apr - Sept 07 **8**	Jul - Dec 13 **55**
Tuberculosis Prevention and Treatment	TB Treatment	Uganda	Percentage of patients diagnosed with TB who were started on treatment during the review period	1	Jul - Dec 13 **73**	N/A
Tuberculosis Prevention and Treatment	Isoniazid Prophylactic Therapy	Haiti	Percentage of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months, excluding deceased and transferred patients and those with active TB	3	Oct 12 - Mar 13 **23**	Oct 13 - Mar 14 **29**
Cotrimoxazole Preventive Therapy (CPT)	CPT	Uganda	Percentage of patients who have been prescribed cotrimoxazole during the review period and are still receiving it at the end of the review period or at time of death	10	Apr - Sept 07 **84**	Jul - Dec 13 **92**
Cotrimoxazole Preventive Therapy (CPT)	CPT	Mozambique	Percentage of patients eligible for cotrimoxazole who received cotrimoxazole during the last 6 months of the review period	3	Jul 08 - Jun 09 **69**	Jul - Dec 12 **73**
Cotrimoxazole Preventive Therapy (CPT)	CPT	Haiti	Percentage of patients who have received cotrimoxazole prophylaxis during the review period	13	Jan - Jun 08 **61**	Oct 13 - Mar 14 **96**
Cotrimoxazole Preventive Therapy (CPT)	CPT	Kenya[1]	Percentage of patients on cotrimoxazole during the review period	2	Jan - Jun 11 **98**	Jul - Dec 11 **97**

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

SUMMARY OF RESULTS FOR CHILDREN:
Growth and Nutrition and **Malaria Prevention and Immunization**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Growth and Nutrition	Weight	Mozambique	Percentage of patients whose weight was documented at each clinical visit during the review period (for rounds 1 and 2, percentage of patients who were weighed during their last clinical visit)	3	Jul 08 - Jun 09 **82**	Jul - Dec 12 **86**
Growth and Nutrition	Height	Mozambique	Percentage of patients whose height was documented at each clinical visit during the review period (for rounds 1 and 2, percentage of patients whose height was measured during their last clinical visit)	3	Jul 08 - Jun 09 **56**	Jul - Dec 12 **55**
Growth and Nutrition	Weight for Height	Mozambique	Percentage of patients whose weight to height ratio or IMC/age was evaluated at each clinical visit during the review period (for rounds 1 and 2, percentage of children whose weight to height ratio was calculated during their last clinical visit)	3	Jul 08 - Jun 09 **47**	Jul - Dec 12 **39**
Growth and Nutrition	Evaluation of Psychomotor Development (PMD)	Mozambique	Percentage of patients whose PMD was evaluated at each clinical visit during the review period (for rounds 1 and 2, percentage of patients whose PMD was evaluated during their last clinical visit)	3	Jul 08 - Jun 09 **53**	Jul - Dec 12 **60**
Growth and Nutrition	Weight	Guyana (Well Child Indicators for HIV-negative children <5 years)	Percentage of children with weight measured at each clinical visit during the review period	4	Jan - Jun 08 **95**	Jan - Jun 12 **97**
Growth and Nutrition	Height/Length	Guyana (Well Child Indicators for HIV-negative children <5 years)	Percentage of children with height/length measured at each clinical visit during the review period	4	Jan - Jun 08 **48**	Jan - Jun 12 **93**
Growth and Nutrition	Weight for Age Plot	Guyana (Well Child Indicators for HIV-negative children <5 years)	Percentage of children with "Weight for Age" plotted on a Growth Chart at each clinical visit during the review period	4	Jan - Jun 08 **89**	Jan - Jun 12 **94**
Growth and Nutrition	Head Circumference	Guyana (Well Child Indicators for HIV-negative children <5 years)	Percentage of children <2 years of age with head circumference measured at each clinical visit during the review period	4	Jan - Jun 08 **6**	Jan - Jun 12 **83**
Growth and Nutrition	Developmental Milestones	Guyana (Well Child Indicators for HIV-negative children <5 years)	Percentage of children with developmental milestones assessed at each clinical visit during the review period (as indicated on Clinic Card)	4	Jan - Jun 08 **69**	Jan - Jun 12 **87**
Growth and Nutrition	Nutrition Evaluation	Haiti	Percentage of patients who had a nutritional evaluation during the review period (malnutrition is measured by growth rate)	13	Jan - Jun 08 **54**	Oct 13 - Mar 14 **62**
Growth and Nutrition	Nutrition Evaluation	Kenya[1]	Percentage of patients who had at least one nutritional assessment (MUAC, BMI or weight for height during the 6-month review period)	2	Jan - Jun 11 **18**	Jul - Dec 11 **13**
Growth and Nutrition	Nutrition Evaluation	Uganda	Percentage of patients with MUAC measurement done during the last 3 months of the review period	2	Jul - Dec 12 **26**	Jul - Dec 13 **28**
Growth and Nutrition	Growth Monitoring	Uganda	Percentage of patients receiving weight-for-age assessments during the last 3 months of the review period	9	Apr - Sept 07 **56**	Jul - Dec 12 **87**
Growth and Nutrition	Nutritional Counseling	Kenya[1]	Percentage of patients who received nutritional counseling during the review period	2	Jan - Jun 11 **61**	Jul - Dec 11 **67**
Growth and Nutrition	Nutrition Support	Uganda	Percentage of patients assessed in the last 3 months of the review period who had malnutrition and received therapeutic or supplementary feeding support	1	Jul - Dec 13 **64**	N/A
Growth and Nutrition	Malnutrition Status	Haiti	Percentage of patients who received a nutritional assessment during the last 6 months (excluding those out of care) who had weight gain of less than -3 standard deviations or, if 1-5 years, MUAC<12.5 cm or a ratio of AC/HC <0.25 (severe malnutrition)	3	Oct 12 - Mar 13 **12**	Oct 13 - Mar 14 **9**
Malaria Prevention and Immunization	Malaria Prevention	Uganda	Percentage of children using insecticide-treated material (ITM) during the last 3 months of the review period	7	Apr - Sept 07 **11**	Jul - Dec 10 **30**
Malaria Prevention and Immunization	Immunization	Haiti	Percentage of patients <5 years old seen during the review period who have had complete vaccinations for their age	10	Jan - Jun 08 **0**	Apr - Sept 12 **53**

SUMMARY OF RESULTS FOR CHILDREN: **Disclosure of Status** and **Mental Health**

Technical Area	Indicator	Country	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Disclosure of Status	Disclosure of Status	Kenya[1]	Percentage of children aged 8-14 years whose status has been disclosed to them	2	Jan - Jun 11 **56**	Jul - Dec 11 **50**
Mental Health	Mental Health Assessment	Haiti	Percentage of patients who received a mental health evaluation during the pat 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation and assessment of sleep and appetite)	3	Oct 12 - Mar 13 **3**	Oct 13 - Mar 14 **4**

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

SUMMARY OF RESULTS FOR CHILDREN: **Uganda**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Clinical Visits and Retention	Clinical Visits	Percentage of patients with at least one clinical visit in the last 3 months of the review period (for rounds 1-8, percentage of patients with at least one clinical visit in each 3-month quarter)	10	Apr - Sept 07 **83**	Jul - Dec 13 **92**
		Appointment Keeping	Percentage of patients on ART who kept the last scheduled clinical appointment in the last 3 months of the review period	1	Jul - Dec 13 **68**	N/A
	ARV Therapy (ART)	ART	Percentage of patients who were eligible and started on ART during the review period	10	Apr - Sept 07 **26**	Jul - Dec 13 **73**
		Infant Referral from PMTCT	Percentage of newly HIV-infected or HIV-exposed pediatric patients who were referred for HIV care from PMTCT based on reviews in pediatric clinics	7	Apr - Sept 07 **6**	Jul - Dec 10 **12**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients with a CD4 test during the review period	10	Apr - Sept 07 **15**	Jul - Dec 13 **35**
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART with an adherence assessment in the last 3 months (for rounds 1-8, percentage of patients who had an adherence assessment during the review period or at time of death)	10	Apr - Sept 07 **43**	Jul - Dec 13 **75**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients who have been screened for TB during the last 3 months (for rounds 1-8, percentage of patients who were assessed for clinical symptoms of TB during the review period)	10	Apr - Sept 07 **57**	Jul - Dec 13 **90**
		TB Diagnostic Evaluation	Percentage of patients with signs and symptoms of TB who have been evaluated for TB during the review period using sputum smear and/or CXR or gene Xpert	10	Apr - Sept 07 **8**	Jul - Dec 13 **55**
		TB Treatment	Percentage of patients diagnosed with TB who were started on treatment during the review period	1	Jul - Dec 13 **73**	N/A
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients who have been prescribed cotrimoxazole during the review period and are still receiving it at the end of the review period or at time of death	10	Apr - Sept 07 **84**	Jul - Dec 13 **92**
	Malaria Prevention and Immunization	Malaria Prevention	Percentage of children using insecticide-treated material (ITM) during the last 3 months of the review period	7	Apr - Sept 07 **11**	Jul - Dec 10 **30**
	Growth and Nutrition	Nutrition Evaluation	Percentage of patients with MUAC measurement done during the last 3 months of the review period	2	Jul - Dec 12 **26**	Jul - Dec 13 **28**
		Nutrition Support	Percentage of patients assessed in the last 3 months of the review period who had malnutrition and received therapeutic or supplementary feeding support	1	Jul - Dec 13 **64**	N/A
		Growth Monitoring	Percentage of patients receiving weight-for-age assessments during the last 3 months of the review period	9	Apr - Sept 07 **56**	Jul - Dec 12 **87**

SUMMARY OF RESULTS FOR CHILDREN: **Mozambique** and **Guyana**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Mozambique	Clinical Visits and Retention	Clinical Visits	Percentage of pre-ART patients in WHO stages 2-4 who had one clinical visit in each month during the last 6 months or in WHO stage 1 (or unknown stage) who had one clinical visit in each 3-month interval. Percentage of ART patients on first year of treatment who had one visit in each month during the last 6 months. Percentage of ART patients on treatment for more than a year who had one visit in each 2-month interval	3	Jul 08 - Jun 09 **7**	Jul - Dec 12 **5**
	ARV Therapy (ART)	ART	Percentage of patients eligible for ART receiving ART during the last 6 months of the review period	3	Jul 08 - Jun 09 **59**	Jul - Dec 12 **81**
	WHO Clinical Staging	WHO Clinical Staging	Percentage of HIV+ children for whom a WHO clinical stage was documented at each clinical visit during the review period (for rounds 1-2, percentage of HIV+ children for whom a WHO clinical stage was documented at the last clinical visit)	3	Jul 08 - Jun 09 **69**	Jul - Dec 12 **94**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients who had a CD4 test in the last 6 months of the review period	3	Jul 08 - Jun 09 **36**	Jul - Dec 12 **46**
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART who had an adherence assessment during the review period	3	Jul 08 - Jun 09 **81**	Jul - Dec 12 **72**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients who were screened for pulmonary TB during the last 6 months of the review period	3	Jul 08 - Jun 09 **34**	Jul - Dec 12 **84**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients eligible for cotrimoxazole who received cotrimoxazole during the last 6 months of the review period	3	Jul 08 - Jun 09 **69**	Jul - Dec 12 **73**
	Growth and Nutrition	Weight	Percentage of patients whose weight was documented at each clinical visit during the review period (for rounds 1 and 2, percentage of patients who were weighed during their last clinical visit)	3	Jul 08 - Jun 09 **82**	Jul - Dec 12 **86**
		Height	Percentage of patients whose height was documented at each clinical visit during the review period (for rounds 1 and 2, percentage of patients whose height was measured during their last clinical visit)	3	Jul 08 - Jun 09 **56**	Jul - Dec 12 **55**
		Weight for Height	Percentage of patients whose weight to height ratio or IMC/age was evaluated at each clinical visit during the review period (for rounds 1 and 2, percentage of children whose weight to height ratio was calculated during their last clinical visit)	3	Jul 08 - Jun 09 **47**	Jul - Dec 12 **39**
		Evaluation of Psychomotor Development (PMD)	Percentage of patients whose PMD was evaluated at each clinical visit during the review period (for rounds 1 and 2, percentage of patients whose PMD was evaluated during their last clinical visit)	3	Jul 08 - Jun 09 **53**	Jul - Dec 12 **60**
Guyana[1] (Well Child Indicators for HIV-negative children <5 years)	Clinical Visits and Retention	Clinical Visits	Percentage of HIV-negative patients < 5 years with at least 2 clinical visits during the review period	4	Jan - Jun 08 **67**	Jan - Jun 12 **75**
	Growth and Nutrition	Weight	Percentage of children with weight measured at each clinical visit during the review period	4	Jan - Jun 08 **95**	Jan - Jun 12 **97**
		Height/ Length	Percentage of children with height/length measured at each clinical visit during the review period	4	Jan - Jun 08 **48**	Jan - Jun 12 **93**
		Weight for Age Plot	Percentage of children with "Weight for Age" plotted on a Growth Chart at each clinical visit during the review period	4	Jan - Jun 08 **89**	Jan - Jun 12 **94**
		Head Circumference	Percentage of children <2 years of age with head circumference measured at each clinical visit during the review period	4	Jan - Jun 08 **6**	Jan - Jun 12 **83**
		Developmental Milestones	Percentage of children with developmental milestones assessed at each clinical visit during the review period (as indicated on Clinic Card)	4	Jan - Jun 08 **69**	Jan - Jun 12 **87**

[1]Guyana Well Child data include HIV-negative patients < 5 years of age. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.

SUMMARY OF RESULTS FOR CHILDREN: **Haiti**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Clinical Visits and Retention	Clinical Visits	Percentage of patients on ART with a clinical visit within 3 months of their last visit during the review period	13	Jan - Jun 08 **69**	Oct 13 - Mar 14 **88**
		Retention	Percentage of patients (pre-ART) with at least one visit in the last 6 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **55**	Oct 13 - Mar 14 **56**
	ARV Therapy (ART)	ART	Percentage of patients eligible for ART who were enrolled on ART during the review period	13	Jan - Jun 08 **44**	Oct 13 - Mar 14 **73**
	HIV Testing	Early HIV Detection	Percentage of children exposed to HIV aged 4 weeks to 1 year who have received early screening by PCR during the last 3 months, excluding those out of care	3	Oct 12 - Mar 13 **22**	Oct 13 - Mar 14 **63**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of newly enrolled patients (within 6-12 months prior to the review period) with a CD4 count test within 2 months of enrollment and between 2 and 8 months after enrollment	10	Jan - Jun 08 **35**	Oct 13 - Mar 14 **20**
		CD4 Monitoring (new)	Percentage of patients (on ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **14**	Oct 13 - Mar 14 **49**
		CD4 Test at Enrollment	Percentage of patients enrolled during the review period who received a CD4 count within 60 days of enrollment	3	Oct 12 - Mar 13 **20**	Oct 13 - Mar 14 **41**
	ART Adherence	ART Adherence Assessment	Percentage of patients on ART who had an adherence assessment (pill count or questionnaire) during the last 3 months of the review period	13	Jan - Jun 08 **30**	Oct 13 - Mar 14 **76**
		Adherence Rate	Percentage of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%	3	Oct 12 - Mar 13 **63**	Oct 13 - Mar 14 **73**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients screened for TB by TST or for symptoms of cough, fever and weight loss during the review period (for rounds 1-6, percentage of patients screened for TB done by TST at enrollment)	13	Jan - Jun 08 **17**	Oct 13 - Mar 14 **91**
		Isoniazid Prophylactic Therapy	Percentage of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months, excluding deceased and transferred patients and those with active TB	3	Oct 12 - Mar 13 **23**	Oct 13 - Mar 14 **29**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients who have received cotrimoxazole prophylaxis during the review period	13	Jan - Jun 08 **61**	Oct 13 - Mar 14 **96**
	Malaria Prevention and Immunization	Immunization	Percentage of patients <5 years old seen during the review period who have had complete vaccinations for their age	10	Jan - Jun 08 **0**	Apr - Sept 12 **53**
	Growth and Nutrition	Nutrition Evaluation	Percentage of patients who had a nutritional evaluation during the review period (malnutrition is measured by growth rate)	13	Jan - Jun 08 **54**	Oct 13 - Mar 14 **62**
		Malnutrition Status	Percentage of patients who received a nutritional assessment during the last 6 months (excluding those out of care) who had weight gain of less than -3 standard deviations or, if 1-5 years, MUAC<12.5 cm or a ratio of AC/HC <0.25 (severe malnutrition)	3	Oct 12 - Mar 13 **12**	Oct 13 - Mar 14 **9**
	Mental Health	Mental Health Assessment	Percentage of patients who received a mental health evaluation during the pat 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation and assessment of sleep and appetite)	3	Oct 12 - Mar 13 **3**	Oct 13 - Mar 14 **4**

SUMMARY OF RESULTS FOR CHILDREN: **Kenya** and **Zimbabwe**

Country	Technical Area	Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Kenya[1]	Clinical Visits and Retention	Clinical Visits	Percentage of patients on ART with at least 2 clinical visits at least 3 months apart during the review period	2	Jan - Jun 11 **74**	Jul - Dec 11 **74**
	ARV Therapy (ART)	ART	Percentage of patients eligible for ART who received ART during the review period	2	Jan - Jun 11 **54**	Jul - Dec 11 **83**
	CD4/Viral Load Monitoring	CD4 Monitoring	Percentage of patients with a CD4 count test during the review period	2	Jan - Jun 11 **54**	Jul - Dec 11 **63**
	Tuberculosis Prevention and Treatment	TB Clinical Screening	Percentage of patients screened for TB at each clinical visit during the review period	2	Jan - Jun 11 **82**	Jul - Dec 11 **78**
	Cotrimoxazole Preventive Therapy (CPT)	CPT	Percentage of patients on cotrimoxazole during the review period	2	Jan - Jun 11 **98**	Jul - Dec 11 **97**
	Disclosure of Status	Disclosure of Status	Percentage of children aged 8-14 years whose status has been disclosed to them	2	Jan - Jun 11 **56**	Jul - Dec 11 **50**
	Nutrition	Nutrition Evaluation	Percentage of patients who had at least one nutritional assessment (MUAC, BMI or weight for height during the 6-month review period)	2	Jan - Jun 11 **18**	Jul - Dec 11 **13**
		Nutritional Counseling	Percentage of patients who received nutritional counseling during the review period	2	Jan - Jun 11 **61**	Jul - Dec 11 **67**
Zimbabwe	ARV Therapy	Pediatric ART Initiation	Percentage of newly diagnosed HIV+ children (<15 years old by end of review period) who initiated ART within one month of diagnosis	1	Jan - Jun 13 **79**	N/A
		ART Initiation in HIV+ Infants	Percentage of HIV+ children <12 months of age who have been initiated on ART	1	Jan - Jun 13 **68**	N/A
	HIV Testing	HIV-exposed Infant Management[2]	Percentage of HIV-exposed infants 12 months of age or younger who had a DBS test performed and received results within one month	1	Jan - Jun 13 **15**	N/A

Additional details including **programmatic information**, **methodology** and **key findings** for core indicators among facilities implementing performance measurement are summarized in the following table by country.

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.
[2]During the baseline round of data collection, a group of sites misinterpreted the definition of the HIV-exposed infant management (DBS test) indicator. Because of errors in data collection, the mean clinic score reported for this indicator may not reflect actual clinical performance during the first round of data collection.

Summary of Program Background, Methodology and Key Findings: Uganda, Mozambique and Namibia

Country	Background	Methodology	Key Findings
Uganda	HIVQUAL-Uganda (HQ-U) began in 2005, led by the MOH with support from the CDC. For the initial round, participating clinics were chosen by the MOH. In 2011, with the implementation of the HIV QoC program through the National Quality Improvement Framework and Strategic Plan, performance data were collected for select adult and pediatric indicators for which performance had been measured under HIVQUAL-Uganda. Additional data have been collected to measure performance on a revised set of HIV QoC indicators.	Baseline data collection reviewed care provided at 20 clinics. Under HQ-U, data collection expanded over 8 rounds to include 123 clinics. Under the national HIV QoC program, QI activities are implemented by all health facilities providing HIV care and treatment. Performance data are then sampled from health facilities throughout the country. Data are collected on sets of adult and pediatric indicators. For each round of data collection, the data manager at each health facility generated a case list from which electronic sampling was conducted to achieve a 90% confidence interval (CI) ±8%. Data abstraction and entry were conducted by clinic staff who were coached by HIV QoC Uganda staff. Data were entered into the Epi Info database and then analyzed using SPSS to generate facility-level summaries, which were compiled using MS Excel to generate facility, regional and national-level aggregate results. Data were further validated, aggregated and bench marked to identify national priorities. Staff at the MOH compiled aggregate and benchmarked reports for dissemination in-country.	For rounds 1-11 of data collection, clinic scores were averaged to calculate a mean clinic score for each indicator. This report presents performance rates for the following 15 indicators: clinical visits, appointment keeping, CD4 monitoring, ARV therapy, ART adherence assessment, cotrimoxazole preventive therapy, TB clinical screen, TB diagnostic evaluation, TB treatment, virology monitoring, malaria prevention, growth monitoring, infant referral from PMTCT, nutrition assessment and nutrition support. Improvement has been demonstrated between baseline and most recent follow-up scores in 7 of 10 adult indicators and 11 of 14 pediatric indicators, most notably for clinical visits (adult), appointment keeping (adult), ARV therapy (adult and ped), ART adherence assessment (adult and ped), TB clinical screen (adult and ped) and growth monitoring (ped). Fluctuating scores for the adult TB diagnostic evaluation indicator and low baseline performance on the virology monitoring indicator suggest areas for improvement.
Mozambique	HQ-Mozambique was launched in 2006 to promote quality of care and provide a systematic model of quality assessment and improvement. Now renamed CLINIQUAL, Mozambique's program is integrated into MOH HIV/AIDS core activities. Indicators have been updated from round to round of data collection to reflect the new guidelines issued by MISAU on care and treatment for HIV-infected individuals. CLINIQUAL, part of the broad National Quality and Humanization Strategy, is expanding gradually to cover more health facilities up-country that have recognized the need to establish the culture of quality among health providers.	The first round of data collection reviewed adult care provided at 31 clinics. Over 5 review periods, data collection has expanded to include 195 clinics. Data collection on pediatric indicators was introduced during the third round of performance measurement. Staff at health facilities abstracted adult and pediatric data using CLINIQUAL software. Data were analyzed by the facility-level ART Committee and sent to the provincial office level for generation of a provincial-level report. Staff at the provincial office sent the data to the Ministry of Health for further analysis and validation. For each round, data were aggregated by MISAU staff to produce a national report that was disseminated among all participating sites and partners. Results in the form of aggregated data are used at the Ministry of Health to identify national priorities and guide decision making.	For rounds 1-5 of data collection, clinic scores were averaged to calculate a mean clinic score for each indicator. This report presents performance rates for the following 12 indicators: clinical visits, CD4 monitoring, ARV therapy, adherence assessment, CPT, prevention education and TB clinical screen, WHO clinical staging, psychomotor development, weight, height and weight for height. Improvement between baseline and most recent follow-up scores has been demonstrated in all 7 adult indicators and 7 of 11 pediatric indicators, most notably in clinical visits (adult), CD4 monitoring (adult and ped), ART adherence assessment (adult), ARV therapy (ped), WHO Staging (ped) and TB clinical screening (adult and ped). Fluctuating scores for the pediatric indicators clinical visits, ART adherence assessment, height and weight for height suggest areas for improvement.
Namibia	HQ-Namibia implementation began in 2007 as a collaboration between the Ministry of Health and Social Services (MoHSS) and CDC-Namibia. The MoHSS has been responsible for the development of the indicators, training and related activities, and the expansion of HQ-Namibia. The CDC has provided technical assistance for program implementation support, data collection and analysis.	The first round of data collection reviewed care provided at 16 clinics. Over 10 review periods, participation in HQ data collection has expanded to include 38 clinics. Data are collected for a set of adult indicators. QI teams at ART facilities retrieved eligibility case lists from a national electronic Patient Management System. Chart sampling and data collection were performed following standard HIVQUAL methodologies. Patient charts corresponding to those listed in a randomized case list were selected for data abstraction. Once submitted to the national office, facility-level data were further validated, aggregated and analyzed to identify national priorities. The results are reported on a biannual basis in-country.	For rounds 2-10, clinic scores were averaged to calculate a mean clinic score for each indicator. This report presents performance rates for the following 11 indicators: clinical visits, CD4 monitoring, ARV therapy, ART adherence assessment, CPT, TB clinical screening, IPT-TB, prevention education, weight monitoring, food security and alcohol screening. Improvement between baseline and most recent follow-up scores has been demonstrated in 10 of 11 indicators. Performance has remained consistently high for ARV therapy, ART adherence assessment, CPT and weight monitoring. Scores have fluctuated for CD4 monitoring, IPT screening and prevention education, highlighting further opportunities for improvement.

Summary of Program Background, Methodology and Key Findings: Haiti, Guyana and Kenya

Country	Background	Methodology	Key Findings
Haiti	HIVQUAL-Haiti began in 2007 through a collaboration between the MOH, CDC and implementing partners. Technical support and guidance are provided by CDC-Haiti. The National Quality Committee developed and defined indicators, chose participating facilities and developed an organizational system to support these activities. HIVQUAL-Haiti's data collection process is fully integrated with a nationally implemented electronic medical record system.	The first round of data collection reviewed care provided at 18 clinics. Over 13 review periods, data collection has expanded to include 106 clinics. Data are collected for sets of adult and pediatric indicators. For each round of performance measurement, Haiti's EMR enabled retrospective review of data for all eligible patients, thus eliminating the need for sampling. In clinics that were fully IT-equipped with local servers, multiple PCs and internet connection, health care providers filled out patient charts directly in the EMR. In clinics that were not fully IT-equipped, health care providers filled out a paper version of the patient charts.	For rounds 1-13 of data collection, clinic scores were averaged to calculate a mean clinic score for each indicator. This report presents performance rates for the following 19 indicators: clinical visits, CD4 monitoring, ARV therapy, adherence assessment, CPT, TB clinical screen, nutrition evaluation, immunization, ART for pregnant women, family planning, CD4 at enrollment, clinical retention, adherence rate, INH prophylaxis, malnutrition status, mental health assessment, syphilis treatment, cervical cancer screening and early HIV detection. Improvement between baseline and most recent follow-up scores has been demonstrated in 15 of 17 adult indicators, most notably for CPT, ARV therapy, family planning and ART for pregnant women. Lower scores in the early rounds of data collection for cervical cancer screening suggest an area for future improvement. Performance data demonstrate improvement between baseline and most recent follow-up scores in 14 of 15 pediatric indicators, most notably for clinical visits, ARV therapy, ART adherence assessment and CPT. Performance on pediatric mental health assessment highlights an opportunity for improvement.
Guyana	HEALTHQUAL-Guyana began in 2008 with the mission of improving national healthcare, including HIV care, by building capacity for quality management. Led by the MOH through a partnership between the National AIDS Programme Secretariat and the Maternal Child Health Department, and guided by a steering committee composed of representatives from AIDS Relief, UNICEF, CDC-Guyana and FXB-Guyana, HQ-Guyana initially developed 15 indicators. HQ-Guyana's extension of their program into well child populations (HIV-negative children < 5 years old) and general medical care represents the first adaptation of the HIVQUAL framework beyond HIV care.	The first round of data collection reviewed care provided at 15 clinics. Over 4 review periods, data collection has expanded to include 17 HIV clinics and 116 MCH clinics. Data are collected for sets of HIV/AIDS and Well Child indicators. Adult case lists were generated by listing patients from the pre-ART and ART registers, and then entered into HIVQUAL software for randomization. For well children (HIV-negative), a sample was selected of pediatric patients (<5 years old) using the same methodology as the adult sampling. Trained staff at health facilities validated data, which were then submitted to the MOH, where facility-level data were aggregated and analyzed. After each round of data collection, reports were produced and disseminated to participating sites to guide the development of their quality improvement projects and to inform program planning initiatives.	For rounds 1-4 of data collection, clinic scores were averaged to calculate a mean clinic score for each indicator. This report presents performance rates for the following 9 HIV/AIDS care indicators: clinical visits, CD4 monitoring, ARV therapy, ART adherence assessment, CPT, TB clinical screen, pulse, temperature and blood pressure. Performance rates are also presented for the following 6 well child care indicators: clinical visits, weight, height, head circumference, weight for age plot and developmental milestones. Improvement has been demonstrated in 6 of 9 HIV/AIDS indicators and in all 6 Well Child indicators, most notably in ART adherence assessment, cotrimoxazole preventive therapy, temperature, pulse, blood pressure, height and head circumference. Performance has remained consistently high for the weight and weight for age Well Child indicators. Performance on the HIV/AIDS indicators clinical visits, CD4 monitoring and TB clinical screening suggests opportunities for improvement.
Kenya	In 2009, HIVQUAL-Kenya held its first meeting for senior MOH staff and key stakeholders to discuss and agree upon key quality indicators. A technical working group comprised of MOH/NASCOP development and implementing partners was formed to guide implementation of HIVQUAL-Kenya. The three regions of Kenya with the highest HIV disease burden in the country (Nyanza, Nairobi and Coast) were prioritized for piloting. The criteria for selected sites included having partner support, a high caseload of HIV patients in care and treatment and having ongoing QI activities.	The first round of data collection reviewed care provided at 15 clinics. Over 4 review periods, data collection has expanded to include 38 clinics. Data are collected for sets of adult, pediatric and PMTCT indicators. Chart sampling and data abstraction were performed following standard HIVQUAL methodologies. Case lists of eligible patients were entered into the randomizer in the HIVQUAL software. Patient charts, identified by a record number, corresponding to those listed in the randomized case list were selected for data abstraction. Adult sample sizes were sufficient to achieve a 90% CI with a 10% margin of error for the first round of data collection. For subsequent rounds, sample sizes achieved a 95% CI with an 8% margin of error.	For rounds 1-4 of data collection, clinic scores were averaged to calculate a mean clinic score for each indicator. This report presents performance rates for the following 14 indicators: clinical visits, CD4 monitoring, ARV therapy, adherence assessment, CPT, TB clinical screening, family planning, counseling on partner testing, disclosure of status, PMTCT ART prophylaxis, partner testing, ART assessment for pregnant women, nutritional counseling and nutritional assessment. As of 2011, improvement had been demonstrated in 8 of 14 indicators. Performance remained high for the adult ARV therapy and CPT indicators. Adult TB clinical screening and pediatric disclosure of status suggested areas for improvement.

Summary of Program Background, Methodology and Key Findings: Vietnam and Zimbabwe

Country	Background	Methodology	Key Findings
Vietnam	HIVQUAL-Vietnam began in 2012 through a collaboration between the Ministry of Health (MOH), Vietnam AIDS Administration (VAAC), and implementing partners. Technical support and guidance is provided by PEPFAR and CDC-Vietnam. TWG and OPC staff developed and defined indicators, chose participating facilities, and developed an organizational system to support the data collection and analysis process.	The first round of data collection reviewed adult care provided at 11 clinics. Over 4 review periods, data collection has expanded to include 68 clinics. Data are collected for sets of adult ART and pre-ART indicators. Using standardized HIVQUAL methodologies, local OPC staff generated adult (>15 years old) case lists first by listing patients from the OPC register. The total eligible population and minimum sample were then entered into HIVQUAL software and a randomized patient list was generated using the software's randomizer. Data were then abstracted from the selected patient charts and entered into HIVQUAL software. After validation, facility-level data were submitted to the MOH. Staff at the central level further validated, analyzed and aggregated data. Results were analyzed to identify national priorities in quality improvement.	For rounds 1-4, clinic scores were averaged to calculate a mean clinic score for each indicator. This report presents performance rates for the following 9 indicators: clinical visits, initial CD4 count, CD4 monitoring, 2 ART initiation indicators, ART medication pick-up, ART adherence assessment, cotrimoxazole preventive therapy and TB clinical screen. Performance rates are also presented for a late diagnosis indicator, which assesses the accessibility of early ARV treatment. Improvement has been demonstrated between baseline and most recent follow-up scores for all 10 indicators, most notably for CPT and TB clinical screen. Performance on the ART adherence assessment indicator has remained consistently high. Although the clinical visits, initial CD4 count, CD4 monitoring and ART Initiation indicators have shown improvement, relatively lower follow-up scores on these indicators suggest opportunities for further improvement in subsequent review periods.
Zimbabwe	In 2010, the Ministry of Health and Child Care (MoHCC) established a formal department for Quality Assurance/Quality Improvement to coordinate the development and implementation of quality management systems in health care nationally. The Department provides technical guidance on QA/QI, coordinates execution of related activities and provides leadership and support for the development of quality systems and activities. Quality Improvement for HIV and TB Programs was initiated in Zimbabwe in 2011 under the leadership of the MoHCC with technical support from HEALTHQUAL-International, supported through CDC-Zimbabwe. Introduction and scale-up of improvement is following a phased approach, initially focusing on a small set of core performance measures which were developed by a technical working group in coordination with HEALTHQUAL staff.	Baseline performance data represent care provided to samples of patients in the ART and PMTCT programs across 9 clinical indicators, which were chosen by the MoHCC to monitor the quality of HIV care. The baseline round of data collection reviewed ART and PMTCT care provided at 35 clinics. Chart sampling and data abstraction were performed following standard HIVQUAL methodologies. Staff at each health facility generated a case list of eligible patients from existing patient registers for each indicator. The total eligible population and minimum sample size were then entered into the randomizer in HIVQUAL software. Patient charts corresponding to those listed in the randomized case list were selected for data abstraction. Nurses extracted patient files and entered data onto manual abstraction tools. The health information officer subsequently used the abstraction tools to enter data into HIVQUAL software. After validation, facility-level data were exported to the Data Manager at the MoHCC for further validation and aggregation.	For round 1 of data collection, clinic scores were averaged to calculate a mean clinic score for each indicator. This report presents baseline performance rates for the following 9 indicators: retention, ART adherence assessment, CD4 monitoring, TB clinical screening, pediatric ART initiation, ART eligibility assessment in HIV+ pregnant women, ART initiation in HIV+ pregnant women, HIV-exposed infant management (DBS test) and ART initiation in HIV+ infants. The results from the baseline round of data collection reflect a range of challenges noted across implementing health facilities, including data quality issues that compromised the accuracy of the reported facility-level performance. Because of incomplete data in source documents from which patient-level data were abstracted, baseline performance scores may not accurately reflect clinical performance during the first round of data collection.

While achievement of program objectives may vary between countries, this report demonstrates high-level support from Ministries of Health to lead national quality activities, strengthen health systems and improve quality of care for people living with HIV and other chronic diseases. The figures reported in this document represent the mean scores of the facilities that submitted data and should not be construed as national performance means.

HEALTHQUAL Quality Management Program Framework

The HEALTHQUAL framework consists of three main elements: performance measurement (PM), quality improvement (QI) and the quality management program (QMP).

Performance Measurement

Each country has adopted data collection processes most conducive to building sustainable clinic level capacity for performance measurement and informed by the existing M&E system in place. HEALTHQUAL software facilitates immediate use of data by clinic level staff to inform improvement. Data methods are designed to produce reliable and meaningful results from representative samples of patient data from health care facilities.

Quality Improvement

Improving care is a fundamental goal of the HEALTHQUAL model. Improvement methods and strategies are adapted in each country down to the facility level. Improvement-focused education through coaching, mentoring and training provides hands-on opportunities for rapid uptake of QI skills for clinic staff to use immediately.

Quality Management

HEALTHQUAL emphasizes sustainability through the development of government level systems and processes essential to building a national quality management framework. Each country develops a team of leaders, who are trained and equipped to provide coaching and instruction to clinic teams. The collaboration between HEALTHQUAL and the MOH is designed to promote full country ownership and infuse a culture of QI to build capacity at the local, regional and national levels of care.

Introduction

HEALTHQUAL International (HQ-I) provides technical assistance to Ministries of Health to facilitate sustainable national quality management programs with the goal of improving quality of care and patient outcomes in low- and middle-income countries. This initiative requires attention to care provided at all levels – clinic, district, provincial, national – and requires access to reliable performance measurement data from health care facilities based on national guidelines and globally accepted standards of care.

To accomplish this, HEALTHQUAL provides technical assistance to build skills and expertise in performance measurement for improvement.

HEALTHQUAL began as HIVQUAL International, launched in Thailand in 2003 and modeled on the New York State and US-Ryan White HIVQUAL programs. It quickly expanded globally to PEPFAR focus countries in Africa, Asia, the Caribbean, South America and the South Pacific. The HIVQUAL framework for quality management has been successfully adapted by Ministries of Health and implemented by country teams in these regions. In 2010, HIVQUAL International transitioned to HEALTHQUAL, reflecting an expanded focus on a public health approach to quality management, including and extending beyond HIV care, to encompass other chronic and infectious diseases. HEALTHQUAL is characterized by a broader focus on population health to strengthen overall quality of care across national health systems.

HEALTHQUAL provides coaching, mentoring, training, technical assistance (TA) and tools to country programs for both monitoring and documentation of the quality of patient care and improvement. Health care workforce and patient involvement support government-led capacity for the scale-up of HIV treatment and care and advancement of overall population health. Promotion of peer learning among teams from clinics augments coaching to accelerate improvement.

Progress is now demonstrable in many of the clinics currently collecting data across the eight HEALTHQUAL implementing countries in this report, including Uganda, Mozambique, Namibia, Haiti, Guyana, Kenya, Vietnam and Zimbabwe. To date, throughout the national programs supported by HEALTHQUAL, clinics have guided over 900,000 patient chart reviews representing assessment of quality of care provided to hundreds of thousands of patients. Program expansion is now underway in Zambia and Papua New Guinea.

Global Expansion of HEALTHQUAL by Year



The HEALTHQUAL model approaches performance measurement as a system with a focus on improving in-country systems and processes for collecting clinical performance data and ensuring data integrity and quality. Through ongoing technical support and assistance, HEALTHQUAL International staff collaborate with partners in-country to develop sustainable and adaptable systems of clinical quality data management, collection, analysis, visualization and reporting. Continued refinements of performance measures and data collection processes have resulted in more meaningful and detailed data. Collaboration between HEALTHQUAL International staff and partners in-country to further clean, validate, analyze and report national-level performance data promotes improvement in data quality.

Implementing countries are beginning to adopt measures pertinent to patient care beyond HIV, addressing broader population health issues and challenges. This transition from HIVQUAL to HEALTHQUAL includes a focus on general medicine, prevention of mother-to-child transmission, pediatric HIV care, and well child care, among other relevant care domains. Measurement for improvement has evolved beyond clinical indicators to address national priorities, such as alcohol monitoring and food security in Namibia, and nutritional assessments in Haiti.

HEALTHQUAL International Performance Measurement Overview

Performance measurement is fundamental to quality improvement. Clinical performance data collection, analysis and reporting for improvement provides evidence for effective decision making and informs development of targeted strategies to improve patient care and ultimately population health.

The performance measurement process involves the systematic process of data collection to track patient outcomes and is designed to inform activities that continuously improve the quality of patient care. Country-specific data collection processes are designed to build sustainable clinic-level capacity. Indicators of care are developed based on national guidelines and region specific priorities. HEALTHQUAL software facilitates immediate use of data by clinic staff to drive improvement.

The **performance measurement process** includes:

- Data abstraction and collection
- Data management and storage from patient measurement through national reporting
- Data quality assurance
- Data analysis
- Data visualization into useful graphics to facilitate interpretation
- Reporting and interpretation
- Communication and dissemination of results



This report reflects national commitment to building performance measurement systems for improvement among Ministries of Health in Uganda, Mozambique, Namibia, Haiti, Guyana, Kenya, Vietnam and Zimbabwe. Progress has been achieved with ongoing coordination and planning with US Government teams and other implementing partners in these countries. In each case, HEALTHQUAL has facilitated the adaptation of a model responding to differences in health care systems, national guidelines and local resources, which has been designed to measure core aspects of care.

Number of HQ Clinics that have submitted data by the last review period in each year

Country	2006	2007	2008	2009	2010	2011	2012	2013	2014	Number of clinics that have submitted at least one round of data
Uganda	20	40	98	100	72	N/A	N/A	N/A		123*
Mozambique		31	46	108		150	65			195
Namibia		16	16	33	36	36	36	38		38
Haiti			24	48	51	57	64	99	104	106
Guyana			19	30		70	89			125
Kenya				15	6	28				38
Vietnam						11	11	68		68
Zimbabwe								35		35
Total	20	87	203	334	165	352	265	240	104	728

*Under HIVQUAL-Uganda, at least 123 clinics participated in data collection over the course of all 8 rounds. Since the implementation of the National Quality Improvement Framework and Strategic Plan in 2011, all health facilities providing HIV care and treatment participate in quality improvement activities but all health facilities do not submit performance data annually.

Data Collection and Sampling Methodologies

Each country selects a core package of simple and improvable measures addressing adult and pediatric HIV care and treatment. These measures increasingly include prevention of mother to child transmission (PMTCT), and well child and maternal child health (MCH) indicators. All countries have selected measures representing essential HIV care processes and outcomes including clinical visits, ART initiation for eligible patients based on national guidelines, ART adherence assessment, CD4 monitoring and cotrimoxazole preventive therapy. Each country is encouraged to select at least one unique indicator in addition to its core package. For example:

- Namibia included weight monitoring & screening for alcohol use.
- Haiti has chosen several indicators that ensure HIV-exposed and infected children are prescribed cotrimoxazole prophylaxis and eligible HIV-infected pregnant women receive ARV prophylaxis.
- Mozambique has incorporated an indicator which measures the uptake of post-exposure prophylaxis (PEP) for healthcare workers who have been exposed to HIV at work.

With the exception of HIVQUAL-Haiti, which does not conduct sampling, each country's program follows the same general procedure for chart sampling and data collection:

- A case list is developed, based on the eligibility criteria determined specifically in each country. Ineligible patients are eliminated.
- A statistical table is utilized to arrive at the sample size, with the sample sufficient to achieve a 95% confidence interval (CI) with a spread of ±8%
- Charts are randomly sampled using one of three methods: HEALTHQUAL software; random number generator (internet option); or Charts ordered alphabetically or by medical record number with every "nth" case analyzed (manual). If the chart is not found, the following chart on the list is chosen. However, clinics are encouraged to locate missing charts.
- Medical records or charts are then reviewed by the clinic team, which may include data managers, nurses or doctors depending on availability. Data entry personnel are trained in data collection methods and chart review. Abstraction forms are often used for medical review from which information is entered into the HEALTHQUAL software; both are tailored for each country.
- Data reports can be generated through the software for immediate use by clinic staff.

Initial data were collected from the first group of clinics, and implementation later expanded to additional clinics, which are chosen by the Ministry of Health in each country, encompassing a cross-section of facility types, including regional referral hospitals, district hospitals and health centers.

Sampling Methodologies by Country

Country	Target Confidence Interval	Methodology
Uganda	90% ±8%	Case lists were generated based on country-specific eligibility criteria. Using the case load, sample sizes were determined from a standardized HIVQUAL sampling table. Paper-based sites systematically sampled (every nth patient) and collected data using manual reporting forms. Electronic sites generated a random list of charts to sample using the HIVQUAL software randomizer. Data were aggregated in Microsoft Excel.
Mozambique	95% ±8%	Case lists were generated based on country-specific eligibility criteria. Using the case load, sample sizes were determined from a standardized HIVQUAL sampling table. Sites either generated a random list of charts to sample using the HIVQUAL software randomizer or systematically sampled (every nth patient). Data were aggregated using HIVQUAL software.
Namibia	95% ±8%	Namibia queried for eligible patients based on country-specific eligibility criteria from their EHR system to generate a case list. Information was transferred to an Excel spreadsheet and duplicates were removed. Using the case load, sample sizes were determined from a standardized HIVQUAL sampling table. Sites generated a random list of charts to sample using the HIVQUAL software randomizer. Data were aggregated using HIVQUAL software.
Haiti	N/A	Haiti's EMR allowed them to analyze all eligible patients.
Guyana	95% ±8%	Case lists were generated based on country-specific eligibility criteria. Using the case load, sample sizes were determined from a standardized HIVQUAL sampling table. Sites generated a random list of charts to sample using the HIVQUAL software randomizer. Data were aggregated using HIVQUAL software.
Kenya	95% ±8%	Case lists were generated based on country-specific eligibility criteria. Using the case load, sample sizes were determined from a standardized HIVQUAL sampling table. Sites generated a random list of charts to sample using the HIVQUAL software randomizer. One site systematically sampled (every nth patient). Data were aggregated using HIVQUAL software.
Vietnam	95% ±8%	Case lists were generated based on country-specific eligibility criteria. Using the case load, sample sizes were determined from a standardized HIVQUAL sampling table. Sites generated a random list of charts to sample using the HIVQUAL software randomizer. One site systematically sampled (every nth patient). Data were aggregated using HIVQUAL software.
Zimbabwe	95% ±8%	Case lists were generated based on country-specific eligibility criteria. Using the case load, sample sizes were determined from a standardized HIVQUAL sampling table. Sites generated a random list of charts to sample using the HIVQUAL software randomizer. One site systematically sampled (every nth patient). Data were aggregated using HIVQUAL software.

Summary of Adult Results by Review Period

HQ Adult Mean Clinic Scores by Country, Round of Data Collection and Indicator: UGANDA and MOZAMBIQUE

mean score (%) and the **number of submitting clinics | number of eligible patients**

Round	1		2		3		4		5		6		7		8	
Uganda	Mar - Aug 06		Apr - Sep 07		Feb - Aug 08		Jul - Dec 08		Jan - Jun 09		Jul - Dec 09		Jan - Jun 10		Jul - Dec 10	
CD4 Monitoring	**31**	20 | 1318	**37**	20 | 1695	**47**	72 | 5838	**43**	16 | 1438	**57**	51 | 4683	**45**	53 | 4393	**47**	32 | 2629	**49**	59 | 4994
Clinical Visits	**70**	20 | 1318	**86**	20 | 1695	**81**	72 | 5838	**83**	16 | 1438	**85**	51 | 4683	**82**	53 | 4393	**88**	32 | 2629	**90**	59 | 4994
Prev. Education	**23**	20 | 1318	**55**	20 | 1695	**50**	72 | 5838	**64**	16 | 1438	**63**	51 | 4683	**24**	53 | 4393	**42**	32 | 2629	**30**	59 | 4994
CPT	**88**	20 | 1318	**94**	20 | 1695	**86**	72 | 5838	**91**	16 | 1438	**91**	51 | 4683	**87**	53 | 4393	**91**	31 | 2529	**90**	59 | 4994
ARV Therapy	**76**	20 | 715	**77**	20 | 805	**71**	70 | 2424	**68**	16 | 438	**78**	50 | 1635	**74**	52 | 1251	**80**	30 | 757	**71**	56 | 1620
Adherence Assess.	**60**	20 | 709	**86**	20 | 924	**82**	71 | 2869	**75**	16 | 669	**85**	50 | 2664	**82**	51 | 2305	**91**	31 | 1569	**80**	58 | 3016
TB Clinical Scrn.	**57**	20 | 1318	**83**	20 | 1695	**66**	72 | 5838	**77**	16 | 1438	**79**	51 | 4683	**82**	53 | 4393	**86**	31 | 2529	**87**	59 | 4994
TB Diagnostic Eval.	**23**	20 | 834	**53**	20 | 444	**93**	59 | 378	**98**	15 | 93	**88**	45 | 373	**85**	44 | 307	**87**	22 | 189	**86**	48 | 204

Round	9		10		11	
Uganda (continued)	Jul - Dec 11		Jul - Dec 12		Jul - Dec 13	
CD4 Monitoring		-	**39**	94 | 5674	**43**	136 | 9523
Clinical Visits		-	**92**	94 | 5325	**92**	136 | 9430
App. Keeping	**16**	129 | 8402	**87**	94 | 5324	**87**	136 | 9430
ARV Therapy	**87**	128 | 6556	**92**	93 | 3704	**96**	135 | 5915
Adherence Assess.	**85**	128 | 8349	**87**	93 | 4093	**86**	136 | 6859
TB Clinical Scrn.	**91**	129 | 12661	**90**	94 | 5674	**94**	136 | 9523
TB Diagnostic Eval.		-	**52**	47 | 116	**47**	75 | 213
TB Treatment		-		-	**93**	59 | 123
Virology Monitoring		-		-	**1**	135 | 5805

Round	1		2		3		4		5	
Mozambique[1]	Jan - Jun 07		Jul 07 - Jun 08		Jul 08 - Jun 09		Jul 10 - Jun 11		Jul - Dec 12	
Clin. Visits (ART)	**83**	31 | 3215								
Clin. Visits (pre-ART)	**74**	29 | 3284								
Clinical Visits		-	**49**	46 | 4090	**55**	108 | 7936	**69**	136 | 11530	**92**	62 | 7213
CD4 Mon. (ART)	**70**	31 | 3215								
CD4 Mon. (pre-ART)	**65**	29 | 2390								
CD4 Monitoring		-	**40**	46 | 4656	**35**	108 | 8933	**37**	136 | 13318	**89**	62 | 7213
ART Therapy	**80**	31 | 2270	**81**	46 | 1401	**73**	108 | 3348	**67**	136 | 4624	**85**	62 | 2041
Adherence Assess.	**66**	31 | 3215	**73**	46 | 3314	**82**	106 | 4606	**92**	108 | 7208	**84**	62 | 5308
CPT(ART)	**36**	31 | 2897								
CPT (pre-ART)	**21**	29 | 1244								
CPT		-	**65**	39 | 1436	**65**	102 | 2220	**73**	135 | 7157	**79**	62 | 5093
Prev Educ (ART)	**49**	31 | 3215								
Prev Educ (pre-ART)	**40**	29 | 2390								
Prev Educ		-	**66**	40 | 2626	**58**	104 | 5243	**80**	135 | 9385	**84**	62 | 7213
TB Clin. Scrn (ART)	**18**	31 | 3002								
TB Scrn (pre-ART)	**14**	29 | 2310								
TB Clinical Scrn.		-	**25**	46 | 4848	**35**	108 | 8657	**60**	135 | 12058	**89**	62 | 6951

1. Mozambique data collection in round one was stratified by ART status. Subsequent rounds were not stratified by ART status. Clinical visits and CD4 monitoring indicator were changed after round 1.

HQ Adult Mean Clinic Scores by Country, Round of Data Collection and Indicator: NAMIBIA and HAITI

mean score (%) and the **number of submitting clinics | number of eligible patients**

Round	1			2			3			4			5			6			7			8		
Namibia[1]	Jul - Dec 07			Jan - Jun 08			Jul - Dec 08			Jan - Jun 09			Jul - Dec 09			Jan - Jun 10			Oct 10 - Mar 11			Oct 11 - Mar 12		
Clinical Visits (ART)	-			**79**	16	1631	**85**	16	1522	**88**	31	2790	**82**	33	3087	**87**	36	3680	**87**	36	3704	**86**	36	4297
CD4 Monitoring (ART)	-			**74**	16	1631	**65**	16	1522	**73**	31	2790	**70**	33	3087	**67**	36	3680	**62**	36	3704	**63**	36	4297
ARV Therapy	-			**83**	16	826	**79**	16	791	**78**	31	1111	**78**	33	1099	**82**	36	1213	**86**	36	926	**89**	36	936
Adherence Assessment	-			**90**	16	1631	**97**	16	1522	**88**	31	2790	**94**	33	3087	**98**	36	3680	**97**	36	3704	**97**	36	4297
CPT	-			**86**	16	1145	**90**	16	1040	**88**	31	1640	**86**	33	1560	**93**	36	1879	**92**	36	1486	**92**	36	1397
TB Clinical Screen	-			**81**	16	1684	**84**	16	1321	**82**	30	2193	**84**	33	2549	**87**	35	2426	**90**	35	1912	**95**	35	1650
IPT-TB	-			**16**	16	1977	**22**	16	1646	**25**	30	2789	**21**	32	3156	**30**	35	3204	**28**	35	2533	**35**	35	2230
Prevention Education	-			**37**	16	2296	**39**	16	2259	**46**	31	4043	**44**	33	4330	**49**	36	5079	**41**	36	4664	**45**	36	4989
Weight Monitoring	-			**84**	16	2296	**93**	16	2259	**94**	30	4006	**91**	33	4330	**94**	36	5079	**97**	36	4664	**96**	36	4989
Food Security	-			**24**	16	2296	**34**	16	2259	**24**	31	4043	**27**	33	4330	**38**	36	5079	**46**	36	4664	**47**	36	4989
Alcohol Screen	-			**24**	16	2296	**35**	16	2259	**29**	31	4043	**33**	33	4330	**41**	36	5079	**49**	36	4664	**49**	36	4989

Round	9			10		
Namibia[1] **(continued)**	Apr - Sept 12			Oct 12 - Mar 13		
Clinical Visits (ART)	**82**	35	4042	**85**	37	4476
CD4 Monitoring (ART)	**61**	35	4042	**66**	37	4476
ARV Therapy	**90**	35	752	**92**	37	724
Adherence Assessment	**98**	35	4042	**98**	37	4476
CPT	**95**	35	1181	**92**	37	1170
TB Clinical Screen	**94**	34	1483	**92**	36	1667
IPT-TB	**32**	34	1992	**25**	36	2086
Prevention Education	**46**	35	4679	**41**	37	5125
Weight Monitoring	**97**	35	4679	**96**	37	5125
Food Security	**46**	35	4679	**47**	37	5125
Alcohol Screen	**47**	35	4679	**47**	37	5125

Round	1			2			3			4			5			6			7			8		
Haiti[2]	Jan - Jun 08			Jul - Dec 08			Jan - Jun 09			Jul - Dec 09			Jan - Jun 10			Jul - Dec 10			Jan - Jun 11			Jul - Dec 11		
Clinical Visits (ART)	**76**	11	3111	**78**	15	5008	**78**	14	6287	**77**	27	10267	**72**	27	11733	**71**	31	13237	**73**	40	19955	**68**	55	22343
CD4 Monitoring	**31**	16	2752	**32**	22	3706	**39**	22	3354	**32**	36	4892	**30**	38	4220	**21**	40	3455	**25**	49	4459	**27**	57	5078
ARV Therapy	**45**	11	2520	**43**	15	3110	**43**	14	3326	**44**	27	4105	**37**	27	3805	**40**	31	4330	**42**	40	6010	**43**	57	7106
CPT	**62**	18	10316	**72**	24	13782	**76**	24	16038	**70**	48	23654	**72**	48	23301	**74**	51	25104	**79**	49	26534	**82**	57	30817
Adherence Assessment	**29**	11	2134	**53**	15	3535	**77**	14	4129	**80**	27	7709	**78**	27	7844	**82**	30	8799	**81**	40	12401	**70**	51	15286
TB Clinical Screening[2]	**29**	16	2990	**32**	22	3510	**33**	22	3981	**30**	38	4156	**25**	37	3283	**29**	40	3509	**77**	49	4454	**84**	57	4569
Nutrition Evaluation	**77**	16	8912	**80**	22	12159	**85**	22	14173	**73**	38	19684	**74**	38	19261	**76**	40	21207	**76**	49	27808	**76**	57	31916
Family Planning	**6**	16	5238	**6**	22	7104	**5**	22	8298	**8**	38	11375	**11**	38	10998	**19**	40	11960	**32**	49	15593	**40**	57	18037
ART for Pregnant Women[3]	**32**	16	289	**41**	23	446	**47**	22	404	**45**	45	648	**40**	41	428	**46**	45	474	**55**	44	844	**72**	52	786

Round	9			10			11			12			13		
Haiti[2] **(continued)**	Oct 11 - Mar 12			Apr - Sept 12			Oct 12 - Mar 13			Apr - Sept 13			Oct 13 - Mar 14		
Clinical Visits (ART)	**71**	58	23814	**84**	58	38313	**84**	71	42257	**84**	91	51500	**80**	95	58264
CD4 Monitoring	**30**	57	5106	**30**	63	5177	**18**	71	35200	**40**	90	39224	**46**	94	41757
ARV Therapy	**48**	57	6945	**58**	57	8157	**57**	73	9797	**71**	91	11094	**71**	95	9723
CPT	**85**	57	31818	**88**	64	46595	**90**	73	47834	**91**	92	55759	**94**	95	58762
Adherence Assessment	**76**	55	15966	**83**	57	27001	**77**	59	22103	**75**	90	40207	**79**	94	44181
TB Clinical Screening[3]	**86**	57	4447	**92**	64	6147	**90**	73	5064	**95**	88	6004	**93**	93	5453
Nutrition Evaluation	**79**	57	33553	**80**	64	46595	**83**	73	47834	**86**	92	58536	**86**	94	56422
Family Planning	**42**	57	18656	**41**	63	20616	**45**	73	26158	**47**	92	31202	**51**	94	30730
ART for Pregnant Women[4]	**81**	46	617	**86**	58	912	**83**	66	689	**89**	82	1468	**91**	84	867

HQ Adult Mean Clinic Scores by Country, Round of Data Collection and Indicator: HAITI, GUYANA and KENYA

mean score (%) and the **number of submitting clinics | number of eligible patients**

Round	11		12		13			
Haiti (continued)	Oct 12 - Mar 13		Apr - Sept 13		Oct 13 - Mar 14			
Retention	**57**	73 | 39404	**60**	91 | 33537	**58**	95 | 35465		
Adherence Rate	**67**	55 | 20365	**69**	72 | 30853	**72**	78 | 31090		
CD4 Test at Enrollment[5]	**62**	73 | 7088	**64**	90 | 9419	**66**	94 | 8462		
INH Prophylaxis	**42**	73 | 46602	**45**	90 | 23689	**52**	95 | 25693		
Malnutrition Status	**2**	71 | 34390	**1**	91 | 40979	**2**	92 | 41676		
Syphilis Treatment	**10**	19 | 78	**21**	29 | 81	**41**	32 | 111		
Cervical Cancer Scrn.	**8**	62 | 19209	**8**	80 | 21815	**6**	81 | 21804		
Mental Health Assess.	**45**	62 | 33411	**45**	80 | 38151	**53**	81 | 38128		
Round	1		2		3		4	
Guyana[6]	Jan - Jun 08		Jul - Dec 09		Jan - Jun 11		Jan - Jun 12	
Clinical Visits (HIV)	**85**	15 | 1076	**81**	15 | 1078	**83**	15 | 1447	**79**	15 | 1260
CD4 Monitoring	**83**	15 | 1013	**73**	14 | 1036	**76**	15 | 1249	**66**	15 | 1161
ARV Therapy	**71**	15 | 471	**74**	14 | 427	**76**	15 | 424	**84**	15 | 395
Adherence Assessment	**56**	15 | 360	**77**	14 | 327	**80**	15 | 314	**82**	15 | 321
TB Clinical Scrn (TST)	**89**	15 | 853	**100**	13 | 847	**91**	14 | 992	**85**	14 | 874
CPT	**78**	14 | 257	**69**	15 | 209	**78**	15 | 308	**84**	14 | 267
Temperature	**39**	15 | 1013	**69**	14 | 1036	**86**	15 | 1249	**86**	15 | 1161
Pulse	**48**	15 | 1013	**74**	14 | 1036	**89**	15 | 1249	**90**	15 | 1161
Blood Pressure	**69**	15 | 866	**79**	14 | 884	**91**	15 | 1074	**89**	15 | 1027
Vaccinations[3]		-		-		-		-
Weight[3]	**95**	3 | 350	**94**	21 | 1541	**98**	61 | 4601	**97**	78 | 4435
Height[3]	**48**	3 | 350	**63**	21 | 1541	**87**	61 | 4601	**93**	78 | 4435
Head Circumference[7]	**6**	3 | 214	**42**	21 | 1157	**69**	60 | 2613	**83**	78 | 2639
Weight for age plot[7]	**89**	3 | 350	**89**	21 | 1541	**91**	61 | 4601	**94**	78 | 4435
Dev. Milestones[7]	**69**	3 | 350	**71**	21 | 1541	**81**	61 | 4601	**87**	78 | 4435
Round	1		2		3		4	
Kenya	Jul - Dec 09		Jul - Dec 10		Jan - Jun 11		Jul - Dec 11	
Clinical Visits (ART)	**67**	15 | 1411	**84**	6 | 488	**66**	26 | 2314	**73**	28 | 2877
CD4 Monitoring	**63**	15 | 1880	**81**	6 | 678	**63**	26 | 3104	**66**	28 | 3664
ARV Therapy	**86**	15 | 553	**93**	6 | 224	**89**	26 | 1329	**90**	28 | 1444
Adherence Assessment	**96**	15 | 1384	**95**	6| 490	**94**	26 | 2323	**89**	28 | 2912
CPT	**97**	15 | 1847	**99**	6 | 678	**98**	26 | 3104	**98**	28 | 3687
TB Clinical Screen	**93**	15 | 1692	**98**	6 | 646	**89**	26 | 2859	**81**	28 | 3453
Partner Testing	**36**	14 | 1730	**79**	6 | 678	**50**	26 | 3104	**48**	28 | 3633
Family Planning		-	**30**	6 | 564	**32**	26 | 2041	**36**	28 | 2467
PMTCT ART Prophylaxis		-		-		-	**90**	13 | 249
PMTCT Partner Testing		-		-		-	**76**	13 | 286
PMTCT Adh. Assess.		-		-		-	**73**	13 | 249

1. Namibia Round 1 (July - December 2007) was intentionally omitted because technical difficulties with data capture comprised the accuracy of several indicators.
2. In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.
3. Indicator was changed in round 7 to include eligible patients who were screened for TB symptoms of cough, fever and weight loss in the numerator in addition to those who received a TST.
4. In 2011, eligibility for ART prophylaxis for pregnant patients was changed from gestational age > 28 weeks to >14 weeks or 98 days from the date of last menstrual period.
5.As of the Oct 12 - Mar 13 review period, the CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring, measured by the percentage of all patients enrolled prior to the 6-month review period who received 2 CD4 tests in the last 12 months and (2) CD4 Test at Enrollment, measured by the percentage of patients newly enrolled during the 6-month review period who received a CD4 test within 60 days of enrollment.
6. Data includes adult and pediatric patients. In round 1, Guyana collected well child and HIV indicators together. In round 2, Guyana collected well child and HIV indicators separately.
7. Guyana well child (<5 years old) indicators. Vaccination data will be included in future versions of this report, pending further validation.

HQ Adult Mean Clinic Scores by Country, Round of Data Collection and Indicator: VIETNAM and ZIMBABWE

mean score (%) and the **number of submitting clinics | number of eligible patients**

Round	1		2		3		4	
Vietnam	Jul - Dec 11		Apr - Sept 12		Oct 12 - Mar 13		Apr - Sept 13	
Clinical Visits (pre-ART)	**55**	11 | 397	**54**	11 | 400	**68**	65 | 2222	**75**	66 | 2270
Initial CD4 Count	**65**	11 | 215	**85**	11 | 301	**80**	68 | 1884	**79**	67 | 2083
CD4 Monitoring	**74**	11 | 1371	**79**	11 | 1379	**70**	68 | 9162	**75**	68 | 8883
Pre-ART Initiation	**14**	11 | 333	**8**	11 | 409	**10**	68 | 3500	**9**	68 | 3193
ART Medication Pick-up	**68**	11 | 1205	**86**	11 | 1311	**84**	68 | 8307	**89**	68 | 9006
ART Initiation	**58**	11 | 259	**71**	11 | 377	**59**	68 | 2049	**72**	67 | 2013
ART Adherence Assess.	**97**	11 | 1219	**97**	11 | 1333	**86**	68 | 7916	**96**	68 | 8518
CPT	**40**	11 | 1008	**58**	11 | 940	**72**	68 | 4680	**84**	68 | 4551
TB Clinical Screen	**51**	11 | 1470	**88**	11 | 1575	**84**	68 | 9415	**95**	68 | 10230

Round	1	
Zimbabwe	Jan - Jun 13	
Retention	**71**	31 | 2533
ART Adherence Assess.	**55**	35 | 4799
CD4 Monitoring	**17**	35 | 4799
TB Clinical Screening	**53**	35 | 4796
ART Elig. Assess. (PMTCT)[1]	**60**	30 | 878
ART in HIV+ preg. women	**41**	30 | 589

[1]The ART Eligibility Assessment in HIV+ pregnant women indicator was chosen prior to the adoption of Option B+

Summary of Pediatric Results by Review Period

HQ Pediatric Mean Clinic Scores by Country, Round of Data Collection and Indicator: UGANDA and HAITI

mean score (%) and the **number of submitting clinics | number of eligible patients**

Round	2			3			4			5			6			7			8			9		
Uganda	Apr - Sep 07			Feb - Aug 08			Jul - Dec 08			Jan - Jun 09			Jul - Dec 09			Jan - Jun 10			Jul - Dec 10			Jul - Dec 11		
Clinical Visits	**83**	17	509	**84**	8	523	**82**	20	993	**93**	20	1038	**91**	27	1357	**91**	12	595	**93**	27	1548	**88**	117	8230
CD4 Monitoring	**15**	17	509	**67**	8	523	**43**	20	993	**57**	20	1038	**42**	27	1357	**37**	12	595	**42**	27	1548	**46**	117	8231
Growth Monitoring	**56**	17	509	**26**	8	523	**47**	20	993	**68**	20	753	**70**	26	692	**73**	12	278	**64**	27	671	**75**	111	2352
CPT	**84**	17	509	**95**	8	523	**76**	20	993	**94**	20	1038	**85**	27	1357	**83**	12	595	**91**	27	1548	**89**	117	8231
Malaria Prevention (ITM)	**11**	17	509	**61**	8	523	**19**	20	992	**38**	20	1038	**28**	27	1357	**36**	12	595	**30**	27	1548	-		
TB Clinical Screen	**57**	16	440	**73**	8	492	**61**	20	830	**77**	20	1026	**85**	27	1354	**65**	12	602	**82**	27	1541	**85**	117	8231
TB Diag. Eval.	**8**	5	34	**67**	3	4	**63**	16	150	**80**	9	36	**54**	24	151	**63**	8	77	**76**	18	51	**55**	52	8276
Infant Ref. from PMTCT	**6**	17	509	**19**	8	523	**17**	20	993	**17**	20	1038	**10**	27	1357	**14**	12	595	**12**	27	1509	-		
ARV Therapy	**26**	17	382	**61**	7	127	**81**	19	251	**77**	15	186	**63**	25	291	**92**	10	121	**81**	24	315	**85**	115	5193
Adherence Assessment	**43**	10	137	**69**	8	207	**72**	19	351	**88**	20	544	**88**	26	650	**89**	12	360	**86**	27	895	**81**	115	5617

Round	10			11		
Uganda (continued)	Jul - Dec 12			Jul - Dec 13		
Clinical Visits	**85**	66	609	**92**	130	4069
App. Keeping	-			**68**	130	4069
CD4 Monitoring	**36**	65	599	**35**	130	4069
Growth Monitoring	**87**	66	609	-		
CPT	**96**	66	609	**92**	130	4069
TB Clinical Screen	**86**	66	609	**90**	130	4069
TB Diag. Eval.	**36**	27	53	**59**	42	65
TB Treatment	-			**73**	11	11
ARV Therapy	**96**	60	270	**73**	130	4069
Adherence Assess.	**41**	62	273	**75**	124	2856
Nutrition Assess.	**26**	65	603	**28**	130	4069
Nutrition Support	-			**65**	30	88

Round	1			2			3			4			5			6			7			8		
Haiti[1,2]	Jan - Jun 08			Jul - Dec 08			Jan - Jun 09			Jul - Dec 09			Jan - Jun 10			Jul - Dec 10			Jan - Jun 11			Jul - Dec 11		
Clinical Visits (ART)	**69**	9	133	**79**	15	269	**86**	14	346	**75**	24	769	**64**	25	903	**71**	27	955	**77**	37	1200	**69**	42	1294
CD4 Monitoring	**35**	15	259	**17**	21	292	**19**	20	319	**21**	33	594	**14**	35	674	**12**	35	482	**13**	40	550	**10**	41	589
ARV Therapy	**44**	11	244	**41**	15	245	**35**	13	258	**35**	25	420	**32**	26	328	**45**	28	358	**45**	34	386	**43**	43	442
CPT	**61**	11	350	**76**	19	468	**78**	21	591	**70**	39	1204	**64**	39	1186	**74**	40	1331	**78**	38	1416	**92**	30	1442
Adherence Assessment	**30**	8	93	**49**	15	173	**63**	14	200	**75**	24	547	**63**	24	619	**79**	24	570	**72**	36	739	**73**	36	832
TB Clinical Screen[2]	**17**	15	266	**18**	20	324	**20**	20	437	**8**	35	713	**11**	35	527	**17**	34	567	**81**	40	608	**87**	42	867
Nutrition Evaluation	**54**	16	691	**50**	22	898	**56**	22	1161	**43**	38	2269	**41**	37	2092	**41**	37	2279	**41**	48	2663	**34**	55	3544
Immunization	**0**	16	327	**2**	22	423	**3**	22	592	**53**	33	1235	**47**	32	1128	**46**	32	1242	**49**	31	1282	**48**	33	1633

Round	9			10			11			12			13		
Haiti[1,2] (continued)	Oct 11 - Mar 12			Apr - Sept 12			Oct 12 - Mar 13			Apr - Sept 13			Oct 13 - Mar 14		
Clinical Visits (ART)	**75**	42	1415	**87**	52	2147	**88**	61	2278	**89**	75	2421	**88**	82	2474
CD4 Monitoring	**16**	40	650	**20**	46	379	**14**	49	1330	**44**	61	1476	**49**	74	1526
ARV Therapy	**49**	42	411	**48**	47	567	**56**	56	380	**70**	69	451	**73**	68	366
CPT	**84**	39	1598	**83**	53	3420	**90**	51	2537	**91**	63	2639	**96**	67	2420
Adherence Assessment	**77**	39	949	**83**	48	1684	**83**	45	1296	**78**	69	2067	**76**	78	2138
TB Clinical Screen[3]	**86**	42	813	**90**	55	1068	**91**	59	378	**93**	69	464	**91**	66	415
Nutrition Evaluation	**33**	55	3293	**41**	60	4857	**61**	67	3646	**56**	79	3905	**62**	83	3637
Immunization[4]	**48**	33	1594	**53**	43	1895	-			-			-		

1. In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.
2. With the exception of Nutrition Evaluation, Haiti pediatric data from Groups 4 and 5 are not included in the aggregate calculations until the 10th roud of data collection, Apr - Sept 12, due to small numbers of eligible patients in previous rounds.
3. Indicator was changed in round 7 to include eligible patients who were screened for TB symptoms of cough, fever and weight loss in the numerator in addition to those who received a tuberculin skin test (TST).
4. Immunization data captured during Oct 12 - Mar 13 and Apr - Sept 13 review periods are omitted, pending further validation.

HQ Pediatric Mean Clinic Scores by Country, Round of Data Collection and Indicator: HAITI, MOZAMBIQUE, KENYA and ZIMBABWE

mean score (%) and the **number of submitting clinics | number of eligible patients**

Round	11			12			13		
Haiti (continued)	Oct 12 - Mar 13			Apr - Sept 13			Oct 13 - Mar 14		
Retention	**55**	67	2371	**59**	77	2054	**56**	82	1497
Adherence Rate	**63**	43	1073	**61**	53	1522	**73**	60	1616
CD4 Test at Enrollment[1]	**20**	21	96	**24**	23	127	**41**	19	122
INH Prophylaxis	**23**	59	1453	**18**	42	898	**29**	47	929
Malnutrition Status	**12**	62	1787	**10**	67	1964	**9**	75	1936
Early HIV Detection	**22**	43	978	**57**	50	1209	**63**	54	991
Mental Health Assess.	**3**	56	2716	**1**	67	3088	**4**	70	2815
Round	1			2			3		
Mozambique	Jul 08 - Jun 09			Jul 10 - Jun 11			Jul - Dec 12		
Clinical Visits	**7**	68	1228	**15**	114	3607	**5**	50	1717
CD4 Monitoring	**36**	64	906	**39**	114	3065	**46**	51	2216
ARV Therapy	**59**	61	696	**58**	111	1961	**81**	50	1035
Adherence Assessment	**81**	60	725	**57**	37	486	**72**	50	1658
CPT	**69**	51	407	**72**	109	1802	**73**	50	1658
WHO Status	**69**	68	1230	**88**	111	2799	**93**	51	2216
Weight	**82**	64	1047	**90**	108	2532	**86**	51	2216
Height	**56**	51	607	**74**	102	1953	**55**	51	2216
Weight for Height	**47**	39	292	**60**	92	1353	**39**	51	2216
Tuberculosis Screen	**34**	65	1142	**58**	108	2672	**84**	51	2128
Eval. Child PMD	**53**	44	205	**62**	95	1568	**60**	51	2216
Round	1			2					
Kenya	Jan - Jun 11			Jul - Dec 11					
Clinical Visits (ART)	**74**	21	1121	**74**	25	1137			
CD4 Monitoring	**54**	21	1437	**63**	25	1417			
ART Initiation	**54**	21	1452	**83**	25	1417			
CPT	**98**	21	1437	**97**	25	1417			
TB Clinical Screening	**87**	21	1295	**78**	25	1314			
Disclosure of Status	**56**	21	621	**50**	25	695			
Round	1								
Zimbabwe	Jan - Jun 13								
ART Initiation (<15 years)	**79**	17	166						
HIV-exp. Infant Management	**30**	30	979						
ART Initiation in HIV+ infants	**19**	19	91						

1. As of the Oct 12 - Mar 13 review period, the CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring, measured by the percentage of all patients enrolled prior to the 6-month review period who received 2 CD4 tests in the last 12 months and (2) CD4 Test at Enrollment, measured by the percentage of patients newly enrolled during the 6-month review period who received a CD4 test within 60 days of enrollment.

Reporting Conventions and Glossary

This living document continues to be constantly updated as the historical data are cleaned and analyzed in different ways. Raw data analyzed in this report were submitted by participating HEALTHQUAL countries and are up-to-date as of February 2015.

Clinic level indicator scores were used to calculate aggregate results: total number of clinics, total number of patients eligible, means, medians, percentiles, minimums and maximums.

Clinical Visits Indicator by Review Period and Group

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Total (all groups)	Jan - Jun 09	15	2525	57		61	37	71	13	94
	Jul - Dec 09	30	4130	56		50	28	89	11	100
	Jan - Jun 10	50	6923	54		53	31	80	10	98
Group 1	Jan - Jun 09	15	2525	57		61	37	71	13	94
	Jul - Dec 09	15	2130	49		43	23	73	11	100
	Jan - Jun 10	15	2323	54		50	34	79	10	93
Group 2	Jul - Dec 09	15	2000	63		68	41	91	23	100
	Jan - Jun 10	15	1700	49		50	20	73	10	98
Group 3	Jan - Jun 10	20	2900	68		63	36	82	11	96

Mean - the average clinic score. All means are clinic means unless otherwise noted

Median - score separating the top half from the bottom half of all clinic scores

Percentiles - score below which a certain percentage of clinic scores fall

Maximum - highest clinic score

Minimum - lowest clinic score

Number of clinics - number of clinics with a score for a particular indicator

Number of eligible patients - total number of sampled patients who are eligible for a particular indicator

Spread - displays the distribution of clinic scores. Each line represents one clinic score. The mean clinic score is highlighted in red.



Review Period - time frame during which performance rates were measured. All patient records from which data are extracted correspond to a specific review period.

Group # - Describes a collection of clinics that have been integrated into the HEALTHQUAL program at the same time. For example, Group 1 clinics refer to the clinics that participated in the first data collection for a specific country, and Group 2 clinics refer to clinics that joined the HEALTHQUAL program at a subsequent review period. Each longitudinal run chart in the report reflects the number of clinics within each group that submitted data by the end of the most recent review period.

Round # - Corresponds with a specific review period and describes the chronological order of data collection for a particular group of clinics. For example, data collected during review period 1 would be Group 1 Round 1 data. If a second group of clinics joins the program and collects data for review period 2, their data would be described as Group 2 Round 1 data. Round terminology is used as a way to monitor the progress of different Groups of clinics within each country.

HIV QoC Uganda Performance Measurement

Adult and Pediatric HIV Care

Overview

• Clinics implementing HIVQUAL-Uganda collected 8 rounds of performance data from March 2006 through December 2010. Since the rollout of the National Quality Improvement Framework and Strategic Plan in 2011, performance measurement is implemented through the HIV Quality of Care Unit in the AIDS Control Program (HIV QoC). Under HIV QoC, 3 additional rounds of performance measurement have been collected representing care provided from July 2011 through December 2013.
• Under HIVQUAL-Uganda, at least 123 clinics participated in data collection over the course of all 8 rounds. Since the implementation of the National Quality Improvement Framework and Strategic Plan in 2011, all health facilities providing HIV care and treatment participate in quality improvement activities but all health facilities do not submit performance data annually.
• This report reflects performance rates for the following 15 indicators: clinical visits, appointment keeping, CD4 monitoring, ARV therapy, ART adherence assessment, cotrimoxazole preventive therapy (CPT, pediatric only since 2011), TB clinical screen, TB diagnostic evaluation, TB treatment, virology monitoring (adult only), malaria prevention (pediatric only), growth monitoring (pediatric only), infant referral from PMTCT, nutrition assessment (pediatric only) and nutrition support (pediatric only).
• Improvement has been demonstrated between baseline and most recent follow-up scores in 7 of 10 adult indicators and 11 of 14 pediatric indicators, most notably for clinical visits (adult), appointment keeping (adult), ARV therapy (adult and pediatric), ART adherence assessment (adult and pediatric), TB clinical screen (adult and pediatric) and growth monitoring (pediatric). Fluctuating scores for the adult TB diagnostic evaluation indicator and low baseline performance on the virology monitoring indicator suggest areas for improvement.

Background

HIVQUAL-Uganda (HQ-U) began in 2005, led by the Ministry of Health with support from the CDC. For the initial round, participating clinics were chosen by the MOH and encompassed a cross section of facility types, including regional referral hospitals, district hospitals and health centers. Indicators were chosen by a core team including representation from Ministry of Health (MOH) and CDC. For the second round of data collection, HQ-U expanded to include pediatric indicators.

In 2011, with the implementation of the HIV QoC program through the National Quality Improvement Framework and Strategic Plan, performance data were collected for select adult and pediatric indicators for which performance had been measured under HIVQUAL-Uganda: ARV Therapy, ART Adherence Assessment, TB Clinical Screening, clinical visits (pediatric only), CD4 Monitoring (pediatric only), cotrimoxazole preventive therapy (pediatric only) and growth monitoring (pediatric only). Additional data have been collected to measure performance on a revised set of HIV QoC indicators developed under the National Quality Improvement Framework and Strategic Plan.

Data Collection

HIVQUAL-Uganda

Baseline data collection reviewed care provided at 20 clinics from March 1, 2006 through August 31, 2006. Although data submission has been inconsistent for subsequent review periods, the total number of participating clinics has continued to expand. Over 8 review periods, participation in data collection expanded to include a total of 123 clinics under HIVQUAL-Uganda, with 100 clinics collecting at least one round of adult data and 53 clinics collecting at least one round of pediatric data.

The adjacent tables summarize the expansion of adult and pediatric data collection through the addition of new groups of clinics that collected and submitted baseline performance data under HIVQUAL-Uganda. For each group of participating clinics, the tables present the group's baseline review period and number of clinics included in the group.

Expansion of HIVQUAL-Uganda adult data collection by Group

Group #	Baseline Review Period for Group	# of Clinics in Group
1	March - August 2006	20
2	February - August 2008	60
3	January - June 2009	11
4	July - December 2009	5
5	January - June 2010	3
6	July - December 2010	1
Total # of clinics that have submitted data		**100**

Expansion of HIVQUAL-Uganda pediatric data collection by Group

Group #	Baseline Review Period for Group	# of Clinics in Group
1	April - September 2007	21
2	February - August 2008	8
3	January - June 2009	2
4	July - December 2009	17
5	January - June 2010	1
6	July - December 2010	4
Total # of clinics that have submitted data		**53**

HIV QoC

Under the national HIV QoC program, QI activities are implemented by all health facilities providing HIV care and treatment. Performance data are sampled from health facilities throughout the country. The following table summarizes the number of facilities submitting performance data in each review period under the national HIV QoC program.

Number of facilities that submitted data under HIV QoC by review period

Review Period	Total # of facilities providing HIV care and treatment	# of facilities that submitted adult data	# of facilities that submitted pediatric data
July - December 2011	475	131	117
July - December 2012	784	94	66
July - December 2013	1552	136	130

For each round of data collection, the data manager at each health facility generated a case list from which electronic sampling was conducted to achieve a 90% confidence interval (CI) ±8%. Data abstraction and entry were conducted by clinic staff who were coached by HIV QoC Uganda staff. Data were entered into the Epi Info database and then analyzed using SPSS to generate facility-level summaries, which were compiled using MS Excel to generate facility, regional and national-level aggregate results. Data were further validated, aggregated and bench marked to identify national priorities. Staff at the MOH compiled aggregate and benchmarked reports for dissemination in-country.

For rounds 1-11, clinic scores were averaged to calculate a mean clinic score for each indicator. Mean clinic scores are reported in the following graphs and tables by indicator and review period.

HIV QoC Uganda Adult and Pediatric Mean Clinic Scores by Round of Data Collection and Indicator

mean score (%) and the number of clinics | number of eligible patients

Round	1		2		3		4		5		6		7		8	
Adult Indicators	Mar - Aug 06*		Apr - Sep 07		Feb - Aug 08		Jul - Dec 08		Jan - Jun 09		Jul - Dec 09		Jan - Jun 10		Jul - Dec 10	
CD4 Monitoring	**31**	20 | 1318	**37**	20 | 1695	**47**	72 | 5838	**43**	16 | 1438	**57**	51 | 4683	**45**	53 | 4393	**47**	32 | 2629	**49**	59 | 4994
Clinical Visits	**70**	20 | 1318	**86**	20 | 1695	**81**	72 | 5838	**83**	16 | 1438	**85**	51 | 4683	**82**	53 | 4393	**88**	32 | 2629	**90**	59 | 4994
CPT	**88**	20 | 1318	**94**	20 | 1695	**86**	72 | 5838	**91**	16 | 1438	**91**	51 | 4683	**87**	53 | 4393	**91**	31 | 2529	**90**	59 | 4994
ARV Therapy	**76**	20 | 715	**77**	20 | 805	**71**	70 | 2424	**68**	16 | 438	**78**	50 | 1635	**74**	52 | 1251	**80**	30 | 757	**71**	56 | 1620
Adherence Assess.	**60**	20 | 709	**86**	20 | 924	**82**	71 | 2869	**75**	16 | 669	**85**	50 | 2664	**82**	51 | 2305	**91**	31 | 1569	**80**	58 | 3016
TB Clinical Screening	**57**	20 | 1318	**83**	20 | 1695	**66**	72 | 5838	**77**	16 | 1438	**79**	51 | 4683	**82**	53 | 4393	**86**	31 | 2529	**87**	59 | 4994
TB Diag. Eval.	**24**	19 | 834	**53**	20 | 444	**93**	59 | 378	**98**	15 | 93	**88**	45 | 373	**85**	44 | 307	**87**	22 | 189	**86**	48 | 204

Round	9		10		11	
Adult Indicators	Jul - Dec 11		Jul - Dec 12		Jul - Dec 13	
CD4 Monitoring		-	**39**	94 | 5674	**43**	136 | 9523
Clinical Visits		-	**92**	94 | 5325	**92**	136 | 9430
App. Keeping	**16**	129 | 8402	**87**	94 | 5324	**87**	136 | 9430
ARV Therapy	**87**	128 | 6556	**92**	93 | 3704	**96**	135 | 5915
Adherence Assess.	**85**	128 | 8349	**87**	93 | 4093	**86**	136 | 6859
TB Clinical Screening	**91**	129 | 12661	**90**	94 | 5674	**94**	136 | 9523
TB Diag. Eval.		-	**52**	47 | 116	**47**	75 | 213
TB Treatment		-		-	**93**	59 | 123
Virology Monitoring		-		-	**1**	135 | 5805

Round	1		2		3		4		5		6		7		8	
Pediatric Indicators	Mar - Aug 06*		Apr - Sep 07		Feb - Aug 08		Jul - Dec 08		Jan - Jun 09		Jul - Dec 09		Jan - Jun 10		Jul - Dec 10	
Clinical Visits	-		**83**	17 | 509	**84**	8 | 523	**82**	20 | 993	**93**	20 | 1038	**91**	27 | 1357	**91**	12 | 595	**93**	27 | 1548
CD4 Monitoring	-		**15**	17 | 509	**67**	8 | 523	**43**	20 | 993	**57**	20 | 1038	**42**	27 | 1357	**37**	12 | 595	**42**	27 | 1548
Growth Monitoring	-		**56**	17 | 509	**26**	8 | 523	**47**	20 | 993	**68**	20 | 753	**70**	26 | 692	**73**	12 | 278	**64**	27 | 671
CPT	-		**84**	17 | 509	**95**	8 | 523	**76**	20 | 993	**94**	20 | 1038	**85**	27 | 1357	**83**	12 | 595	**91**	27 | 1548
Malaria Prevention	-		**11**	17 | 509	**61**	8 | 523	**19**	20 | 992	**38**	20 | 1038	**28**	27 | 1357	**36**	12 | 595	**30**	27 | 1548
TB Clinical Screening	-		**57**	16 | 440	**73**	8 | 492	**61**	20 | 830	**77**	20 | 1026	**85**	27 | 1354	**65**	12 | 602	**82**	27 | 1541
TB Diag. Eval.			**8**	5 | 34	**67**	3 | 4	**63**	16 | 150	**80**	9 | 36	**54**	24 | 151	**63**	8 | 77	**76**	18 | 51
Ref. from PMTCT	-		**6**	17 | 509	**19**	8 | 523	**17**	20 | 993	**17**	20 | 1038	**10**	27 | 1357	**14**	12 | 595	**12**	27 | 1509
ARV Therapy	-		**26**	17 | 382	**61**	7 | 127	**81**	19 | 251	**77**	15 | 186	**63**	25 | 291	**92**	10 | 121	**81**	24 | 315
Adherence Assess.	-		**43**	10 | 137	**69**	8 | 207	**72**	19 | 351	**88**	20 | 544	**88**	26 | 650	**89**	12 | 360	**86**	27 | 895

Round	9		10		11	
Pediatric Indicators	Jul - Dec 11		Jul - Dec 12**		Jul - Dec 13	
Clinical Visits	**88**	117 | 8230	**85**	66 | 609	**92**	130 | 4069
App. Keeping		-		-	**68**	130 | 4069
CD4 Monitoring	**46**	117 | 8231	**36**	65 | 599	**35**	130 | 4069
Growth Monitoring	**75**	111 | 2352	**87**	66 | 609		-
CPT	**89**	117 | 8231	**96**	66 | 609	**92**	130 | 4069
TB Clinical Screening	**85**	117 | 8231	**86**	66 | 609	**90**	130 | 4069
TB Diag. Eval.	**55**	52 | 8276	**36**	27 | 53	**59**	42 | 65
TB Treatment		-		-	**73**	11 | 11
ARV Therapy	**85**	115 | 5193	**96**	60 | 270	**73**	130 | 4069
Adherence Assess.	**81**	115 | 5617	**41**	62 | 273	**75**	124 | 2856
Nutrition Assess.		-	**26**	65 | 603	**28**	130 | 4069
Nutrition Support		-		-	**65**	30 | 88

*Not enough charts were reviewed during round 1 to reach intended sample sizes for Uganda. Intended sample sizes were chosen to be sufficient for a 90% confidence interval (CI) ±8%, based on maximum uncertainty using a conservative estimate of 50%. However, all clinics achieved at least a 90% CI ±12%.

**For the July - December 2012 review period, sampling was not conducted to review pediatric care. Clinical performance on pediatric indicators was measured from a random selection of up to 10 patient charts at each participating health facility.

Uganda Adult Indicators for Rounds 1-11 of Data Collection

Eligibility (Adult): All HIV-infected adults >15 years old with at least one clinical visit during the 6-month review period.

Indicator	Numerator	Denominator
Clinical Visits	Rounds 10-11: Number of HIV-infected patients with at least one clinical visit in the last 3 months of the review period Rounds 1-8: Number of patients with at least one clinical visit (encounter with health care provider) in each 3-month quarter	Rounds 10-11: Number of HIV-infected patients with a scheduled appointment visit in the past 3 months Rounds 1-8: Number of patients with at least one clinical visit (encounter with a health care provider) during the 6-month review period
Appointment Keeping	Rounds 9-11 (adult): Number of patients who missed their scheduled appointment and did not show up within seven days after the scheduled appointment date	Rounds 9-11 (adult): Total number of patients on ART with scheduled appointments in the reporting period
CD4 Monitoring	Number of patients with a CD4 (% or count) test during the 6-month review period	Number of patients with at least 1 clinical visit during the 6-month review period
ARV Therapy	Rounds 9-11: Number of HIV+ patients who are eligible for ART, who have been started on ART within the past month Rounds 1-8: Number of patients who are eligible and receiving ART during the 6-month review period or at the time of death	Rounds 9-11: Number of HIV+ patients eligible for ART within the past month (CD4 count ever ≤ 350 or WHO clinical stage 3 or 4) Rounds 1-8: Number of patients meeting MOH criteria for ART. Adults: CD4 < 200 or WHO Stage 3 or 4.
ART Adherence Assessment	Rounds 9-11: Number of patients on ART seen at the clinic who have had an adherence assessment in the last 3 months Rounds 1-8: Number of patients who have had an adherence assessment during the 6-month review period or at time of death	Rounds 9-11: Total number of patients on ART who have been seen at least once in the past 3 months Rounds 1-8: Number of patients receiving ART during the 6-month review period or at time of death
Cotrimoxazole Preventive Therapy (CPT)	Rounds 1-8: Number of patients who have been prescribed cotrimoxazole (Trimethoprim-sulphamethoxazole) during the 6-month review period and are still receiving it at the end of the review period or at the time of death	Rounds 1-8: Number of patients with at least one clinical visit during the 6-month review period. All HIV-infected patients are eligible for cotrimoxazole prophylaxis
TB Clinical Screening	Rounds 9-11: Number of HIV+ patients (in general care or on ART) seen in the clinic within the past (month) who were assessed for active TB at every visit Rounds 1-8: Number of patients who have been assessed for clinical symptoms of TB during the 6-month review period. TB Clinical Symptom Assessment: questioning for the existence of a cough of >3 weeks duration, weight loss, hemoptysis, night sweats, and evening fevers	Rounds 9-11: Total number of HIV+ patients (in general care or on ART) seen in the clinic within the past month Rounds 1-8: Number of patients not on TB treatment who visited the clinic at least once during the 6-month review period
TB Diagnostic Evaluation	Number of patients who have been evaluated for TB during the 6-month review period using sputum smear and/or CXR or gene Xpert	Number of patients with signs and symptoms of TB during the 6-month review period
TB Treatment	Round 11: Number of patients diagnosed with TB started on treatment	Round 11: Number of patients diagnosed with TB
Virology Monitoring	Round 11: Number of patients on ART having a viral load done	Round 11: Number of patients on ART

Uganda Pediatric Indicators for Rounds 1-11 of Data Collection

Eligibility (Pediatric): All HIV-infected children <15 years old with at least one clinical visit during the 6-month review period.

Indicator	Numerator	Denominator
Clinical Visits	Rounds 9-11: Number of HIV-infected patients with at least one clinical visit in the last 3 months of the review period Rounds 1-8: Number of patients with at least one clinical visit (encounter with health care provider) in each 3-month quarter	Rounds 9-11: Number of HIV-infected patients with a scheduled appointment visit in the past 3 months Rounds 1-8: Number of patients with at least one clinical visit (encounter with a health care provider) during the 6-month review period
Appointment Keeping	Rounds 10-11: Number of HIV+ children on ART who kept the last scheduled appointment in the last 3 months of the review period	Rounds 10-11: Number of HIV+ children on ART who were scheduled for a clinic visit in the last 3 months of the review period
CD4 Monitoring	Number of patients with a CD4 (% or count) test during the 6-month review period	Number of patients with at least 1 clinical visit during the 6-month review period
ARV Therapy	Rounds 10-11: Number of HIV+ children on ART Round 9: Number of eligible HIV+ children initiated on ART Rounds 1-8: Number of patients who are eligible and receiving ART during the 6-month review period or at the time of death	Rounds 10-11: Total number of HIV-infected children with at least 1 visit during the past 6 months (all HIV+ children are eligible for ART) Round 9: Total number of HIV-infected children who are eligible for ART receiving care in the review period. (All children < 2 years irrespective of CD4 count or WHO clinical stage; 2-5 years: CD4 < 25% or CD4 count < 750 cells/mL; 5 years and older: CD4 count < 350; all children with WHO clinical stage 3 and 4) Rounds 1-8: Number of patients meeting MOH criteria for ART. [Children 0-18 months: HIV-exposed infants with PCR positive and WHO staging 3 or 4 or CD4 ≤20%. Children >18 months: WHO staging 3 or 4 or CD4 ≤ 15% or TLC≤1800 (<5 years) or TLC ≤1200 (5-12 years)]
ART Adherence Assessment	Rounds 9-11: Number of patients on ART seen at the clinic who have had an adherence assessment in the last 3 months Rounds 1-8: Number of patients who have had an adherence assessment during the 6-month review period or at time of death	Rounds 9-11: Total number of patients on ART who have been seen at least once in the past 3 months Rounds 1-8: Number of patients receiving ART during the 6-month review period or at time of death
Cotrimoxazole Preventive Therapy (CPT)	Rounds 10-11 (pediatric only): Number of HIV-infected children receiving cotrimoxazole during the last visit of the review period Round 9: Number of HIV-infected children receiving cotrimoxazole during the last 3 months Rounds 1-8: Number of patients who have been prescribed cotrimoxazole (Trimethoprim-sulphamethoxazole) during the 6-month review period and are still receiving it at the end of the review period or at the time of death	Rounds 10-11: Number of HIV-infected children who visited the facility during the review period Round 9: Number of HIV-infected children with at least 1 visit during the past 3 months Rounds 1-8: Number of patients with at least one clinical visit during the 6-month review period. All HIV-infected patients are eligible for cotrimoxazole prophylaxis
TB Clinical Screening	Rounds 9-11: Number of HIV-infected children who have been screened for TB during the last 3 months Rounds 1-8: Number of patients who have been assessed for clinical symptoms of TB during the 6-month review period. TB Clinical Symptom Assessment: questioning for the existence of a cough of >3 weeks duration, weight loss, hemoptysis, night sweats, and evening fevers	Rounds 9-11: Number of HIV-infected children with at least 1 visit in the past 3 months who have not been diagnosed with active TB (for Rounds 10-11: Number of HIV-infected children with at least 1 visit in the past 6 months) Rounds 1-8: Number of patients not on TB treatment who visited the clinic at least once during the 6-month review period
TB Diagnostic Evaluation	Number of patients who have been evaluated for TB during the 6-month review period using sputum smear and/or CXR or gene Xpert	Number of patients with signs and symptoms of TB during the 6-month review period (for Rounds 10-11: or have history of TB contact during the last 6 months of the review period)
TB Treatment	Round 11: Number of children receiving TB treatment or referred for TB treatment during the last 3 months of the review period	Round 11: Number of children diagnosed with TB during the last 3 months of the review period
Growth Monitoring	Rounds 2-10: Number of children receiving weight for age assessment at least once during the last 3 months of the 6-month review period	Rounds 2-10: Number of children with at least one clinical visit during the 6-month review period
Malaria Prevention	Rounds 2-8: Number of children using ITM during the last 3 months of the 6-month review period	Rounds 2-8: Number of children with at least one clinical visit during the 6-month review period
Referral from PMTCT	Rounds 2-8: Number of newly HIV-infected or HIV-exposed children who were referred from PMTCT	Rounds 2-8: Number of newly HIV-infected or HIV-exposed children aged 0-14 years old with at least 1 clinical visit during the 6-month review period
Nutrition Assessment	Rounds 10-11: Number of HIV-infected children with MUAC measurement done during the last 3 months of the review period	Rounds 10-11: Number of HIV positive children who visited the clinic in the last 3 months of the review period
Nutrition Support	Round 11: Number of HIV-infected children assessed in the last 3 months of the review period, who had malnutrition and received therapeutic or supplementary feeding support	Round 11: Number of HIV-infected children assessed in the last 3 months of the review period who had malnutrition

Uganda Clinical Visits and Appointment Keeping

Clinical Visits: Percentage of adult patients with at least one clinical visit in the last 3 months of the review period

Appointment Keeping: Percentage of adult patients who missed their scheduled appointment and did not show up within seven days after the scheduled appointment date

Total (all clinics) Uganda Adult Clinical Visits and Appointment Keeping Scores (%) by Review Period



Total (all clinics) Uganda Adult Clinical Visits Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Mar - Aug 06	20	1318	70		74	63	86	0	98
Apr - Sep 07	20	1695	86		90	80	96	47	100
Feb - Aug 08	72	5838	81		87	72	94	0	100
Jul - Dec 08	16	1438	83		88	77	97	33	100
Jan - Jun 09	51	4710	85		89	78	98	11	100
Jul - Dec 09	53	4393	82		91	75	97	0	100
Jan - Jun 10	32	2629	88		92	84	97	35	100
Jul - Dec 10	59	4994	90		94	88	98	41	100
Jul - Dec 11	-	-	-		-	-	-	-	-
Jul - Dec 12	94	5325	92		96	90	98	25	100
Jul - Dec 13	136	9430	92		95	87	98	55	100

Total (all clinics) Uganda Adult Appointment Keeping Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jul - Dec 11	129	8402	16		12	7	20	0	100
Jul - Dec 12	94	5324	87		92	83	97	0	100
Jul - Dec 13	136	9430	87		91	83	97	19	100

Uganda CD4 Monitoring

Percentage of adult patients with at least one CD4 count during the 6-month review period

Total (all clinics) Uganda Adult CD4 Monitoring Scores (%) by Review Period



Total (all clinics) Uganda Adult CD4 Monitoring Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Mar - Aug 06	20	1318	31		29	6	54	0	79
Apr - Sep 07	20	1695	37		42	19	53	0	81
Feb - Aug 08	72	5838	47		48	32	65	0	94
Jul - Dec 08	16	1438	43		42	25	64	10	81
Jan - Jun 09	51	4683	57		60	39	73	13	97
Jul - Dec 09	53	4393	45		43	25	64	0	95
Jan - Jun 10	32	2629	47		46	28	67	3	95
Jul - Dec 10	59	4994	49		50	24	71	9	100
Jul - Dec 11	-	-	-		-	-	-	-	-
Jul - Dec 12	94	5674	39		37	17	59	7	90
Jul - Dec 13	136	9523	43		40	24	59	0	91

Uganda Virology Monitoring

Percentage of adult patients on ART who had a viral load measured during the review period (baseline score)

Total (all clinics) Uganda Adult Virology Monitoring Baseline Score (%)

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jul - Dec 13	135	5805	1		0	0	0	0	14

Uganda ARV Therapy

•Rounds 1-8: Percentage of patients who were eligible and started on ART during the 6-month review period
•Rounds 9-11: Percentage of patients who were eligible and started on ART within the past month

Total (all clinics) Uganda Adult ARV Therapy Scores (%) by Review Period



Total (all clinics) Uganda Adult ARV Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Mar - Aug 06	20	715	76		79	63	100	0	100
Apr - Sep 07	20	805	77		81	64	100	18	100
Feb - Aug 08	70	2424	71		76	53	92	14	100
Jul - Dec 08	16	438	68		70	51	87	33	100
Jan - Jun 09	50	1635	77		82	61	94	38	100
Jul - Dec 09	52	1251	74		75	61	94	19	100
Jan - Jun 10	30	757	80		89	70	100	4	100
Jul - Dec 10	56	1620	71		75	61	95	0	100
Jul - Dec 11	128	6556	87		92	82	100	0	100
Jul - Dec 12	93	3704	92		96	92	97	8	100
Jul - Dec 13	135	5915	96		100	97	100	25	100

Uganda Adherence Assessment

•Rounds 1-8: Percentage of adult patients on ART during the 6-month review period who had at least one adherence assessment during the 6-month review period
•Rounds 9-11: Percentage of adult patients on ART who have had an adherence assessment in the last 3 months

Total (all clinics) Uganda Adult Adherence Assessment Scores (%) by Review Period



Total (all clinics) Uganda Adult Adherence Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Mar - Aug 06	19	709	63		71	51	82	3	100
Apr - Sep 07	19	924	90		95	87	97	50	100
Feb - Aug 08	71	2869	82		94	76	99	0	100
Jul - Dec 08	16	669	75		87	62	97	0	100
Jan - Jun 09	50	2664	85		96	85	100	0	100
Jul - Dec 09	51	2305	82		90	78	100	0	100
Jan - Jun 10	31	1569	91		99	87	100	0	100
Jul - Dec 10	58	3016	80		93	70	100	0	100
Jul - Dec 11	128	8349	85		92	81	100	0	100
Jul - Dec 12	93	4093	87		95	85	98	7	100
Jul - Dec 13	136	6859	86		93	84	99	4	100

Uganda TB Clinical Screening

•Rounds 1-8: Percentage of adult patients not on TB treatment who were assessed for TB clinical symptoms during the 6-month review period

•Rounds 9-11: Percentage of HIV-infected patients (in general care or on ART) seen in the clinic within the past month who were assessed for active TB at every visit

Total (all clinics) Uganda Adult TB Clinical Screening Scores (%) by Review Period



Total (all clinics) Uganda Adult TB Clinical Screening Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Mar - Aug 06	20	1318	57		58	38	78	3	98
Apr - Sep 07	20	1695	83		86	82	96	25	100
Feb - Aug 08	72	5838	66		77	36	95	0	100
Jul - Dec 08	16	1438	77		90	64	95	3	100
Jan - Jun 09	51	4683	77		92	65	98	5	100
Jul - Dec 09	53	4393	82		94	80	100	5	100
Jan - Jun 10	31	2529	86		95	87	100	0	100
Jul - Dec 10	59	4994	87		95	81	100	18	100
Jul - Dec 11	129	12661	91		97	88	100	11	100
Jul - Dec 12	94	5674	90		95	86	98	0	100
Jul - Dec 13	136	9523	94		97	94	99	21	100

Uganda TB Diagnostic Evaluation

Percentage of adult patients with signs and symptoms of TB who were evaluated by sputum smear or CXR during the 6-month review period

Total (all clinics) Uganda Adult TB Diagnostic Evaluation Scores* (%) by Review Period



*Sharp increase in the percentage of the TB diagnostic indicator may be explained by the clarification of the meaning of the indicator after round 1. Subsequent rounds of data collection resulted in fewer patients being eligible in the denominator of this indicator.

Total (all clinics) Uganda Adult TB Diagnostic Evaluation Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Mar - Aug 06	19	834	24		11	8	28	0	100
Apr - Sep 07	20	444	53		54	14	84	0	100
Feb - Aug 08	59	378	93		100	100	100	0	100
Jul - Dec 08	15	93	98		100	100	100	78	100
Jan - Jun 09	45	373	88		100	94	100	0	100
Jul - Dec 09	44	307	85		100	94	100	0	100
Jan - Jun 10	22	189	87		100	89	100	27	100
Jul - Dec 10	48	204	86		100	75	100	0	100
Jul - Dec 11	-	-	-		-	-	-	-	-
Jul - Dec 12	47	116	52		60	0	100	0	100
Jul - Dec 13	75	213	47		50	0	100	0	100

Uganda TB Treatment

Percentage of adult patients diagnosed with TB started on TB Treatment (baseline score)

Total (all clinics) Uganda Adult TB Treatment Baseline Score (%)

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jul - Dec 13	59	123	93		100	100	100	0	100

Uganda Adult Cotrimoxazole Preventive Therapy (CPT)*

Percentage of adult patients prescribed cotrimoxazole during the 6-month review period

Total (all clinics) Uganda Adult CPT Scores (%) by Review Period



Total (all clinics) Uganda Adult Cotrimoxazole Preventive Therapy (CPT) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Mar - Aug 06	20	1318	88		89	84	93	73	100
Apr - Sep 07	20	1695	94		96	92	98	78	100
Feb - Aug 08	72	5838	86		92	83	97	0	100
Jul - Dec 08	16	1438	91		95	87	99	64	100
Jan - Jun 09	51	4721	90		95	86	98	46	100
Jul - Dec 09	53	4393	87		94	81	98	41	100
Jan - Jun 10	31	2529	91		96	90	100	47	100
Jul - Dec 10	59	4994	90		96	90	99	24	100

*With the implementation of the HIV QoC program through the National Quality Improvement Framework and Strategic Plan in 2011, the adult CPT indicator was discontinued. Mean clinic scores for this indicator reported through the July - December 2010 review period are included in this report for historical reference.

Uganda Clinical Visits

•Rounds 1-8: Percentage of pediatric patients with at least one clinical visit in each 3-month quarter of the 6-month review period

•Rounds 9-11: Percentage of HIV-infected children with at least one clinical visit during the last 3 months of the 6-month review period

Total (all clinics) Uganda Pediatric Clinical Visits Scores (%) by Review Period



Total (all clinics) Uganda Pediatric Clinical Visits Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	17	509	83		88	71	97	43	100
Feb - Aug 08	8	523	84		84	79	88	67	100
Jul - Dec 08	20	993	82		92	74	100	33	100
Jan - Jun 09	20	1038	93		96	90	100	70	100
Jul - Dec 09	27	1357	91		97	89	100	40	100
Jan - Jun 10	12	595	91		92	87	99	62	100
Jul - Dec 10	27	1548	93		97	90	100	50	100
Jul - Dec 11	117	8230	88		96	77	100	35	100
Jul - Dec 12	66	609	85		90	78	100	33	100
Jul - Dec 13	130	4069	92		95	88	100	50	100

Uganda Appointment Keeping

Percentage of HIV+ children on ART who kept the last scheduled appointment in the last 3 months of the review period (baseline score)

Total (all clinics) Uganda Pediatric Appointment Keeping Baseline Score (%)

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jul - Dec 13	130	4069	68		73	52	82	0	100

Uganda CD4 Monitoring

Percentage of pediatric patients with at least one CD4 count during the 6-month review period

Total (all clinics) Uganda Pediatric CD4 Monitoring Scores (%) by Review Period



Total (all clinics) Uganda Pediatric CD4 Monitoring Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	17	509	15		0	0	14	0	75
Feb - Aug 08	8	523	67		84	64	87	0	94
Jul - Dec 08	20	993	43		34	23	65	0	100
Jan - Jun 09	20	1038	57		61	26	88	0	100
Jul - Dec 09	27	1357	42		44	17	66	0	96
Jan - Jun 10	12	595	37		29	15	49	0	98
Jul - Dec 10	27	1548	42		43	19	57	0	98
Jul - Dec 11	117	8231	46		45	23	72	0	100
Jul - Dec 12	65	599	36		30	17	50	0	90
Jul - Dec 13	130	4069	35		35	15	53	0	96

Uganda Cotrimoxazole Preventive Therapy (CPT)

- Rounds 1-8: Percentage of pediatric patients prescribed cotrimoxzaole during the 6-month review period
- Round 9: Percentage of HIV-infected children receiving cotrimoxazole during the last 3 months who had at least one clinical visit during the past 3 months of the 6-month review period
- Rounds 10-11: Percentage of HIV-infected children receiving cotrimoxazole during the last visit of the review period

Total (all clinics) Uganda Pediatric Cotrimoxazole Preventive Therapy Scores (%) by Review Period



Total (all clinics) Uganda Pediatric Cotrimoxazole Preventive Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	17	509	84		88	76	94	38	100
Feb - Aug 08	8	523	95		95	94	98	88	100
Jul - Dec 08	20	993	76		88	75	99	2	100
Jan - Jun 09	20	1038	94		96	91	100	74	100
Jul - Dec 09	27	1357	85		96	75	100	0	100
Jan - Jun 10	12	595	83		96	70	100	35	100
Jul - Dec 10	27	1548	91		100	94	100	35	100
Jul - Dec 11	117	8231	89		100	85	100	0	100
Jul - Dec 12	66	609	96		100	100	100	50	100
Jul - Dec 13	130	4069	92		97	92	100	0	100

Uganda ARV Therapy

Percentage of pediatric patients who were eligible and started on ART during the 6-month review period

Total (all clinics) Uganda Pediatric ARV Therapy Scores (%) by Review Period



Total (all clinics) Uganda Pediatric ARV Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	17	382	26		8	0	50	0	100
Feb - Aug 08	7	127	61		63	56	71	34	78
Jul - Dec 08	19	251	81		90	70	100	0	100
Jan - Jun 09	15	186	77		78	62	100	43	100
Jul - Dec 09	25	291	63		67	43	97	0	100
Jan - Jun 10	10	121	92		100	97	100	62	100
Jul - Dec 10	24	315	81		91	64	100	20	100
Jul - Dec 11	115	5193	85		100	82	100	0	100
Jul - Dec 12	60	270	96		100	100	100	0	100
Jul - Dec 13	130	4069	73		79	63	88	8	100

Uganda Adherence Assessment

•Rounds 1-8: Percentage of pediatric patients on ART during the 6-month review period who had at least one adherence assessment during the 6-month review period
•Rounds 9-11: Percentage of HIV-infected children on ART who had an adherence assessment in the last 3 months with at least one clinical visit in the last 3 months of the 6-month review period

Total (all clinics) Uganda Pediatric Adherence Assessment Scores (%) by Review Period



Total (all clinics) Uganda Pediatric Adherence Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	10	137	43		37	0	84	0	100
Feb - Aug 08	8	207	69		76	62	90	6	100
Jul - Dec 08	19	351	72		80	65	98	0	100
Jan - Jun 09	20	544	88		97	85	100	25	100
Jul - Dec 09	26	650	88		100	84	100	29	100
Jan - Jun 10	12	360	89		100	87	100	45	100
Jul - Dec 10	27	895	86		100	81	100	0	100
Jul - Dec 11	115	5617	81		97	74	100	0	100
Jul - Dec 12	62	273	41		37	20	60	0	100
Jul - Dec 13	124	2856	75		87	67	100	0	100

Uganda TB Clinical Screening

•Rounds 1-8: Percentage of pediatric patients not on TB treatment who were assessed for TB clinical symptoms during the 6-month review period

•Rounds 9-11: Percentage of HIV-infected children not on TB treatment screened for TB during the last 3 months with at least one clinical visit in the past 3 months of the 6-month review period

Total (all clinics) Uganda Pediatric TB Clinical Screening Scores (%) by Review Period



Total (all clinics) Uganda Pediatric TB Clinical Screening Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	16	440	57		69	32	81	0	100
Feb - Aug 08	8	492	73		91	66	100	1	100
Jul - Dec 08	20	830	61		83	18	91	0	100
Jan - Jun 09	20	1026	77		83	70	100	0	100
Jul - Dec 09	27	1354	85		100	87	100	0	100
Jan - Jun 10	12	602	65		76	25	100	0	100
Jul - Dec 10	27	1541	82		98	75	100	0	100
Jul - Dec 11	117	8231	85		95	79	100	0	100
Jul - Dec 12	66	609	86		90	80	100	17	100
Jul - Dec 13	130	4069	90		95	85	100	0	100

Uganda TB Diagnostic Evaluation

Percentage of pediatric patients with signs and symptoms of TB who were evaluated by sputum smear or CXR during the 6-month review period

Total (all clinics) Uganda Pediatric TB Diagnostic Evaluation Scores (%) by Review Period



Total (all clinics) Uganda Pediatric TB Diagnostic Evaluation Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	5	34	8		0	0	0	0	41
Feb - Aug 08	3	4	67		100	50	100	0	100
Jul - Dec 08	16	150	63		86	31	100	0	100
Jan - Jun 09	9	36	80		100	67	100	0	100
Jul - Dec 09	26	151	51		47	0	100	0	100
Jan - Jun 10	8	77	63		88	19	100	0	100
Jul - Dec 10	18	51	76		100	52	100	0	100
Jul - Dec 11	52	276	54		100	0	100	0	100
Jul - Dec 12	27	53	36		0	0	100	0	100
Jul - Dec 13	40	61	55		90	0	100	0	100

Uganda TB Treatment

Percentage of pediatric patients diagnosed with TB who receive TB treatment or are referred for TB treatment during the last 3 months of the review period (baseline score)

Total (all clinics) Uganda Pediatric TB Treatment Baseline Score (%)

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jul - Dec 13	11	11	73		100	50	100	0	100

Uganda Nutrition Assessment

Percentage of HIV-positive children with MUAC measurement done during the last 3 months of the review period

Total (all clinics) Uganda Pediatric Nutrition Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jul - Dec 12	65	603	26		10	0	50	0	100
Jul - Dec 13	130	4069	28		11	0	53	0	99

Uganda Nutrition Support

Percentage of HIV-positive children assessed in the last 3 months of the review period, who had malnutrition and received therapeutic or supplementary feeding support (baseline score)

Total (all clinics) Uganda Pediatric Nutrition Support Baseline Score (%)

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jul - Dec 13	30	88	64		83	13	100	0	100

Uganda Pediatric Growth Monitoring

Percentage of pediatric patients receiving weight-for-age assessments during the last 3 months of the 6-month review period

Total (all clinics) Uganda Pediatric Growth Monitoring Scores (%) by Review Period



review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	17	509	56		65	43	76	0	100
Feb - Aug 08	8	523	26		10	3	38	0	96
Jul - Dec 08	20	993	47		41	25	77	0	95
Jan - Jun 09	20	753	68		79	42	94	0	100
Jul - Dec 09	26	692	70		96	48	100	0	100
Jan - Jun 10	12	278	73		85	59	100	0	100
Jul - Dec 10	27	671	64		92	13	100	0	100
Jul - Dec 11	111	2352	75		92	60	100	0	100
Jul - Dec 12	66	609	87		90	80	100	22	100

Uganda Pediatric Malaria Prevention

Percentage of pediatric patients using Insecticide-treated material (ITM) during the last 3 months of the 6-month review period

Total (all clinics) Uganda Pediatric Malaria Prevention Scores (%) by Review Period



review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	17	509	11		0	0	6	0	88
Feb - Aug 08	8	523	61		71	55	78	1	88
Jul - Dec 08	20	992	19		0	0	12	0	100
Jan - Jun 09	20	1038	38		18	0	77	0	98
Jul - Dec 09	27	1357	28		1	0	55	0	100
Jan - Jun 10	12	595	36		21	0	70	0	100
Jul - Dec 10	27	1548	30		0	0	61	0	100

Uganda Infant Referral from PMTCT

Percentage of newly HIV-infected or HIV-exposed pediatric patients who were referred for HIV care from PMTCT based on reviews in pediatric clinics

Total (all clinics) Uganda Infant Referral from PMTCT Scores (%) by Review Period



review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Apr - Sep 07	17	509	6		0	0	8	0	24
Feb - Aug 08	8	523	19		10	8	16	0	87
Jul - Dec 08	20	993	17		6	0	32	0	65
Jan - Jun 09	20	1038	17		11	2	17	0	97
Jul - Dec 09	27	1357	10		4	0	10	0	83
Jan - Jun 10	12	595	14		10	0	21	0	46
Jul - Dec 10	27	1509	12		1	0	12	0	91

*With the implementation of the HIV QoC program through the National Quality Improvement Framework and Strategic Plan in 2011, the pediatric malaria prevention and infant referral indicators were discontinued. Mean clinic scores for these indicators reported through the July - December 2010 review period are included in this report for historical reference.

HIV QoC Uganda Performance Measurement

Adult and Pediatric HIV Care

Results

The Uganda quality program has conducted 11 rounds of data collection measuring 8 adult indicators for rounds 1-8, dropping one indicator - CPT - after consistently high levels of performance, and expanding to 3 new indicators in the last 2 rounds.

Key areas of improvement included clinical visits, (measured as one visit every 3 months for the first 8 rounds, and then one visit in the last 3 months of the review period for rounds 10 - 11) and a complementary new indicator of appointment keeping. Clinical visits increased from baseline with 20 clinics measuring and a mean of 70% to 136 clinics measuring and a mean of 92%. Appointment keeping, measured during the last 3 rounds of data collection, started with a baseline mean of 16% and has moved to 87%. In addition to overall improvement from baseline, this indicator has remained relatively consistent in mean performance with the spread in performance closing between the clinics. This indicator also involves many processes and systems that can impact reliability if they are not standardized in the clinic. These may include appointment systems, reminders, identifying and contacting missed appointments, and harmonizing appointments with other services. Other areas of improvement include ART adherence assessment, ARV therapy and TB clinical screen. Scores for the TB diagnostic evaluation indicator, for which measurement depends on equipment and reagent availability, have fluctuated over time.

There was also improvement in 11 of 14 pediatric indicators including ARV therapy, ART adherence assessment, TB clinical screening and growth monitoring. CD4 monitoring continues to show variable results in each round of data collection and offers an opportunity for improvement. Similarly for adult care, the CD4 monitoring indicator can be linked to harmonizing appointment systems and ensuring lab services, CD4 machines and supplies are available to match demands.

Virology monitoring was a new indicator with only one round of data collection and low results – a mean performance of 1%. Cost and availability of tests as well as possible limitations across laboratories being able to conduct the test present barriers to performance. It will be important to define implementation processes that address and highlight these larger system barriers that may contribute to success in implementing this indicator. Also, with introducing new guidelines and changes in clinical science it is important to define specific processes for dissemination and sharing new knowledge and consider gaps in these areas when interpreting performance. Low results may represent clinics not knowing the new guideline is to conduct VL testing and who is eligible or they may not have updated tools and materials to implement and capture the change – if a VL test was actually performed.

There are general limitations in the data to consider during interpretation. The clinics across review periods are different and may not represent 'groups' of the same clinics measuring over time. The baseline data collection started with 20 clinics. The last performance review included 136 clinics which represent a sample of the health facilities providing HIV care and treatment in the country. All clinics implement QI activities under the national HIV QoC program however for each review period only a sample of these clinics conduct performance measurement and the clinics in the sample can change.

In January 2015, data collection will begin for the next review period, July - December 2014.

CLINIQUAL Mozambique Performance Measurement

Adult and Pediatric HIV Care

Overview

• CLINIQUAL Mozambique clinics have collected 5 rounds of data representing care provided from January 2007 through December 2012.*
• 195 CLINIQUAL Mozambique clinics have participated in HEALTHQUAL data collection over the course of all official review periods designated by the Ministry of Health.
• As of December 31, 2013, 563 health facilities in Mozambique were providing ART. The 196 health facilities enrolled in CLINIQUAL as of the July - December 2012 review represent 35% of the total number of ART facilities.
• 41,199 adult charts have been reviewed across all rounds.
• 7087 pediatric charts have been reviewed across all rounds.
• Performance rates have been measured for the following indicators: Visits (3 different measures), CD4 monitoring (4 different measures), ARV therapy (1st and 2nd line), adherence (5 different measures), CPT, TB clinical screening, TB diagnostic evaluation, IPT, referrals for TB care, TB medication documentation, prevention education, post-exposure prophylaxis, WHO clinical staging, psychomotor development and nutrition indicators (weight, height, weight for height).
• The following tables and graphs report data for the following 12 indicators: clinical visits, CD4 monitoring, ARV therapy, adherence assessment, CPT, prevention education and TB clinical screening as well as the following pediatric specific indicators: WHO clinical staging, psychomotor development, weight, height and weight for height.
• Improvement between baseline and most recent follow-up scores has been demonstrated in all 7 adult indicators and 7 of 11 pediatric indicators, most notably in clinical visits (adult), CD4 monitoring (adult and ped), ART adherence assessment (adult), ARV therapy (ped), WHO Staging (ped) and TB clinical screening (adult and ped). Fluctuating scores for the pediatric indicators clinical visits, ART adherence assessment, height and weight for height suggest areas for improvement.

Background

HQ-Mozambique was launched in late 2006 to promote quality of care and provide a systematic model of quality assessment and improvement. Now renamed CLINIQUAL, Mozambique's program is integrated into Ministry of Health HIV/AIDS core activities. Indicators were developed based on the Mozambique Ministry of Health (MISAU) HIV treatment guidelines and chosen by a group of providers and government representatives. Since the baseline data collection cycle, CLINIQUAL Mozambique has added several indicators including separate indicators for pediatric performance measurement.

Indicators have been updated from round to round of data collection to reflect the new guidelines issued by MISAU on care and treatment for HIV-infected individuals. CLINIQUAL and Clinical Mentoring are the two programs chosen by MISAU to implement quality improvement for the care and treatment of people living with HIV/AIDS. CLINIQUAL, part of the broad National Quality and Humanization Strategy, is being adapted to be integrated into the national strategy for quality.

Data Collection

Adult

The first round of data collection reviewed adult care provided at 31 clinics between January 1, 2007 and June 30, 2007. For baseline adult data collection, two separate randomized samples were generated to create 95% confidence intervals: one for HIV patients prescribed ART and one for HIV patients not prescribed ART. The indicators for ART and pre-ART patients were based on the difference in the national guidelines for these two groups. For subsequent rounds of data collection, adult indicators were revised and patients were not stratified into ART and pre-ART groups to simplify data collection. Over 5 review periods, participation in CLINIQUAL data collection expanded to include adult data from 193 clinics.

Pediatric

A baseline round of pediatric data was collected from 68 clinics for the July 2008 - June 2009 review period. Over 3 review periods, participation in CLINIQUAL data collection expanded to include pediatric data from 165 clinics.

The following tables summarize the expansion of adult and pediatric data collection through the addition of new groups of clinics that collected and submitted baseline data. For each group of participating clinics, the tables present the group's baseline review period and number of clinics included in the group.

Expansion of adult data collection by Group		
Group #	Baseline Review Period for Group	# of Clinics in Group
1	January - June 2007	31
2	July 2007 - June 2008	19
3	July 2008 - June 2009	75
4	July 2010 - June 2011	49
5	July - December 2012	19
Total # of clinics that have submitted data		**193**

Expansion of pediatric data collection by Group		
Group #	Baseline Review Period for Group	# of Clinics in Group
1	July 2008 - June 2009	68
2	July 2010 - June 2011	67
3	July - December 2012	30
Total # of clinics that have submitted data		**165**

Staff at health facilities abstracted adult and pediatric data using CLINIQUAL software, a Microsoft Access software program which prompted users with entry screens using hierarchical logic algorithms based on clinical criteria. Data were analyzed by the facility-level ART Committee and sent to the provincial office level for generation of a provincial-level report. Staff at the provincial office sent the data to the Ministry of Health for further analysis and validation. For each round, data were aggregated by MISAU staff to produce a national report that was disseminated among all participating sites and partners. Results in the form of aggregated data are used at the Ministry of Health to identify national priorities for improvement and guide decision-making related to policy and program priorities.

For rounds 1-5, clinic scores were aggregated to calculate a mean clinic score for each indicator. Mean clinic scores for clinics that submitted data** are reported in the following graphs and tables by indicator and review period.

*July - December 2012 was the official national review period designated by MISAU for the 5th round of adult data collection (corresponding to the 3rd round of pediatric data collection). In lieu of collecting data for the July - December 2012 review, facilities from Tete and Maputo provinces elected to review care provided during different review periods for the most recent round and, therefore, these data were excluded from this report.

**Because of sporadic submission of data from round to round and variation in the number of participating clinics, the mean clinic score for each review period reflects the aggregate performance only for those clinics that submitted data for the given review period.

HQ Mozambique Mean Clinic Scores by Round of Data Collection and Indicator*

mean score (%) and the number of clinics | number of eligible patients

Round	1		2		3		4		5	
Adult	Jan - Jun 07		Jul 07 - Jun 08		Jul 08 - Jun 09		Jul 10 - Jun 11		Jul - Dec 12	
Clinical Visits (ART)	**83**	31 | 3215								
Clinical Visits (pre-ART)	**74**	29 | 3284								
Clinical Visits			**49**	46 | 4090	**55**	108 | 7936	**69**	136 | 11530	**92**	62 | 7213
CD4 Monitoring (ART)	**70**	31 | 3215								
CD4 Monitoring (pre-ART)	**65**	29 | 2390								
CD4 Monitoring			**40**	46 | 4656	**35**	108 | 8933	**37**	136 | 13318	**89**	62 | 7213
ARV Therapy	**80**	31 | 2270	**81**	46 | 1401	**73**	108 | 3348	**67**	136 | 4624	**85**	62 | 2041
Adherence Assessment	**66**	31 | 3215	**73**	46 | 3314	**82**	106 | 4606	**92**	108 | 7208	**84**	62 | 5308
Cotrimoxazole Preventive Therapy (ART)	**36**	31 | 2897								
Cotrimoxazole Preventive Therapy (pre-ART)	**21**	29 | 1244								
Cotrimoxazole Preventive Therapy			**65**	39 | 1436	**65**	102 | 2220	**73**	135 | 7157	**79**	62 | 5093
Prevention Education (ART)	**49**	31 | 3215								
Prevention Education (pre-ART)	**40**	29 | 2390								
Prevention Education			**66**	40 | 2626	**58**	104 | 5243	**80**	135 | 9385	**84**	62 | 7213
TB Clinical Screening (ART)	**18**	31 | 3002								
TB Clinical Screening (pre-ART)	**14**	29 | 2310								
TB Clinical Screening			**25**	46 | 4848	**35**	108 | 8657	**60**	135 | 12058	**89**	62 | 6951

Round	1		2		3	
Pediatric	Jul 08 - Jun 09		Jul 10 - Jun 11		Jul - Dec 12	
Clinical Visits	**7**	68 | 1228	**15**	114 | 3607	**5**	50 | 1717
CD4 Monitoring	**36**	64 | 906	**39**	114 | 3065	**46**	51 | 2216
ARV Therapy	**59**	61 | 696	**58**	111 | 1961	**81**	50 | 1035
Adherence Assessment	**81**	60 | 725	**57**	37 | 486	**72**	50 | 1658
Cotrimoxazole Preventive Therapy	**69**	51 | 407	**72**	109 | 1802	**73**	50 | 1658
WHO Status	**69**	68 | 1230	**88**	111 | 2799	**93**	51 | 2216
Weight	**82**	64 | 1047	**90**	108 | 2532	**86**	51 | 2216
Height	**56**	51 | 607	**74**	102 | 1953	**55**	51 | 2216
Weight for Height	**47**	39 | 292	**60**	92 | 1353	**39**	51 | 2216
TB Clinical Screening	**34**	65 | 1142	**58**	108 | 2672	**84**	51 | 2128
Evaluation of Child PMD	**53**	44 | 205	**62**	95 | 1568	**60**	51 | 2216

*Indicator definitions and sampling methodology changed significantly between rounds 1 and 2.

**Because of sporadic submission of data from round to round and variation in the number of participating clinics, the mean clinic score for each review period reflects the aggregate performance only for those clinics that submitted data for the given review period.

Clinical Visits

Mozambique Adult Clinical Visits Indicators for Rounds 1 - 5 of Data Collection

Eligibility Criteria

Round 1: All HIV-infected patients on ART with at least one clinical visit during the 6-month review period. All HIV-infected patients not on ART with at least one clinical visit during the past 12 months.

Round 2: All HIV-infected patients over 5 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Rounds 3-4: All HIV-infected patients over 15 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Round 5: All HIV-infected patients over 15 years of age with at least one clinical visit during the 6-month review period.

Definition: A clinical visit is an encounter between a patient and a doctor, tecnico, agente or nurse.

Round 1		Rounds 2 - 5	
Numerator	Denominator	Numerator	Denominator
pre-ART: Number of patients with at least one clinical visit during the 6-month review period ART: Number of patients with at least one clinical visit in last 3 months of the 6-month review period	pre-ART: Number of patients with at least one clinical visit during the past 12 months ART: Number of patients with at least one clinical visit during the 6-month review period	Number of patients (pre-ART and ART) that meet the MISAU criteria for the frequency of clinical visits	Number of patients (pre-ART and ART) with at least one visit during the first 6 months of the 12-month review period (for Round 5, number of patients with at least one visit during the 6-month review period)

MISAU Guidelines for Clinical Visits Frequency for Rounds 2 - 5 of Data Collection

Number of recommended clinical visits based on ART and clinical status during the one year review period

	On ART at the beginning of the review period	pre-ART						
		Lowest WHO Stage during the first 6 months of the review period				Lowest CD4 test result during the first 6 months of the review period		
Round		I	II	III	IV	>500	350 - 500	<350
2	at least one during last 6 months	Not eligible	Not eligible	at least one during last 6 months	at least one during last 6 months	Not eligible	at least one during last 6 months	at least one in each 3 month interval during last 6 months
3-5	at least one during last 6 months	at least one during last 6 months	at least one during last 6 months	at least one in each 3-month interval during last 6 months	at least one in each 3 month interval during last 6 months	Not eligible	at least one during last 6 months	At least one in each 3 month interval during last 6 months

Total (all groups) Mozambique Adult Mean Clinical Visits (pre-ART and ART) Indicator Scores (%) by Review Period



Clinical Visits (continued)

Mozambique Adult Clinical Visits Indicator Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jan - Jun 07 (pre-ART)	29	3284	74		74	64	83	51	96
	Jan - Jun 07 (ART)	31	3215	83		85	80	91	57	97
	Jul 07 - Jun 08	46	4090	49		56	29	70	0	100
	Jul 08 - Jun 09	108	7936	55		54	38	77	0	100
	Jul 10 - Jun 11	136	11530	69		76	54	88	0	100
	Jul - Dec 12	62	7213	92		95	86	99	65	100
group 1	Jan - Jun 07 (pre-ART)	29	3284	74		74	64	83	51	96
	Jan - Jun 07 (ART)	31	3215	83		85	80	91	57	97
	Jul 07 - Jun 08	30	2826	47		51	24	69	0	100
	Jul 08 - Jun 09	20	1581	58		64	37	78	0	100
	Jul 10 - Jun 11	25	2520	72		84	63	87	3	99
	Jul - Dec 12	9	1212	92		98	90	99	65	100
group 2	Jul 07 - Jun 08	16	1264	52		57	36	76	0	100
	Jul 08 - Jun 09	14	977	49		49	32	72	2	86
	Jul 10 - Jun 11	8	745	59		63	42	85	0	97
	Jul - Dec 12	6	829	89		89	81	97	80	100
group 3	Jul 08 - Jun 09	74	5378	55		54	40	76	0	100
	Jul 10 - Jun 11	55	5041	67		71	53	86	8	100
	Jul - Dec 12	22	2429	93		96	88	99	74	100
group 4	Jul 10 - Jun 11	48	3224	71		77	55	91	0	100
	Jul - Dec 12	6	431	96		99	94	100	83	100
group 5	Jul - Dec 12	19	2312	89		86	83	98	76	100

Note: When both clinical staging and CD4 test results are available, the data collection software uses the result that calls for the highest frequency of clinical visits. For example, a patient with a CD4 test results <350 and a WHO clinical stage of III will be assessed for receiving a clinical visit in each 3-month interval during the last six months of the review period.

CD4 Monitoring

Mozambique Adult CD4 Monitoring Indicators for Rounds 1 - 5 of Data Collection

Eligibility Criteria

Round 1: All HIV-infected patients on ART with at least one clinical visit during the 6-month review period. All HIV-infected patients not on ART with at least one clinical visit during the past 12 months.

Round 2: All HIV-infected patients over 5 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Rounds 3-4: All HIV-infected patients over 15 years of age with at least one visit in the first 6 months of the 12 month review period.

Round 5: All HIV-infected patients over 15 years of age with at least one clinical visit during the 6-month review period.

Round 1		Rounds 2-5	
Numerator	Denominator	Numerator	Denominator
ART and pre-ART: Number of patients with at least one CD4 count during the 6-month review period	ART and pre-ART: Number of patients with at least one clinical visit during the 6-month review period	Number of patients who satisfy the MISAU guidelines for CD4 testing frequency	Number of patients with at least one clinical visit during the first 6 months of the 12 month review period (for Round 5, number of patients with at least one visit during the 6-month review period)

MISAU Guidelines for CD4 Monitoring Frequency for Rounds 2 - 5 of Data Collection

Number of recommended CD4 counts based on ART and clinical status during the one year review period

	On ART at the beginning of the review period	pre-ART						
		Lowest WHO Stage during the first 6 months of the review period				Lowest CD4 test result during the first 6 months of the review period		
Round		I	II	III	IV	>500	350 - 500	<350
2	at least one during last 6 months	at least one during last 12 months	at least one during last 12 months	at least one during last 6 months	at least one during last 6 months	at least one during last 12 months	at least one during last 6 months	at least one in each 3 month interval during last 6 months
3-5	at least one during last 6 months	at least one during last 6 months	at least one during last 6 months	at least one in each 3-month interval during last 6 months	at least one in each 3 month interval during last 6 months	at least one during last 12 months	at least one during last 6 months	At least one in each 3 month interval during last 6 months

Note: When both clinical staging and CD4 test results are available, the data collection software uses the result that calls for the highest frequency of CD4 counts. For example, a patient with a CD4 test results <350 and a WHO clinical stage of II will be assessed for receiving a CD4 count in each 3-month interval during the last six months of the review period.

Total (all groups) Mozambique Adult Mean CD4 Monitoring (pre-ART and ART) Indicator Scores (%) by Review Period



CD4 Monitoring (continued)

Mozambique Adult CD4 Monitoring Indicator Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jan - Jun 07 (pre-ART)	29	2390	65		66	53	79	27	97
	Jan - Jun 07 (ART)	31	3215	70		70	57	80	33	100
	Jul 07 - Jun 08	46	4656	40		42	22	52	8	99
	Jul 08 - Jun 09	108	8933	35		35	21	49	0	86
	Jul 10 - Jun 11	136	13318	37		33	23	47	2	100
	Jul - Dec 12	62	7213	89		94	83	98	50	100
group 1	Jan - Jun 07 (pre-ART)	29	2390	65		66	53	79	27	97
	Jan - Jun 07 (ART)	31	3215	70		70	57	80	33	100
	Jul 07 - Jun 08	30	3273	41		46	22	52	8	82
	Jul 08 - Jun 09	20	1752	42		45	31	55	4	75
	Jul 10 - Jun 11	25	2847	34		36	24	43	2	75
	Jul - Dec 12	9	1212	91		96	89	98	59	100
group 2	Jul 07 - Jun 08	16	1383	39		33	23	54	15	99
	Jul 08 - Jun 09	14	1123	31		30	20	37	6	74
	Jul 10 - Jun 11	8	927	35		38	23	50	10	57
	Jul - Dec 12	6	829	78		81	64	94	50	100
group 3	Jul 08 - Jun 09	74	6058	34		33	19	48	0	86
	Jul 10 - Jun 11	55	5831	36		31	22	53	13	75
	Jul - Dec 12	22	2429	93		96	91	99	73	100
group 4	Jul 10 - Jun 11	48	3713	39		37	27	46	2	100
	Jul - Dec 12	6	431	92		98	84	100	74	100
group 5	Jul - Dec 12	19	2312	86		87	80	95	65	99

ARV Therapy

Mozambique Adult ARV Therapy Indicators for Rounds 1 - 5 of Data Collection

Eligibility Criteria

Round 1: All HIV+ patients on ART with at least 1 clinical visit during the 6-month review period. All HIV+ patients not on ART with at least 1 clinical visit during the past 12 months.

Round 2: All HIV-infected patients over 5 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Rounds 3-4: All HIV-infected patients over 15 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Round 5: All HIV-infected patients over 15 years of age with at least one clinical visit during the 6-month review period.

	Round 1		Rounds 2-5	
Indicator	Numerator	Denominator	Numerator	Denominator
ARV Therapy	Number of patients on ART during the 6 month review period	Number of patients with at least one clinical visit during the 6-month review period with CD4 count < 200, or WHO Stage III or IV with CD4 count < 350	Number of patients on ART during the review period	Rounds 2-3: Number of patients with at least one clinical visit during the review period with CD4 count < 250 or WHO Stage III or IV Round 4: Number of patients with at least one clinical visit during the review period with CD4 count < 350 or WHO Stage III or IV Round 5: Number of patients with at least one clinical visit during the review period in WHO clinical stage IV, or in WHO stage I, II or III with a CD4 < or = 350, or who are co-infected with TB

Total (all groups) Mozambique Adult Mean ARV Therapy Indicator Scores (%) by Review Period



ARV Therapy (continued)

Mozambique Adult ARV Therapy Indicator Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jan - Jun 07	31	2270	80		79	72	87	56	100
	Jul 07 - Jun 08	46	1401	81		86	73	95	10	100
	Jul 08 - Jun 09	108	3348	73		81	58	90	0	100
	Jul 10 - Jun 11	136	4624	67		83	59	95	0	100
	Jul - Dec 12	62	2041	85		90	75	99	9	100
group 1	Jan - Jun 07	31	2270	80		79	72	87	56	100
	Jul 07 - Jun 08	30	931	80		88	73	94	10	87
	Jul 08 - Jun 09	20	796	75		84	61	91	27	100
	Jul 10 - Jun 11	25	948	73		87	75	95	0	100
	Jul - Dec 12	9	348	89		93	89	96	46	100
group 2	Jul 07 - Jun 08	16	470	83		83	74	99	33	100
	Jul 08 - Jun 09	14	395	74		83	63	88	29	100
	Jul 10 - Jun 11	8	267	52		63	25	78	0	98
	Jul - Dec 12	6	193	71		77	66	93	9	100
group 3	Jul 08 - Jun 09	74	2157	72		80	57	90	0	100
	Jul 10 - Jun 11	55	2195	60		82	0	92	0	100
	Jul - Dec 12	22	661	88		91	81	98	57	100
group 4	Jul 10 - Jun 11	48	1214	76		87	75	100	0	100
	Jul - Dec 12	6	149	83		98	61	100	50	100
group 5	Jul - Dec 12	19	690	85		89	74	99	63	100

ART Adherence Assessment

Mozambique Adult ART Adherence Assessment Indicators for Rounds 1 - 5 of Data Collection

Eligibility Criteria

Round 1: All HIV+ patients on ART with at least 1 clinical visit during the 6-month review period. All HIV+ patients not on ART with at least 1 clinical visit during the past 12 months.

Round 2: All HIV-infected patients over 5 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Rounds 3-4: All HIV-infected patients over 15 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Round 5: All HIV-infected patients over 15 years of age with at least one clinical visit during the 6-month review period.

	Round 1		Rounds 2-5	
Indicator	Numerator	Denominator	Numerator	Denominator
ART Adherence Assessment*	Number of patients who have had at least one adherence assessment during the last 6 months	Number of patients on ART with at least one clinical visit during the last 6 months	Number of a patients with at least one documented adherence assessment during the review period	Number of patients that were on ART at any time during the review period

*Adherence assessment is defined as a pill count recorded at time of supply, registration of the adherence assessment on the existing form by the pharmacist, or a written notation in the patient file regarding the patient's level of adherence to the ART regimen.

Total (all groups) Mozambique Adult Mean ART Adherence Assessment Indicator Scores (%) by Review Period



ART Adherence Assessment (continued)

Mozambique Adult ART Adherence Assessment Indicator Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jan - Jun 07	31	3215	66		76	37	93	0	100
	Jul 07 - Jun 08	46	3314	73		81	60	93	0	100
	Jul 08 - Jun 09	106	4606	82		92	76	99	0	100
	Jul 10 - Jun 11	108	7208	92		97	92	100	11	100
	Jul - Dec 12	62	5308	83		94	82	99	0	100
group 1	Jan - Jun 07	31	3215	66		76	37	93	0	100
	Jul 07 - Jun 08	30	2270	75		82	72	92	0	100
	Jul 08 - Jun 09	20	996	85		94	76	100	24	99
	Jul 10 - Jun 11	22	1809	92		95	93	99	63	100
	Jul - Dec 12	9	948	90		91	83	100	72	100
group 2	Jul 07 - Jun 08	16	1044	70		73	49	96	22	100
	Jul 08 - Jun 09	14	533	78		87	76	94	10	100
	Jul 10 - Jun 11	6	377	93		95	91	97	80	100
	Jul - Dec 12	6	514	68		86	52	94	0	99
group 3	Jul 08 - Jun 09	72	3077	82		91	79	99	0	100
	Jul 10 - Jun 11	39	2959	91		98	93	100	11	100
	Jul - Dec 12	22	1876	90		96	91	100	5	100
group 4	Jul 10 - Jun 11	41	2063	92		97	92	100	55	100
	Jul - Dec 12	6	391	93		94	90	97	85	100
group 5	Jul - Dec 12	19	1579	75		93	71	98	8	100

*Adherence assessment is defined as a pill count recorded at time of supply, registration of the adherence assessment on the existing form by the pharmacist, or a written notation in the patient file regarding the patient's level of adherence to the ART regimen.

Cotrimoxazole Preventive Therapy (CPT)

Mozambique Adult CPT Indicators for Rounds 1 - 5 of Data Collection

Eligibility Criteria

Round 1: All HIV-infected patients on ART with at least one clinical visit during the 6-month review period. All HIV-infected patients not on ART with at least one clinical visit during the past 12 months.

Round 2: All HIV-infected patients over 5 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Rounds 3-4: All HIV-infected patients over 15 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Round 5: All HIV-infected patients over 15 years of age with at least one clinical visit during the 6-month review period.

Indicator	Round 1	Rounds 2-5	
Cotrimoxazole Preventive Therapy (CPT)	Numerator: Number of patients receiving cotrimoxazole during the 6-month review period Denominator: Number of patients meeting eligibility requirements for cotrimoxazole prophylaxis (all HIV+, asymptomatic with CD4 <350, WHO III or IV) with at least one clinical visit during the 6-month review period	Numerator: Rounds 2-4: Number of patients who received cotrimoxazole in the last 6 months of the 12-month review period	Denominator: Round 2: Number of patients with CD4 count < 350 or WHO Stage III or IV with at least one clinical visit during the last 6 months of the 12-month review period Round 3: Number of patients with CD4 count < 200 or WHO Stage III or IV, or any HIV-infected woman after the second trimester, with at least one clinical visit during the last 6 months Round 4: Number of patients with CD4 count < or = 350 in any WHO Stage; with any CD4 count in WHO Stage III or IV; number of HIV+ patients co-infected with TB; or any HIV+ pregnant woman after the second trimester with at least one clinical visit during the last 6 months
		Round 5: Number of patients who received cotrimoxazole during the 6-month review period	Round 5: Number of patients who are in WHO stage II, III or IV, or HIV+ with CD4 < or = 350, or HIV+ in stage III or IV, or who are co-infected with TB

Total (all groups) Mozambique Adult Mean CPT (pre-ART and ART) Indicator Scores (%) by Review Period



Cotrimoxazole Preventive Therapy (CPT, continued)

Mozambique Adult CPT Indicator Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jan - Jun 07 (pre-ART)	29	1244	21		17	13	24	0	63
	Jan - Jun 07 (ART)	31	2897	36		35	31	44	10	65
	Jul 07 - Jun 08	39	1436	65		72	42	83	0	100
	Jul 08 - Jun 09	102	2220	65		69	50	90	0	100
	Jul 10 - Jun 11	135	7157	73		83	57	95	0	100
	Jul - Dec 12	62	5093	79		86	71	96	14	100
group 1	Jan - Jun 07 (pre-ART)	29	1244	21		17	13	24	0	63
	Jan - Jun 07 (ART)	31	2897	36		35	31	44	10	65
	Jul 07 - Jun 08	25	937	66		74	46	83	10	100
	Jul 08 - Jun 09	19	513	77		88	69	93	21	100
	Jul 10 - Jun 11	25	1526	65		80	34	90	0	100
	Jul - Dec 12	9	933	73		80	57	87	39	98
group 2	Jul 07 - Jun 08	14	499	65		72	46	88	0	100
	Jul 08 - Jun 09	14	242	67		69	57	89	0	100
	Jul 10 - Jun 11	8	394	83		94	74	97	32	100
	Jul - Dec 12	6	633	68		73	63	83	27	91
group 3	Jul 08 - Jun 09	69	1465	62		63	44	88	0	100
	Jul 10 - Jun 11	55	3337	71		77	49	94	11	100
	Jul - Dec 12	22	1678	81		92	74	96	14	100
group 4	Jul 10 - Jun 11	47	1900	80		86	73	96	0	100
	Jul - Dec 12	6	330	89		97	83	99	64	100
group 5	Jul - Dec 12	19	1519	80		86	74	94	22	99

Prevention Education

Mozambique Adult Prevention Education Indicators for Rounds 1 - 5 of Data Collection

Eligibility Criteria

Round 1: All HIV+ patients on ART with at least 1 clinical visit during the 6-month review period. All HIV+ patients not on ART with at least 1 clinical visit during the past 12 months.

Round 2: All HIV-infected patients over 5 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Rounds 3-4: All HIV-infected patients over 15 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Round 5: All HIV-infected patients over 15 years of age with at least one clinical visit during the 6-month review period.

	Round 1		Rounds 2-5	
Indicator	Numerator	Denominator	Numerator	Denominator
Prevention Education	Number of patients who have had HIV prevention education during the 6-month review period	Number patients with at least one clinical visit during the 6-month review period	Number of patients who received prevention education in the last 6 months of the 12-month review period (for Round 5, number of patients who received prevention education during the 6-month review period)	Number of patients with at least one clinical visit during the last 6 months of the 12-month review period (for Round 5, number of patients with at least one clinical visit during the 6-month review period)

Total (all groups) Mozambique Adult Mean Prevention Education (pre-ART and ART) Indicator Scores (%) by Review Period



Prevention Education (continued)

Mozambique Adult Prevention Education Indicator Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jan - Jun 07 (pre-ART)	29	2390	40		32	2	74	0	100
	Jan - Jun 07 (ART)	31	3215	49		46	1	97	0	100
	Jul 07 - Jun 08	40	2626	66		81	41	98	0	100
	Jul 08 - Jun 09	104	5243	58		69	21	93	0	100
	Jul 10 - Jun 11	135	9385	80		93	69	99	0	100
	Jul - Dec 12	62	7213	84		95	84	99	0	100
group 1	Jan - Jun 07 (pre-ART)	29	2390	40		32	2	74	0	100
	Jan - Jun 07 (ART)	31	3215	49		46	1	97	0	100
	Jul 07 - Jun 08	26	1749	69		83	48	98	0	100
	Jul 08 - Jun 09	19	1157	63		74	39	94	0	100
	Jul 10 - Jun 11	25	2070	78		91	69	97	24	100
	Jul - Dec 12	9	1212	84		91	84	99	22	100
group 2	Jul 07 - Jun 08	14	877	61		76	28	95	0	100
	Jul 08 - Jun 09	14	557	72		83	51	97	11	100
	Jul 10 - Jun 11	8	554	84		96	91	100	0	100
	Jul - Dec 12	6	829	74		83	62	88	37	98
group 3	Jul 08 - Jun 09	71	3529	53		63	18	84	0	100
	Jul 10 - Jun 11	55	4162	76		88	60	99	0	100
	Jul - Dec 12	22	2429	80		90	83	98	0	100
group 4	Jul 10 - Jun 11	47	2599	83		95	78	100	5	100
	Jul - Dec 12	6	431	88		98	92	100	43	100
group 5	Jul - Dec 12	19	2312	91		97	96	99	9	100

TB Clinical Screening

Mozambique Adult TB Clinical Screening Indicators for Rounds 1 - 5 of Data Collection

Eligibility Criteria

Round 1: All HIV+ patients on ART with at least 1 clinical visit during the 6-month review period. All HIV+ patients not on ART with at least 1 clinical visit during the past 12 months.

Round 2: All HIV-infected patients over 5 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Rounds 3-4: All HIV-infected patients over 15 years of age with at least one clinical visit during the first 6 months of the 12-month review period.

Round 5: All HIV-infected patients over 15 years of age with at least one clinical visit during the 6-month review period.

Objective: TB Clinical Screen checks for the following: cough > 3 weeks or sputum with blood in the past 3 weeks (in combination with fever (for past 3 weeks), night sweats (for more than 3 weeks), or weight loss of more than 3 kg of normal weight (during past 4 weeks).

	Round 1		Rounds 2-5	
Indicator	Numerator	Denominator	Numerator	Denominator
TB Clinical Screening	Number of patients who have been assessed for TB during the 6-month review period	Number of patients with at least one clinical visit during the 6-month review period who have not been diagnosed with active TB	Rounds 2-4: Number of HIV-infected patients who were assessed for pulmonary TB during the 12-month review period Round 5: Number of patients who have been screened for TB during the 6-month review period	Rounds 2-4: Number of HIV-infected patients who were not diagnosed with TB during the 12-month review period Round 5: Number of patients with at least one clinical visit during the 6-month review period

Total (all groups) Mozambique Adult Mean TB Clinical Screening (pre-ART and ART) Indicator Scores (%) by Review Period



TB Clinical Screen (continued)

Mozambique Adult TB Clinical Screen Indicator Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jan - Jun 07 (pre-ART)	29	2310	14		6	3	18	0	64
	Jan - Jun 07 (ART)	31	3002	18		13	4	24	0	88
	Jul 07 - Jun 08	46	4848	25		21	7	35	0	81
	Jul 08 - Jun 09	108	8657	35		28	7	59	0	94
	Jul 10 - Jun 11	135	12058	60		64	36	84	0	100
	Jul - Dec 12	62	6951	89		97	88	100	2	100
group 1	Jan - Jun 07 (pre-ART)	29	2310	14		6	3	18	0	64
	Jan - Jun 07 (ART)	31	3002	18		13	4	24	0	88
	Jul 07 - Jun 08	30	3420	31		30	18	47	0	81
	Jul 08 - Jun 09	20	1635	47		51	23	70	0	90
	Jul 10 - Jun 11	25	2676	57		64	29	85	5	100
	Jul - Dec 12	9	1139	96		98	95	99	88	100
group 2	Jul 07 - Jun 08	16	1428	13		7	2	24	0	47
	Jul 08 - Jun 09	14	1152	24		15	8	39	2	60
	Jul 10 - Jun 11	8	842	60		79	30	83	6	87
	Jul - Dec 12	6	808	71		90	60	95	2	97
group 3	Jul 08 - Jun 09	74	5870	33		25	6	59	0	94
	Jul 10 - Jun 11	55	5208	67		71	51	87	2	100
	Jul - Dec 12	22	2359	93		97	89	100	73	100
group 4	Jul 10 - Jun 11	47	3332	53		55	30	80	0	100
	Jul - Dec 12	6	410	93		100	99	100	60	100
group 5	Jul - Dec 12	19	2235	85		99	81	100	4	100

Mozambique Pediatric Indicators for Rounds 1- 3 of Pediatric Data Collection

Eligibility Criteria: All HIV-infected children under 15 years of age with at least one clinical visit at a health facility that provides pediatric HIV care during the first 6 months of the 12-month review period (for Round 3, during the 6-month review period) and who were not transferred to another clinic during this period. A clinical visit is an encounter between a patient and a doctor, tecnico, agente or nurse.

Indicator	Numerator	Denominator	Criteria (if applicable)
Clinical Visits	Number of children that satisfy the criteria for the frequency of clinical visits	Number of children who had at least one clinical visit during the first 6 months of the 12-month review period	pre-ART - WHO stages 2-4: one clinical visit in each month during the last 6 months. WHO stage 1 or unknown stage: one visit in each 3-month interval during the last 6 months. ART - Patients on first year of treatment: one visit in each month during the last 6 months. Patients who have been on ART for more than one year: one visit in each 2-month interval during the last 6 months.
CD4 Monitoring	Rounds 1-2: Number of children who had at least one CD4 count during the last 6 months of the 12-month review period Round 3: Number of children who had a CD4 test during the review period	Rounds 1-2: Number of children who had at least one clinical visit during the first 6 months of the 12-month review period Round 3: Number of children who had a clinical visit during the review period	
ARV Therapy	Rounds 1-2: Number of children on ARV therapy during the last 6 months of the 12-month review period Round 3: Number of children on ART during the review period	Rounds 1-2: Number of children who met the eligibility criteria for ARV Therapy Round 3: Number of children who meet the MOH eligibility criteria for ART during the review period	Round 1: All HIV+ children under 12 months of age. 1-3 years old: CD4 count < 20% of TL count (in absence of CD4%, CD4 <750 LT or lymphocytes <3000). 3-12 years old: CD4% <15% (in the absence of CD4%, CD4 <350 LT or lymphocytes <2000). 12+ years old: WHO stage III or IV with CD4<350 or CD4 < 200. In the absence of CD4 testing and LT, all HIV + children older than 1 year old should start ART if they have a pediatric clinical stage III or IV of the WHO. Round 2: Number of children under 12 months of age confirmed to be HIV+; all children born to HIV+ women with < 18 months of diagnosis presumed to be HIV+. For children who are 1-3 years, with CD4 < 20% or in absence of CD4 percent, with CD4 count < 750 or lymphocytes LT < 3000. For children 14 years and older, the number of children with at least one clinical visit during the 6-month review period with CD4 count < 350 or WHO Stage III or IV. Round 3: All HIV+ children < 2 years; all HIV+ children in WHO stage III or IV; for children between 2-5 years, with CD4% < or = 25% or 750 cells (in absence of CD4%, absolute CD4 count can be used); for children > or = 5 years, CD4<350.
ART Adherence Assessment	Number of children who had at least one documented adherence assessment during the review period	Number of children who were on ART at any time during the review period	Adherence assessment is defined as a pill count recorded at time of supply, registration of the adherence assessment on the existing form by the pharmacist, or a written notation in the patient file regarding the patient's level of adherence to the ART regimen
Cotrimoxazole Preventive Therapy (CPT)	Number of children who were on CPT during the last 6 months of the 12-month review period (for Round 3, during the review period)	Number of HIV-infected children who had at least one clinical visit during the first 6 months of the 12-month review period (for Round 3, during the review period) and who were eligible for CPT	Rounds 1-2: All HIV+ children under 12 months of age. 1 - 5 years old: CD4% < 20% (in absence of CD4%, WHO clinical stage III or IV), 5 years old+ asymptomatic patients with CD4 <350. Criteria for discontinuation of CPT: CD4% > 20% followed by a second test of CD4> 20% 6 months later Round 3: All HIV+ children <12 months of age; all HIV+ children with CD4<20%; all HIV+ children who are symptomatic (WHO II, III, IV) for whom it is not possible to perform a CD4 test
TB Clinical Screening	Round 1: Number of HIV-infected children who were assessed for pulmonary TB during the 12-month review period Rounds 2-3: Number of HIV-infected children who were assessed for pulmonary TB during the last 6 months of the 12-month review period (for Round 3, during the review period)	Round 1: Number of children in who were not diagnosed with active TB before the review period Rounds 2-3: Number of children with one clinical visit during the review period who were not diagnosed with active TB during the last 6 months of the review period (for Round 3, during the review period)	TB Clinical Screen checks for the following: cough > 3 weeks or sputum with blood in the past 3 weeks (in combination with fever (for past 3 weeks), night sweats (for more than 3 weeks), or weight loss of more than 3 kgs of normal weight (during past 4 weeks)

Mozambique Pediatric Indicators (continued) for Rounds 1- 3 of Pediatric Data Collection

Eligibility Criteria: All HIV-infected children under 15 years of age with at least one clinical visit at a health facility that provides pediatric HIV care during the first 6 months of the 12-month review period (for Round 3, during the 6-month review period) and who were not transferred to another clinic during this period. A clinical visit is an encounter between a patient and a doctor, tecnico, agente or nurse.

Indicator	Numerator	Denominator
WHO Clinical Staging	Rounds 1-2: Number of HIV-infected children with a WHO clinical stage for their last clinical visit of the review period Round 3: Number of HIV-infected children whose WHO clinical stage was documented at each clinical visit during the review period	Number of children who had at least one clinical visit during the review period
Weight	Rounds 1-2: Number of children who were weighed during their last clinical visit of the review period Round 3: Number of children whose weight was documented at each clinical visit during the review period	Number of children who had at least one clinical visit during the review period
Height	Rounds 1-2: Number of children whose height was measured during their last clinical visit of the review period Round 3: Number of children whose height was documented at each clinical visit during the review period	Number of children who had at least one clinical visit during the review period
Weight for Height	Rounds 1-2: Number of children whose weight to height ratio was calculated during their last clinical visit of the review period Round 3: Number of children whose weight to height ratio or IMC/age was evaluated at each clinical visit during the review period	Number of children who had at least one clinical visit during the review period
Psychomotor Development (PMD)	Rounds 1-2: Number of children whose PMD was evaluated during their last clinical visit of the review period Round 3: Number of children whose PMD was evaluated at each clinical visit during the review period	Number of children who had at least one clinical visit during the review period

Note: For the following indicators, the Round 2 denominator is the number of HIV-infected children who had a clinical visit during the last 6 months of the review period: WHO Clinical Staging, Weight, Height, Weight for Height, Psychomotor Development (PMD).

Mozambique Pediatric Total (all groups) Scores by Indicator and Review Period

Indicator	Review Period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Clinical Visits	Jul 08 - Jun 09	68	1228	7		0	0	13	0	47
	Jul 10 - Jun 11	114	3607	15		11	0	23	0	100
	Jul - Dec 12	50	1717	5		0	0	6	0	40
CD4 Monitoring	Jul 08 - Jun 09	64	906	36		32	0	63	0	100
	Jul 10 - Jun 11	114	3065	39		4	22	55	0	100
	Jul - Dec 12	51	2216	46		45	35	56	0	100
ARV Therapy	Jul 08 - Jun 09	61	696	59		63	50	83	0	100
	Jul 10 - Jun 11	111	1961	58		67	34	87	0	100
	Jul - Dec 12	50	1035	81		91	70	100	0	100
Adherence Assessment	Jul 08 - Jun 09	60	725	81		96	67	100	0	100
	Jul 10 - Jun 11	37	486	57		69	26	82	6	100
	Jul - Dec 12	50	1658	72		84	61	96	0	100
CPT	Jul 08 - Jun 09	51	407	69		81	41	100	0	100
	Jul 10 - Jun 11	109	1802	72		77	53	100	0	100
	Jul - Dec 12	50	1658	73		84	61	96	0	100
TB Clinical Screening	Jul 08 - Jun 09	65	1142	34		25	0	57	0	100
	Jul 10 - Jun 11	108	2672	58		65	28	91	0	100
	Jul - Dec 12	51	2128	84		98	79	100	0	100
WHO Staging	Jul 08 - Jun 09	68	1230	69		84	45	100	0	100
	Jul 10 - Jun 11	111	2799	88		100	87	100	13	100
	Jul - Dec 12	51	2216	93		100	96	100	25	100
Weight	Jul 08 - Jun 09	64	1047	82		92	74	100	13	100
	Jul 10 - Jun 11	108	2532	90		96	85	100	14	100
	Jul - Dec 12	51	2216	86		95	87	100	0	100
Height	Jul 08 - Jun 09	51	607	56		58	23	89	2	100
	Jul 10 - Jun 11	102	1953	74		86	52	100	5	100
	Jul - Dec 12	51	2216	55		58	17	91	0	100
Weight for Height	Jul 08 - Jun 09	39	292	47		43	22	79	2	100
	Jul 10 - Jun 11	92	1353	60		67	31	95	1	100
	Jul - Dec 12	51	2216	39		36	4	70	0	100
PMD	Jul 08 - Jun 09	44	405	53		47	24	85	2	100
	Jul 10 - Jun 11	95	1568	62		67	37	96	3	100
	Jul - Dec 12	51	2216	60		72	29	92	0	100

Mozambique Pediatric Group I Scores by Indicator and Review Period

Indicator	Review Period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Clinical Visits	Jul 08 - Jun 09	68	1228	7		0	0	13	0	47
	Jul 10 - Jun 11	47	1780	17		15	5	26	0	64
	Jul - Dec 12	11	550	10		4	0	15	0	32
CD4 Monitoring	Jul 08 - Jun 09	64	906	36		32	0	63	0	100
	Jul 10 - Jun 11	47	1569	38		41	20	57	0	77
	Jul - Dec 12	11	711	47		45	44	47	24	71
ARV Therapy	Jul 08 - Jun 09	61	696	59		63	50	83	0	100
	Jul 10 - Jun 11	47	950	53		62	13	80	0	100
	Jul - Dec 12	11	300	80		87	77	93	20	100
Adherence Assessment	Jul 08 - Jun 09	60	725	81		96	67	100	0	100
	Jul 10 - Jun 11	18	321	58		70	43	79	6	100
	Jul - Dec 12	11	533	81		86	77	90	43	100
CPT	Jul 08 - Jun 09	51	407	69		81	41	100	0	100
	Jul 10 - Jun 11	47	932	71		77	56	93	3	100
	Jul - Dec 12	11	533	81		86	77	90	43	100
TB Clinical Screening	Jul 08 - Jun 09	65	1142	34		25	0	57	0	100
	Jul 10 - Jun 11	46	1384	66		77	49	92	0	100
	Jul - Dec 12	11	673	87		96	79	100	50	100
WHO Staging	Jul 08 - Jun 09	68	1230	69		84	45	100	0	100
	Jul 10 - Jun 11	46	1435	83		98	78	100	19	100
	Jul - Dec 12	11	711	94		100	92	100	67	100
Weight	Jul 08 - Jun 09	64	1047	82		92	74	100	13	100
	Jul 10 - Jun 11	46	1318	90		95	83	100	50	100
	Jul - Dec 12	11	711	83		92	86	96	0	100
Height	Jul 08 - Jun 09	51	607	56		58	23	89	2	100
	Jul 10 - Jun 11	43	1035	74		86	57	96	5	100
	Jul - Dec 12	11	711	66		79	48	95	0	100
Weight for Height	Jul 08 - Jun 09	39	292	47		43	22	79	2	100
	Jul 10 - Jun 11	37	658	58		59	25	89	3	100
	Jul - Dec 12	11	711	51		43	32	84	0	93
PMD	Jul 08 - Jun 09	44	405	53		47	24	85	2	100
	Jul 10 - Jun 11	42	926	66		68	47	93	4	100
	Jul - Dec 12	11	711	56		69	17	92	0	97

Mozambique Pediatric Group 2 Scores by Indicator and Review Period

Indicator	Review Period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Clinical Visits	Jul 10 - Jun 11	67	1827	14		7	0	22	0	100
	Jul - Dec 12	10	278	2		0	0	2	0	14
CD4 Monitoring	Jul 10 - Jun 11	67	1496	39		40	24	52	0	100
	Jul - Dec 12	10	367	44		43	33	58	11	79
ARV Therapy	Jul 10 - Jun 11	64	1011	63		72	37	100	0	100
	Jul - Dec 12	10	193	67		75	48	99	0	100
Adherence Assessment	Jul 10 - Jun 11	19	165	57		53	26	91	7	100
	Jul - Dec 12	10	262	79		88	64	96	38	100
CPT	Jul 10 - Jun 11	62	870	72		77	51	100	0	100
	Jul - Dec 12	10	262	79		91	64	96	38	100
TB Clinical Screening	Jul 10 - Jun 11	62	1288	53		50	18	89	0	100
	Jul - Dec 12	10	349	96		100	93	100	82	100
WHO Staging	Jul 10 - Jun 11	65	1364	91		100	93	100	13	100
	Jul - Dec 12	10	367	98		100	98	100	81	100
Weight	Jul 10 - Jun 11	62	1214	90		100	86	100	14	100
	Jul - Dec 12	10	367	94		96	94	100	71	100
Height	Jul 10 - Jun 11	59	918	74		90	50	100	6	100
	Jul - Dec 12	10	367	53		54	23	82	7	97
Weight for Height	Jul 10 - Jun 11	55	695	61		67	36	97	1	100
	Jul - Dec 12	10	367	37		30	1	64	0	97
PMD	Jul 10 - Jun 11	53	642	58		56	23	100	3	100
	Jul - Dec 12	10	367	78		88	61	94	38	100

Mozambique Pediatric Group 3 Scores by Indicator and Review Period

Indicator	Review Period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Clinical Visits	Jul - Dec 12	29	889	5		0	0	3	0	40
CD4 Monitoring	Jul - Dec 12	30	1138	46		48	31	57	0	100
ARV Therapy	Jul - Dec 12	29	542	86		95	75	100	0	100
Adherence Assessment	Jul - Dec 12	29	863	67		78	35	98	0	100
CPT	Jul - Dec 12	29	863	67		78	35	98	0	100
TB Clinical Screening	Jul - Dec 12	30	1106	78		98	64	100	0	100
WHO Staging	Jul - Dec 12	30	1138	92		100	96	100	25	100
Weight	Jul - Dec 12	30	1138	85		96	79	100	0	100
Height	Jul - Dec 12	30	1138	51		51	14	88	0	100
Weight for Height	Jul - Dec 12	30	1138	35		19	6	55	0	100
PMD	Jul - Dec 12	30	1138	55		54	18	91	0	100

CLINIQUAL Mozambique Performance Measurement

Adult and Pediatric HIV Care

Results

CLINIQUAL, a performance measurement system in Mozambique, has been implemented in 5 rounds of data collection from January 2007 through December 2012 measuring 7 adult indicators and included 11 pediatric indicators during the last 3 rounds. All 7 adult indicator areas showed improvement from baseline to the last measurement. Consistent improvement was seen with clinical visits (retention frequency), ART assessment, TB clinical screening, CPT, and prevention education.

Although performance improved for all indicators, variation was noted between review periods for both CD4 monitoring and ARV therapy. These indicators have added complexity that may affect performance beyond the activities that are implemented to standardize process. They are often affected by additional conditions, including inputs that influence success or failure. For example, equipment failures, lack of reagents or tubes, medication stock-outs, and uncoordinated appointments burdening the patient are common. Understanding and defining additional processes to prevent failures or manage constraints when these conditions exist offers opportunities for improvement.

Pediatric performance showed improvement in 7 of 11 pediatric indicators. Interpretation should be cautious since there have only been 3 review periods. Several indicators showed more variation between review periods and provide opportunities for improvement including clinical visits, height and weight for height monitoring.

All of the adult indicators underwent changes in eligibility criteria between each round of data collection with the exception of rounds 3 and 4. These definition changes across review periods are noted in the graphs and need to be considered when interpreting and using these data for improvement. Because of these changes, these scores cannot be directly compared.

HIVQUAL Namibia Performance Measurement

Adult HIV Care

Overview

• HQ-Namibia clinics have collected 10 rounds of data representing care provided from July 2007 through March 2013.
• 37 Namibia clinics submitted data for the most recent review period, October 2012 - March 2013. All District Hospitals in the country currently implement HIVQUAL. Of the 43 Health Centres in the country, 3 out of the 37 Health Centres providing ART services implement HIVQUAL. The following table reports the number and proportion of health facilities implementing HIVQUAL during the October 2012 - March 2013 review by facility type:

Number and proportion of Namibia health facilities implementing HIVQUAL by facility type (October 2012 - March 2013)				
Facility Type	Total # in country	# of ART sites	# of HIVQUAL sites	**Proportion of ART sites implementing HIVQUAL**
District Hospitals	34	34	34	**34 of 34 District Hospital ART sites = 100%**
Health Centres	43	37	3	**3 of 37 Health Centre ART sites = 8%**

• A total of 38 Namibia clinics have participated in HIVQUAL data collection over the course of all 10 rounds.
• 37,465 charts have been sampled for rounds 2-10.
• Performance rates are presented for the following 11 indicators: clinical visits, CD4 monitoring, ARV therapy, ART adherence assessment, CPT, TB clinical screening, IPT-TB, prevention education, weight monitoring, food security and alcohol screening.
• Improvement between baseline and most recent follow-up scores has been demonstrated in 10 of 11 indicators. Performance has remained consistently high for ARV therapy, ART adherence assessment, CPT and weight monitoring. Scores have fluctuated for CD4 monitoring, IPT screening and prevention education, highlighting further opportunities for improvement.

Background

HQ-Namibia implementation began in 2007 as a collaboration between the Ministry of Health and Social Services (MoHSS) and CDC-Namibia. The MoHSS has been responsible for the development of the indicators, training and related activities, and the expansion of HQ-Namibia. The CDC has provided technical assistance for program implementation support, data collection and analysis.

Data Collection

The first round of data collection reviewed care provided at 16 clinics between July 1, 2007 and December 31, 2007. Though round 1 data were collected, technical difficulties with electronic data capture resulted in inaccurate results for several indicators. Data from round 1 have thus been omitted from the longitudinal analysis. Over 10 review periods, participation in HIVQUAL data collection has expanded to include 38 clinics. The table below summarizes the expansion of HIVQUAL Namibia data collection through the addition of new groups of clinics that collected and submitted baseline data. For each group of participating clinics, the table presents the group's baseline review period and number of clinics included in the group.

Expansion of HIVQUAL Namibia data collection by Group		
Group #	**Baseline Review Period for Group**	**# of Clinics in Group**
1	July - December 2007	16
2	January - June 2009	16
3	July - December 2009	4
4	January - June 2010	1
5	October 2010 - March 2011	1
Total # of clinics that have submitted data		**38**

The most recent round of data collection reviewed care between October 1, 2012 and March 31, 2013. For each round of performance measurement, the data collection process began at the end of the specified review period in which care was provided. For example, for the review period October 2012 - March 2013, ART facility-level staff commenced data collection in April 2013 for care provided during the previous 6 months. Health facility staff received reminders to prepare for data collection from QI leaders at the national office one week before the end of the review period.

The data collection process in Namibia has been facilitated by the use of a national electronic Patient Management System (ePMS) that functions in all public hospitals and clinics providing ART services. QI teams at ART facilities retrieved eligibility case lists from the ePMS and exported the lists to Microsoft Excel. Chart sampling and data collection were performed following standard HIVQUAL methodologies presented on page 13 of this report. Case lists were entered into the randomizer in the HIVQUAL software. Patient charts corresponding to those listed in the randomized case list were selected for data abstraction.

The resulting sample included all adult patients (15+ years old) who were registered and receiving care. All sampled patients had at least one clinical visit in the 6-month review period. After data verification and validation, facility-level performance data were submitted to the national office. At the national office, the facility-level data were further validated, aggregated and analyzed to identify national priorities. The results are reported on a biannual basis in-country.

For rounds 2-10, clinic scores were averaged to calculate a mean clinic score for each indicator. Mean clinic scores are reported in the following graphs and tables by indicator and review period.

HQ Namibia Mean Clinic Scores by Round of Data Collection and Indicator

mean score (%) and the number of clinics | number of eligible patients

Round	2		3		4		5		6		7		8	
Indicator	Jan - June 08		Jul - Dec 08		Jan - Jun 09		Jul - Dec 09		Jan - Jun 10		Oct 10 - Mar 11		Oct 11 - Mar 12	
Clinical Visits (ART)	**79**	16 | 1631	**85**	16 | 1522	**88**	31 | 2790	**82**	33 | 3087	**87**	36 | 3680	**87**	36 | 3704	**86**	36 | 4297
CD4 Monitoring (ART)	**74**	16 | 1631	**65**	16 | 1522	**72**	31 | 2291	**62**	33 | 3308	**67**	36 | 3680	**62**	36 | 3704	**63**	36 | 4297
ARV Therapy	**83**	16 | 826	**79**	16 | 791	**79**	31 | 1111	**78**	33 | 1099	**82**	36 | 1213	**86**	36 | 926	**89**	36 | 936
Adherence Assessment	**90**	16 | 1631	**97**	16 | 1522	**88**	31 | 2790	**94**	33 | 3087	**98**	36 | 3680	**97**	36 | 3704	**97**	36 | 4297
CPT	**86**	16 | 1145	**90**	16 | 1040	**87**	31 | 1659	**86**	33 | 1560	**93**	36 | 1879	**92**	36 | 1486	**92**	36 | 1397
TB Clinical Screening	**81**	16 | 1684	**84**	16 | 1321	**82**	30 | 2193	**84**	32 | 2549	**87**	35 | 2426	**90**	35 | 1912	**95**	35 | 1650
IPT-TB	**16**	16 | 1977	**22**	16 | 1646	**27**	30 | 2817	**21**	32 | 3156	**30**	35 | 3204	**28**	35 | 2533	**35**	35 | 2230
Prevention Education	**37**	16 | 2296	**39**	16 | 2259	**46**	31 | 4043	**44**	33 | 4330	**49**	36 | 5079	**41**	36 | 4664	**45**	36 | 4989
Weight Monitoring	**84**	16 | 2296	**93**	16 | 2259	**94**	30 | 4006	**91**	33 | 4330	**94**	36 | 5079	**97**	36 | 4664	**96**	36 | 4989
Food Security	**24**	16 | 2296	**34**	16 | 2259	**24**	31 | 4043	**27**	33 | 4330	**38**	36 | 5079	**46**	36 | 4664	**47**	36 | 4989
Alcohol Screening	**24**	16 | 2296	**33**	16 | 2259	**29**	31 | 4043	**33**	33 | 4330	**41**	36 | 5079	**49**	36 | 4664	**49**	36 | 4989

Round	9		10	
Indicator	Apr - Sept 12		Oct 12 - Mar 13	
Clinical Visits (ART)	**82**	35 | 4042	**85**	37 | 4476
CD4 Monitoring (ART)	**61**	35 | 4042	**66**	37 | 4476
ARV Therapy	**90**	35 | 752	**92**	37 | 724
Adherence Assessment	**98**	35 | 4042	**98**	37 | 4476
CPT	**95**	35 | 1181	**92**	37 | 1170
TB Clinical Screening	**94**	34 | 1483	**92**	36 | 1667
IPT-TB	**32**	34 | 1992	**25**	36 | 2086
Prevention Education	**46**	35 | 4679	**41**	37 | 5125
Weight Monitoring	**97**	35 | 4679	**96**	37 | 5125
Food Security	**46**	35 | 4679	**47**	37 | 5125
Alcohol Screening	**47**	35 | 4679	**47**	37 | 5125

[1]Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia Adult Indicators and Eligibility for Rounds 1-10 of Data Collection

Eligibility: All HIV-infected patients with at least one clinical visit during the 6-month review period.

Indicator	Numerator	Denominator
Clinical Visits (ART)	Number of ART patients with at least one clinical visit with a nurse or doctor in the last 3 months of the 6-month review period	Number of ART patients with at least one clinical visit with a nurse or doctor during the 6-month review period
CD4/VL Monitoring (ART)	Number of ART patients with a CD4 count/viral load during the 6-month review period	Number of ART patients with at least one clinical visit during the 6-month review period
ARV Therapy	Number of patients receiving ART during the 6-month review period	Number of patients meeting the MOHSS eligibility criteria for ART (CD4 <200, <250 for pregnant women or WHO Stage 3 or 4)
ART Adherence Assessment	Number of patients who had an adherence assessment during the 6-month review period	Number of patients receiving ART during the 6-month review period or at time of death or transfer out
Cotrimoxazole Preventive Therapy (CPT)	Number of patients who have been prescribed PCP (CTX) prophylaxis during the 6-month review period and are still receiving it at the end of the review period or at the time of death or transfer-out	Number of patients with CD4 < 300 or WHO stage III or IV
TB Clinical Screening	Number of patients who have been screened for signs and symptoms of active TB	Number of patients with at least one clinical visit during the 6-month review period who were not on TB treatment or being screened for active TB
Isoniazid Prophylaxis (IPT)	Number of patients who are currently on Isoniazid Preventive Therapy (IPT)	Number of patients with no documented contraindication to Isoniazid Preventive Therapy and who are not on TB treatment
Prevention Education	Number of patients who received prevention education during the last 3 months of the 6-month review period. For this indicator to be fulfilled, the patient received at least all of the following five messages: (a) Basic HIV education, transmission; (b) Prevention: abstinence, safer sex, condoms; (c) Disclosure; (d) Post-test counseling: implications of results; (e) Reproductive choices, prevention of MTCT.	Number of patients with at least one clinical visit during the 6-month review period
Weight Monitoring	Number of patients whose weight has been recorded during the 6-month review period	Number of patients with at least one clinical visit during the 6-month review period
Food Security	Number of patients assessed for food security (hunger) during the 6-month review period	Number of patients with at least one clinical visit during the 6-month review period
Alcohol Screening	Number of patients who have been screened for alcohol use during the 6-month review period	Number of patients with at least one clinical visit during the 6-month review period

Namibia Clinical Visits

Percentage of adult patients on ART who had at least one clinical visit during the last 3 months of the 6-month review period

Total (all clinics) Namibia Adult Clinical Visits (ART) Scores (%) by Review Period



Total (all clinics) Namibia Adult Clinical Visits (ART) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	1631	79		78	75	88	44	99
Jul - Dec 08	16	1522	85		85	82	90	61	99
Jan - Jun 09	31	2790	88		91	83	96	32	100
Jul - Dec 09	33	3087	82		85	77	90	52	98
Jan - Jun 10	36	3680	87		89	84	94	50	99
Oct 10 - Mar 11	36	3704	87		91	81	96	57	100
Oct 11 - Mar 12	36	4297	86		90	84	95	0	98
Apr - Sept 12	35	4042	82		89	72	92	34	98
Oct 12 - Mar 13	37	4476	85		87	79	92	54	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia CD4 Monitoring

Percentage of adult patients on ART who had at least one CD4 count during the 6-month review period

Total (all clinics) Namibia Adult CD4 Monitoring Scores (%) by Review Period



Total (all clinics) Namibia Adult CD4 Monitoring Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	1631	74		75	68	85	32	96
Jul - Dec 08	16	1522	65		66	47	78	37	92
Jan - Jun 09	31	2791	72		74	62	86	30	100
Jul - Dec 09	33	3308	62		63	55	70	34	95
Jan - Jun 10	36	3680	67		70	59	79	33	89
Oct 10 - Mar 11	36	3704	62		63	54	72	29	85
Oct 11 - Mar 12	36	4297	63		66	52	77	10	100
Apr - Sept 12	35	4042	61		64	47	76	21	100
Oct 12 - Mar 13	37	4476	66		70	54	79	27	97

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia ARV Therapy

Percentage of adult patients eligible for ART who received ART during the 6-month review period

Total (all clinics) Namibia Adult ARV Therapy Scores (%) by Review Period



Total (all clinics) Namibia Adult ARV Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	826	83		80	73	97	63	100
Jul - Dec 08	16	791	79		80	74	92	37	98
Jan - Jun 09	31	1122	78		82	71	90	32	100
Jul - Dec 09	33	1099	78		80	68	92	44	100
Jan - Jun 10	36	1213	82		84	75	92	46	100
Oct 10 - Mar 11	36	926	86		89	76	95	44	100
Oct 11 - Mar 12	36	936	89		93	82	100	56	100
Apr - Sept 12	35	752	90		93	83	100	68	100
Oct 12 - Mar 13	37	724	92		100	88	100	66	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia ART Adherence Assessment

Percentage of adult patients on ART during the 6-month review period who had at least one adherence assessment during the 6-month review period

Total (all clinics) Namibia Adult ART Adherence Assessment Scores (%) by Review Period



Total (all clinics) Namibia Adult ART Adherence Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	1631	90		96	92	98	57	100
Jul - Dec 08	16	1522	97		98	96	100	78	100
Jan - Jun 09	31	2790	88		99	92	100	2	100
Jul - Dec 09	33	3087	94		99	96	100	1	100
Jan - Jun 10	36	3680	98		99	96	100	91	100
Oct 10 - Mar 11	36	3704	97		99	96	100	83	100
Oct 11 - Mar 12	36	4297	97		100	96	100	78	100
Apr - Sept 12	35	4042	98		100	98	100	85	100
Oct 12 - Mar 13	37	4476	98		99	97	100	73	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia Cotrimoxazole Preventive Therapy

Percentage of adult patients who are eligible for CPT who have been prescribed PCP (CTX) prophylaxis during the 6-month review period and are still receiving it at the end of the review period or at the time of death or transfer-out

Total (all clinics) Namibia Adult Cotrimoxazole Preventive Therapy Scores (%) by Review Period



Total (all clinics) Namibia Adult Cotrimoxazole Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	1145	86		91	86	94	50	100
Jul - Dec 08	16	1040	90		93	87	98	70	100
Jan - Jun 09	31	1659	87		91	85	95	53	100
Jul - Dec 09	33	1560	86		92	86	95	30	100
Jan - Jun 10	36	1879	93		97	91	98	54	100
Oct 10 - Mar 11	36	1486	92		96	91	100	62	100
Oct 11 - Mar 12	36	1397	92		95	90	97	52	100
Apr - Sept 12	35	1181	95		96	93	100	74	100
Oct 12 - Mar 13	37	1170	92		95	86	100	74	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia Tuberculosis Clinical Screening

Percentage of adult patients who were screened for symptoms and signs of tuberculosis during the 6-month review period

Total (all clinics) Namibia Adult Tuberculosis Clinical Screening Scores (%) by Review Period



Total (all clinics) Namibia Adult Tuberculosis Clinical Screening Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	1684	81		90	78	96	18	100
Jul - Dec 08	16	1321	84		91	80	97	36	100
Jan - Jun 09	30	2193	82		95	86	100	0	100
Jul - Dec 09	32	2549	84		98	91	100	3	100
Jan - Jun 10	35	2426	87		97	83	100	0	100
Oct 10 - Mar 11	35	1912	90		98	92	100	14	100
Oct 11 - Mar 12	35	1650	95		99	94	100	29	100
Apr - Sept 12	34	1483	94		100	97	100	20	100
Oct 12 - Mar 13	36	1667	92		100	96	100	2	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia Isoniazid Preventive Therapy (IPT) Screening

Percentage of adult patients not on TB treatment who received IPT during the 6-month review period

Total (all clinics) Namibia Adult Isoniazid Preventive Therapy Scores (%) by Review Period



Total (all clinics) Namibia Adult Isoniazid PreventiveTherapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	1977	16		13	7	24	1	47
Jul - Dec 08	16	1646	22		11	6	40	3	62
Jan - Jun 09	30	2817	27		16	5	46	0	83
Jul - Dec 09	32	3156	21		13	2	31	0	87
Jan - Jun 10	35	3204	30		29	10	41	0	95
Oct 10 - Mar 11	35	2533	28		23	11	46	0	73
Oct 11 - Mar 12	35	2230	35		32	15	50	7	92
Apr - Sept 12	34	1992	32		24	16	45	2	92
Oct 12 - Mar 13	36	2086	25		24	12	34	0	67

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia Prevention Education

Percentage of adult patients who received prevention education during the last 3 months of the 6-month review period

Total (all clinics) Namibia Adult Prevention Education Scores (%) by Review Period



Total (all clinics) Namibia Adult Prevention Education Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	2296	37		29	19	48	1	98
Jul - Dec 08	16	2259	39		36	15	58	1	86
Jan - Jun 09	31	4043	46		39	11	84	0	99
Jul - Dec 09	33	4330	44		49	11	77	0	99
Jan - Jun 10	36	5079	49		55	21	77	0	100
Oct 10 - Mar 11	36	4664	41		31	21	61	0	100
Oct 11 - Mar 12	36	4989	45		36	18	66	1	100
Apr - Sept 12	35	4679	46		45	12	73	0	100
Oct 12 - Mar 13	37	5125	41		32	12	70	0	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia Weight Monitoring

Percentage of adult patients whose weight was recorded during the 6-month review period

Total (all clinics) Namibia Adult Weight Monitoring Scores (%) by Review Period



Total (all clinics) Namibia Adult Weight Monitoring Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	2296	84		93	82	97	29	100
Jul - Dec 08	16	2259	93		96	90	99	73	100
Jan - Jun 09	30	4006	94		96	93	98	71	100
Jul - Dec 09	33	4330	91		97	92	99	17	100
Jan - Jun 10	36	5079	94		98	95	99	55	100
Oct 10 - Mar 11	36	4664	97		98	95	99	81	100
Oct 11 - Mar 12	36	4989	96		97	94	99	83	100
Apr - Sept 12	35	4679	97		99	96	100	78	100
Oct 12 - Mar 13	37	5125	96		99	97	99	58	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia Food Security

Percentage of adult patients assessed for food security during the 6-month review period

Total (all clinics) Namibia Adult Food Security Scores (%) by Review Period



Total (all clinics) Namibia Adult Food Security Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	2296	24		11	2	33	0	98
Jul - Dec 08	16	2259	34		28	6	55	0	91
Jan - Jun 09	31	4043	24		3	0	42	0	96
Jul - Dec 09	33	4330	27		5	0	53	0	97
Jan - Jun 10	36	5079	38		37	1	59	0	100
Oct 10 - Mar 11	36	4664	46		38	15	80	0	100
Oct 11 - Mar 12	36	4989	47		39	16	90	0	100
Apr - Sept 12	35	4679	46		46	10	86	0	100
Oct 12 - Mar 13	37	5125	47		44	9	85	0	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Namibia Alcohol Screening

Percentage of adult patients who were screened for alcohol use during the 6-month review period

Total (all clinics) Namibia Adult Alcohol Screening Scores (%) by Review Period



Total (all clinics) Namibia Adult Alcohol Screening Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	2296	24		13	2	31	0	97
Jul - Dec 08	16	2259	33		28	9	55	0	88
Jan - Jun 09	31	4043	29		6	0	50	0	97
Jul - Dec 09	33	4330	33		14	0	55	0	97
Jan - Jun 10	36	5079	41		40	7	64	0	100
Oct 10 - Mar 11	36	4664	49		38	18	82	0	100
Oct 11 - Mar 12	36	4989	49		42	17	91	1	100
Apr - Sept 12	35	4679	47		46	9	87	0	100
Oct 12 - Mar 13	37	5125	47		44	13	86	0	100

*Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

HIVQUAL Namibia Performance Measurement
Adult HIV Care

Results

HQ-Namibia has conducted 10 rounds of data collection measuring 11 adult indicators. Technical difficulties in the first round of performance measurement resulted in missing or erroneous data that resulted in elimination of data for this round.

10 out of 11 indicators demonstrated improvement between the first reported review period and the last measurement period. Key areas showing improvement or consistent high scores include ARV therapy, ART adherence assessment, CPT, TB screening, and weight monitoring. Although slight improvement was observed in the rates of food security and alcohol screening as well as prevention education, mean and median scores were all generally low. The prevention education measure was a composite indicator which required that 5 different messages be communicated within 3 months of the visit in order to be met, requiring a level of detailed information about the components in order to use these data for improving care.

Food security and alcohol screening are unique indicators to Namibia and highlight the importance of acknowledging broader issues that influence a patient's ability to maintain treatment and improve health beyond medical care and treatment. Although documentation systems for these indicators were not well-developed, they were the focus of many improvement projects which raised awareness of the importance of integrating these assessments into general medical care. Screening and assessment indicators lend themselves to standardization more easily than other indicators that have multiple processes or rely on external systems for success since they depend largely on provider interventions and are not influenced by structural factors such as stock outs. Wide variation in performance was noted between clinics over several review periods with some scoring 100% and others scoring zero. These findings offered interesting opportunities at the national level for improvement including educational programs and coordination of services with community food providers. Focused coaching activities and regional group sessions to connect teams for sharing of interventions across the performance spectrum also contributed to the spread of improvement strategies in these areas.

Data collection is currently underway for the next two review periods, April – September 2013 and October 2013 – March 2014.

HEALTHQUAL Haiti Performance Measurement

Adult and Pediatric HIV Care

Overview

• The HEALTHQUAL-Haiti program has conducted 13 rounds of data collection and analysis representing care provided from January 1, 2008 through March 31, 2014.
• 106 HQ-Haiti clinics have participated in HEALTHQUAL data collection, representing 74% of 143 HIV clinics and 12% of 908 health facilities in-country.
• The most recent round of data collection reviewed care provided to 103,203 patients, representing 69% of the estimated total number of people living with HIV in-country (150,000 people).
• From January 2008 - March 2014, performance rates have been measured for the following 10 indicators: clinical visits, CD4 monitoring, ARV Therapy, adherence assessment, cotrimoxazole preventive therapy (CPT), TB clinical screening, nutrition evaluation, immunization (pediatric only), ART for pregnant women and family planning (adult only).
• Since the October 2012 - March 2013 review period, additional data have been collected to measure performance on the following 9 new indicators: CD4 test at enrollment, retention, adherence rate, INH prophylaxis, malnutrition status, mental health assessment, syphilis treatment (adult only), cervical cancer screening (adult only) and early HIV detection (pediatric only).
• HEALTHQUAL Haiti indicators are programmed directly into a fully integrated national electronic medical record system.
• Improvement between baseline and most recent follow-up scores has been demonstrated in 15 of 17 adult indicators, most notably for CPT, ARV therapy, family planning and ART for pregnant women. Lower scores in the early rounds of data collection for cervical cancer screening suggest an area for future improvement. Performance data demonstrate improvement between baseline and most recent follow-up scores in 14 of 15 pediatric indicators, most notably for clinical visits, ARV therapy, ART adherence assessment and CPT. Performance on pediatric mental health assessment highlights an opportunity for improvement.

Background

HEALTHQUAL-Haiti began in 2007 through a collaboration between the MOH, CDC and implementing partners. Technical support and guidance are provided by CDC-Haiti. The National Quality Committee developed and defined indicators, chose participating facilities and developed an organizational system to support these activities. HEALTHQUAL-Haiti's data collection process is fully integrated with a nationally implemented electronic medical record system.

Data Collection

For each round of performance measurement, Haiti's EMR enabled quarterly retrospective reviews of data for all eligible patients at each clinic, thus eliminating the need for sampling. HEALTHQUAL-Haiti performance data were extracted directly from the EMR iSante for all sites and from the information systems used by PIH and GHESKIO. In clinics that were fully IT-equipped with local servers, multiple PCs and internet connection, health care providers entered patient data directly into the EMR, which is installed on a local server. In clinics that were not fully IT-equipped, health care providers filled out a paper version of the patient chart forms in the EMR. At the end of each day, a data clerk (for example, the Disease Reporting Officer at the health facility) captured data from the paper forms and entered the information into the EMR on the internet server. HQ reports can be automatically generated for any selected review period by all users of the EMR.

Baseline data from January 1, 2008 - June 30, 2008 were collected from 18 clinics. Indicators address a range of services including HIV care, PMTCT and ART. Over 13 review periods, participation in HEALTHQUAL data collection expanded to include 106 clinics. The adjacent table summarizes the expansion of data collection through the addition of new groups of clinics that collected and submitted baseline performance data. For each group of participating clinics, the table presents the group's baseline review period and number of clinics included in the group.

Expansion of HEALTHQUAL-Haiti data collection by Group

Group #	Baseline Review Period for Group	# of Clinics in Group
1	January - June 2008	18
2	July - December 2008	6
3	July - December 2009	24
4	July - December 2010	4
5	July - December 2011	6
6	April - September 2012	12
7	October 2012 - March 2013	18
8	April - September 2013	14
9	October 2013 - March 2014	4
Total # of clinics that have submitted data		**106**

In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but 9 clinics. Data for those 9 clinics (except for CPT) are not included in the aggregate results for the first 6 review periods. Beginning in the 7th review period, January - June 2011, data from all clinics are stratified and included in the aggregate results. Because of low numbers of eligible patients, pediatric data from Group 4 and Group 5 clinics are not included until the 10th round aggregate scores.

For rounds 1-13, a mean clinic score was calculated for each indicator. Mean clinic scores are reported in the following graphs and tables by indicator and review period. Technical problems with data capture and/or small numbers of eligible patients have resulted in variation in the number of clinics whose performance rates are included in each group's aggregate results from round to round. The details of the number of clinics submitting data within each group and the number of eligible patients are reported in Appendix A.

HQ Haiti Adult Mean Clinic Scores by Round of Data Collection and Indicator

mean score (%) and the number of clinics | number of eligible patients

Round	1			2			3			4			5			6			7		
Adult Indicators	Jan - Jun 08			Jul - Dec 08			Jan - Jun 09			Jul - Dec 09			Jan - Jun 10			Jul - Dec 10			Jan - Jun 11		
Clinical Visits (ART)	**76**	11	3111	**78**	15	5008	**78**	14	6287	**77**	27	10267	**72**	27	11733	**71**	31	13237	**73**	40	19955
CD4 Monitoring[4]	**31**	16	2752	**32**	22	3706	**39**	22	3354	**32**	36	4892	**30**	38	4220	**21**	40	3455	**25**	49	4459
ARV Therapy	**45**	11	2520	**43**	15	3110	**43**	14	3326	**44**	27	4105	**37**	27	3805	**40**	31	4330	**42**	40	6010
CPT	**62**	18	10316	**72**	24	13782	**76**	24	16038	**70**	48	23654	**72**	48	23301	**74**	51	25104	**79**	49	26534
Adherence Assessment	**29**	11	2134	**53**	15	3535	**77**	14	4129	**80**	27	7709	**78**	27	7844	**82**	30	8799	**81**	40	12401
TB Clinical Screening[1]	**29**	16	2990	**32**	22	3150	**33**	22	3981	**30**	38	4156	**25**	37	3283	**29**	40	3509	**77**	49	4454
Nutrition Evaluation	**77**	16	8912	**80**	22	12159	**85**	22	14173	**73**	38	19684	**74**	38	19261	**76**	40	21207	**76**	49	27808
Family Planning	**6**	16	5238	**6**	22	7104	**5**	22	8298	**8**	38	11375	**11**	38	10998	**19**	40	11960	**32**	49	15593
ART for Pregnant Women[2]	**32**	16	289	**41**	23	446	**47**	22	404	**45**	45	648	**40**	41	428	**46**	45	474	**55**	44	844

Round	8			9			10			11			12			13		
Adult Indicators	Jul - Dec 11			Oct 11 - Mar 12			Apr - Sept 12			Oct 12 - Mar 13			Apr - Sept 13			Oct 13 - Mar 14		
Clinical Visits (ART)	**68**	55	22343	**71**	58	23814	**84**	58	38313	**84**	71	42257	**84**	91	51500	**80**	95	58264
CD4 Monitoring[4]	**27**	57	5078	**30**	57	5106	**30**	63	5177	**18**	71	35200	**40**	90	39224	**46**	94	41757
ARV Therapy	**43**	57	7106	**48**	57	6945	**58**	57	8157	**57**	73	9797	**71**	91	11094	**71**	95	9723
CPT	**82**	57	30817	**85**	57	31818	**88**	64	46595	**90**	73	47834	**91**	92	55759	**94**	95	58762
Adherence Assessment	**70**	51	15286	**76**	55	15966	**83**	57	27001	**77**	59	22103	**75**	90	40207	**79**	94	44181
TB Clinical Screening[1]	**84**	57	4569	**86**	57	4447	**92**	64	6147	**90**	73	5064	**95**	88	6004	**93**	93	5453
Nutrition Evaluation	**76**	57	31916	**79**	57	33553	**80**	64	46595	**83**	73	47834	**86**	92	58536	**86**	94	56422
Family Planning	**40**	57	18037	**42**	57	18656	**41**	63	20616	**45**	73	26158	**47**	92	31202	**51**	94	30730
ART for Pregnant Women[2]	**72**	52	786	**81**	46	617	**86**	58	912	**83**	66	689	**89**	82	1468	**91**	84	867
Retention		-			-			-		**57**	73	39404	**60**	91	33537	**58**	95	35465
Adherence Rate		-			-			-		**67**	55	20365	**69**	72	30853	**72**	78	31090
CD4 Test at Enrollment		-			-			-		**62**	73	7088	**64**	90	9419	**66**	94	8462
INH Prophylaxis		-			-			-		**42**	73	46602	**45**	90	23689	**52**	95	25693
Malnutrition Status		-			-			-		**2**	71	34390	**1**	91	40979	**2**	92	41676
Syphilis Treatment		-			-			-		**10**	19	78	**21**	29	81	**41**	32	111
Cervical Cancer Screening		-			-			-		**8**	62	19209	**8**	80	21815	**6**	81	21804
Mental Health Assessment		-			-			-		**45**	62	33411	**45**	80	38151	**53**	81	38128

HQ Haiti Pediatric Mean Clinic Scores by Round of Data Collection and Indicator

mean score (%) and the number of clinics | number of eligible patients

Round	1			2			3			4			5			6			7		
Pediatric Indicators	Jan - Jun 08			Jul - Dec 08			Jan - Jun 09			Jul - Dec 09			Jan - Jun 10			Jul - Dec 10			Jan - Jun 11		
Clinical Visits (ART)	**69**	9	133	**79**	15	269	**86**	14	346	**75**	24	769	**64**	25	903	**71**	27	955	**77**	37	1200
CD4 Monitoring[4]	**35**	15	259	**17**	21	292	**19**	20	319	**21**	33	594	**14**	35	674	**12**	35	482	**13**	40	550
ARV Therapy	**44**	11	244	**41**	15	245	**35**	13	258	**35**	25	420	**32**	26	328	**45**	28	358	**45**	34	386
CPT	**61**	11	350	**76**	19	468	**78**	21	591	**70**	39	1204	**64**	39	1186	**74**	40	1331	**78**	38	1416
Adherence Assessment	**30**	8	93	**49**	15	173	**63**	14	200	**75**	24	547	**63**	24	619	**79**	24	570	**72**	36	739
TB Clinical Screen[1]	**17**	15	266	**18**	20	324	**20**	20	437	**8**	35	713	**11**	35	527	**17**	34	567	**81**	40	608
Nutrition Evaluation	**54**	16	691	**50**	22	898	**56**	22	1161	**43**	38	2269	**41**	37	2092	**41**	37	2279	**41**	48	2663
Immunization[3]	**0**	16	327	**2**	22	423	**3**	22	592	**53**	33	1235	**47**	32	1128	**46**	32	1242	**49**	31	1282

Round	8			9			10			11			12			13		
Pediatric Indicators	Jul - Dec 11			Oct 11 - Mar 12			Apr - Sept 12			Oct 12 - Mar 13			Apr - Sept 13			Oct 13 - Mar 14		
Clinical Visits (ART)	**69**	42	1294	**75**	42	1415	**87**	52	2147	**88**	61	2278	**89**	75	2421	**88**	82	2474
CD4 Monitoring[4]	**10**	41	589	**16**	40	650	**20**	46	379	**14**	49	1330	**44**	61	1476	**49**	74	1526
ARV Therapy	**43**	43	442	**49**	42	411	**48**	47	567	**56**	56	380	**70**	69	451	**73**	68	366
CPT	**92**	30	1442	**84**	39	1598	**83**	53	3420	**90**	51	2537	**91**	63	2639	**96**	67	2420
Adherence Assessment	**73**	36	832	**77**	39	949	**83**	48	1684	**83**	45	1296	**78**	69	2067	**76**	78	2138
TB Clinical Screen[1]	**87**	42	867	**86**	42	813	**90**	55	1068	**91**	59	378	**93**	69	464	**91**	66	415
Nutrition Evaluation	**34**	55	3544	**33**	55	3293	**41**	60	4857	**61**	67	3646	**56**	79	3905	**62**	83	3637
Immunization[3]	**48**	33	1633	**48**	33	1594	**53**	43	1895	-			-			-		
Retention	-			-			-			**55**	67	2371	**59**	77	2054	**56**	82	1497
Adherence Rate	-			-			-			**63**	43	1073	**61**	53	1522	**73**	60	1616
CD4 Test at Enrollment	-			-			-			**20**	21	96	**24**	23	127	**41**	19	122
INH Prophylaxis	-			-			-			**23**	59	1453	**18**	42	898	**29**	47	929
Malnutrition Status	-			-			-			**12**	62	1787	**10**	67	1964	**9**	75	1936
Early HIV Detection	-			-			-			**22**	43	978	**57**	50	1209	**63**	54	991
Mental Health Assessment	-			-			-			**3**	56	2716	**1**	67	3088	**4**	70	2815

1. Indicator was changed in round 7 to include eligible patients who were screened for TB symptoms of cough, fever and weight loss in the numerator in addition to those who received a tuberculin skin test (TST).
2. In 2011, eligibility for ART prophylaxis for pregnant patients was changed from gestational age > 28 weeks to >14 weeks or 98 days from the date of last menstrual period.
3. Immunization data captured during the Oct 12 - Mar 13, Apr - Sept 13, and Oct 13 - Mar 14 review periods are omitted, pending further validation.
4. **As of the Oct 12 - Mar 13 review period, the CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring, measured by the percentage of all patients enrolled prior to the 6-month review period who received 2 CD4 tests in the last 12 months and (2) CD4 test at Enrollment, measured by the percentage of patients newly enrolled during the 6-month review period who received a CD4 test within 60 days of enrollment.

Haiti Indicators for Rounds 1-13 of Data Collection

Eligibility: All HIV-infected patients with at least one clinical visit during the 6-month review period. Adult: >15 years old. Pediatric: <15 years old

Indicator	Numerator	Denominator
Clinical Visits	Number of patients on ART with at least one clinical visit within 3 months of their last visit. All patients who have received at least one dispensation of ART drugs at the reporting clinic are considered on ART.	Number of patients (all ages) on ART who have been in the program at least 3 months
CD4 Monitoring	Rounds 1-10: Number of patients (all ages) with a CD4 count at enrollment (within the two months of enrollment) and at 6 months (between two and eight months) Rounds 11-13: Number of HIV+ patients (on ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months	Rounds 1-10: Number of patients (all ages) enrolled in the program within the preceding 6-12 months of the 6-month review period. Rounds 11-13: Number of HIV+ patients (on ART and pre-ART) enrolled in care for more than 6 months excluding deceased patients, transferred patients and children with negative PCR results
ART	Number of patients (all ages) enrolled in ARV therapy according to WHO criteria during the 6-month review period	Number of patients (all ages) eligible for ART during the 6-month review period, according to WHO criteria: CD4 <200; TLC <1200; WHO stage III and CD4 <350; or WHO stage IV.
Adherence Assessment	Number of patients on ART (all ages) who have had an adherence assessment (pill-count or questionnaire) during the last 3 months of the 6-month review period	Number of patients (all ages) on ART having had at least one medical visit during the last 3 months of the 6-month review period
Cotrimoxazole Preventive Therapy (CPT)	Adult (>15 years old): Number of adult patients who have received cotrimoxazole prophylaxis during the 6-month review period Pediatric (<15 years old): Number of children HIV-exposed and infected children receiving follow up who are eligible for and have received cotrimoxazole prophylaxis during the 6-month review period	Adult (>15 years old): Number of adult patients who had at least one medical visit in the during the 6-month review period. Cotrimoxazole prophylaxis is recommended for all HIV-infected adults and adolescents. Pediatric (<15 years old): Number of HIV-exposed and infected children receiving follow-up during the 6-month review period. Cotrimoxazole prophylaxis is recommended for HIV-exposed and infected children age 6 weeks - 12 months (unless HIV infection is ruled out in exposed children age < 12 months); HIV-infected children age 1 to 4 years with WHO stage II, III or IV disease; and HIV-infected children age > 5 yrs regardless of WHO stage.
TB Clinical Screening	Rounds 1-6: Number of patients (all ages) screened for TB done by tuberculin skin test (TST) at enrollment during the 6-month review period. (Patients with greater than or equal to 5 mm would benefit from a chest x-ray to eliminate active TB). Round 7: Number of patients (all ages) screened for TB by TST or for symptoms of cough, fever and weight loss.	Number of HIV patients (all ages) enrolled in care during the 6-month review period
Nutrition Evaluation	Number of patients having had a nutritional evaluation during the 6-month review period	Number of HIV patients who have had at least one medical visit during the 6-month review period. Adults: BMI should be calculated at enrollment and weight must be measured at each visit. BMI less than 16 is severe malnutrition; BMI between 16 and 18.5 is moderate malnutrition. Pediatric: malnutrition is measured by growth rate.
Family Planning	Number of HIV-infected women of childbearing age who accepted a family planning method during the 6-month review period	Number of HIV-infected women of childbearing age who received at least one visit during the 6-month review period
ART for Pregnant Women	Number of HIV-infected pregnant women who have received ARV prophylaxis during the 6-month review period	Number of HIV seropositive pregnant women who were eligible for ARV prophylaxis during the 6-month review period. Rounds 1-6 eligibility: All pregnant HIV+ women should receive ARV prophylaxis from the 28th week of pregnancy according to the protocol in effect if she is not eligible for tri-therapy. Round 7 New Eligibility for ART prophylaxis for pregnant patients is defined as 'Gestational age > 14 weeks, or 98 days from the date of last menstrual period.
Immunization (Pediatric only)	Number of children under age 5 years exposed to or infected with HIV being seen at the clinic who have had complete vaccinations for their age during the 6-month review period	Number of children exposed to or infected with HIV being seen at the clinic during the 6-month review period

Haiti Indicators (continued) for Rounds 11-13 of Data Collection

Eligibility: All HIV-infected patients with at least one clinical visit during the 6-month review period. Adult: >15 years old. Pediatric: <15 years old

Indicator	Numerator	Denominator
Retention	Cumulative number of patients not enrolled in ARV treatment with at least one visit in the last 6 months	Cumulative number of patients not enrolled in ART care excluding deceased and transferred patients
Adherence Rate	Cumulative number of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%	Cumulative number of patients enrolled on ART for more than 3 months who received an adherence assessment, excluding deceased or transferred patients
CD4 Test at Enrollment	Number of patients enrolled during the review period who received at least one CD4 count during the first 60 days of their enrollment	Number of patients enrolled during the review period excluding deceased patients, transferred patients and children with negative PCR results
INH Prophylaxis	Number of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months	Number of patients enrolled in HIV care during the past 6 months who made at least one clinical visit during the last 6 months, excluding patients who are deceased, transferred or who have active TB
Malnutrition Status	Adult: Number of patients with a body mass index (BMI) of 16 or lower (severe malnutrition) during the past 6 months Pediatric: Number of HIV-infected children with severe malnutrition (any child with a weight gain of less than -3 standard deviations or any child aged 1-5 years with MUAC <12.5 cm or a ratio of AC / HC <0.25)	Adult: Number of HIV-infected patients who received a BMI assessment during the last 6 months, excluding deceased and transferred patients Pediatric: Number of HIV-infected children who received a nutritional assessment during the past 6 months, excluding those out of care
Syphilis Treatment (adult only)	Number of women who tested positive for syphilis who completed treatment	Number of women who tested positive for syphilis, excluding deceased and transferred patients
Cervical Cancer Screening (adult only)	Number of HIV-infected women aged 25-64 years screened for cervical cancer (visual inspection of the cervix with acetic acid [VIA] or a cervical cytology)	Number of HIV-infected women aged 25-64 years with at least one clinical visit during the past 6 months, excluding deceased and transferred patients
Mental Health Assessment	Number of patients who received a mental health evaluation during the past 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation, and assessment of sleep and appetite)	Number of HIV-infected patients with at least one clinical visit during the past 6 months, excluding deceased and transferred patients
Early HIV Detection (pediatric only)	Number of children exposed to HIV aged 4 weeks to 1 year who have received early screening by PCR during the last 3 months excluding those out of care	Number of children (aged 4 weeks to 1 year) seen in the clinic during the last 3 months who were born to HIV-positive mothers

Haiti Clinical Visits (ART) and Retention (pre-ART)

Clinical Visits: Percentage of adult patients on ART who had at least one clinical visit within three months of their last visit during the six-month review period

Retention: Percentage of patients not enrolled in ARV treatment with at least one visit in the last 6 months

Total (all clinics) Haiti Adult Clinical Visits (ART) and Retention (pre-ART) Scores (%) by Review Period



Total (all clinics) Haiti Adult Clinical Visits (ART) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	11	3111	76		81	69	85	52	89
Jul - Dec 08	15	5008	78		80	74	85	54	88
Jan - Jun 09	14	6287	78		80	75	84	55	91
Jul - Dec 09	27	10267	77		81	66	87	47	100
Jan - Jun 10	27	11733	72		78	69	84	9	96
Jul - Dec 10	31	13237	71		77	67	81	3	93
Jan - Jun 11	40	19955	73		77	65	87	1	99
Jul - Dec 11	55	22343	68		75	64	81	0	99
Oct 11 - Mar 12	58	23814	71		77	67	86	0	99
Apr - Sept 12	58	38313	84		85	77	94	41	100
Oct 12 - Mar 13	71	42257	84		86	78	94	44	100
Apr - Sept 13	91	51500	84		89	75	95	0	100
Oct 13 - Mar 14	95	58264	80		83	70	92	0	100

Total (all clinics) Haiti Adult Retention (pre-ART) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	73	39404	57		58	37	80	6	97
Apr - Sept 13	91	33537	60		59	38	82	3	100
Oct 13 - Mar 14	95	35465	58		60	38	80	12	99

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti CD4 Monitoring** (Rounds 1-10)

Percentage of newly enrolled adult patients (within preceding 6-12 months of review period) who had a CD4 count within two months of enrollment and between two and eight months after enrollment

Total (all clinics) Haiti Adult CD4 Monitoring (Rounds 1-10) Scores (%) by Review Period



Total (all clinics) Haiti Adult CD4 Monitoring (Rounds 1-10) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	2752	31		32	18	38	0	76
Jul - Dec 08	22	3706	32		29	22	39	2	84
Jan - Jun 09	22	3354	39		37	21	53	6	88
Jul - Dec 09	36	4892	32		30	14	44	0	76
Jan - Jun 10	38	4220	30		27	11	49	0	100
Jul - Dec 10	40	3455	21		18	6	28	0	71
Jan - Jun 11	49	4459	25		15	8	39	0	97
Jul - Dec 11	57	5078	27		22	7	45	0	85
Oct 11 - Mar 12	57	5106	30		27	10	46	0	79
Apr - Sept 12	63	5177	30		28	6	47	0	84

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

**As of the Oct 12 - Mar 13 review period, the CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring, measured by the percentage of all patients enrolled prior to the 6-month review period who received 2 CD4 tests in the last 12 months and (2) CD4 Test at Enrollment, measured by the percentage of patients newly enrolled during the 6-month review period who received a CD4 test within 60 days of enrollment. Results from the revised CD4 Monitoring indicators are reported separately.

Haiti CD4 Monitoring and CD4 Test at Enrollment (Rounds 11-13)

CD4 Monitoring: Percentage of patients (ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months, excluding deceased and transferred patients

CD4 Test at Enrollment: Percentage of patients newly enrolled during the 6-month review period who received a CD4 test within 60 days of enrollment, excluding deceased and transferred patients

As of the Oct 12 - Mar 13 review period, the Haiti CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring and (2) CD4 Test at Enrollment. The results for each of these revised CD4 Monitoring inidcators are reported in the following graph and tables.

Total (all clinics) Haiti Adult CD4 Monitoring and CD4 Test at Enrollment Scores (%) by Review Period



Total (all clinics) Haiti Adult CD4 Monitoring (Rounds 11-13) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	71	35200	18		14	6	28	0	53
Apr - Sept 13	90	39224	40		37	14	65	0	93
Oct 13 - Mar 14	94	41757	46		47	23	68	0	95

Total (all clinics) Haiti Adult CD4 Test at Enrollment (Rounds 11-13) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	73	7088	62		68	46	85	0	100
Apr - Sept 13	90	9419	64		71	49	85	0	100
Oct 13 - Mar 14	94	8462	66		69	56	87	0	100

Haiti Cotrimoxazole Preventive Therapy

Percentage of adult patients who received cotrimoxazole prophylaxis during the six-month review period

Total (all clinics) Haiti Adult Cotrimoxazole Preventive Therapy Scores (%) by Review Period



Total (all clinics) Haiti Adult Cotrimoxazole Preventive Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	18	10316	62		72	34	84	23	88
Jul - Dec 08	24	13782	72		80	63	88	0	98
Jan - Jun 09	24	16038	76		84	74	91	0	99
Jul - Dec 09	48	23654	70		79	46	92	3	99
Jan - Jun 10	48	23301	72		81	58	91	4	98
Jul - Dec 10	51	25104	74		84	56	96	10	99
Jan - Jun 11	49	26534	79		89	69	96	7	99
Jul - Dec 11	57	30817	82		92	71	97	9	100
Oct 11 - Mar 12	57	31818	85		95	79	97	32	100
Apr - Sept 12	64	46595	88		95	90	98	30	100
Oct 12 - Mar 13	73	47834	90		96	89	99	21	100
Apr - Sept 13	92	55759	91		97	92	99	0	100
Oct 13 - Mar 14	95	58762	94		96	92	98	61	100

*For every review period, CPT data from all clinics are stratified into adult and pediatric (<15 years old) data and are included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti ARV Therapy

Percentage of adult patients eligible for ART who were enrolled in ART during the six-month review period

Total (all clinics) Haiti Adult ARV Therapy Scores (%) by Review Period



Total (all clinics) Haiti Adult ARV Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	11	2520	45		46	35	54	20	73
Jul - Dec 08	15	3110	43		42	34	51	17	76
Jan - Jun 09	14	3326	43		45	39	52	23	60
Jul - Dec 09	27	4105	44		42	36	49	24	85
Jan - Jun 10	27	3805	37		36	22	47	0	69
Jul - Dec 10	31	4330	40		42	25	54	9	69
Jan - Jun 11	40	6010	42		43	29	56	3	81
Jul - Dec 11	57	7106	43		43	26	64	0	85
Oct 11 - Mar 12	57	6945	48		46	33	63	2	89
Apr - Sept 12	57	8157	58		57	46	70	9	100
Oct 12 - Mar 13	73	9797	57		59	47	73	0	98
Apr - Sept 13	91	11094	71		74	63	83	0	100
Oct 13 - Mar 14	95	9723	71		73	61	83	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti ART Adherence Assessment and Adherence Rate

ART Adherence Assessment: Percentage of adult patients on ART who had an adherence assessment during the six-month review period

Adherence Rate: Percentage of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%

Total (all clinics) Haiti Adult ART Adherence Assessment and Adherence Rate Scores (%) by Review Period



Total (all clinics) Haiti Adult ART Adherence Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	11	2134	29		3	0	71	0	89
Jul - Dec 08	15	3535	53		55	15	90	0	93
Jan - Jun 09	14	4129	77		90	67	98	0	100
Jul - Dec 09	27	7709	80		94	76	97	0	100
Jan - Jun 10	27	7844	78		93	68	98	1	100
Jul - Dec 10	30	8799	82		95	90	98	0	100
Jan - Jun 11	40	12401	81		97	90	98	0	100
Jul - Dec 11	51	15286	70		92	54	97	0	100
Oct 11 - Mar 12	55	15966	76		94	71	98	0	100
Apr - Sept 12	57	27001	83		95	85	98	0	100
Oct 12 - Mar 13	59	22103	77		93	77	97	0	100
Apr - Sept 13	90	40207	75		92	66	96	0	100
Oct 13 - Mar 14	94	44181	79		91	72	96	0	100

Total (all clinics) Haiti Adult Adherence Rate Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	55	20365	67		76	59	85	0	100
Apr - Sept 13	72	30853	69		73	60	84	1	100
Oct 13 - Mar 14	78	31090	72		76	62	86	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti TB Clinical Screening and INH Prophylaxis

TB Clinical Screening: Percentage of adult patients screened for TB by tuberculin skin test (or by symptoms of cough, fever and weight loss) during the six-month review period

INH Prophylaxis: Percentage of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months

Total (all clinics) Haiti Adult TB Clinical Screening and INH Prophylaxis Scores (%) by Review Period



Total (all clinics) Haiti Adult TB Clinical Screening Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	2990	29		30	21	36	0	56
Jul - Dec 08	22	3510	32		33	27	40	0	63
Jan - Jun 09	22	3981	33		32	26	41	0	59
Jul - Dec 09	38	4156	30		28	16	40	0	75
Jan - Jun 10	37	3283	25		28	14	33	0	65
Jul - Dec 10	40	3509	29		28	10	46	0	74
Jan - Jun 11	49	4454	77		97	82	100	0	100
Jul - Dec 11	57	4569	84		98	87	100	11	100
Oct 11 - Mar 12	57	4447	86		98	85	100	14	100
Apr - Sept 12	64	6147	92		99	89	100	44	100
Oct 12 - Mar 13	73	5064	90		96	87	100	11	100
Apr - Sept 13	88	6004	95		100	95	100	48	100
Oct 13 - Mar 14	93	5453	93		99	93	100	50	100

Total (all clinics) Haiti Adult INH Prophylaxis Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	73	46602	42		35	15	66	1	97
Apr - Sept 13	90	23689	45		42	22	70	0	100
Oct 13 - Mar 14	95	25693	52		55	27	72	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti Nutrition Evaluation

Percentage of adult patients who had a nutritional evaluation during the six-month review period

Total (all clinics) Haiti Adult Nutrition Evaluation Scores (%) by Review Period



Total (all clinics) Haiti Adult Nutrition Evaluation Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	8912	77		81	70	90	11	99
Jul - Dec 08	22	12159	80		88	71	94	14	99
Jan - Jun 09	22	14173	85		88	84	91	26	98
Jul - Dec 09	38	19684	73		79	64	92	3	99
Jan - Jun 10	38	19261	74		82	62	93	2	99
Jul - Dec 10	40	21207	76		85	68	93	1	99
Jan - Jun 11	49	27808	76		86	67	91	1	99
Jul - Dec 11	57	31916	76		84	67	94	0	100
Oct 11 - Mar 12	57	33553	79		87	73	93	0	100
Apr - Sept 12	64	46595	80		89	79	95	0	100
Oct 12 - Mar 13	73	47834	83		91	76	96	0	100
Apr - Sept 13	92	58536	86		92	81	96	2	100
Oct 13 - Mar 14	94	56422	86		93	83	97	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti Malnutrition Status

Percentage of patients with a body mass index (BMI) of 16 or lower (severe malnutrition) during the past 6 months

Total (all clinics) Haiti Adult Malnutrition Status Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	71	34390	2		1	0	2	0	9
Apr - Sept 13	91	40979	1		1	0	2	0	8
Oct 13 - Mar 14	92	41676	2		1	0	1	0	13

Haiti Family Planning

Percentage of HIV-infected women of childbearing age who accepted a family planning method during the six-month review period

Haiti Adult Family Planning Scores (%) by Review Period



Total (all groups) Haiti Adult Family Planning Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	5238	6		5	3	8	1	12
Jul - Dec 08	22	7104	6		4	3	8	0	21
Jan - Jun 09	22	8298	5		4	2	7	0	17
Jul - Dec 09	38	11375	8		5	2	10	0	44
Jan - Jun 10	38	10998	11		7	3	16	0	50
Jul - Dec 10	40	11960	19		13	6	25	0	70
Jan - Jun 11	49	15593	32		29	11	50	1	79
Jul - Dec 11	57	18037	40		44	22	59	4	83
Oct 11 - Mar 12	57	18656	42		41	23	59	5	84
Apr - Sept 12	63	20616	41		40	22	64	0	84
Oct 12 - Mar 13	73	26158	45		45	23	67	0	92
Apr - Sept 13	92	31202	47		45	33	65	0	91
Oct 13 - Mar 14	94	30730	51		51	36	65	0	96

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti ART for Pregnant Women

Percentage of HIV+ pregnant women who were eligible for and received ARV prophylaxis during the six-month review period. Eligibility was changed from 28th to 14th week of pregnancy for the Jan - Jun 2011 review period onward.

Haiti ART for Pregnant Women Scores (%) by Review Period**



Total (all groups) Haiti ART for Pregnant Women Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	289	32		30	19	47	0	67
Jul - Dec 08	23	446	41		44	31	53	0	75
Jan - Jun 09	22	404	47		43	33	59	0	100
Jul - Dec 09	45	648	45		41	26	60	0	100
Jan - Jun 10	41	428	40		40	14	58	0	100
Jul - Dec 10	45	474	46		43	25	68	0	100
Jan - Jun 11	44	844	55		52	33	74	0	100
Jul - Dec 11	52	786	72		75	59	95	0	100
Oct 11 - Mar 12	46	617	81		85	67	100	0	100
Apr - Sept 12	58	912	86		92	79	100	0	100
Oct 12 - Mar 13	66	689	83		89	73	100	0	100
Apr - Sept 13	82	1468	89		95	88	100	0	100
Oct 13 - Mar 14	84	867	91		100	89	100	0	100

*In 2011, eligibility for ART prophylaxis for pregnant patients was changed from gestational age > 28 weeks to > 14 weeks or 98 days from the date of last menstrual period. As of March 2012, MSPP adopted the B+ option requiring all HIV+ pregnant women to be systematically placed on ART.
**Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti Syphilis Treatment

Percentage of women who tested positive for syphilis who completed treatment

Total (all clinics) Haiti Adult Syphilis Treatment Scores (%) by Review Period



Total (all clinics) Haiti Adult Syphilis Treatment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	19	78	10		0	0	8	0	60
Apr - Sept 13	29	81	21		0	0	30	0	100
Oct 13 - Mar 14	32	111	41		28	0	88	0	100

Haiti Cervical Cancer Screening

Percentage of women aged 25-64 years screened for cervical cancer (visual inspection of the cervix with acetic acid [VIA] or a cervical cytology)

Total (all clinics) Haiti Adult Cervical Cancer Screening Scores (%) by Review Period



Total (all clinics) Haiti Adult Cervical Cancer Screening Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	62	19209	8		6	0	11	0	94
Apr - Sept 13	80	21815	8		4	1	11	0	93
Oct 13 - Mar 14	81	21804	6		3	0	6	0	60

Haiti Mental Health Assessment

Percentage of patients who received a mental health assessment during the past 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation and assessment of sleep and appetite)

Total (all clinics) Haiti Adult Mental Health Assessment Scores (%) by Review Period



Total (all clinics) Haiti Adult Mental Health Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	62	33411	45		43	9	78	0	100
Apr - Sept 13	80	38151	45		45	6	77	0	100
Oct 13 - Mar 14	81	38128	53		56	20	81	0	99

Haiti Clinical Visits (ART) and Retention (pre-ART)

Clinical Visits: Percentage of pediatric patients on ART who had at least one clinical visit within 3 months of their last visit during the 6-month review period

Retention: Percentage of patients not enrolled in ARV treatment with at least one visit in the last 6 months

Total (all clinics) Haiti Pediatric Clinical Visits (ART) and Retention (pre-ART) Scores (%) by Review Period



Total (all clinics) Haiti Pediatric Clinical Visits (ART) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	9	133	69		79	50	86	29	100
Jul - Dec 08	15	269	79		85	68	100	25	100
Jan - Jun 09	14	346	86		91	85	100	24	100
Jul - Dec 09	24	769	75		83	63	90	0	100
Jan - Jun 10	25	903	64		75	50	84	0	100
Jul - Dec 10	27	955	71		78	60	88	0	100
Jan - Jun 11	37	1200	77		80	67	95	8	100
Jul - Dec 11	42	1294	69		77	66	89	0	100
Oct 11 - Mar 12	42	1415	75		81	67	94	0	100
Apr - Sept 12	52	2147	87		90	78	100	50	100
Oct 12 - Mar 13	61	2278	88		95	79	100	45	100
Apr - Sept 13	75	2421	89		98	83	100	0	100
Oct 13 - Mar 14	82	2474	88		96	82	100	18	100

Total (all clinics) Haiti Pediatric Retention (pre-ART) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	67	2371	55		59	28	82	0	100
Apr - Sept 13	77	2054	59		61	33	89	0	100
Oct 13 - Mar 14	82	1497	56		56	34	75	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.
**Pediatric data from Groups 4 and 5 are not included in the total (all groups) aggregate calculations until the 10th round of data collection, Apr - Sept 12, due to small numbers of eligible patients in previous rounds. Appendix A shows pediatric data by group and review period for all rounds of data collection.

Haiti CD4 Monitoring** (Rounds 1-10)

rcentage of newly enrolled pediatric patients (within preceding 6-12 months of review period) who had a CD4 count within 2 months of enrollment and between 2 and 8 months after enrollment

Total (all clinics) Haiti Pediatric CD4 Monitoring (Rounds 1-10) Scores (%) by Review Period



Total (all clinics) Haiti Pediatric CD4 Monitoring (Rounds 1-10) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	259	35		33	0	41	0	100
Jul - Dec 08	21	292	17		10	0	23	0	100
Jan - Jun 09	20	319	19		17	2	27	0	56
Jul - Dec 09	33	594	21		9	0	40	0	100
Jan - Jun 10	35	674	14		6	0	20	0	80
Jul - Dec 10	35	482	12		0	0	13	0	100
Jan - Jun 11	40	550	13		5	0	20	0	100
Jul - Dec 11	41	589	10		4	0	18	0	57
Oct 11 - Mar 12	40	650	16		7	0	29	0	100
Apr - Sept 12	46	379	20		0	0	24	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.
**As of the Oct 12 - Mar 13 review period, the CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring, measured by the percentage of all patients enrolled prior to the 6-month review period who received 2 CD4 tests in the last 12 months and (2) CD4 test at Enrollment, measured by the percentage of patients newly enrolled during the 6-month review period who received a CD4 test within 60 days of enrollment. Results from the revised CD4 Monitoring indicators are reported separately.
**Pediatric data from Groups 4 and 5 are not included in the total (all groups) aggregate calculations until the 10th round of data collection, Apr - Sept 12, due to small numbers of eligible patients in previous rounds. Appendix A shows pediatric data by group and review period for all rounds of data collection.

Haiti CD4 Monitoring and CD4 Test at Enrollment (Rounds 11-13)

CD4 Monitoring: Percentage of patients (ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months, excluding deceased and transferred patients and children with negative PCR results

CD4 Test at Enrollment: Percentage of patients newly enrolled during the 6-month review period who received a CD4 test within 60 days of enrollment, excluding deceased and transferred patients and children with negative PCR results

As of the Oct 12 - Mar 13 review period, the Haiti CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring and (2) CD4 Test at Enrollment. The results for each of these revised CD4 Monitoring inidcators are reported in the following graph and tables.

Total (all clinics) Haiti Pediatric CD4 Monitoring and CD4 Test at Enrollment Scores (%) by Review Period



Total (all clinics) Haiti Pediatric CD4 Monitoring (Rounds 11-13) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	49	1330	14		7	0	23	0	100
Apr - Sept 13	61	1476	44		42	13	67	0	100
Oct 13 - Mar 14	74	1526	49		48	23	78	0	100

Total (all clinics) Haiti Pediatric CD4 Test at Enrollment (Rounds 11-13) Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	21	96	20		0	0	25	0	100
Apr - Sept 13	23	127	24		0	0	50	0	100
Oct 13 - Mar 14	19	122	41		40	0	78	0	100

Haiti ARV Therapy

Percentage of pediatric patients eligible for ART who were enrolled in ART during the 6-month review period.

Total (all clinics) Haiti Pediatric ARV Therapy Scores (%) by Review Period



Total (all clinics) Haiti Pediatric ARV Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	11	244	44		46	20	60	0	100
Jul - Dec 08	15	245	41		40	13	60	0	100
Jan - Jun 09	13	258	35		31	25	40	0	100
Jul - Dec 09	25	420	35		35	15	55	0	82
Jan - Jun 10	26	328	32		35	2	50	0	100
Jul - Dec 10	28	358	45		48	21	67	0	100
Jan - Jun 11	34	386	45		42	18	77	0	100
Jul - Dec 11	43	442	43		46	16	64	0	100
Oct 11 - Mar 12	42	411	49		48	28	69	0	100
Apr - Sept 12	47	567	48		45	28	69	0	100
Oct 12 - Mar 13	56	380	56		50	33	100	0	100
Apr - Sept 13	69	451	70		82	50	100	0	100
Oct 13 - Mar 14	68	366	73		85	50	100	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**Pediatric data from Groups 4 and 5 are not included in the total (all groups) aggregate calculations until the 10th round of data collection, Apr - Sept 12, due to small numbers of eligible patients in previous rounds. Appendix A shows pediatric data by group and review period for all rounds of data collection.

Haiti ART Adherence Assessment and Adherence Rate

ART Adherence Assessment: Percentage of pediatric patients on ART who had an adherence assessment during the six-month review period

Adherence Rate: Percentage of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%

Total (all clinics) Haiti Pediatric ART Adherence Assessment and Adherence Rate Scores (%) by Review Period



Total (all clinics) Haiti Pediatric ART Adherence Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	8	93	30		4	0	50	0	100
Jul - Dec 08	15	173	49		65	0	89	0	100
Jan - Jun 09	14	200	63		92	25	100	0	100
Jul - Dec 09	24	547	75		94	62	100	0	100
Jan - Jun 10	24	619	63		82	38	96	0	100
Jul - Dec 10	24	570	79		100	75	100	0	100
Jan - Jun 11	36	739	72		92	31	100	0	100
Jul - Dec 11	36	832	73		97	62	100	0	100
Oct 11 - Mar 12	39	949	77		97	67	100	0	100
Apr - Sept 12	48	1684	83		95	83	100	0	100
Oct 12 - Mar 13	45	1296	83		97	80	100	0	100
Apr - Sept 13	69	2067	78		100	73	100	0	100
Oct 13 - Mar 14	78	2138	76		94	51	100	0	100

Total (all clinics) Haiti Pediatric Adherence Rate Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	43	1073	63		68	41	100	0	100
Apr - Sept 13	53	1522	61		64	40	100	0	100
Oct 13 - Mar 14	60	1616	73		86	50	100	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**Pediatric data from Groups 4 and 5 are not included in the total (all groups) aggregate calculations until the 10th round of data collection, Apr - Sept 12, due to small numbers of eligible patients in previous rounds. Appendix A shows pediatric data by group and review period for all rounds of data collection.

Haiti Cotrimoxazole Preventive Therapy

Percentage of pediatric patients (HIV-exposed and HIV-infected) who received cotrimoxazole prophylaxis during the 6-month review period.

Total (all clinics) Haiti Pediatric Cotrimoxazole Preventive Therapy Scores (%) by Review Period



Total (all clinics) Haiti Pediatric Cotrimoxazole Preventive Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	11	350	61		67	50	75	25	86
Jul - Dec 08	19	468	76		88	71	98	0	100
Jan - Jun 09	21	591	78		89	73	100	0	100
Jul - Dec 09	39	1204	70		82	55	98	0	100
Jan - Jun 10	39	1186	64		69	45	94	0	100
Jul - Dec 10	40	1331	74		92	58	100	0	100
Jan - Jun 11	38	1416	78		93	65	100	0	100
Jul - Dec 11	30	1442	92		98	93	100	17	100
Oct 11 - Mar 12	39	1598	84		95	73	100	23	100
Apr - Sept 12	53	3420	83		94	71	100	17	100
Oct 12 - Mar 13	51	2537	90		100	90	100	0	100
Apr - Sept 13	63	2639	91		100	93	100	0	100
Oct 13 - Mar 14	67	2420	96		100	98	100	38	100

*For every review period, CPT data from all clinics are stratified and included in the aggregate results.

**Pediatric data from Groups 4 and 5 are not included in the total (all groups) aggregate calculations until the 10th round of data collection, Apr - Sept 12, due to small numbers of eligible patients in previous rounds. Appendix A shows pediatric data by group and review period for all rounds of data collection.

Haiti TB Clinical Screening and INH Prophylaxis

TB Clinical Screening: Percentage of pediatric patients screened for TB by tuberculin skin test (or by symptoms of cough, fever and weight loss) during the 6-month review period

INH Prophylaxis: Percentage of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months

Total (all clinics) Haiti Pediatric TB Clinical Screening and INH Prophylaxis Scores (%) by Review Period



Total (all clinics) Haiti Pediatric TB Clinical Screening Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	266	17		11	0	23	0	63
Jul - Dec 08	20	324	18		11	0	22	0	100
Jan - Jun 09	20	437	20		9	0	30	0	100
Jul - Dec 09	35	713	8		0	0	13	0	50
Jan - Jun 10	35	527	11		4	0	17	0	100
Jul - Dec 10	34	567	17		7	0	19	0	100
Jan - Jun 11	40	608	81		100	87	100	0	100
Jul - Dec 11	42	867	87		99	89	100	0	100
Oct 11 - Mar 12	42	813	86		100	83	100	0	100
Apr - Sept 12	55	1068	90		100	91	100	0	100
Oct 12 - Mar 13	59	378	91		100	93	100	0	100
Apr - Sept 13	69	464	93		100	100	100	0	100
Oct 13 - Mar 14	66	415	91		100	92	100	0	100

Total (all clinics) Haiti Pediatric INH Prophylaxis Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	59	1453	23		8	0	36	0	100
Apr - Sept 13	42	898	18		0	0	27	0	100
Oct 13 - Mar 14	47	929	29		16	0	50	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**Pediatric data from Groups 4 and 5 are not included in the total (all groups) aggregate calculations until the 10th round of data collection, Apr - Sept 12, due to small numbers of eligible patients in previous rounds. Appendix A shows pediatric data by group and review period for all rounds of data collection.

Haiti Nutrition Evaluation

Percentage of pediatric patients who had a nutritional evaluation during the 6-month review period

Total (all clinics) Haiti Pediatric Nutrition Evaluation Scores (%) by Review Period



Total (all clinics) Haiti Pediatric Nutrition Evaluation Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	691	54		61	27	77	0	100
Jul - Dec 08	22	898	50		50	33	66	0	84
Jan - Jun 09	22	1161	56		66	35	75	0	100
Jul - Dec 09	38	2269	43		38	17	69	0	100
Jan - Jun 10	37	2092	41		36	16	66	0	92
Jul - Dec 10	37	2279	41		34	19	71	0	90
Jan - Jun 11	48	2663	41		40	8	72	0	100
Jul - Dec 11	55	3544	34		33	7	56	0	94
Oct 11 - Mar 12	55	3293	33		40	2	55	0	92
Apr - Sept 12	60	4857	41		46	16	68	0	92
Oct 12 - Mar 13	67	3646	61		67	45	83	0	100
Apr - Sept 13	79	3905	56		64	33	84	0	100
Oct 13 - Mar 14	83	3637	62		71	46	83	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results. Mean clinic scores by indicator and review period are presented for all groups in Appendix A.

Haiti Malnutrition Status

Percentage of patients with severe malnutrition (weight gain of less than -3 standard deviations or, if 1-5 years, MUAC <12.5 cm or a ratio of AC/HC < 0.25)

Total (all clinics) Haiti Pediatric Malnutrition Status Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	62	1787	12		0	0	4	0	100
Apr - Sept 13	67	1964	10		0	0	9	0	67
Oct 13 - Mar 14	75	1936	9		0	0	7	0	100

Haiti Immunization

Percentage of pediatric patients (<5 years old) seen during the 6-month review period who have had complete vaccinations for their age.

Total (all clinics) Haiti Pediatric Immunization (%) by Review Period



Total (all clinics) Haiti Pediatric Immunization Scores (%) by Review Period**

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	16	327	0		0	0	0	0	5
Jul - Dec 08	22	423	2		0	0	0	0	13
Jan - Jun 09	22	592	3		0	0	2	0	17
Jul - Dec 09	33	1235	53		57	30	70	0	100
Jan - Jun 10	32	1128	47		47	29	61	0	100
Jul - Dec 10	32	1242	46		37	25	67	0	100
Jan - Jun 11	31	1282	49		47	31	59	19	100
Jul - Dec 11	33	1633	48		42	36	54	0	100
Oct 11 - Mar 12	33	1594	48		44	33	57	0	100
Apr - Sept 12	43	1895	53		46	33	75	0	100

*Pediatric data from Groups 4 and 5 are not included in the total (all groups) aggregate calculations until the 10th round of data collection, Apr - Sept 12, due to small numbers of eligible patients in previous rounds. Appendix A shows pediatric data by group and review period for all rounds of data collection.

**Immunization data captured during the Oct 12 - Mar 13, Apr - Sept 13 and Oct 13 - Mar 14 review periods are omitted, pending further validation.

Haiti Early HIV Detection

Percentage of patients exposed to HIV aged 4 weeks to 1 year who have received early screening by PCR during the last 3 months, excluding those out of care

Total (all clinics) Haiti Pediatric Early HIV Detection Scores (%) by Review Period



Total (all clinics) Haiti Pediatric Early HIV Detection Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	43	978	22		14	0	34	0	100
Apr - Sept 13	50	1209	57		62	33	92	0	100
Oct 13 - Mar 14	54	991	63		82	13	95	0	100

Haiti Mental Health Assessment

Percentage of patients who received a mental health assessment during the past 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation and assessment of sleep and appetite)

Total (all clinics) Haiti Pediatric Mental Health Assessment Scores (%) by Review Period



Total (all clinics) Haiti Pediatric Mental Health Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Oct 12 - Mar 13	56	2716	3		0	0	0	0	67
Apr - Sept 13	67	3088	1		0	0	0	0	33
Oct 13 - Mar 14	70	2815	4		0	0	1	0	50

HEALTHQUAL Haiti Performance Measurement
Adult and Pediatric HIV Care

Results

HEALTHQUAL-Haiti has conducted 13 rounds of data collection measuring 9 adult indicators and 8 pediatric indicators. During the last 3 rounds of data collection, HQ-Haiti added 8 new adult indicators and 7 pediatric indicators to measure a total of 17 adult and 15 pediatric indicators respectively. All indicators are programmed into a national electronic medical record system enabling HQ-Haiti to review data for all eligible patients avoiding the need to sample records.

Improvement was demonstrated in 15 out of 17 adult indicators and 14 out of 15 pediatric indicators. Key areas of improvement in the adult indicators were ARV therapy, CPT, adherence assessment, TB screening, nutrition evaluation, family planning and ART for pregnant women. Clinical visits also showed slight improvement while demonstrating consistent performance over several review periods.

HQ-Haiti used their performance data to set national improvement goals and prioritize specific areas as a national focus for all facilities. Observed gaps in clinical performance data mobilized the ministry to prioritize family planning and ART for pregnant women among all clinics implementing HQ-Haiti as part of the national quality management program. Through a coordinated national effort, improvement was demonstrated in both of these areas. The number of women using a family planning method, derived from EMR data, increased 45% between baseline (6%) and the last measurement period (51%) and ART for pregnant women increased 59% between baseline (32%) and the last measurement period (91%). Improvement interventions will continue as part of the national program and as new priority areas are identified.

Clinical visits data (for ART patients) and scores for the newer measure clinical retention (visits for non-ART patients) highlight the need to focus on processes of appointment booking, keeping and follow-up as well as opportunities to harmonize linkage activities with other providers. Although the clinical retention indicator for non-ART patients has only been measured across 3 review periods, performance remained at approximately 58%, highlighting a 38% gap in attendance between patients on ART (80% in 2014) and those not on ART. These findings underscore important opportunities to improve processes of ART-eligibility assessment, enrollment in care and linkage to continuing services.

Cervical cancer screening showed the greatest need for improvement, however this newly added indicator has only been measured in three quarters and may require more time to show performance improvement. Cervical cancer screening rates demonstrated a large spread with some sites performing well. Understanding the reasons why some clinics perform better than others will reveal strategies that may be spread to raise performance in those with lower scores. Cervical cancer screening also requires equipment and reagents which can influence results and be addressed through addressing these specific causes.

Pediatric results were similar to those for adults, with improvement demonstrated between baseline and the final measurement period in clinical visits, ARV therapy, adherence assessment, CPT, and TB screening. Nutrition evaluation scores were relatively consistent in the 50% range with a slight overall increase in scores from 54% at baseline to 62% at the last measurement but still offer an opportunity for improvement. The immunization indicator initially demonstrated a sharp increase in improvement and then stable performance over several review periods, but remained near 50%, suggesting a need to focus improvement efforts. Data from the last 3 review periods are still being validated and are therefore not included in the report.

CD4 monitoring for both adult and pediatric patients remains an area to examine closely and understand system gaps and factors that may be influencing performance. HQ-Haiti revised the CD4 indicator definition for the last 3 review periods separating it into 2 different indicators, CD4 for patients newly enrolled during the 6 month review period and CD4 for patients already enrolled prior to the review period. These results will be useful to clarify the different guidelines for different types of patients highlighting the need to implement different kinds of process improvements.

Data collection for the next review period, April - September 2014, is currently underway.

HEALTHQUAL Guyana Performance Measurement

Adult and Pediatric HIV/AIDS Care and General Pediatric Well Child Care

Overview

• HQ-Guyana clinics have collected 4 rounds of data representing care provided from January 1, 2008 through June 30, 2012.
• 17 HIV clinics and 116 MCH Guyana clinics have participated in HEALTHQUAL data collection across all rounds.
• 4861 charts in HIV/AIDS care clinics and 11,205 charts in MCH care clinics have been reviewed across all rounds.
• The proportion of HIV/AIDS care patients sampled in the most recent round, January - June 2012, represents 26.3% of the total patient population.
• Performance rates have been measured for the following 9 indicators for HIV/AIDS care: clinical visits, CD4 monitoring, ARV therapy, ART adherence assessment, CPT, TB clinical screen (TST), pulse, temperature, and blood pressure
• HEALTHQUAL-Guyana also collects 6 Well Child indicators: growth monitoring (4 different indicators), developmental milestones and vaccinations*
• Improvement has been demonstrated in 6 of 9 HIV/AIDS care indicators and in all 6 Well Child care indicators, most notably in ART adherence assessment, cotrimoxazole preventive therapy, temperature, pulse, blood pressure, height and head circumference. Performance has remained consistently high for the weight and weight for age Well Child indicators. Performance on the HIV/AIDS care indicators clinical visits, CD4 monitoring and TB clinical screening suggests opportunities for improvement.

Background

HEALTHQUAL-Guyana began in 2008 with the mission of improving national healthcare, including HIV care, by building capacity for quality management. Led by the Ministry of Health (MOH) through a partnership between the National AIDS Programme Secretariat and the Maternal Child Health Department, and guided by a steering committee composed of representatives from AIDS Relief, UNICEF, CDC-Guyana and FXB-Guyana, HQ-Guyana initially developed 15 indicators. HQ-Guyana's extension of their program into well child populations (HIV-negative children < 5 years old) and general medical care represents the first adaptation of the HIVQUAL framework beyond HIV care.

Data Collection

HIV/AIDS Care

Adult (>15 years old) case lists were generated by first listing patients from the pre-ART register and then subsequently from the ART register to create a complete list. Some clinics entered patients manually by hand while others used an automated electronic system. The total eligible population and minimum sample size were then entered into HIVQUAL software for randomization. Patient charts corresponding to those listed in the randomized case list were selected for data abstraction.

All eligible HIV+ and HIV-exposed children (<15 years old) were included in the HIV care review.

Adult and pediatric data were extracted by trained clinic staff from patient medical records onto a data extraction form and subsequently entered into HIVQUAL software. Trained staff at HIV/AIDS care clinics validated data, which were then submitted to the MOH. Facility-level data were aggregated and analyzed by staff in the MOH. After each round of data collection, reports were produced and disseminated to participating sites to guide the development of their quality improvement projects and to inform program planning initiatives.

Baseline data were collected from 15 clinics providing HIV/AIDS care between January 1, 2008 and June 30, 2008. Over 4 review periods, participation in HEALTHQUAL data collection has expanded to include a total of 17 clinics providing HIV/AIDS care.

The following table summarizes the expansion of HIV/AIDS Care data collection through the addition of new groups of clinics that collected and submitted baseline data. For each group of participating clinics, the table presents the group's number, baseline review period and number of clinics included in the group.

Expansion of HIV/AIDS Care data collection by Group		
Group #	Baseline Review Period for Group	# of Clinics in Group
1	January - June 2008	15
2	July - December 2009	1
3	January - June 2012	1
Total # of clinics that have submitted data		**17**

Well Child Care

For well children (HIV-negative), a sample was selected of pediatric patients (< 5 years old) using the same methodology as the adult sampling of patients receiving HIV/AIDS care. Using standardized HIVQUAL methodologies presented on page 13 of this report, local clinic staff generated case lists from paper records and entered the total eligible population and sample size into HIVQUAL software for randomization. Patient charts corresponding to those listed in the randomized case list were selected for data abstraction. Baseline data were collected from 3 clinics providing Well Child care between January 1, 2008 and June 30, 2008. Over 4 review periods, participation in HEALTHQUAL data collection has expanded to include a total of 116 clinics providing Well Child care.

The following table summarizes the expansion of Well Child Care data collection through the addition of new groups of clinics that collected and submitted baseline data. For each group of participating clinics, the table presents the group's baseline review period and number of clinics included in the group.

Expansion of Well Child Care data collection by Group		
Group #	**Baseline Review Period for Group**	**# of Clinics in Group**
1	January - June 2008	3
2	July - December 2009	19
3	January - June 2011	45
4	January - June 2012	49
Total # of clinics that have submitted data		**116**

For rounds 1-4, clinic scores were averaged to calculate a mean clinic score for each indicator. Mean clinic scores are reported in the following graphs and tables by indicator and review period.

HQ-Guyana HIV/AIDS Mean Clinic Scores by Round of Data Collection and Indicator

mean score (%) and the number of clinics | number of eligible patients

Round	1		2		3		4	
HIV Indicators	Jan - Jun 08		Jul - Dec 09		Jan - Jun 11		Jan - Jun 12	
Clinical Visits	**85**	15 | 1076	**81**	15 | 1078	**83**	15 | 1447	**79**	15 | 1260
CD4 Monitoring	**83**	15 | 1013	**73**	14 | 1036	**76**	15 | 1249	**66**	15 | 1161
ARV Therapy	**71**	15 | 471	**74**	14 | 427	**76**	15 | 424	**84**	15 | 395
Adherence Assessment	**56**	15 | 360	**77**	14 | 327	**80**	15 | 314	**82**	15 | 321
TB Clinical Screen (TST)	**89**	15 | 853	**100**	13 | 847	**91**	14 | 992	**85**	14 | 874
CPT	**78**	14 | 257	**69**	15 | 209	**78**	15 | 308	**84**	14 | 267
Temperature	**39**	15 | 1013	**69**	14 | 1036	**86**	15 | 1249	**86**	15 | 1161
Pulse	**48**	15 | 1013	**74**	14 | 1036	**89**	15 | 1249	**90**	15 | 1161
Blood Pressure	**69**	15 | 866	**79**	14 | 884	**91**	15 | 1074	**89**	15 | 1027

HQ-Guyana Well Child Mean Clinic Scores by Round of Data Collection and Indicator

mean score (%) and the number of clinics | number of eligible patients

Round	1		2		3		4	
Well Child Indicators	Jan - Jun 08		Jul - Dec 09		Jan - Jun 11		Jan - Jun 12	
Clinical Visits	**67**	3 | 352	**66**	21 | 1558	**71**	61 | 4795	**75**	78 | 4500
Weight	**95**	3 | 350	**94**	21 | 1541	**98**	61 | 4601	**97**	78 | 4435
Height	**48**	3 | 350	**63**	21 | 1541	**87**	61 | 4601	**93**	78 | 4435
Head Circumference	**6**	3 | 214	**42**	21 | 1157	**69**	60 | 2613	**83**	78 | 2639
Weight for age plot	**89**	3 | 350	**89**	21 | 1541	**91**	61 | 4601	**94**	78 | 4435
Developmental Milestones	**69**	3 | 350	**71**	21 | 1541	**81**	61 | 4601	**87**	78 | 4435

*Well Child Vaccination data will be included in future versions of the report pending further validation.

Guyana HIV/AIDS Care Indicators for Rounds 1-4 of Data Collection		
Eligibility: All HIV-exposed infants and HIV-infected patients (all ages) who had at least one clinical visit during the 6-month review period		
Indicator	Numerator	Denominator
Clinical Visits	Number of patients with at least 2 clinical visits during the 6-month review period	Number of all eligible patients
CD4 Monitoring	Number of patients with a CD4 test during the 6-month review period	Number of HIV+ patients
ARV Therapy	Number of patients prescribed HAART during the 6-month review period	Number of eligible patients who meet the HAART eligibility criteria: • <12 months: WHO Stage III or IV or WHO Pediatric Stage I or II with CD4 < 25% • 1-5 years: WHO Stage III or IV or WHO Stage 1 or II with CD4 < 20% • 5 years and older: WHO Stage III or IV or CD4 < 350 cells/mm^3
Cotrimoxazole Preventive Therapy	Number of patients receiving cotrimoxazole during the 6-month review period	Number of HIV+ patients with CD4 <200 or with active TB
	Number of exposed infants starting cotrimoxazole by two months of age	Number of exposed infants between 2 and 18 months of age
ART Adherence Assessment	Number of patients prescribed ARVs who have had an adherence assessment at each clinic visit during the 6-month review period	Number of HIV+ patients prescribed HAART
TB Clinical Screen (TST)	Number of patients who have been screened during the past 12 months with Tuberculin Skin Test (TST)	Number of HIV+ patients who have never been treated for TB, have never had a positive Tuberculin Skin Test (TST) and are not currently on treatment for TB
General Medical Care (Temperature, Pulse, Blood Pressure)	Number of patients (ages 16+) with temperature and pulse documented at each clinic visit during the 6-month review period.	Number of all exposed infants and HIV+ patients

During rounds 1 and 2 of data collection, 5 HIV clinics also collected child health indicator data for HIV-exposed infants and HIV+ children under 5, demonstrating the collaboration between the HIV and MCH programs. Data for those HIV clinics were not combined with well child data from MCH clinics below because sample sizes were small.

Guyana HIV/AIDS Clinical Visits

Number of patients (all ages) with at least 2 clinical visits during the 6-month review period

Total (all clinics) Guyana HIV/AIDS Clinical Visits Scores (%) by Review Period



Total (all clinics) Guyana HIV/AIDS Clinical Visits Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	1076	85		87	86	90	57	94
Jul - Dec 09	15	1078	81		82	76	91	46	100
Jan - Jun 11	15	1447	84		84	80	89	68	96
Jan - Jun 12	15	1260	79		84	79	94	11	98

Guyana HIV/AIDS CD4 Monitoring

Number of patients (all ages) with a CD4 test during the six-month review period

Total (all clinics) Guyana HIV/AIDS CD4 Monitoring Scores (%) by Review Period



Total (all clinics) Guyana HIV/AIDS CD4 Monitoring Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	1013	83		86	80	88	48	100
Jul - Dec 09	14	1036	73		72	69	79	50	92
Jan - Jun 11	15	1249	76		79	74	83	38	91
Jan - Jun 12	15	1161	66		71	62	85	17	89

Guyana HIV/AIDS ARV Therapy

Number of patients (all ages) prescribed HAART during the six-month review period

Total (all clinics) Guyana HIV/AIDS ARV Therapy Scores (%) by Review Period



Total (all clinics) Guyana HIV/AIDS ARV Therapy Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	471	71		67	56	87	40	100
Jul - Dec 09	14	427	74		78	65	83	36	100
Jan - Jun 11	15	424	76		78	66	86	43	100
Jan - Jun 12	15	395	84		85	78	96	41	100

Guyana HIV/AIDS ART Adherence Assessment

Number of patients (all ages) prescribed ARVs who have had an adherence assessment at each clinic visit during the six-month review period

Total (all clinics) Guyana HIV/AIDS Adherence Assessment Scores (%) by Review Period



Total (all clinics) Guyana HIV/AIDS ART Adherence Assessment Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	360	56		67	23	85	0	100
Jul - Dec 09	14	327	77		80	68	90	35	100
Jan - Jun 11	15	314	80		90	68	97	18	100
Jan - Jun 12	15	321	82		83	77	100	14	100

Guyana HIV/AIDS TB Clinical Screen (TST)

Number of patients (all ages) who have been screened during the past 12 months with Tuberculin Skin Test (TST)

Total (all clinics) Guyana HIV/AIDS TB Clinical Screen Scores (%) by Review Period



Total (all clinics) Guyana HIV/AIDS TB Clinical Screen Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	853	89		100	98	100	19	100
Jul - Dec 09	13	847	100		100	99	100	96	100
Jan - Jun 11	14	992	91		100	96	100	10	100
Jan - Jun 12	14	874	85		100	96	100	0	100

Guyana HIV/AIDS Cotrimoxazole Preventive Therapy (CPT)

- Number of patients (all ages) receiving cotrimoxazole during the six-month review period

- Number of exposed infants starting cotrimoxazole by 2 months of age

Total (all clinics) Guyana HIV/AIDS CPT Scores (%) by Review Period



Total (all clinics) Guyana HIV/AIDS CPT Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	14	257	71		76	71	84	0	100
Jul - Dec 09	15	209	69		81	67	93	0	100
Jan - Jun 11	15	308	78		86	63	88	31	100
Jan - Jun 12	14	267	84		88	81	95	50	100

Guyana HIV/AIDS General Medical Care

Temperature: Number of patients (ages 16+) with temperature documented at each clinic visit during the six-month review period

Pulse: Number of patients (ages 16+) with pulse documented at each clinic visit during the six-month review period

Blood Pressure: Number of patients (ages 16+) with blood pressure documented at each clinic visit during the six-month review period

Total (all clinics) Guyana HIV/AIDS General Medical Care Scores (%) by Review Period



Total (all clinics) Guyana HIV/AIDS Temperature Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	1013	39		24	0	82	0	100
Jul - Dec 09	14	1036	69		86	51	90	0	98
Jan - Jun 11	15	1249	86		94	80	97	27	100
Jan - Jun 12	15	1161	86		89	84	96	49	100

Total (all clinics) Guyana HIV/AIDS Pulse Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	1013	48		61	7	83	0	100
Jul - Dec 09	14	1036	74		85	80	91	0	100
Jan - Jun 11	15	1249	89		94	85	97	55	100
Jan - Jun 12	15	1161	90		94	84	99	70	100

Total (all clinics) Guyana HIV/AIDS Blood Pressure Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	15	866	69		75	58	84	24	100
Jul - Dec 09	14	884	79		87	82	91	0	100
Jan - Jun 11	15	1074	91		96	91	98	59	100
Jan - Jun 12	15	1027	89		92	83	99	67	100

Guyana Well Child Health Indicators for Rounds 1-4 of Data Collection		
Eligibility: All children <5 years with at least one clinical visit during the 6-month review period		
Indicator	**Numerator**	**Denominator**
Clinical Visits	Number of children with at least two clinical visits during the 6-month review period.	Number of all eligible children
Vaccinations*	Number of children with all age-appropriate vaccines administered.	Number of all eligible children.
Growth Monitoring: Weight	Number of children with weight measured at each clinic visit during the review period	Number of all eligible children
Growth Monitoring: Height/Length	Number of children with height/length measured at each clinic visit during the review period	Number of all eligible children
Growth Monitoring: Head Circumference	Number of children with head circumference measured at each clinic visit during the review period	Number of all eligible children < 2 years of age
Growth Monitoring: Weight for Age Plotted	Number of children with "Weight for Age" plotted on Growth Chart at each clinic visit during the review period	Number of all eligible children
Developmental Milestones Assessment	Number of children with developmental milestones assessed at each clinic visit during the review period (as indicated on Clinic Card)	Number of all eligible children

*Well Child Vaccination data will be included in future versions of the report pending further validation.

Guyana Well Child Clinical Visits

Number of children with at least two clinical visits during the 6-month review period

Total (all clinics) Guyana Well Child Clinical Visits Scores (%) by Review Period



Total (all clinics) Guyana Well Child Clinical Visits Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	3	352	67		71	61	75	50	80
Jul - Dec 09	21	1558	66		67	62	73	45	80
Jan - Jun 11	61	4795	71		73	65	78	45	100
Jan - Jun 12	78	4500	75		77	67	82	40	95

Guyana Well Child Growth Monitoring: Weight

Number of children with weight measured at each clinic visit during the review period

Total (all clinics) Guyana Well Child Weight Scores (%) by Review Period



Total (all clinics) Guyana Well Child Weight Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	3	350	95		98	93	99	88	100
Jul - Dec 09	21	1541	94		98	95	98	72	100
Jan - Jun 11	61	4601	98		99	97	100	75	100
Jan - Jun 12	78	4435	97		99	97	100	77	100

Guyana Well Child Growth Monitoring: Height

Number of children with height/length measured at each clinic visit during the review period

Total (all clinics) Guyana Well Child Height Scores (%) by Review Period



Total (all clinics) Guyana Well Child Height Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	3	350	48		32	22	66	13	100
Jul - Dec 09	21	1541	63		68	31	95	0	98
Jan - Jun 11	61	4601	87		96	82	99	22	100
Jan - Jun 12	78	4435	93		99	95	100	0	100

Guyana Well Child Growth Monitoring: Head Circumference

Number of children with head circumference measured at each clinic visit during the review period

Total (all clinics) Guyana Well Child Head Circumference Scores (%) by Review Period



Total (all clinics) Guyana Well Child Head Circumference Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	3	214	6		5	3	9	2	13
Jul - Dec 09	21	1157	42		30	3	87	0	100
Jan - Jun 11	60	2613	69		85	58	95	0	100
Jan - Jun 12	78	2639	83		95	78	100	0	100

Guyana Well Child Growth Monitoring: Weight for Age Plot

Number of children with "Weight for Age" plotted on Growth Chart at each clinic visit during the review period

Total (all clinics) Guyana Well Child Weight for Age Plot Scores (%) by Review Period



Total (all clinics) Guyana Well Child Weight for Age Plot Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	3	350	89		91	86	93	81	95
Jul - Dec 09	21	1541	89		92	82	97	58	100
Jan - Jun 11	61	4601	91		97	90	99	25	100
Jan - Jun 12	78	4435	94		97	94	100	31	100

Guyana Well Child Developmental Milestones Assessment

Number of children with developmental milestones assessed at each clinic visit during the review period (as indicated on Clinic Card)

Total (all clinics) Guyana Well Child Developmental Milestones Scores (%) by Review Period



Total (all clinics) Guyana Well Child Developmental Milestones Scores (%) by Review Period

review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Jan - Jun 08	3	350	69		57	54	79	51	100
Jul - Dec 09	21	1541	71		76	51	92	15	98
Jan - Jun 11	61	4601	81		90	68	98	7	100
Jan - Jun 12	78	4435	87		96	84	100	3	100

HEALTHQUAL Guyana Performance Measurement

Adult and Pediatric HIV/AIDS Care and General Pediatric Well Child Care

Results

HQ-Guyana has conducted 4 rounds of data collection measuring 9 HIV-specific indicators and 6 measuring the quality of well child care. Key areas of improvement were noted for ARV therapy, adherence assessment, CPT, pulse and blood pressure. Although mean scores for TB screening decreased from 89% at baseline to 85% at the last measurement, the spread and median suggest that this change was influenced by a small number of clinics with low scores. The majority of clinics performed consistently well.

All 6 of the well child indicators demonstrated consistent improvement with height, head circumference, and developmental milestones showing the greatest increases. The well child growth monitoring indicators for weight and weight for age showed consistently high results with a smaller spread in results. Although performance of these screening measures is straightforward, the Ministry of Health used this opportunity to reinforce guidelines and promote improvement in these practices through discussions at provider meetings and sharing of data.

Areas for further examination and improvement include clinical visits and CD4 monitoring. Rates for clinical visits were relatively consistent with an average of 82% across review periods. Visit frequency represents an important measure of engagement in care which can be strengthened by system-level improvements including appointment and reminder systems, as well as outreach and navigation services. These indicators are often more difficult to improve because of the multiple diverse factors influencing performance.

HIVQUAL Kenya Performance Measurement

Adult and Pediatric HIV Care and PMTCT Care

Overview

• As of December 2011, HQ-Kenya clinics collected 4 rounds of data. The fourth round reviewed care provided during the July - December 2011 review period.
• 38 HQ-Kenya clinics have participated in HIVQUAL data collection over the course of the first 4 rounds.
• 12,771 charts have been sampled across the first 4 rounds.
• Performance rates have been measured for the following adult and pediatric indicators: clinical visits, CD4 monitoring, ARV therapy, adherence assessment, cotrimoxazole preventive therapy (CPT), TB clinical screening, family planning (adult only), counseling on partner testing (adult only) and disclosure of status (pediatric only).
• During the July - December 2011 review period, performance rates were measured by 13 clinics using 3 PMTCT indicators: ART Prophylaxis, Partner Testing and ART Assessment.
• As of 2011, improvement has been demonstrated in 8 of 14 indicators. Performance remained high for the adult ARV therapy and CPT indicators. Adult TB clinical screening and pediatric disclosure of status represent areas for improvement.

Background

In 2009, HIVQUAL-Kenya held its first meeting for senior MOH staff and key stakeholders to discuss and agree upon key quality indicators. A technical working group comprised of MOH/NASCOP development and implementing partners was formed to guide implementation of HIVQUAL-Kenya. The three regions of Kenya with the highest HIV disease burden in the country (Nyanza, Nairobi and Coast) were prioritized for piloting. A total of 15 sites (5 sites per region) comprised of both public and private sector facilities (level 3 and above) were selected for piloting as Group I of the program. The criteria for selected sites included having partner support, a high caseload of HIV patients on care and treatment and having ongoing QI activities.

Data Collection

The first round of data collection reviewed care provided at 15 clinics between July 1, 2009 and December 31, 2009. Over the course of 4 review periods, participation in HIVQUAL data collection expanded to include data from 38 clinics.

The following table summarizes the expansion of data collection through the addition of new groups of clinics that collected and submitted baseline performance data. For each group of participating clinics, the table presents the group's baseline review period and number of clinics included in the group.

Expansion of HIVQUAL Kenya data collection by Group		
Group #	Baseline Review Period for Group	# of Clinics
1	July - December 2009	15
2	July - December 2010	6
3	January - June 2011	11
4	July - December 2011	6
Total # of clinics that have submitted data		38

During the first review period, additional data were collected representing care provided for pediatric and pregnant women patient populations. However, because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric and PMTCT data are first reported for the January - June 2011 and July - December 2011 review periods, respectively.

Chart sampling and data abstraction were performed following standard HIVQUAL methodologies presented on page 13 of this report. Case lists of eligible patients were entered into the randomizer in the HIVQUAL software. Patient charts, identified by a record number, corresponding to those listed in the randomized case list were selected for data abstraction. Sites that did not have a computer applied systematic sampling methods to identify charts for review based on sample size. Adult sample sizes were sufficient to achieve a 90% CI with a 10% margin of error for the first round of data collection. For subsequent rounds, sample sizes achieved a 95% CI with an 8% margin of error.

For rounds 1-4, clinic scores were averaged to calculate a mean clinic score for each indicator. Because of variation in the number of clinics submitting data per group in each review period, total (all groups) mean clinic scores are reported in the following tables by indicator and review period instead of in graphs for greater clarity of interpretation.

HQ-Kenya Adult, Pediatric and PMTCT Mean Clinic Scores by Review Period and Indicator

mean score (%) and number of clinics | number of eligible patients

Adult Indicators	Jul - Dec 09		Jul - Dec 10*		Jan - Jun 11		Jul - Dec 11	
Clinical Visits (ART)	**67**	15 | 1411	**84**	6 | 488	**66**	26 | 2314	**73**	28 | 2877
Clinical Visits (pre-ART)		-	**44**	6 | 188	**48**	25 | 779	**59**	28 | 807
CD4 Monitoring	**63**	15 | 1880	**81**	6 | 678	**63**	26 | 3104	**66**	28 | 3664
ARV Therapy	**86**	15 | 553	**93**	6 | 224	**89**	26 | 1329	**90**	28 | 1444
Adherence Assessment	**96**	15 | 1384	**95**	6 | 490	**94**	26 | 2323	**89**	28 | 2912
CPT	**97**	15 | 1847	**99**	6 | 678	**98**	26 | 3104	**98**	28 | 3687
TB Clinical Screen	**93**	15 | 1692	**98**	6 | 646	**89**	26 | 2859	**81**	28 | 3453
Counseling on Partner Testing	**36**	14 | 1730	**79**	6 | 678	**50**	26 | 3104	**48**	28 | 3633
Family Planning		-	**30**	6 | 564	**32**	26 | 2041	**36**	28 | 2467

Pediatric Indicators	Jan - Jun 11		Jul - Dec 11	
Clinical Visits (ART)	**74**	21 | 1121	**74**	25 | 1137
CD4 Monitoring	**54**	21 | 1437	**63**	25 | 1417
ART Initiation	**54**	21 | 1452	**83**	25 | 1417
CPT	**98**	21 | 1437	**97**	25 | 1417
TB Clinical Screening	**87**	21 | 1295	**78**	25 | 1314
Disclosure of Status	**56**	21 | 621	**50**	25 | 695

PMTCT Indicators	Jul - Dec 11	
ART Prophylaxis	**90**	13 | 249
Counseling on Partner Testing	**76**	13 | 286
ART Assessment	**73**	13 | 249

*The 6 clinics that submitted adult data for the July - December 2010 review period represent a different cohort of clinics (Group 2) from the original cohort of 15 clinics (Group 1) that submitted adult data in the first round, July - December 2009. The 15 original Group 1 clinics did not submit data for the July - December 2010 review period. Mean clinic scores reported in the third and fourth review periods reflect data from both Group 1 and Group 2 clinics, in addition to data from subsequent groups.

Kenya Indicators for Rounds 1-4 of Data Collection

Adult Eligibility: All HIV-infected adults (≥15 years) with at least one clinical visit during the 6-month review period.

Pediatric Eligibility: All HIV-infected children (<15 years) with at least one clinical visit during the 6-month review period.

PMTCT Eligibility: All HIV-infected pregnant women seeking antenatal care services either in an ANC clinic or CCC.

Indicator	Numerator	Denominator
Clinical Visits	ART: Number of patients who are on ART and had at least two clinical visits at least three months apart during the 6-month review period pre-ART: Number of patients who are not on ART and had at least two clinical visits at least three months apart during the 6-month review period	ART: Number of patients who are on ART and had at least one clinical visit during the 6-month review period [Excludes patients who started ART in months 4-6 of the review period, transferred, or died in the first month] pre-ART: Number of patients who are not on ART with at least one clinical visit during the 6-month review period [Excludes patients in care in months 4-6 of the reivew period, transferred, or died in the first month]
CD4 Monitoring	Number of patients with at least one CD4 count during the 6-month review period	Number of patients who had at least one clinical visit during the 6-month review period
ARV Therapy	Number of ART eligible patients on ART during the 6-month review period.	Number of patients who had at least one clinical visit and were eligible for ART during the 6-month review period. ART eligibility criteria: • <18 mo: all patients should be on ART • 18-59 mo: CD4 < 1000 OR CD4% < 25% OR WHO Stage III/IV • 6-15 yrs: CD4 < 350 or CD4% < 20% or WHO Stage III/IV • 15+ yrs: CD4 < 250 cells/mm3 OR WHO Stage III/IV
Adherence Assessment	Number of patients with at least one documented adherence assessment in the last three months of the 6-month review period	Number of patients on ART who had at least one clinical visit during the 6-month review period
Cotrimoxazole Preventive therapy (CPT)	Number of patients on cotrimoxazole during the 6-month review period	Number of patients who had at least one clinical visit during the 6-month review period
TB Clinical Screening	Number of patients screened for TB at every clinical visit during the 6-month review period	Number of patients who had at least one clinical visit and not currently on treatment for TB during the 6-month review period
Counseling on Partner Testing	Number of patients who have been counseled about partner testing during the 6-month review period	Number of patients with at least one clinical visit during the 6-month review period
Family Planning	Number of non-pregnant women age 15 – 49 years, not already on FP, initiating modern contraception during the 6-month review period	Number of non-pregnant women age 15 – 49 years, not already on FP, who had at least one clinical visit during the 6-month review period
Disclosure of Status (pediatric only)	Number of children 8 - 14 years old whose status has been disclosed to them	Number of children 8 -14 years who had at least one clinical visit during the 6-month review period
PMTCT ART Prophylaxis	Number of HIV infected pregnant women receiving preventive ART, either HAART or more efficacious short course prophylactic ARV regiments (AZT + sdNVP) during the 6-month review period	Number of HIV-infected pregnant women enrolled in PMTCT with at least one clinical visit during the 6-month review period
PMTCT Counseling on Parter Testing	Number of HIV-infected pregnant women enrolled in PMTCT counseled on partner testing	Number of HIV-infected pregnant women enrolled in PMTCT with at least one clinical visit during the 6-month review period
PMTCT Assessment for ART eligibility	Number of HIV-infected pregnant women assessed for ART eligibility by WHO staging during the 6-month review period Number of HIV-infected pregnant women assessed for ART eligibility by CD4 count during the 6-month review period	Number of HIV-infected pregnant women with at least one clinical visit during the 6-month review period

Kenya Adult Mean Clinic Scores (%) by Indicator and Review Period*

indicator	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Clinical Visits (ART)	Jul - Dec 09	15	1411	67		74	56	80	0	90
	Jul - Dec 10	6	488	84		82	80	87	78	93
	Jan - Jun 11	26	2314	66		71	58	79	19	92
	Jul - Dec 11	28	2877	73		78	62	83	33	95
Clinical Visits (pre-ART)	Jul - Dec 09	-	-	-		-	-	-	-	-
	Jul - Dec 10	6	188	44		56	11	67	0	82
	Jan - Jun 11	25	779	48		50	38	60	0	100
	Jul - Dec 11	28	807	59		62	48	72	0	100
CD4 Monitoring	Jul - Dec 09	15	1880	63		70	46	87	26	89
	Jul - Dec 10	6	678	81		79	72	90	70	93
	Jan - Jun 11	26	3104	63		61	44	86	16	95
	Jul - Dec 11	28	3664	66		72	54	83	29	92
ARV Therapy	Jul - Dec 09	15	553	86		90	81	94	62	97
	Jul - Dec 10	6	224	93		94	91	95	86	96
	Jan - Jun 11	26	1329	89		91	85	94	62	100
	Jul - Dec 11	28	1444	90		91	86	96	75	100
ART Adherence Assessment	Jul - Dec 09	15	1384	96		97	95	100	90	100
	Jul - Dec 10	6	490	95		99	98	100	71	100
	Jan - Jun 11	26	2323	94		98	94	100	34	100
	Jul - Dec 11	28	2912	89		98	91	100	2	100
CPT	Jul - Dec 09	15	1847	97		99	95	99	91	100
	Jul - Dec 10	6	678	99		99	99	100	97	100
	Jan - Jun 11	26	3104	98		99	97	99	93	100
	Jul - Dec 11	28	3687	98		99	98	100	93	100
TB Clinical Screening	Jul - Dec 09	15	1692	93		96	91	99	70	100
	Jul - Dec 10	6	646	98		100	98	100	89	100
	Jan - Jun 11	26	2859	89		98	89	99	0	100
	Jul - Dec 11	28	3453	81		96	88	99	0	100
Counseling on Partner Testing	Jul - Dec 09	14	1730	36		36	15	48	3	96
	Jul - Dec 10	6	678	79		89	84	91	22	100
	Jan - Jun 11	26	3104	50		49	25	78	0	100
	Jul - Dec 11	28	3633	48		43	21	75	0	99
Family Planning	Jul - Dec 09	-	-	-		-	-	-	-	-
	Jul - Dec 10	6	564	30		32	30	33	1	52
	Jan - Jun 11	26	2041	32		33	6	53	0	82
	Jul - Dec 11	28	2467	36		40	18	51	0	82

*The 6 clinics that submitted adult data for the July - December 2010 review period represent a different cohort of clinics (Group 2) from the original cohort of 15 clinics (Group 1) that submitted adult data in the first round, July - December 2009. The 15 original Group 1 clinics did not submit data for the July - December 2010 review period. Mean clinic scores reported in the third and fourth review periods reflect data from both Group 1 and Group 2 clinics, in addition to data from subsequent groups.

Kenya PMTCT Mean Clinic Scores (%) by Indicator and Review Period

indicator	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
ART Prophylaxis	Jul - Dec 11	13	249	90		100	86	100	43	100
Coun. Part. Testing	Jul - Dec 11	13	286	76		90	75	100	0	100
ART Assessment	Jul - Dec 11	13	249	73		100	44	100	0	100

Kenya Pediatric Mean Clinic Scores (%) by Indicator and Review Period*

indicator	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Clinical Visits (ART)	Jul - Dec 09	5	361	79		81	75	90	59	90
	Jan - Jun 11	21	1121	74		82	67	86	31	98
	Jul - Dec 11	25	1137	74		77	67	87	36	100
CD4 Monitoring	Jul - Dec 09	5	443	64		69	50	85	26	88
	Jan - Jun 11	21	1437	54		52	38	77	0	94
	Jul - Dec 11	25	1417	63		65	50	80	8	98
ART Initiation	Jul - Dec 09	5	154	84		83	79	100	59	100
	Jan - Jun 11	21	1452	54		75	0	90	0	100
	Jul - Dec 11	25	1417	83		94	82	99	0	100
CPT	Jul - Dec 09	5	443	99		100	99	100	95	100
	Jan - Jun 11	21	1437	98		100	98	100	85	100
	Jul - Dec 11	25	1417	97		100	97	100	71	100
TB Clinical Screening	Jul - Dec 09	5	426	100		100	100	100	100	100
	Jan - Jun 11	21	1306	82		99	89	100	0	100
	Jul - Dec 11	25	1314	78		98	76	100	0	100
Disclosure of Status	Jul - Dec 09	5	228	24		20	0	51	0	52
	Jan - Jun 11	21	621	56		60	17	96	0	100
	Jul - Dec 11	25	695	50		46	15	89	0	100

*During the first round of data collection, 10/15 Group I clinics did not sample enough eligible pediatric patients to produce reliable data. Here we show the aggregate scores of the remaining 5/15 Group I clinics that achieved the intended sample size for the July - December 2009 review period.

-

In 2011, HEALTHQUAL Kenya began a collaboration project with University Research Co., LLC (URC) to identify and improve key nutrition clinical processes across all clinics involved in the collaboration. The collaboration will provide an opportunity to exchange resources, successes, challenges and techniques while pursuing this common goal. Nutritional process indicators were developed using in-country clinical standards with input from nutritionists and senior staff from both organizations. The indicators were then programmed into the existing HQ-Kenya data collection software. The first group of participating clinics (15 Group 1 clinics) have collected two rounds of nutrition indicators data. Round 1 reviews care provided from January to June 2011 and Round 2 reviews care provided from July to December 2011. Here we show the baseline (Jan - Jun 11) and follow-up (Jul - Dec 11) results for the nutritional counseling and nutritional assessment indicators.

Kenya Nutrition Indicators

Adult Eligibility: All HIV-infected adults (≥ years old) with at least one clinical visit during the 6-month review period.

Pediatric Eligibility: All HIV-infected children (<15 years old) with at least one clinical visit during the 6-month review period.

Indicator	Numerator	Denominator
Nutritional Counseling	Number of patients who received nutritional counseling during the 6-month review period	Number of patients who had at least one clinical visit during the 6-month review period and did not require inpatient therapeutic care
Nutritional Assessment	Number of patients who had at least one nutritional assessment (MUAC, BMI or weight for height) during the 6-month review period	Number of patients who had at least one clinical visit during the 6-month review period and did not require inpatient therapeutic care
Nutritional Classification	Number of patients who had nutritional status determined during the 6-month review period	Number of patients who had at least one nutritional assessment during the 6-month review period
Nutritional Intervention	Number of patients receiving the correct food by prescription (FBP) intervention based off of the provider's nutritional classification during the 6-month review period	Number of patients who were classified as moderately or severely malnourished by the provider during the 6-month review period
Safe Water Intervention	Number of patients receiving safe water solution during the 6-month review period	Number of patients who were classified as moderately or severely malnourished by the provider during the 6-month review period

Kenya Nutrition Mean Clinic Scores (%) by Indicator and Review Period

service area	indicator	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Adult	Nutr. Counseling	Jan - Jun 11	12	1476	42		16	7	93	0	99
		Jul - Dec 11	12	1483	51		52	17	87	1	99
	Nutr. Assessment	Jan - Jun 11	12	1476	4		0	0	0	0	44
		Jul - Dec 11	12	1483	18		0	0	14	0	93
Pediatric	Nutr. Counseling	Jan - Jun 11	13	1036	61		86	19	95	0	100
		Jul - Dec 11	11	540	67		82	37	98	20	100
	Nutr. Assessment	Jan - Jun 11	13	1036	18		1	0	8	0	100
		Jul - Dec 11	11	540	13		0	0	0	0	99

HIVQUAL Kenya Performance Measurement
Adult and Pediatric HIV Care and PMTCT Care

Results

HIVQUAL-Kenya has conducted 4 rounds of data collection measuring 8 adult indicators, 3 rounds of data collection measuring 6 pediatric indicators, and one round of data collection measuring 3 PMTCT indicators. Key areas of consistent high performance were demonstrated by the scores for ARV Therapy, CPT, and Adherence Assessment. TB Clinical Screening has also maintained relatively high levels of performance. Even though mean performance rates have decreased, high median scores indicate consistent implementation of standardized processes in these clinics. The variation in TB screening is associated with the addition of sites that were new to the performance measurement process, requiring that they develop or improve existing measurement systems. Mean scores reflect the performance at these sites.

The first round of data collection for the pediatric indicators was not reported for 10 of the 15 clinics because of sample sizes that were too small to produce reliable data. However, the individual clinics used their data results and feedback from the data collection process to clarify documentation and organize medical records for more accurate performance measurement in the future. Although some of the pediatric sample sizes did not meet criteria originally defined by HIVQUAL-Kenya, the clinics were still able to recognize system of care issues at the clinic level by using process mapping of these systems of care to identify areas of focus for QI projects.

Through collaboration with ASSIST (University Research Co., LLC (URC)), HIVQUAL-Kenya added 5 nutrition indicators for both adult and pediatric reviews during the last 2 rounds of data collection. Wide variation in clinic performance on these indicators indicated the need to elevate this topic for discussion with Ministry of Health nutrition leaders and other nutrition partners to clarify the guidelines. At the clinic level, especially in sites where there was limited or no nutrition staff, guidelines were not being interpreted consistently, including the specific steps and messages that are part of nutrition counseling and how they should be measured. This information compelled the ministry and nutrition partners to clarify guidelines, redesign nutrition tools and collaborate to ensure increased provider access to nutritionists.

NASCOP revised its HIV indicators and data collection process in 2012 and is working with county governments to facilitate local implementation of quality management. Counties started training sites on the new performance measurement system in 2014 and will be conducting data collection for the updated indicators as part of this process.

HIVQUAL Vietnam Performance Measurement

Adult HIV Care

Overview

• The HIVQUAL-Vietnam program has conducted four rounds of data collection and analysis representing care provided from July 1, 2011 through September 30, 2013.
• As of September 30, 2013, 68 HQ-Vietnam clinics from a total of 13 provinces were implementing HIVQUAL, representing 23% of the 302 health facilities in Vietnam.
• 27, 221 adult charts have been sampled across all 4 rounds.
• Performance rates have been measured for the following 9 indicators: clinical visits (pre-ART), initial CD4 count test, CD4 monitoring, 2 ART initiation indicators, ART medication pick-up, ART adherence assessment, cotrimoxazole preventive therapy (CPT) and TB clinical screen.
• To assess the accessibility of early ARV treatment, a late diagnosis indicator measures percentages of patients who had a CD4 level within one of four specified ranges at ART Initiation: CD4 level 1: CD4 < 100; CD4 level 2: 100 < CD4 < 250; CD4 level 3: 250 < CD4 < 350; and CD4 level 4: CD4 > 350.
• Improvement has been demonstrated between baseline and follow-up scores for all 10 indicators, most notably for CPT and TB clinical screen. Performance on the ART adherence assessment indicator has remained consistently high. Although the clinical visits, initial CD4 count test, CD4 monitoring and ART initiation indicators have shown improvement over the first four rounds of performance measurement, relatively lower follow-up scores on these indicators suggest opportunities for further improvement.

Background

HIVQUAL-Vietnam began in 2012 through a collaboration between the Ministry of Health (MOH), Vietnam AIDS Administration (VAAC), and implementing partners. Technical support and guidance is provided by PEPFAR and CDC-Vietnam. TWG and outpatient clinic (OPC) staff developed and defined indicators, chose participating facilities, and developed an organizational system to support the data collection and analysis process.

Data Collection

The first round of data collection reviewed adult care provided at 11 clinics from July 1, 2011 - December 31, 2011. The selection of indicators included 3 pre-ART indicators, 4 ART indicators, and 3 indicators for both pre-ART and ART care. A follow-up round of data was collected from the same 11 clinics representing care provided from April 1, 2012 - September 30, 2012. Over 4 review periods, participation in HIVQUAL data collection has expanded to include 68 clinics. The table below summarizes the expansion of data collection through the addition of new groups of clinics that collected and submitted baseline performance data. For each group of participating clinics, the table presents the group's baseline review period and number of clinics included in the group.

Expansion of HIVQUAL-Vietnam data collection by Group		
Group #	Baseline Review Period for Group	# of Clinics in Group
1	July - December 2011	11
2	October 2012 - March 2013	57
Total # of clinics that have submitted data		**68**

Using standardized HIVQUAL methodologies presented on page 13 of this report, local OPC staff generated adult (>15 years old) case lists first by listing patients from the OPC register. The total eligible population and sample size were then entered into HIVQUAL software and a randomized patient list was generated using the software's randomizer. Data were then abstracted from the selected patient charts and entered into HIVQUAL software. After validation, facility-level data were submitted to the MOH. Staff at the central level further validated, analyzed and aggregated data. Results were analyzed to identify national priorities in quality improvement.

For rounds 1-4, clinic scores were aggregated to calculate a mean clinic score for each indicator. Mean clinic scores are reported in the following graphs and tables by indicator and review period.

HQ Vietnam Mean Clinic Scores by Round of Data Collection and Indicator

mean score (%) and the number of clinics | number of eligible patients

Round	1		2		3		4	
Adult Indicators	Jul - Dec 11		Apr - Sept 12		Oct 12 - Mar 13		Apr - Sept 13	
Clinical Visits (pre-ART) (CS2)	**55**	11 | 397	**54**	11 | 400	**68**	65 | 2222	**75**	66 | 2270
Initial CD4 Count Test (CS1)	**65**	11 | 215	**85**	11 | 301	**80**	68 | 1884	**79**	67 | 2083
CD4 Monitoring (CS10)	**74**	11 | 1371	**79**	11 | 1379	**70**	68 | 9162	**75**	68 | 8883
ART Initiation (not started on ART) (CS3)	**14**	11 | 333	**8**	11 | 409	**10**	68 | 3500	**9**	68 | 3193
ART Initiation (started on ART) (CS6)	**58**	11 | 259	**71**	11 | 377	**59**	68 | 2049	**72**	67 | 2013
ART Medication Pick-up (CS4)	**68**	11 | 1205	**86**	11 | 1311	**84**	68 | 8307	**89**	68 | 9006
ART Adherence Assessment (CS5)	**97**	11 | 1219	**97**	11 | 1333	**86**	68 | 7916	**96**	68 | 8518
Cotrimoxazole Preventive Therapy (CS8)	**40**	11 | 1008	**58**	11 | 940	**72**	68 | 4680	**84**	68 | 4551
TB Clinical Screen (CS9)	**51**	11 | 1470	**88**	11 | 1575	**84**	68 | 9415	**95**	68 | 10230
CD4 < 100 (Level 1) at ART Initiation (CS7)	**41**	11 | 235	**46**	11 | 365	**38**	68 | 1954	**36**	67 | 2033
100 < CD4 < 250 (Level 2) at ART Initiation (CS7)	**31**	11 | 235	**23**	11 | 365	**27**	68 | 1954	**24**	67 | 2033
250 < CD4 < 350 (Level 3) at ART Initiation (CS7)	**20**	11 | 235	**22**	11 | 365	**22**	68 | 1954	**23**	67 | 2033

Vietnam Indicators for Rounds 1-4 of Data Collection

Eligibility: HIV-infected patients with at least one clinical visit during the 6-month review period

Indicator	Numerator	Denominator
Clinical Visits (pre-ART) (CS2)	Number of pre-ART patients with at least one clinical visit in the last 3 months	Number of pre-ART patients registered at the health facility
Initial CD4 Count Test (CS1)	Number of newly registered patients who are tested for CD4 count within 15 days of enrollment	Number of patients who are newly registered at the health facility in the last 6 months, excluding newly referred patients who were previously tested for CD4 count
CD4 Monitoring (CS10)	Number of patients who are tested for CD4 count at least once in the last 6 months	Number of patients registered at the health facility
ART Initiation (started on ART) (CS6)	Number of patients who initiated ART within 30 days	Number of patients with CD4 count <350 cells/mm^3 or in WHO stage 3/4 in the last 6 months
ART Initiation (not started on ART) (CS3)	Number of eligible patients not started on ART	Number of patients with CD4 count <350 cells/mm^3 or in WHO stage 3/4 in the last 6 months
ART Medication Pick-up (CS4)	Number of patients on ART who picked up medication during their last scheduled medical visit	Number of patients on ART registered at the health facility
ART Adherence Assessment (CS5)	Number of patients on ART who were assessed for adherence to treatment at the last clinical visit	Number of patients on ART registered at the health facility
Cotrimoxazole Preventive Therapy (CS8)	Number of patients who are prescribed cotrimoxazole or dapsone in the last clinical visit	Number of patients with CD4 count <350 cells/mm^3 or in WHO stage 3/4 in the last clinical visit
TB Clinical Screen (CS9)	Number of patients who are screened for TB in the last clinical visit (includes screening for fever, night sweats, cough and weight loss)	Number of patients registered at the health facility, excluding patients on treatment for TB

Vietnam Clinical Visits (pre-ART) (CS2)

Percentage of pre-ART patients with at least one clinical visit in the last 3 months of the 6-month review period

Total (all clinics) Vietnam Adult Clinical Visits (pre-ART) Scores (%) by Review Period



Vietnam Adult Clinical Visits (pre-ART) Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jul - Dec 11	11	397	55		57	46	66	36	71
	Apr - Sept 12	11	400	54		63	29	80	0	100
	Oct 12 - Mar 13	65	2222	68		73	53	82	25	100
	Apr - Sept 13	66	2270	75		79	64	90	0	100
group 1	Jul - Dec 11	11	397	55		57	46	66	36	71
	Apr - Sept 12	11	400	54		63	29	80	0	100
	Oct 12 - Mar 13	11	314	77		84	66	94	34	100
	Apr - Sept 13	11	314	80		85	70	96	38	100
group 2	Oct 12 - Mar 13	54	1908	66		71	51	79	25	100
	Apr - Sept 13	55	1956	74		78	63	89	0	100

Vietnam Initial CD4 Count Test (CS1) and CD4 Monitoring (CS10)

Initial CD4 Count Test: Percentage of newly registered patients who are tested for CD4 count within 15 days of enrollment

CD4 Monitoring: Percentage of patients who are tested for CD4 count at least once in the last 6 months

Total (all clinics) Vietnam Adult Initial CD4 Count Test and CD4 Monitoring Scores (%) by Review Period



Vietnam Adult Initial CD4 Count Test Total (all clinics) Scores (%) by Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jul - Dec 11	11	215	65		73	50	90	0	100
	Apr - Sept 12	11	301	85		90	77	92	67	100
	Oct 12 - Mar 13	68	1884	80		86	71	93	27	100
	Apr - Sept 13	67	2083	79		87	67	95	24	100

Vietnam Adult CD4 Monitoring Total (all clinics) Scores (%) by Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jul - Dec 11	11	1371	74		79	71	83	41	92
	Apr - Sept 12	11	1379	79		78	74	86	66	88
	Oct 12 - Mar 13	68	9162	70		74	66	81	20	93
	Apr - Sept 13	68	8883	75		77	69	84	26	95

Vietnam ART Medication Pick-up (CS4)

Percentage of patients on ART visiting the health facility to pick up medication as scheduled at the last clinical visit

Total (all clinics) Vietnam Adult ART Medication Pick-up Scores (%) by Review Period



Vietnam Adult ART Medication Pick-up Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jul - Dec 11	11	1205	68		85	71	89	0	98
	Apr - Sept 12	11	1311	86		88	79	93	75	98
	Oct 12 - Mar 13	68	8307	84		88	83	92	15	98
	Apr - Sept 13	68	9006	89		90	87	94	71	99
group 1	Jul - Dec 11	11	1205	68		85	71	89	0	98
	Apr - Sept 12	11	1311	86		88	79	93	75	98
	Oct 12 - Mar 13	11	1321	79		87	73	90	47	96
	Apr - Sept 13	11	1415	88		88	85	92	73	99
group 2	Oct 12 - Mar 13	57	6986	86		88	83	93	15	98
	Apr - Sept 13	57	7591	90		90	87	95	71	99

Vietnam ART Initiation (CS3 and CS6)

ART Eligibility Criteria: CD4 count < 350 cells/mm[3] or WHO clinical stage 3 or 4

Total (all clinics) Vietnam Adult ART Initiation Scores (%) by Review Period



Percentage of patients eligible for ART who initate ART within 30 days

Vietnam Adult ART Initiation Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jul - Dec 11	11	259	58		59	40	79	14	100
	Apr - Sept 12	11	377	71		65	61	84	45	94
	Oct 12 - Mar 13	68	2049	59		66	42	80	4	100
	Apr - Sept 13	67	2013	72		74	63	85	8	100
group 1	Jul - Dec 11	11	259	58		59	40	79	14	100
	Apr - Sept 12	11	377	71		65	61	84	45	94
	Oct 12 - Mar 13	11	307	75		80	73	83	39	96
	Apr - Sept 13	11	317	82		82	74	92	63	100
group 2	Oct 12 - Mar 13	57	1742	56		60	38	77	4	100
	Apr - Sept 13	56	1696	70		72	59	84	8	100

Vietnam ART Adherence Assessment (CS5)

Percentage of patients on ART who received an adherence assessment at the last clinical visit

Total (all clinics) Vietnam Adult ART Adherence Assessment Scores (%) by Review Period



Vietnam Adult ART Adherence Assessment Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jul - Dec 11	11	1219	97		98	96	99	93	100
	Apr - Sept 12	11	1333	97		98	96	99	90	100
	Oct 12 - Mar 13	68	7916	86		97	88	99	0	100
	Apr - Sept 13	68	8518	96		99	97	99	42	100
group 1	Jul - Dec 11	11	1219	97		98	96	99	93	100
	Apr - Sept 12	11	1333	97		98	96	99	90	100
	Oct 12 - Mar 13	11	1271	97		99	97	99	80	100
	Apr - Sept 13	11	1350	98		99	98	100	94	100
group 2	Oct 12 - Mar 13	57	6645	84		97	87	99	0	100
	Apr - Sept 13	57	7168	96		98	97	99	42	100

Vietnam Cotrimoxazole Preventive Therapy (CS8)

Percentage of eligible HIV patients who are prescribed cotrimoxazole or dapsone in the last clinical visit

Total (all clinics) Vietnam Adult Cotrimoxazole Preventive Therapy Scores (%) by Review Period



Vietnam Adult Cotrimoxazole Preventive Therapy Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jul - Dec 11	11	1008	40		44	30	50	23	53
	Apr - Sept 12	11	940	58		59	49	63	38	81
	Oct 12 - Mar 13	68	4680	72		81	57	90	0	100
	Apr - Sept 13	68	4551	84		89	78	93	24	100
group 1	Jul - Dec 11	11	1008	40		44	30	50	23	53
	Apr - Sept 12	11	940	58		59	49	63	38	81
	Oct 12 - Mar 13	11	790	85		88	80	91	64	99
	Apr - Sept 13	11	726	90		92	86	96	80	98
group 2	Oct 12 - Mar 13	57	3890	70		78	56	88	0	100
	Apr - Sept 13	57	3825	82		88	76	93	24	100

Vietnam Tuberculosis Clinical Screen (CS9)

Percentage of patients who are screened for tuberculosis in the last clinical visit

Total (all clinics) Vietnam Adult Tuberculosis Clinical Screen Scores (%) by Review Period



Vietnam Adult Tuberculosis Clinical Screen Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
total (all groups)	Jul - Dec 11	11	1470	51		62	13	87	0	98
	Apr - Sept 12	11	1575	88		93	85	96	51	97
	Oct 12 - Mar 13	68	9415	84		93	84	98	0	100
	Apr - Sept 13	68	10230	95		99	95	99	0	100
group 1	Jul - Dec 11	11	1470	51		62	13	87	0	98
	Apr - Sept 12	11	1575	88		93	85	96	51	97
	Oct 12 - Mar 13	11	1492	95		97	91	99	82	100
	Apr - Sept 13	11	1567	90		99	98	100	0	100
group 2	Oct 12 - Mar 13	57	7923	81		92	80	98	0	100
	Apr - Sept 13	57	8663	95		98	95	99	37	100

Vietnam Adult Total (all clinics) Mean Percentages of CD4 Count at ART Initiation by Review Period

Round 1 (n =235)	Round 2 (n=365)	Round 3 (n=1954)	Round 4 (n=2033)
Jul - Dec 11	Apr - Sept 12	Act 12 - Mar 13	Apr - Sept 13



Eligibility: HIV-infected patients with at least one clinical visit during the 6-month review period

CD4 Level	Definition
CD4 Level 1: CD4 < 100	Number of patients who have a CD4 level < 100 cells at ART initiation
CD4 Level 2: 100 < CD4 < 250	Number of patients who have a CD4 level between 100 and 250 cells at ART initiation
CD4 Level 3: 250 < CD4 < 350	Number of patients who have a CD4 level between 250 and 350 cells at ART initiation
CD4 Level 4: CD4 > 350	Number of patients who have a CD4 level > 350 cells ART initiation

HIVQUAL Vietnam Performance Measurement

Adult HIV Care

Results

HQ-Vietnam has conducted 4 rounds of data collection measuring 10 indicators including a late diagnosis indicator (CD4 count at the time of first clinical visit) that assesses access to treatment for eligible patients that have not yet initiated ART. Key areas of improvement included clinical visits for pre-ART patients, ART medication pick-up, CPT and TB clinical screening. Scores for adherence assessment were consistently very high with the exception of minor variation during the third review period. This review period was the baseline review for the second group of clinics which lowered the mean score.

Initiation of ART in eligible patients demonstrated improvement represented by increases in proportions of patients initiating therapy with CD4>350 and simultaneously decreasing rates of initiation when CD4<100.

Although all indicators improved from baseline to the most recent review period, a few areas showed variability and signal room for improvement including first CD4 count measurement, CD4 monitoring, and ART initiation. The clinical visits measure is closely linked with these indicators and reflects opportunities to align processes to maximize to improve performance in all of these areas.

HIVQUAL Zimbabwe Performance Measurement
Adult and Pediatric ART Care and PMTCT Care

Overview
• Health facilities in Zimbabwe have submitted one round of baseline data representing care provided from January 1 through June 30, 2013.
• 35 health facilities in Zimbabwe have participated in HIVQUAL data collection.
• 8919 adult charts have been sampled.
• Performance rates have been measured for the following 5 indicators from the ART program: Retention, ART adherence assessment, CD4 monitoring, TB clinical screening and Pediatric (<15 years) ART initiation
• Performance rates have been measured for the following 4 indicators from the PMTCT program: ART Eligibility Assessment in HIV+ pregnant women, ART initiation in HIV+ pregnant women, HIV-exposed infant management (DBS test) and ART initiation in HIV+ infants
• The results from the baseline round of data collection reflect a range of challenges noted across implementing health facilities, including data quality that compromised the accuracy of reported facility-level performance. Because of incomplete data contained in source documents from which patient-level data were abstracted, baseline performance scores may not accurately reflect clinical performance during the first round of data collection.

Background
In 2010, the Ministry of Health and Child Care (MoHCC) established a formal department for Quality Assurance/Quality Improvement to coordinate the development and implementation of quality management systems in health care nationally. The QA/QI department is situated in the division of Policy, Planning, Monitoring and Evaluation within the MoHCC. The Department provides technical guidance on QA/QI, coordinates execution of related activities and provides leadership and support for the development of quality systems and activities.

Quality Improvement for HIV and TB Programs was initiated in Zimbabwe in 2011 under the leadership of the MoHCC with technical support from HEALTHQUAL-International, supported through CDC-Zimbabwe. Introduction and scale-up of improvement is following a phased approach, initially focusing on a small set of core performance measures that were chosen by a technical working group and developed with technical input from HEALTHQUAL staff. Baseline performance data represent care provided to samples of patients in the ART and PMTCT programs using 9 clinical indicators to monitor the quality of HIV care.

Data Collection
The baseline round of data collection included 35 clinics. These 35 facilities were selected on the basis of providing ART services and represented all 10 provinces in Zimbabwe as well as all levels of health service delivery.

Chart sampling and data abstraction were performed following the standard HIVQUAL methodologies presented on page 13 of this report. Staff at each health facility generated a case list of eligible patients from existing patient registers for each indicator. The total eligible population was then entered into the randomizer in HIVQUAL software. Patient charts corresponding to those listed in the randomized case list were selected for data abstraction. Nurses extracted patient files and entered data onto manual abstraction tools. The health information officer subsequently used the abstraction tools to enter data into HIVQUAL software. After validation, facility-level data were exported to the Data Manager at the MoHCC for further validation and aggregation.

For round 1 of data collection, clinic scores were averaged to calculate a mean clinic score for each indicator. Mean clinic scores are reported in the following tables by indicator and review period. The results from the baseline round of data collection reflect a range of challenges noted across implementing health facilities, including data quality issues that compromised the accuracy of the reported facility-level performance. Because of incomplete data in source documents from which patient-level data were abstracted, baseline performance scores may not reflect actual clinical performance during the first round of data collection.

HQ-Zimbabwe ART and PMTCT Mean Clinic Scores by Review Period and Indicator

mean score (%) and number of clinics | number of eligible patients

ART Indicators	Jan - Jun 13	
Retention	71	31 | 2533
ART Adherence Assessment	55	35 | 4799
CD4 Monitoring	17	35 | 4799
TB Clinical Screening	53	35 | 4796
Pediatric (<15 years) ART Initiation	79	17 | 166
PMTCT Indicators	**Jan - Jun 13**	
ART Eligibility Assessment in HIV+ pregnant women*	60	30 | 878
ART Initiation in HIV+ pregnant women	41	30 | 589
HIV-exposed Infant Management (DBS test)	30	30 | 979
ART Initiation in HIV+ infants	19	19 | 91

*The ART Eligibility Assessment in HIV+ pregnant women indicator was chosen prior to the adoption of Option B+

Zimbabwe ART Indicators for Round 1 of Data Collection

Eligibility: HIV-infected patients with at least one clinical visit during the 6-month review period

Indicator	Numerator	Denominator
Retention	Number of patients who visited the clinic at least once during the 6-month review period Note: Eligibility for the retention indicator is limited to patients on ART who visited the clinic in the 6 months **prior** to the review period	Number of patients who visited clinic in the 6 months prior to the review period
ART Adherence Assessment	Number of patients who had an ART adherence assessment at the most recent visit	Number of patients on ART with one visit during review period
CD4 Monitoring	Number of patients on ART with at least one CD4 test performed during the review period	Number of patients on ART with one visit during review period
TB Clinical Screening	Number of patients who had standard TB screening (all 5 components) performed at their last visit during the review period	Number of HIV+ patients with at least one visit during the review period
Pediatric (<15 years) ART Initiation	Number of children who initiated ART within one month of diagnosis	Number of newly diagnosed HIV+ children (<15 years old by end of review)

Zimbabwe ART Scores (%) by Indicator and Review Period

indicator	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
Retention	Jan - Jun 13	31	2533	71		79	69	94	0	100
Adh. Assess.[1]	Jan - Jun 13	35	4799	55		62	31	88	0	100
CD4 Monitoring	Jan - Jun 13	35	4799	17		10	4	24	0	88
TB Clin. Screen	Jan - Jun 13	35	4796	53		53	14	96	0	100
Pediatric ART[2]	Jan - Jun 13	17	166	79		100	80	100	0	100

[1] Some health facilities used outdated registers that did not capture the ART adherence assessment indicator, resulting in the reporting of 0% performance.

[2] Because of small sample sizes, facility-level scores reported for the pediatric ART initiation indicator may not reflect actual clinical performance during the first round of data collection.

Zimbabwe PMTCT Indicators for Round 1 of Data Collection

Eligibility: Patients with at least one clinical visit during the 6-month review period

Indicator	Numerator	Denominator
ART Eligibility Assessment in HIV+ pregnant women	Number of HIV+ pregnant women who had a CD4 test performed and received results within one week of diagnosis	Number of pregnant women newly diagnosed with HIV during the review period
ART Initiation in HIV+ pregnant women	Number of eligible HIV+ pregnant women (CD4<=350 or WHO III/IV) who initiated ART within one-month of eligibility	Number of HIV+ pregnant women with at least one visit during the review period
HIV-exposed Infant Management (DBS test)	Number of HIV-exposed infants < or = to 12 months of age who had a DBS test performed and received results within one month	Number of HIV-exposed infants < or = to 12 months old at end of the review period
ART Initiation in HIV+ infants	Number of HIV-infected children <12 months of age who have been initiated on ART	Number of confirmed HIV-infected children <12 months of age at end of the review period

Zimbabwe PMTCT Pregnant Women Scores (%) by Indicator and Review Period

indicator	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
ART Eligibility	Jan - Jun 13	30	878	60		65	46	87	0	100
ART Initiation	Jan - Jun 13	30	589	41		32	18	68	0	100

Zimbabwe PMTCT Infant Scores (%) by Indicator and Review Period

indicator	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
HIV-exp. DBS test[3]	Jan - Jun 13	30	979	15		0	0	9	0	100
ART Initiation	Jan - Jun 13	19	91	68		73	47	100	0	100

[3] During the baseline round of data collection, a group of sites misinterpreted the definition of the HIV-exposed infant management (DBS test) indicator. Because of errors in data collection by these sites, the mean clinic score reported for this indicator may not reflect actual clinical performance during the first round of data collection.

HIVQUAL Zimbabwe Performance Measurement

Adult and Pediatric ART Care and PMTCT Care

Results

The Zimbabwe quality program has conducted one round of data collection. Although data are insufficient to assess whether improvement has occurred, the initial round of data collection often identifies opportunities for improvement in the data collection process itself, which, in turn, improves data quality for future rounds of measurement. Zimbabwe is measuring 6 adult indicators and 3 pediatric indicators including infants. Since initiating data collection, there was a change in the Zimbabwe care guidelines for PMTCT to Option B+ making the measurement of ART eligibility assessment for pregnant women irrelevant. Furthermore, because the current indicators exclude patients who were not tested for HIV, a separate indicator that monitors performance on pediatric HIV testing has been recommended.

The data collection process also highlighted limited concordance between the data sources defined, abstraction tools and software which result in compromised data quality. These findings and observations are important for providers and program implementers to understand before using the data for improvement and decision making in order to interpret performance correctly. Changes to information systems can be made a part of system-level improvements to address these inconsistencies as part of the program improvement strategy.

The Zimbabwe quality program conducted another round of data collection for new clinics using a July – December 2013 review period and has since revised indicators to reflect updated guidelines. As a result, the data collection process and software are being revised and will be used for the next round of data collection.

Appendix A: HIVQUAL Namibia Performance Measurement

group aggregate scores by indicator*

Namibia Adult Performance Measurement

Shown is a breakdown by group of Namibia's adult aggregate results calculated from clinic level indicator scores (total number of clinics, total number of patients eligible, means, medians, percentiles, minimums and maximums).

Namibia Clinical Visits

Percentage of adult patients on ART who had at least one clinical visit during the last 3 months of the 6-month review period

Namibia Adult Clinical Visits (ART) Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	1631	79		78	75	88	44	99
	Jul - Dec 08	16	1522	85		85	82	90	61	99
	Jan - Jun 09	16	1601	86		90	84	93	32	99
	Jul - Dec 09	14	1487	82		84	78	90	52	97
	Jan - Jun 10	16	1781	89		90	84	94	68	99
	Oct 10 - Mar 11	16	1809	87		92	81	94	65	99
	Oct 11 - Mar 12	16	2011	86		91	84	95	50	98
	Apr - Sept 12	16	2033	78		84	71	93	34	98
	Oct 12 - Mar 13	16	1986	82		85	78	92	54	100
group 2 (n=16)	Jan - Jun 09	15	1189	90		93	82	96	75	100
	Jul - Dec 09	15	1394	85		87	81	90	58	98
	Jan - Jun 10	15	1516	86		90	84	94	50	96
	Oct 10 - Mar 11	15	1518	89		91	85	97	61	100
	Oct 11 - Mar 12	15	1786	90		92	86	95	77	98
	Apr - Sept 12	15	1652	85		89	80	91	62	98
	Oct 12 - Mar 13	16	1920	87		88	82	92	77	96
group 3 (n=4)	Jul - Dec 09	4	206	67		68	63	72	59	73
	Jan - Jun 10	4	311	87		88	87	88	85	89
	Oct 10 - Mar 11	3	259	88		90	86	91	81	92
	Oct 11 - Mar 12	4	379	88		88	84	91	80	95
	Apr - Sept 12	4	357	85		91	83	93	61	96
	Oct 12 - Mar 13	4	445	86		85	78	93	77	95
group 4 (n=1)	Jan - Jun 10	1	72	79		79	79	79	79	79
	Oct 10 - Mar 11	1	94	57		57	57	57	57	57
	Oct 11 - Mar 12	1	121	0		0	0	0	0	0
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	125	89		89	89	89	89	89
group 5 (n=1)	Oct 10 - Mar 11	1	24	92		92	92	92	92	92
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-



*Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia CD4 Monitoring

Percentage of adult patients on ART who had at least one CD4 count during the 6-month review period

Namibia Adult CD4 Monitoring Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	1631	74		75	68	85	32	96
	Jul - Dec 08	16	1522	65		66	47	78	37	92
	Jan - Jun 09	16	1601	69		73	62	78	36	98
	Jul - Dec 09	14	1487	67		65	60	77	41	95
	Jan - Jun 10	16	1781	72		74	62	82	42	89
	Oct 10 - Mar 11	16	1809	68		68	62	77	44	83
	Oct 11 - Mar 12	16	2011	68		71	60	79	10	100
	Apr - Sept 12	16	2033	64		65	51	76	32	100
	Oct 12 - Mar 13	16	1986	70						
group 2 (n=16)	Jan - Jun 09	15	1190	74		74	63	88	30	100
	Jul - Dec 09	15	1394	59		61	50	64	35	85
	Jan - Jun 10	15	1516	61		60	50	70	33	86
	Oct 10 - Mar 11	15	1518	59		61	49	68	29	85
	Oct 11 - Mar 12	15	1786	56		54	42	69	34	78
	Apr - Sept 12	15	1652	57		53	42	75	21	94
	Oct 12 - Mar 13	16	1920	62						
group 3 (n=4)	Jul - Dec 09	4	427	61		59	50	70	34	91
	Jan - Jun 10	4	311	73		74	68	79	60	85
	Oct 10 - Mar 11	3	259	58		61	56	62	51	63
	Oct 11 - Mar 12	4	379	64		70	59	76	38	79
	Apr - Sept 12	4	357	66		71	59	78	36	86
	Oct 12 - Mar 13	4	445	64						
group 4 (n=1)	Jan - Jun 10	1	72	69		69	69	69	69	69
	Oct 10 - Mar 11	1	94	36		36	36	36	36	36
	Oct 11 - Mar 12	1	121	75		75	75	75	75	75
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	125	72						
group 5 (n=1)	Oct 10 - Mar 11	1	24	63		63	63	63	63	63
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia ARV Therapy

Percentage of adult patients eligible for ART who received ART during the 6-month review period

Namibia Adult ARV Therapy Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	826	83		80	73	97	63	100
	Jul - Dec 08	16	791	79		80	74	92	37	98
	Jan - Jun 09	16	628	83		84	77	88	61	100
	Jul - Dec 09	14	517	82		84	71	95	44	100
	Jan - Jun 10	16	527	85		87	80	91	66	100
	Oct 10 - Mar 11	16	416	87		91	79	97	44	100
	Oct 11 - Mar 12	16	467	91		93	88	100	64	100
	Apr - Sept 12	16	371	91		93	84	100	74	100
	Oct 12 - Mar 13	16	322	94		100	88	100	79	100
group 2 (n=16)	Jan - Jun 09	15	494	74		75	57	92	32	100
	Jul - Dec 09	15	442	76		80	67	86	44	100
	Jan - Jun 10	15	516	76		79	58	91	46	100
	Oct 10 - Mar 11	15	385	84		88	76	94	60	100
	Oct 11 - Mar 12	15	366	86		93	80	100	56	100
	Apr - Sept 12	15	301	91		93	85	100	68	100
	Oct 12 - Mar 13	16	278	92		100	87	100	66	100
group 3 (n=4)	Jul - Dec 09	4	140	70		68	60	78	46	100
	Jan - Jun 10	4	133	89		86	84	91	83	100
	Oct 10 - Mar 11	3	84	87		96	81	98	65	100
	Oct 11 - Mar 12	4	85	89		93	82	100	70	100
	Apr - Sept 12	4	80	88		87	84	91	79	100
	Oct 12 - Mar 13	4	98	90		92	86	96	75	100
group 4 (n=1)	Jan - Jun 10	1	37	95		95	95	95	95	95
	Oct 10 - Mar 11	1	27	81		81	81	81	81	81
	Oct 11 - Mar 12	1	18	100		100	100	100	100	100
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	26	85		85	85	85	85	85
group 5 (n=1)	Oct 10 - Mar 11	1	14	93		93	93	93	93	93
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

*Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia ART Adherence Assessment

Percentage of adult patients on ART during the 6-month review period who had at least one adherence assessment during the 6-month review period

Namibia Adult ART Adherence Assessment Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	1631	90		96	92	98	57	100
	Jul - Dec 08	16	1522	97		98	96	100	78	100
	Jan - Jun 09	16	1601	93		99	94	100	29	100
	Jul - Dec 09	14	1487	98		99	98	100	94	100
	Jan - Jun 10	16	1781	98		100	97	100	91	100
	Oct 10 - Mar 11	16	1809	98		99	98	100	83	100
	Oct 11 - Mar 12	16	2011	96		99	97	100	78	100
	Apr - Sept 12	16	2033	99		100	98	100	95	100
	Oct 12 - Mar 13	16	1986	97		100	99	100	73	100
group 2 (n=16)	Jan - Jun 09	15	1189	83		96	87	100	2	100
	Jul - Dec 09	15	1394	91		99	94	99	1	100
	Jan - Jun 10	15	1516	98		99	97	100	91	100
	Oct 10 - Mar 11	15	1518	97		99	94	100	88	100
	Oct 11 - Mar 12	15	1786	98		100	95	100	86	100
	Apr - Sept 12	15	1652	97		99	98	100	85	100
	Oct 12 - Mar 13	16	1920	98		99	97	100	90	100
group 3 (n=4)	Jul - Dec 09	4	206	93		95	92	97	82	100
	Jan - Jun 10	4	311	99		100	99	100	95	100
	Oct 10 - Mar 11	3	259	96		95	95	97	94	100
	Oct 11 - Mar 12	4	379	98		99	98	99	95	100
	Apr - Sept 12	4	357	99		100	99	100	97	100
	Oct 12 - Mar 13	4	445	97		98	95	100	90	100
group 4 (n=1)	Jan - Jun 10	1	72	96		96	96	96	96	96
	Oct 10 - Mar 11	1	94	93		93	93	93	93	93
	Oct 11 - Mar 12	1	121	100		100	100	100	100	100
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	125	99		99	99	99	99	99
group 5 (n=1)	Oct 10 - Mar 11	1	24	96		96	96	96	96	96
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia Cotrimoxazole Preventive Therapy

Percentage of adult patients who are eligible for CPT who have been prescribed PCP (CTX) prophylaxis during the 6-month review period and are still receiving it at the end of the review period or at the time of death or transfer-out

Namibia Adult Cotrimoxazole Preventive Therapy Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	1145	86		91	86	94	50	100
	Jul - Dec 08	16	1040	90		93	87	98	70	100
	Jan - Jun 09	16	932	89		91	85	95	69	100
	Jul - Dec 09	14	730	92		93	87	97	77	100
	Jan - Jun 10	16	863	96		97	95	98	84	100
	Oct 10 - Mar 11	16	696	93		97	92	100	62	100
	Oct 11 - Mar 12	16	706	93		94	90	96	80	100
	Apr - Sept 12	16	585	95		96	93	100	83	100
	Oct 12 - Mar 13	16	515	93		95	86	100	76	100
group 2 (n=16)	Jan - Jun 09	15	727	86		91	86	97	53	100
	Jul - Dec 09	15	647	86		92	83	95	43	100
	Jan - Jun 10	15	762	89		93	88	98	54	100
	Oct 10 - Mar 11	15	614	91		95	90	98	67	100
	Oct 11 - Mar 12	15	534	89		93	88	96	52	100
	Apr - Sept 12	15	468	95		94	93	100	74	100
	Oct 12 - Mar 13	16	462	91		94	84	98	74	100
group 3 (n=4)	Jul - Dec 09	4	183	71		77	56	92	30	98
	Jan - Jun 10	4	200	93		95	89	99	84	100
	Oct 10 - Mar 11	3	122	92		94	88	97	82	100
	Oct 11 - Mar 12	4	123	96		96	95	97	91	100
	Apr - Sept 12	4	128	94		95	93	96	91	97
	Oct 12 - Mar 13	4	151	97		100	97	100	89	100
group 4 (n=1)	Jan - Jun 10	1	54	98		98	98	98	98	98
	Oct 10 - Mar 11	1	37	78		78	78	78	78	78
	Oct 11 - Mar 12	1	34	97		97	97	97	97	97
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	42	86		86	86	86	86	86
group 5 (n=1)	Oct 10 - Mar 11	1	17	100		100	100	100	100	100
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

*Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia Tuberculosis Clinical Screening

Percentage of adult patients who were screened for symptoms and signs of tuberculosis during the 6-month review period

Namibia Adult Tuberculosis Clinical Screening Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	1684	81		90	78	96	18	100
	Jul - Dec 08	16	1321	84		91	80	97	36	100
	Jan - Jun 09	15	975	88		95	83	100	51	100
	Jul - Dec 09	13	885	92		100	98	100	9	100
	Jan - Jun 10	15	739	91		98	87	100	58	100
	Oct 10 - Mar 11	15	808	93		98	93	100	63	100
	Oct 11 - Mar 12	15	695	96		98	95	100	79	100
	Apr - Sept 12	15	788	92		100	94	100	20	100
	Oct 12 - Mar 13	15	641	87		98	85	100	2	100
group 2 (n=16)	Jan - Jun 09	15	1218	77		94	87	98	0	100
	Jul - Dec 09	15	1328	86		96	90	99	3	100
	Jan - Jun 10	15	1265	87		97	87	100	0	100
	Oct 10 - Mar 11	15	846	91		98	92	100	53	100
	Oct 11 - Mar 12	15	784	92		98	94	100	29	100
	Apr - Sept 12	15	536	95		100	98	100	60	100
	Oct 12 - Mar 13	16	759	95		100	100	100	33	100
group 3 (n=4)	Jul - Dec 09	4	336	54		58	28	85	10	92
	Jan - Jun 10	4	375	76		88	68	95	28	100
	Oct 10 - Mar 11	3	157	98		98	97	99	95	100
	Oct 11 - Mar 12	4	164	98		100	98	100	93	100
	Apr - Sept 12	4	159	99		100	99	100	97	100
	Oct 12 - Mar 13	4	207	98		99	97	100	94	100
group 4 (n=1)	Jan - Jun 10	1	47	62		62	62	62	62	62
	Oct 10 - Mar 11	1	84	14		14	14	14	14	14
	Oct 11 - Mar 12	1	7	100		100	100	100	100	100
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	60	97		97	97	97	97	97
group 5 (n=1)	Oct 10 - Mar 11	1	17	100		100	100	100	100	100
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

*Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia Isoniazid Preventive Therapy (IPT) Screening

Percentage of adult patients not on TB treatment who received IPT during the 6-month review period

Namibia Adult Isoniazid Preventive Therapy Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	1977	16		13	7	24	1	47
	Jul - Dec 08	16	1646	22		11	6	40	3	62
	Jan - Jun 09	15	1361	31		23	13	46	3	83
	Jul - Dec 09	13	1243	31		25	9	48	0	87
	Jan - Jun 10	15	1142	41		36	26	46	7	95
	Oct 10 - Mar 11	15	1057	28		23	13	46	6	63
	Oct 11 - Mar 12	15	954	34		32	16	50	8	75
	Apr - Sept 12	15	1044	29		21	12	43	2	71
	Oct 12 - Mar 13	15	815	28		25	11	37	2	67
group 2 (n=16)	Jan - Jun 09	15	1456	22		7	1	40	0	76
	Jul - Dec 09	15	1559	16		6	2	25	0	45
	Jan - Jun 10	15	1529	22		25	2	32	0	65
	Oct 10 - Mar 11	15	1126	31		25	9	46	5	73
	Oct 11 - Mar 12	15	992	31		32	11	42	7	92
	Apr - Sept 12	15	736	35		33	20	46	5	92
	Oct 12 - Mar 13	16	928	23		18	13	33	0	57
group 3 (n=4)	Jul - Dec 09	4	354	3		0	0	3	0	13
	Jan - Jun 10	4	440	14		10	3	21	0	37
	Oct 10 - Mar 11	3	217	22		17	9	33	0	49
	Oct 11 - Mar 12	4	238	41		30	22	49	14	89
	Apr - Sept 12	4	212	28		23	19	32	9	54
	Oct 12 - Mar 13	4	264	21		19	12	28	6	40
group 4 (n=1)	Jan - Jun 10	1	93	49		49	49	49	49	49
	Oct 10 - Mar 11	1	112	25		25	25	25	25	25
	Oct 11 - Mar 12	1	46	85		85	85	85	85	85
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	79	24		24	24	24	24	24
group 5 (n=1)	Oct 10 - Mar 11	1	21	19		19	19	19	19	19
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

*Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia Prevention Education

Percentage of adult patients who received prevention education during the last 3 months of the 6-month review period

Namibia Adult Prevention Education Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	2296	37		29	19	48	1	98
	Jul - Dec 08	16	2259	39		36	15	58	1	86
	Jan - Jun 09	16	2248	50		44	31	71	8	95
	Jul - Dec 09	14	2000	57		55	34	82	2	96
	Jan - Jun 10	16	2324	60		61	37	84	13	100
	Oct 10 - Mar 11	16	2276	45		33	23	70	10	93
	Oct 11 - Mar 12	16	2311	56		59	30	86	8	99
	Apr - Sept 12	16	2303	54		57	30	74	6	100
	Oct 12 - Mar 13	16	2277	53		55	26	84	0	100
group 2 (n=16)	Jan - Jun 09	15	1795	41		23	0	96	0	99
	Jul - Dec 09	15	1935	34		20	1	68	0	99
	Jan - Jun 10	15	2179	37		23	9	70	0	100
	Oct 10 - Mar 11	15	1931	31		24	18	41	0	99
	Oct 11 - Mar 12	15	2105	31		33	11	46	1	95
	Apr - Sept 12	15	1953	38		23	7	70	0	100
	Oct 12 - Mar 13	16	2204	29		22	7	42	2	98
group 3 (n=4)	Jul - Dec 09	4	395	36		34	14	56	0	77
	Jan - Jun 10	4	468	39		31	16	54	0	92
	Oct 10 - Mar 11	3	297	41		40	36	45	32	50
	Oct 11 - Mar 12	4	437	37		19	18	38	17	96
	Apr - Sept 12	4	423	47		53	38	61	12	73
	Oct 12 - Mar 13	4	497	31		17	14	35	11	81
group 4 (n=1)	Jan - Jun 10	1	108	66		66	66	66	66	66
	Oct 10 - Mar 11	1	134	61		61	61	61	61	61
	Oct 11 - Mar 12	1	136	100		100	100	100	100	100
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	147	99		99	99	99	99	99
group 5 (n=1)	Oct 10 - Mar 11	1	26	100		100	100	100	100	100
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia Weight Monitoring

Percentage of adult patients whose weight was recorded during the 6-month review period

Namibia Adult Weight Monitoring Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	2296	84		93	82	97	29	100
	Jul - Dec 08	16	2259	93		96	90	99	73	100
	Jan - Jun 09	16	2248	96		97	95	99	92	100
	Jul - Dec 09	14	2000	97		99	97	99	90	100
	Jan - Jun 10	16	2324	98		98	97	99	92	100
	Oct 10 - Mar 11	16	2276	97		98	95	99	90	100
	Oct 11 - Mar 12	16	2311	97		97	94	100	90	100
	Apr - Sept 12	16	2303	98		99	98	99	91	100
	Oct 12 - Mar 13	16	2277	98		99	97	99	91	100
group 2 (n=16)	Jan - Jun 09	14	1758	92		95	90	97	71	100
	Jul - Dec 09	15	1935	93		95	90	98	78	99
	Jan - Jun 10	15	2179	92		97	91	99	63	100
	Oct 10 - Mar 11	15	1931	96		98	95	99	81	100
	Oct 11 - Mar 12	15	2105	96		98	94	99	83	100
	Apr - Sept 12	15	1953	96		98	95	100	78	100
	Oct 12 - Mar 13	16	2204	94		99	96	100	58	100
group 3 (n=4)	Jul - Dec 09	4	395	62		66	30	97	17	99
	Jan - Jun 10	4	468	88		99	88	99	55	100
	Oct 10 - Mar 11	3	297	97		99	96	99	94	99
	Oct 11 - Mar 12	4	437	95		97	93	99	86	99
	Apr - Sept 12	4	423	95		100	95	100	82	100
	Oct 12 - Mar 13	4	497	97		99	96	99	90	100
group 4 (n=1)	Jan - Jun 10	1	108	99		99	99	99	99	99
	Oct 10 - Mar 11	1	134	96		96	96	96	96	96
	Oct 11 - Mar 12	1	136	100		100	100	100	100	100
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	147	100		100	100	100	100	100
group 5 (n=1)	Oct 10 - Mar 11	1	26	100		100	100	100	100	100
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

*Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia Food Security

Percentage of adult patients assessed for food security during the 6-month review period

Namibia Adult Food Security Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	2296	24		11	2	33	0	98
	Jul - Dec 08	16	2259	34		28	6	55	0	91
	Jan - Jun 09	16	2248	45		42	16	78	0	96
	Jul - Dec 09	14	2000	57		63	24	90	1	97
	Jan - Jun 10	16	2324	56		53	35	88	0	100
	Oct 10 - Mar 11	16	2276	54		69	18	80	0	97
	Oct 11 - Mar 12	16	2311	58		59	32	96	1	100
	Apr - Sept 12	16	2303	57		61	29	90	0	100
	Oct 12 - Mar 13	16	2277	58		59	33	91	0	100
group 2 (n=16)	Jan - Jun 09	15	1795	2		0	0	1	0	19
	Jul - Dec 09	15	1935	1		0	0	1	0	13
	Jan - Jun 10	15	2179	24		2	0	50	0	95
	Oct 10 - Mar 11	15	1931	31		18	8	44	0	99
	Oct 11 - Mar 12	15	2105	30		31	10	47	0	97
	Apr - Sept 12	15	1953	31		16	0	49	0	100
	Oct 12 - Mar 13	16	2204	32		27	5	47	0	98
group 3 (n=4)	Jul - Dec 09	4	395	20		18	2	37	0	46
	Jan - Jun 10	4	468	29		30	12	46	5	52
	Oct 10 - Mar 11	3	297	80		86	70	93	54	100
	Oct 11 - Mar 12	4	437	56		58	14	99	7	100
	Apr - Sept 12	4	423	62		73	38	97	3	98
	Oct 12 - Mar 13	4	497	54		58	17	95	1	99
group 4 (n=1)	Jan - Jun 10	1	108	0		0	0	0	0	0
	Oct 10 - Mar 11	1	134	0		0	0	0	0	0
	Oct 11 - Mar 12	1	136	98		98	98	98	98	98
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	147	95		95	95	95	95	95
group 5 (n=1)	Oct 10 - Mar 11	1	26	100		100	100	100	100	100
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

*Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Namibia Alcohol Screening

Percentage of adult patients who were screened for alcohol use during the 6-month review period

Namibia Adult Alcohol Screening Scores (%) by Group and Review Period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n=16)	Jan - Jun 08	16	2296	24		13	2	31	0	97
	Jul - Dec 08	16	2259	33		28	9	55	0	88
	Jan - Jun 09	16	2248	48		47	20	84	0	95
	Jul - Dec 09	14	2000	61		63	42	91	1	97
	Jan - Jun 10	16	2324	62		60	37	92	0	100
	Oct 10 - Mar 11	16	2276	56		71	20	82	0	98
	Oct 11 - Mar 12	16	2311	60		66	31	96	1	99
	Apr - Sept 12	16	2303	59		61	38	91	0	100
	Oct 12 - Mar 13	16	2277	58		58	33	91	1	100
group 2 (n=16)	Jan - Jun 09	15	1795	9		0	0	4	0	97
	Jul - Dec 09	15	1935	9		0	0	5	0	97
	Jan - Jun 10	15	2179	25		8	1	55	0	94
	Oct 10 - Mar 11	15	1931	35		22	17	44	0	100
	Oct 11 - Mar 12	15	2105	32		33	15	47	1	98
	Apr - Sept 12	15	1953	31		16	0	49	0	100
	Oct 12 - Mar 13	16	2204	32		25	6	46	0	98
group 3 (n=4)	Jul - Dec 09	4	395	21		18	2	37	0	46
	Jan - Jun 10	4	468	31		29	15	45	13	51
	Oct 10 - Mar 11	3	297	80		86	70	93	54	99
	Oct 11 - Mar 12	4	437	55		58	13	100	5	100
	Apr - Sept 12	4	423	62		72	38	96	6	98
	Oct 12 - Mar 13	4	497	55		58	18	95	3	99
group 4 (n=1)	Jan - Jun 10	1	108	6		6	6	6	6	6
	Oct 10 - Mar 11	1	134	11		11	11	11	11	11
	Oct 11 - Mar 12	1	136	99		99	99	99	99	99
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	1	147	94		94	94	94	94	94
group 5 (n=1)	Oct 10 - Mar 11	1	26	100		100	100	100	100	100
	Oct 11 - Mar 12	-	-	-		-	-	-	-	-
	Apr - Sept 12	-	-	-		-	-	-	-	-
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-

*Namibia Round 1 data (July - December 2007) were intentionally omitted from longitudinal analysis because technical difficulties with data capture comprised the accuracy of several indicators.

Appendix A: HIVQUAL Haiti Performance Measurement

group aggregate scores by indicator*

Haiti Adult Performance Measurement

Shown is a breakdown by group of Haiti's adult aggregate results calculated from clinic level indicator scores (total number of clinics, total number of patients eligible, means, medians, percentiles, minimums and maximums).

Haiti Adult Clinical Visits (ART) Scores (%) by Group and Review Period

Percentage of adult patients on ART who had at least one clinical visit within 3 months of their last visit during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	11	3111	76		81	69	85	52	89
	Jul - Dec 08	12	4251	77		79	73	87	54	88
	Jan - Jun 09	11	5389	78		79	76	83	55	91
	Jul - Dec 09	11	6430	74		76	65	87	47	93
	Jan - Jun 10	11	7266	72		78	72	83	21	91
	Jul - Dec 10	13	8025	72		77	75	80	3	93
	Jan - Jun 11	15	10348	73		78	72	83	4	95
	Jul - Dec 11	17	11319	68		78	68	81	0	90
	Oct 11 - Mar 12	18	11959	68		76	69	81	0	92
	Apr - Sept 12	18	13876	85		85	80	91	64	98
	Oct 12 - Mar 13	18	15043	84		85	75	92	67	98
	Apr - Sept 13	18	16605	86		91	76	95	69	99
	Oct 13 - Mar 14	17	15867	83		87	73	94	54	98
group 2 (n = 6)	Jul - Dec 08	3	757	79		81	78	81	75	82
	Jan - Jun 09	3	898	82		85	79	86	73	88
	Jul - Dec 09	3	1102	85		86	84	87	82	88
	Jan - Jun 10	3	1264	84		84	82	86	81	87
	Jul - Dec 10	3	1373	83		80	80	85	80	90
	Jan - Jun 11	3	1479	84		84	82	85	80	87
	Jul - Dec 11	6	1679	80		80	75	86	65	93
	Oct 11 - Mar 12	6	1922	82		84	77	87	71	92
	Apr - Sept 12	5	2409	92		93	88	94	86	99
	Oct 12 - Mar 13	6	2980	92		96	90	98	74	99
	Apr - Sept 13	5	3209	95		95	91	96	91	100
	Oct 13 - Mar 14	6	3489	84		84	76	94	67	98
group 3 (n = 24)	Jul - Dec 09	13	2735	78		80	70	83	50	100
	Jan - Jun 10	13	3203	68		73	58	85	9	96
	Jul - Dec 10	13	3582	72		71	63	83	43	92
	Jan - Jun 11	19	7079	76		76	64	93	31	99
	Jul - Dec 11	24	8080	68		77	62	83	0	99
	Oct 11 - Mar 12	24	8534	72		78	64	89	0	99
	Apr - Sept 12	19	9109	79		80	74	90	41	100
	Oct 12 - Mar 13	19	8391	83		84	78	96	44	100
	Apr - Sept 13	19	10986	80		80	70	94	38	100
	Oct 13 - Mar 14	19	11803	76		78	68	92	33	99

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult Clinical Visits (ART) Scores (%) by Group and Review Period

Percentage of adult patients on ART who had at least one clinical visit within 3 months of their last visit during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 4 (n = 4)	Jul - Dec 10	2	257	41		41	23	59	5	77
	Jan - Jun 11	3	1049	44		54	28	65	1	76
	Jul - Dec 11	4	1228	58		75	54	79	0	82
	Oct 11 - Mar 12	4	1214	63		77	51	89	2	96
	Apr - Sept 12	3	1268	88		89	86	91	83	93
	Oct 12 - Mar 13	4	1760	79		79	74	84	68	88
	Apr - Sept 13	4	2236	76		76	70	83	67	84
	Oct 13 - Mar 14	4	2497	78		81	75	84	65	84
group 5 (n = 6)	Jul - Dec 11	4	37	64		66	61	68	50	73
	Oct 11 - Mar 12	6	185	72		74	63	81	59	86
	Apr - Sept 12	6	924	92		96	90	98	76	98
	Oct 12 - Mar 13	6	1412	90		89	87	93	85	98
	Apr - Sept 13	5	1474	93		94	89	98	87	99
	Oct 13 - Mar 14	6	2230	89		88	83	96	80	98
group 6 (n = 12)	Apr - Sept 12	7	10727	79		80	76	89	50	97
	Oct 12 - Mar 13	9	12010	83		82	78	91	68	94
	Apr - Sept 13	12	14227	86		93	75	97	64	99
	Oct 13 - Mar 14	11	15514	85		85	80	92	68	100
group 7 (n = 18)	Oct 12 - Mar 13	9	661	83		86	73	90	63	100
	Apr - Sept 13	16	2334	80		85	69	89	47	100
	Oct 13 - Mar 14	18	5980	68		75	56	84	0	96
group 8 (n = 14)	Apr - Sept 13	12	429	81		90	85	94	0	100
	Oct 13 - Mar 14	11	728	84		84	77	90	69	95
group 9 (n = 4)	Oct 13 - Mar 14	3	156	88		86	85	90	83	94

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult CD4 Monitoring** (Rounds 1-10) Scores (%) by Group and Review Period

Percentage of newly enrolled adult patients (within preceding 6-12 months of review period) who had a CD4 count within 2 months of and between 2-8 months after enrollment

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	16	2752	31		32	18	38	0	76
	Jul - Dec 08	16	3127	34		30	23	42	2	84
	Jan - Jun 09	16	2812	41		37	30	53	6	88
	Jul - Dec 09	16	3064	36		33	24	45	0	76
	Jan - Jun 10	16	2491	27		21	14	40	2	65
	Jul - Dec 10	16	2001	23		19	15	25	0	71
	Jan - Jun 11	17	2218	29		29	13	41	8	65
	Jul - Dec 11	17	2346	30		26	18	38	5	66
	Oct 11 - Mar 12	17	2138	39		40	26	48	4	79
	Apr - Sept 12	18	2083	40		34	29	60	2	78
group 2 (n = 6)	Jul - Dec 08	6	579	27		28	23	34	6	46
	Jan - Jun 09	6	542	33		30	17	48	14	55
	Jul - Dec 09	6	816	44		42	38	55	7	75
	Jan - Jun 10	6	594	43		45	35	53	7	73
	Jul - Dec 10	6	402	22		23	8	35	0	47
	Jan - Jun 11	6	392	44		40	32	55	8	84
	Jul - Dec 11	6	473	53		53	47	57	27	85
	Oct 11 - Mar 12	6	509	48		41	39	50	35	79
	Apr - Sept 12	6	487	46		48	31	55	22	78
group 3 (n = 24)	Jul - Dec 09	14	1012	23		17	6	30	0	71
	Jan - Jun 10	16	1135	29		26	7	39	0	100
	Jul - Dec 10	15	969	22		15	8	36	0	71
	Jan - Jun 11	22	1594	20		10	2	35	0	97
	Jul - Dec 11	24	1631	24		14	6	45	0	83
	Oct 11 - Mar 12	24	1691	24		15	9	32	0	76
	Apr - Sept 12	21	1399	25		19	2	46	0	84
group 4 (n = 4)	Jul - Dec 10	3	83	2		0	0	3	0	6
	Jan - Jun 11	4	255	4		1	0	5	0	15
	Jul - Dec 11	4	212	18		2	0	19	0	67
	Oct 11 - Mar 12	4	253	17		4	0	21	0	59
	Apr - Sept 12	3	201	30		40	21	44	2	49
group 5 (n = 6)	Jul - Dec 11	6	416	14		15	6	22	1	27
	Oct 11 - Mar 12	6	515	20		15	7	26	4	52
	Apr - Sept 12	6	519	23		21	9	28	3	59
group 6 (n = 12)	Apr - Sept 12	9	488	13		9	0	21	0	47

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.
**As of the Oct 12 - Mar 13 review period, the CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring, measured by the percentage of all patients enrolled prior to the 6-month review period who received the last 2 CD4 tests during the 6-month review period and (2) CD4 at Enrollment, measured by the percentage of patients newly enrolled during the 6-month review period who received a CD4 test at enrollment. Results from the revised CD4 Monitoring indicators are reported separately.

Haiti Adult CD4 Monitoring (Rounds 11-13) Scores (%) by Group and Review Period

Percentage of all patients enrolled prior to the 6-month review period who received the last 2 CD4 tests during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Oct 12 - Mar 13	18	15442	24		25	14	33	1	45
	Apr - Sept 13	18	16102	55		55	43	72	17	93
	Oct 13 - Mar 14	17	15289	57		56	41	72	30	92
group 2 (n = 6)	Oct 12 - Mar 13	6	3220	30		27	24	35	13	50
	Apr - Sept 13	5	3353	76		81	72	82	53	89
	Oct 13 - Mar 14	6	3581	73		76	67	85	47	89
group 3 (n = 24)	Oct 12 - Mar 13	19	9780	18		13	5	26	1	53
	Apr - Sept 13	19	10669	45		43	20	73	3	90
	Oct 13 - Mar 14	19	11402	47		38	25	76	2	93
group 4 (n = 4)	Oct 12 - Mar 13	4	1847	13		7	1	19	1	38
	Apr - Sept 13	4	2038	32		23	8	48	3	81
	Oct 13 - Mar 14	4	2200	v48		45	30	63	14	88
group 5 (n = 6)	Oct 12 - Mar 13	6	1683	24		23	13	36	8	39
	Apr - Sept 13	5	1493	67		78	46	83	42	85
	Oct 13 - Mar 14	6	2188	67		63	61	76	48	85
group 6 (n = 12)	Oct 12 - Mar 13	9	2570	11		9	4	20	1	25
	Apr - Sept 13	11	3538	34		37	13	51	0	71
	Oct 13 - Mar 14	11	4159	51		47	23	73	19	95
group 7 (n = 18)	Oct 12 - Mar 13	9	658	6		7	2	8	0	14
	Apr - Sept 13	17	1784	16		13	8	24	0	65
	Oct 13 - Mar 14	17	2268	30		30	3	46	0	70
group 8 (n = 14)	Apr -Sept 13	11	247	24		15	2	43	0	57
	Oct 13 - Mar 14	11	540	28		23	3	52	0	63
group 9 (n = 4)	Oct 13 - Mar 14	3	130	16		13	12	18	12	23

Haiti Adult CD4 at Enrollment (Rounds 11-13) Scores (%) by Group and Review Period

Percentage of patients newly enrolled during the 6-month review period who received a CD4 test at enrollment

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Oct 12 - Mar 13	18	2152	72		72	60	90	38	96
	Apr - Sept 13	18	2519	75		79	64	86	39	98
	Oct 13 - Mar 14	17	1856	73		76	62	86	41	96
group 2 (n = 6)	Oct 12 - Mar 13	6	630	88		86	86	89	81	100
	Apr - Sept 13	5	570	87		89	81	90	74	100
	Oct 13 - Mar 14	6	455	88		92	80	96	70	100
group 3 (n = 24)	Oct 12 - Mar 13	19	1214	65		71	53	85	8	98
	Apr - Sept 13	19	1740	71		72	62	91	11	97
	Oct 13 - Mar 14	19	1397	69		66	59	87	27	95
group 4 (n = 4)	Oct 12 - Mar 13	4	277	47		42	20	69	10	91
	Apr - Sept 13	4	358	58		60	42	76	16	98
	Oct 13 - Mar 14	4	351	69		77	54	92	28	95
group 5 (n = 6)	Oct 12 - Mar 13	6	533	68		64	55	77	54	95
	Apr - Sept 13	5	458	83		82	78	89	73	95
	Oct 13 - Mar 14	6	687	74		69	67	83	63	90
group 6 (n = 12)	Oct 12 - Mar 13	11	1712	50		52	33	70	1	91
	Apr - Sept 13	12	2064	72		76	69	84	12	98
	Oct 13 - Mar 14	11	2077	80		87	77	91	23	100
group 7 (n = 18)	Oct 12 - Mar 13	9	570	33		21	20	50	0	69
	Apr - Sept 13	17	1188	44		43	29	64	0	95
	Oct 13 - Mar 14	17	1030	55		68	16	84	0	100
group 8 (n = 14)	Apr - Sept 13	10	522	35		41	25	50	0	53
	Oct 13 - Mar 14	11	444	48		50	29	70	2	87
group 9 (n = 4)	Oct 13 - Mar 14	3	165	35		35	20	50	5	66

Haiti Adult Cotrimoxazole Preventive Therapy Scores (%) by Group and Review Period

Percentage of adult patients who received cotrimoxazole prophylaxis during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	18	10316	62		72	34	84	23	88
	Jul - Dec 08	18	11862	69		74	60	90	0	98
	Jan - Jun 09	18	13598	72		84	62	89	0	99
	Jul - Dec 09	18	13632	78		83	74	95	28	99
	Jan - Jun 10	18	13468	78		85	70	95	28	98
	Jul - Dec 10	17	13985	82		92	77	97	37	99
	Jan - Jun 11	17	14704	85		95	83	98	40	98
	Jul - Dec 11	17	15611	89		95	90	98	41	99
	Oct 11 - Mar 12	17	15818	89		95	91	96	41	100
	Apr - Sept 12	18	17173	91		96	93	97	30	100
	Oct 12 - Mar 13	18	17406	94		96	91	99	81	99
	Apr - Sept 13	18	18354	95		96	94	98	81	99
	Oct 13 - Mar 14	17	16591	95		96	95	98	82	99
group 2 (n = 6)	Jul - Dec 08	6	1920	80		83	79	85	61	88
	Jan - Jun 09	6	2440	88		90	83	92	79	97
	Jul - Dec 09	6	2675	92		94	88	97	83	99
	Jan - Jun 10	6	2619	92		93	89	96	84	97
	Jul - Dec 10	6	2754	90		93	85	98	74	99
	Jan - Jun 11	6	2976	94		94	93	96	89	97
	Jul - Dec 11	6	3298	96		96	95	97	92	100
	Oct 11 - Mar 12	6	3422	98		98	97	100	96	100
	Apr - Sept 12	6	3638	98		98	97	99	94	100
	Oct 12 - Mar 13	6	3902	98		99	97	100	93	100
	Apr - Sept 13	5	4017	98		98	97	99	97	99
	Oct 13 - Mar 14	6	4116	98		99	98	99	96	99
group 3 (n = 24)	Jul - Dec 09	24	7347	58		58	33	84	3	95
	Jan - Jun 10	24	7214	63		70	46	82	4	94
	Jul - Dec 10	24	7610	67		71	50	91	10	98
	Jan - Jun 11	22	8052	74		86	60	94	7	99
	Jul - Dec 11	24	9457	77		88	59	95	32	99
	Oct 11 - Mar 12	24	9835	81		93	65	97	34	100
	Apr - Sept 12	21	10132	83		96	68	97	31	100
	Oct 12 - Mar 13	19	9199	86		95	77	99	38	100
	Apr - Sept 13	19	11077	89		96	80	99	53	100
	Oct 13 - Mar 14	19	11049	91		94	88	97	61	100
group 4 (n = 4)	Jul - Dec 10	4	755	59		58	33	85	25	95
	Jan - Jun 11	4	802	56		52	31	76	21	98
	Jul - Dec 11	4	1064	55		56	39	72	9	99
	Oct 11 - Mar 12	4	1092	63		61	50	74	32	98
	Apr - Sept 12	3	1629	76		84	64	91	45	98
	Oct 12 - Mar 13	4	2040	89		92	86	94	72	99
	Apr - Sept 13	4	2243	92		92	87	97	83	99
	Oct 13 - Mar 14	4	2378	93		93	91	95	88	98



*For every review period, CPT data from all clinics are stratified into adult and pediatric (< 15 years old) data and are included in the aggregate results.

Haiti Adult Cotrimoxazole Preventive Therapy Scores (%) by Group and Review Period

Percentage of adult patients who received cotrimoxazole prophylaxis during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 5 (n = 6)	Jul - Dec 11	6	1387	86		87	81	93	71	100
	Oct 11 - Mar 12	6	1651	91		92	87	95	82	99
	Apr - Sept 12	6	2057	94		94	92	95	90	99
	Oct 12 - Mar 13	6	2291	95		95	94	97	90	100
	Apr - Sept 13	5	1995	97		97	94	99	94	100
	Oct 13 - Mar 14	6	2972	97		97	96	98	96	100
group 6 (n = 12)	Apr - Sept 12	10	11966	89		93	88	97	63	98
	Oct 12 - Mar 13	11	11677	84		96	92	98	21	100
	Apr - Sept 13	12	14083	90		97	93	99	48	100
	Oct 13 - Mar 14	11	14345	96		98	97	99	85	100
group 7 (n = 18)	Oct 12 - Mar 13	9	1319	90		92	89	97	71	99
	Apr - Sept 13	17	3161	92		95	91	98	59	100
	Oct 13 - Mar 14	18	5894	92		96	88	99	63	100
group 8 (n = 14)	Apr - Sept 13	12	829	83		97	86	99	0	100
	Oct 13 - Mar 14	11	1097	95		97	94	98	84	100
group 9 (n = 4)	Oct 13 - Mar 14	3	320	90		90	87	93	84	96

*For every review period, CPT data from all clinics are stratified into adult and pediatric (< 15 years old) data and are included in the aggregate results.

Haiti Adult ARV Therapy Scores (%) by Group and Review Period

Percentage of adult patients eligible for ART who were enrolled in ART during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	11	2520	45		46	35	54	20	73
	Jul - Dec 08	12	2615	45		45	40	55	17	76
	Jan - Jun 09	11	2711	45		46	39	53	29	60
	Jul - Dec 09	11	2435	45		47	36	56	24	62
	Jan - Jun 10	11	2287	37		39	27	46	18	61
	Jul - Dec 10	13	2529	30		30	14	40	9	55
	Jan - Jun 11	15	3193	37		32	26	49	10	65
	Jul - Dec 11	17	3106	43		43	26	62	0	74
	Oct 11 - Mar 12	17	3045	43		45	33	51	2	74
	Apr - Sept 12	18	3688	53		53	46	61	9	92
	Oct 12 - Mar 13	18	3326	55		56	46	62	33	82
	Apr - Sept 13	18	3370	67		63	55	81	47	90
	Oct 13 - Mar 14	17	2354	69		69	60	76	48	89
group 2 (n = 6)	Jul - Dec 08	3	495	32		30	28	35	27	39
	Jan - Jun 09	3	615	37		41	32	44	23	46
	Jul - Dec 09	3	718	33		36	31	36	26	36
	Jan - Jun 10	3	637	26		28	23	31	17	34
	Jul - Dec 10	3	646	25		25	24	26	22	27
	Jan - Jun 11	3	717	31		33	24	39	15	45
	Jul - Dec 11	6	960	53		51	46	63	24	79
	Oct 11 - Mar 12	6	806	59		67	43	78	15	85
	Apr - Sept 12	5	748	54		56	53	63	29	70
	Oct 12 - Mar 13	6	830	56		66	49	74	7	77
	Apr - Sept 13	5	644	65		74	50	75	50	77
	Oct 13 - Mar 14	6	561	59		65	58	71	13	80

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult ARV Therapy Scores (%) by Group and Review Period

Percentage of adult patients eligible for ART who were enrolled in ART during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 3 (n = 24)	Jul - Dec 09	13	952	45		43	38	47	25	85
	Jan - Jun 10	13	881	39		38	20	57	0	69
	Jul - Dec 10	13	1092	50		54	43	63	14	69
	Jan - Jun 11	19	1929	44		48	28	58	3	81
	Jul - Dec 11	24	2262	42		42	19	63	0	85
	Oct 11 - Mar 12	24	2275	47		45	33	62	9	89
	Apr - Sept 12	19	1970	65		63	55	76	30	100
	Oct 12 - Mar 13	19	1678	66		71	55	75	34	98
	Apr - Sept 13	19	1690	78		82	70	87	47	98
	Oct 13 - Mar 14	19	1488	79		83	79	88	37	100
group 4 (n = 4)	Jul - Dec 10	2	63	55		55	54	57	52	59
	Jan - Jun 11	3	171	58		55	54	61	52	67
	Jul - Dec 11	4	236	39		44	15	68	0	68
	Oct 11 - Mar 12	4	196	61		70	57	74	24	79
	Apr - Sept 12	3	194	78		81	77	81	74	81
	Oct 12 - Mar 13	4	337	79		81	75	85	62	91
	Apr - Sept 13	4	339	84		83	80	87	80	89
	Oct 13 - Mar 14	4	289	86		87	81	91	77	93
group 5 (n = 6)	Jul - Dec 11	6	542	43		42	30	55	27	64
	Oct 11 - Mar 12	6	623	48		48	37	52	27	77
	Apr - Sept 12	6	908	50		46	42	55	32	78
	Oct 12 - Mar 13	6	877	53		54	50	54	37	71
	Apr - Sept 13	5	634	70		72	64	74	61	77
	Oct 13 - Mar 14	6	711	61		63	59	66	50	68
group 6 (n = 12)	Apr - Sept 12	6	649	52		52	42	63	34	69
	Oct 12 - Mar 13	11	2121	44		50	27	65	0	74
	Apr - Sept 13	12	2585	67		71	63	80	24	89
	Oct 13 - Mar 14	11	2196	66		67	60	81	26	94
group 7 (n = 18)	Oct 12 - Mar 13	9	628	55		49	47	65	31	78
	Apr - Sept 13	16	1456	74		77	67	89	29	95
	Oct 13 - Mar 14	18	1589	68		72	64	82	0	99
group 8 (n = 14)	Apr - Sept 13	12	376	63		66	59	79	0	100
	Oct 13 - Mar 14	11	420	76		80	67	85	45	95
group 9 (n = 4)	Oct 13 - Mar 14	3	115	58		63	53	66	42	68

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult ART Adherence Assessment Scores (%) by Group and Review Period

Percentage of adult patients on ART who had an adherence assessment during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	11	2134	29		3	0	71	0	89
	Jul - Dec 08	12	2936	51		61	6	90	0	93
	Jan - Jun 09	11	3496	74		95	59	98	0	100
	Jul - Dec 09	11	4866	85		95	76	98	48	100
	Jan - Jun 10	11	5074	74		93	70	98	1	99
	Jul - Dec 10	13	5767	75		95	57	99	0	100
	Jan - Jun 11	15	7006	78		96	64	98	10	100
	Jul - Dec 11	17	8283	59		72	0	97	0	99
	Oct 11 - Mar 12	16	7811	72		89	67	97	0	99
	Apr - Sept 12	17	10013	80		95	79	96	0	99
	Oct 12 - Mar 13	16	10912	85		93	83	97	26	98
	Apr - Sept 13	18	13668	88		94	91	96	27	100
	Oct 13 - Mar 14	17	12979	82		93	90	96	2	99
group 2 (n = 6)	Jul - Dec 08	3	599	62		55	49	72	44	88
	Jan - Jun 09	3	633	89		90	88	90	87	90
	Jul - Dec 09	3	970	95		94	94	95	93	96
	Jan - Jun 10	3	1054	93		94	93	94	92	94
	Jul - Dec 10	3	1150	95		96	94	97	92	98
	Jan - Jun 11	3	1219	95		93	93	96	92	99
	Jul - Dec 11	6	1473	84		95	74	98	50	100
	Oct 11 - Mar 12	6	1744	88		95	87	97	58	100
	Apr - Sept 12	5	2001	95		95	94	97	94	97
	Oct 12 - Mar 13	6	2638	93		97	92	98	75	100
	Apr - Sept 13	5	2931	98		98	97	99	94	100
	Oct 13 - Mar 14	6	3135	95		98	94	99	84	99
group 3 (n = 24)	Jul - Dec 09	13	1873	73		89	56	98	0	100
	Jan - Jun 10	13	1716	77		92	67	99	23	100
	Jul - Dec 10	12	1733	88		96	92	97	8	99
	Jan - Jun 11	19	3783	87		98	96	99	0	100
	Jul - Dec 11	22	4760	84		96	92	97	0	100
	Oct 11 - Mar 12	23	5393	84		97	91	98	0	100
	Apr - Sept 12	19	5998	90		97	93	98	0	99
	Oct 12 - Mar 13	13	5094	80		96	92	98	0	100
	Apr - Sept 13	19	8488	86		94	80	97	39	99
	Oct 13 - Mar 14	19	8792	84		94	90	97	0	99
group 4 (n = 4)	Jul - Dec 10	2	149	78		78	71	84	65	91
	Jan - Jun 11	3	393	41		25	13	61	1	97
	Jul - Dec 11	3	752	46		38	19	68	0	99
	Oct 11 - Mar 12	4	893	73		96	70	99	0	100
	Apr - Sept 12	3	1135	88		94	82	97	71	100
	Oct 12 - Mar 13	3	550	85		91	78	95	65	99
	Apr - Sept 13	4	1682	54		52	15	92	14	99
	Oct 13 - Mar 14	4	1922	79		81	64	96	54	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult ART Adherence Assessment Scores (%) by Group and Review Period

Percentage of adult patients on ART who had an adherence assessment during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 5 (n = 6)	Jul - Dec 11	3	18	29		0	0	44	0	88
	Oct 11 - Mar 12	6	125	44		47	8	71	0	98
	Apr - Sept 12	6	379	61		65	37	88	15	98
	Oct 12 - Mar 13	6	1113	85		88	84	93	62	96
	Apr - Sept 13	5	1173	84		95	77	96	56	97
	Oct 13 - Mar 14	6	1867	81		87	83	94	36	96
group 6 (n = 12)	Apr - Sept 12	7	7475	78		93	77	99	0	100
	Oct 12 - Mar 13	7	1397	68		95	46	95	0	97
	Apr - Sept 13	12	10599	69		94	42	97	0	98
	Oct 13 - Mar 14	11	11175	89		88	86	97	69	99
group 7 (n = 18)	Oct 12 - Mar 13	8	399	42		21	9	88	0	97
	Apr - Sept 13	16	1423	52		63	16	90	0	98
	Oct 13 - Mar 14	17	3691	73		86	60	93	0	98
group 8 (n = 14)	Apr - Sept 13	11	243	69		83	69	90	0	96
	Oct 13 - Mar 14	11	521	69		86	62	95	0	100
group 9 (n = 4)	Oct 13 - Mar 14	3	99	25		15	8	37	0	58

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult TB Clinical Screen** Scores (%) by Group and Review Period

Percentage of adult patients screened for TB by tuberculin skin test (or by symptoms of cough, fever and weight loss) during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	16	2990	29		30	21	36	0	56
	Jul - Dec 08	16	2872	34		35	28	40	0	63
	Jan - Jun 09	16	3072	35		37	26	41	0	59
	Jul - Dec 09	16	2454	35		34	26	42	0	75
	Jan - Jun 10	16	1941	29		29	18	38	0	65
	Jul - Dec 10	15	1789	33		34	14	47	0	70
	Jan - Jun 11	17	2194	84		98	87	99	0	100
	Jul - Dec 11	17	1879	87		97	87	98	23	100
	Oct 11 - Mar 12	17	1813	88		97	87	98	49	100
	Apr - Sept 12	18	1822	92		95	86	100	73	100
	Oct 12 - Mar 13	18	1550	90		93	88	98	63	100
	Apr - Sept 13	18	1603	93		96	89	98	75	100
	Oct 13 - Mar 14	17	1021	94		99	95	100	67	100
group 2 (n = 6)	Jul - Dec 08	6	638	28		32	19	39	3	43
	Jan - Jun 09	6	909	28		30	21	33	0	56
	Jul - Dec 09	6	603	33		31	24	38	0	73
	Jan - Jun 10	6	409	24		28	12	34	4	43
	Jul - Dec 10	6	480	30		28	25	43	0	51
	Jan - Jun 11	6	512	96		98	94	100	87	100
	Jul - Dec 11	6	425	97		100	95	100	92	100
	Oct 11 - Mar 12	6	415	98		100	99	100	89	100
	Apr - Sept 12	6	326	98		100	98	100	92	100
	Oct 12 - Mar 13	6	395	98		100	96	100	91	100
	Apr - Sept 13	5	318	97		99	98	100	87	100
	Oct 13 - Mar 14	6	242	90		93	82	99	75	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**Indicator changed after the Jul - Dec 10 review period. The numerator now includes patients who have been assessed for TB clinical symptoms *in addition* to those who have received a TST.

Haiti Adult TB Clinical Screen** Scores (%) by Group and Review Period

Percentage of adult patients screened for TB by tuberculin skin test (or by symptoms of cough, fever and weight loss) during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 3 (n = 24)	Jul - Dec 09	16	1099	23		17	7	31	0	66
	Jan - Jun 10	15	933	22		17	10	33	0	55
	Jul - Dec 10	16	1141	29		23	4	46	0	74
	Jan - Jun 11	22	1520	67		93	20	99	0	100
	Jul - Dec 11	24	1549	74		98	43	100	11	100
	Oct 11 - Mar 12	24	1558	78		99	52	100	14	100
	Apr - Sept 12	21	1318	85		96	70	100	44	100
	Oct 12 - Mar 13	19	721	86		94	72	100	46	100
	Apr - Sept 13	19	986	94		98	96	100	48	100
	Oct 13 - Mar 14	19	795	92		96	89	100	57	100
group 4 (n = 4)	Jul - Dec 10	3	99	9		0	0	13	0	27
	Jan - Jun 11	4	228	75		100	75	100	0	100
	Jul - Dec 11	4	253	85		100	85	100	42	100
	Oct 11 - Mar 12	4	208	90		100	90	100	59	100
	Apr - Sept 12	3	181	92		90	88	95	87	100
	Oct 12 - Mar 13	4	171	90		87	87	91	86	100
	Apr - Sept 13	4	234	100		100	100	100	99	100
	Oct 13 - Mar 14	4	241	100		100	100	100	99	100
group 5 (n = 6)	Jul - Dec 11	6	463	99		100	99	100	98	100
	Oct 11 - Mar 12	6	453	97		99	95	100	93	100
	Apr - Sept 12	6	542	98		100	96	100	94	100
	Oct 12 - Mar 13	6	427	97		100	94	100	91	100
	Apr - Sept 13	4	339	98		100	98	100	93	100
	Oct 13 - Mar 14	6	330	98		99	98	100	93	100
group 6 (n = 12)	Apr - Sept 12	10	1958	99		100	99	100	94	100
	Oct 12 - Mar 13	11	1576	93		99	91	100	63	100
	Apr - Sept 13	12	1837	92		100	94	100	50	100
	Oct 13 - Mar 14	11	1879	89		97	83	100	50	100
group 7 (n = 18)	Oct 12 - Mar 13	9	224	83		97	88	100	11	100
	Apr - Sept 13	16	394	97		100	99	100	70	100
	Oct 13 - Mar 14	16	711	93		100	96	100	50	100
group 8 (n = 14)	Apr - Sept 13	10	293	98		100	96	100	92	100
	Oct 13 - Mar 14	11	198	95		100	98	100	67	100
group 9 (n = 4)	Oct 13 - Mar 14	3	36	93		100	89	100	79	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**Indicator changed after the Jul - Dec 10 review period. The numerator now includes patients who have been assessed for TB clinical symptoms *in addition* to those who have received a TST.

Haiti Adult Nutrition Evaluation Scores (%) by Group and Review Period

Percentage of adult patients who had a nutritional evaluation during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	16	8912	77		81	70	90	11	99
	Jul - Dec 08	16	10239	81		88	75	93	14	99
	Jan - Jun 09	16	11733	83		88	83	91	26	98
	Jul - Dec 09	16	12280	83		88	74	95	35	99
	Jan - Jun 10	16	12092	83		88	78	94	33	99
	Jul - Dec 10	15	12705	82		87	79	95	18	99
	Jan - Jun 11	17	15163	78		87	74	91	36	99
	Jul - Dec 11	17	16155	83		89	79	92	42	99
	Oct 11 - Mar 12	17	16345	85		89	79	92	39	98
	Apr - Sept 12	18	17173	88		92	86	95	48	97
	Oct 12 - Mar 13	18	17406	85		92	84	96	0	99
	Apr - Sept 13	18	18354	91		94	91	95	70	98
	Oct 13 - Mar 14	17	16591	90		93	88	96	70	98
group 2 (n = 6)	Jul - Dec 08	6	1920	76		82	58	95	48	98
	Jan - Jun 09	6	2440	90		90	86	93	83	98
	Jul - Dec 09	6	2675	94		92	91	97	89	99
	Jan - Jun 10	6	2619	93		92	91	95	88	97
	Jul - Dec 10	6	2754	93		94	91	98	83	98
	Jan - Jun 11	6	2976	92		93	91	94	82	97
	Jul - Dec 11	6	3298	92		96	95	98	69	99
	Oct 11 - Mar 12	6	3422	91		97	95	97	65	99
	Apr - Sept 12	6	3638	90		96	92	97	60	100
	Oct 12 - Mar 13	6	3902	97		97	96	98	92	100
	Apr - Sept 13	5	4017	97		98	97	98	95	99
	Oct 13 - Mar 14	6	4116	97		98	96	98	93	98
group 3 (n = 24)	Jul - Dec 09	16	4729	56		57	47	72	3	90
	Jan - Jun 10	16	4550	58		60	39	82	2	97
	Jul - Dec 10	16	5326	65		69	41	88	1	99
	Jan - Jun 11	22	8587	69		74	59	88	1	95
	Jul - Dec 11	24	9623	68		76	57	91	0	100
	Oct 11 - Mar 12	24	10579	72		79	61	90	0	100
	Apr - Sept 12	21	10132	79		85	76	93	24	100
	Oct 12 - Mar 13	19	9199	85		90	77	95	63	99
	Apr - Sept 13	19	11077	85		88	75	96	61	99
	Oct 13 - Mar 14	19	11049	86		92	81	97	46	99
group 4 (n = 4)	Jul - Dec 10	3	422	79		81	74	84	67	88
	Jan - Jun 11	4	1082	81		84	77	88	67	89
	Jul - Dec 11	4	1453	90		94	89	95	72	99
	Oct 11 - Mar 12	4	1556	85		87	83	90	71	97
	Apr - Sept 12	3	1629	95		96	94	97	91	97
	Oct 12 - Mar 13	4	2040	95		96	94	97	90	97
	Apr - Sept 13	4	2243	95		95	94	97	92	99
	Oct 13 - Mar 14	4	2378	95		95	93	97	91	99



*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult Nutrition Evaluation Scores (%) by Group and Review Period

Percentage of adult patients who had a nutritional evaluation during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 5 (n = 6)	Jul - Dec 11	6	1387	64		82	52	85	1	90
	Oct 11 - Mar 12	6	1651	78		79	73	89	57	91
	Apr - Sept 12	6	2057	85		86	85	91	64	96
	Oct 12 - Mar 13	6	2291	87		89	86	91	69	96
	Apr - Sept 13	5	1995	88		88	84	90	81	95
	Oct 13 - Mar 14	6	2972	92		95	91	97	76	98
group 6 (n = 12)	Apr - Sept 12	10	11966	57		68	35	84	0	100
	Oct 12 - Mar 13	11	11677	73		77	61	95	15	100
	Apr - Sept 13	12	16860	82		84	72	97	47	100
	Oct 13 - Mar 14	11	14345	91		96	88	97	68	99
group 7 (n = 18)	Oct 12 - Mar 13	9	1319	70		86	33	89	31	98
	Apr - Sept 13	17	3161	85		87	81	92	50	100
	Oct 13 - Mar 14	17	3554	81		88	75	97	25	100
group 8 (n = 14)	Apr - Sept 13	12	829	77		85	76	94	2	100
	Oct 13 - Mar 14	11	1097	83		93	84	94	7	99
group 9 (n = 4)	Oct 13 - Mar 14	3	320	45		50	25	67	0	84

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult Family Planning Scores (%) by Group and Review Period

Percentage of HIV-infected women of childbearing age who accepted a family planning method during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	16	5238	6		5	3	8	1	12
	Jul - Dec 08	16	5949	6		4	3	7	1	21
	Jan - Jun 09	16	6755	5		4	2	7	1	12
	Jul - Dec 09	16	6944	6		4	2	9	1	22
	Jan - Jun 10	16	6819	13		9	3	15	1	50
	Jul - Dec 10	15	7058	22		19	7	34	1	68
	Jan - Jun 11	17	8404	35		30	17	47	3	79
	Jul - Dec 11	17	8924	40		44	23	54	4	79
	Oct 11 - Mar 12	17	8963	41		43	20	56	7	72
	Apr - Sept 12	18	9168	45		47	29	61	7	76
	Oct 12 - Mar 13	18	9264	47		44	31	62	15	86
	Apr - Sept 13	18	9655	53		54	38	72	14	80
	Oct 13 - Mar 14	17	8619	52		52	39	65	14	96
group 2 (n = 6)	Jul - Dec 08	6	1155	6		5	4	9	0	12
	Jan - Jun 09	6	1543	6		5	4	8	0	17
	Jul - Dec 09	6	1654	14		9	7	11	6	44
	Jan - Jun 10	6	1612	13		6	5	19	0	39
	Jul - Dec 10	6	1656	25		17	10	31	6	70
	Jan - Jun 11	6	1813	35		29	14	47	7	79
	Jul - Dec 11	6	1983	55		56	45	73	12	83
	Oct 11 - Mar 12	6	2054	58		68	50	75	9	84
	Apr - Sept 12	6	2157	60		74	48	79	11	84
	Oct 12 - Mar 13	6	2341	68		82	60	91	3	92
	Apr - Sept 13	5	2387	80		81	75	88	65	91
	Oct 13 - Mar 14	6	2401	74		79	64	85	54	89

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult Family Planning Scores (%) by Group and Review Period

Percentage of HIV-infected women of childbearing age who accepted a family planning method during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 3 (n = 24)	Jul - Dec 09	16	2777	8		4	2	14	0	30
	Jan - Jun 10	16	2567	9		5	2	15	0	38
	Jul - Dec 10	16	3001	15		10	4	21	0	47
	Jan - Jun 11	22	4800	29		24	10	44	1	71
	Jul - Dec 11	24	5524	39		44	21	60	4	75
	Oct 11 - Mar 12	24	5851	40		40	23	57	5	81
	Apr - Sept 12	21	5525	41		38	18	65	7	77
	Oct 12 - Mar 13	19	4990	43		38	17	68	3	84
	Apr - Sept 13	19	5967	45		38	33	61	14	80
	Oct 13 - Mar 14	19	5805	54		57	39	68	19	89
group 4 (n = 4)	Jul - Dec 10	3	245	8		8	6	11	3	13
	Jan - Jun 11	4	576	30		31	10	51	5	52
	Jul - Dec 11	3	792	55		59	52	60	45	62
	Oct 11 - Mar 12	4	832	49		56	34	71	13	71
	Apr - Sept 12	3	802	64		72	55	76	38	81
	Oct 12 - Mar 13	4	1076	52		60	39	73	13	77
	Apr - Sept 13	4	1172	53		53	34	72	20	87
	Oct 13 - Mar 14	4	1272	54		54	36	72	19	88
group 5 (n = 6)	Jul - Dec 11	6	814	25		27	17	36	7	39
	Oct 11 - Mar 12	6	956	30		38	27	38	5	40
	Apr - Sept 12	6	1154	36		37	31	43	17	47
	Oct 12 - Mar 13	6	1303	42		36	32	52	30	65
	Apr - Sept 13	5	1143	54		57	43	59	35	74
	Oct 13 - Mar 14	6	1717	47		45	39	53	21	78
group 6 (n = 12)	Apr - Sept 12	9	1810	20		16	5	27	0	51
	Oct 12 - Mar 13	11	6405	36		33	17	55	0	76
	Apr - Sept 13	12	8469	40		39	28	56	5	71
	Oct 13 - Mar 14	11	7920	53		48	40	65	32	85
group 7 (n = 18)	Oct 12 - Mar 13	9	779	39		40	19	52	15	70
	Apr - Sept 13	17	1929	43		39	34	55	18	72
	Oct 13 - Mar 14	17	2167	51		47	37	59	25	86
group 8 (n = 14)	Apr - Sept 13	12	480	35		38	18	48	0	75
	Oct 13 - Mar 14	11	646	35		41	17	49	0	80
group 9 (n = 4)	Oct 13 - Mar 14	3	183	22		22	20	24	19	26

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Adult PMTCT ARV Prophylaxis** Scores (%) by Group and Review Period

Percentage of HIV+ pregnant women who were eligible for and received ARV prophylaxis during the 6-month review period.

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	16	289	32		30	19	47	0	67
	Jul - Dec 08	18	403	43		45	33	53	6	75
	Jan - Jun 09	18	352	43		38	33	53	0	83
	Jul - Dec 09	18	344	41		38	22	59	0	83
	Jan - Jun 10	17	191	39		50	20	56	0	80
	Jul - Dec 10	17	195	44		52	14	67	0	90
	Jan - Jun 11	16	404	50		50	33	71	0	91
	Jul - Dec 11	17	364	73		75	58	80	47	100
	Oct 11 - Mar 12	17	296	79		82	67	95	43	100
	Apr - Sept 12	18	320	84		90	76	94	50	100
	Oct 12 - Mar 13	18	251	87		88	79	100	67	100
	Apr - Sept 13	17	325	88		91	80	95	67	100
	Oct 13 - Mar 14	15	204	95		100	92	100	80	100
group 2 (n = 6)	Jul - Dec 08	5	43	34		33	29	35	0	75
	Jan - Jun 09	4	52	63		55	48	70	43	100
	Jul - Dec 09	5	56	55		47	44	84	0	100
	Jan - Jun 10	5	45	80		68	67	100	67	100
	Jul - Dec 10	6	53	53		51	33	73	33	76
	Jan - Jun 11	6	115	66		70	55	74	33	100
	Jul - Dec 11	5	91	96		100	92	100	89	100
	Oct 11 - Mar 12	5	86	89		89	88	100	67	100
	Apr - Sept 12	4	87	94		96	92	98	83	100
	Oct 12 - Mar 13	4	86	93		94	91	96	86	100
	Apr - Sept 13	5	97	97		100	98	100	90	100
	Oct 13 - Mar 14	6	57	89		97	93	100	50	100
group 3 (n = 24)	Jul - Dec 09	22	248	46		40	30	65	0	100
	Jan - Jun 10	19	192	29		20	0	38	0	100
	Jul - Dec 10	19	180	48		37	27	64	0	100
	Jan - Jun 11	18	258	58		63	35	75	17	100
	Jul - Dec 11	22	275	67		67	53	92	10	100
	Oct 11 - Mar 12	14	130	82		90	76	100	0	100
	Apr - Sept 12	20	211	92		100	92	100	56	100
	Oct 12 - Mar 13	18	156	88		94	80	100	43	100
	Apr - Sept 13	18	321	92		97	90	100	50	100
	Oct 13 - Mar 14	18	293	91		92	89	100	60	100
group 4 (n = 4)	Jul - Dec 10	3	46	34		25	18	46	10	67
	Jan - Jun 11	4	67	40		37	28	49	14	75
	Jul - Dec 11	3	18	56		67	33	83	0	100
	Oct 11 - Mar 12	4	73	66		61	46	81	43	100
	Apr - Sept 12	3	51	90		91	87	94	83	97
	Oct 12 - Mar 13	4	18	86		86	71	100	71	100
	Apr - Sept 13	4	74	73		72	64	80	50	96
	Oct 13 - Mar 14	4	57	87		90	82	96	67	100



*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**In 2011, eligibility for ART prophylaxis for pregnant patients was changed from gestational age > 28 weeks to > 14 weeks or 98 days from the date of last menstrual period. As of March 2012, MSPP adopted the B+ option requiring all HIV+ pregnant women to be systematically placed on ART.

Haiti Adult PMTCT ARV Prophylaxis** Scores (%) by Group and Review Period

Percentage of HIV+ pregnant women who were eligible for and received ARV prophylaxis during the 6-month review period.

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 5 (n = 6)	Jul - Dec 11	5	38	74		75	63	100	30	100
	Oct 11 - Mar 12	6	32	88		92	81	100	63	100
	Apr - Sept 12	6	67	83		84	72	91	69	100
	Oct 12 - Mar 13	6	63	86		89	76	98	67	100
	Apr - Sept 13	5	53	97		100	93	100	92	100
	Oct 13 - Mar 14	6	58	95		96	90	100	87	100
group 6 (n = 12)	Apr - Sept 12	7	176	67		71	58	91	0	100
	Oct 12 - Mar 13	9	63	76		93	67	100	0	100
	Apr - Sept 13	12	363	82		92	83	100	0	100
	Oct 13 - Mar 14	10	65	83		94	78	100	0	100
group 7 (n = 18)	Oct 12 - Mar 13	7	52	63		80	43	89	0	100
	Apr - Sept 13	12	178	92		93	89	100	68	100
	Oct 13 - Mar 14	13	89	87		90	80	100	65	100
group 8 (n = 14)	Apr - Sept 13	9	57	91		100	100	100	53	100
	Oct 13 - Mar 14	9	41	98		100	100	100	80	100
group 9 (n = 4)	Oct 13 - Mar 14	3	3	100		100	100	100	100	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**In 2011, eligibility for ART prophylaxis for pregnant patients was changed from gestational age > 28 weeks to > 14 weeks or 98 days from the date of last menstrual period. As of March 2012, MSPP adopted the B+ option requiring all HIV+ pregnant women to be systematically placed on ART.

Haiti Pediatric Performance Measurement

Shown is a breakdown by group of Haiti's pediatric aggregate results calculated from clinic level indicator scores (total number of clinics, total number of patients eligible, means, medians, percentiles, minimums and maximums).

Haiti Pediatric Clinical Visits (ART) Scores (%) by Group and Review Period

Percentage of pediatric patients on ART who had at least one clinical visit within 3 months of their last visit during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	9	133	69		79	50	86	29	100
	Jul - Dec 08	12	235	76		83	58	93	25	100
	Jan - Jun 09	11	309	83		88	82	97	24	100
	Jul - Dec 09	11	370	79		85	69	90	40	100
	Jan - Jun 10	11	421	67		78	55	92	0	100
	Jul - Dec 10	13	468	66		78	64	84	0	100
	Jan - Jun 11	15	545	74		78	65	89	8	100
	Jul - Dec 11	15	571	75		75	69	87	33	100
	Oct 11 - Mar 12	15	627	77		75	67	92	42	100
	Apr - Sept 12	17	626	88		89	80	99	70	100
	Oct 12 - Mar 13	17	658	87		89	76	100	70	100
	Apr - Sept 13	16	728	89		97	79	99	65	100
	Oct 13 - Mar 14	15	657	86		87	80	95	60	100
group 2 (n = 6)	Jul - Dec 08	3	34	92		100	89	100	77	100
	Jan - Jun 09	3	37	98		100	97	100	94	100
	Jul - Dec 09	3	48	91		89	86	94	84	100
	Jan - Jun 10	3	59	77		75	74	80	73	84
	Jul - Dec 10	3	63	73		79	69	80	60	82
	Jan - Jun 11	3	59	82		82	81	82	80	83
	Jul - Dec 11	5	61	51		78	0	86	0	92
	Oct 11 - Mar 12	5	69	57		80	33	83	0	89
	Apr - Sept 12	5	79	94		98	91	100	83	100
	Oct 12 - Mar 13	6	104	95		100	98	100	75	100
	Apr - Sept 13	5	105	94		98	97	100	76	100
	Oct 13 - Mar 14	6	124	88		92	85	95	67	98
group 3 (n = 24)	Jul - Dec 09	10	351	66		74	49	83	0	100
	Jan - Jun 10	11	423	57		53	41	81	0	100
	Jul - Dec 10	11	424	75		64	60	97	45	100
	Jan - Jun 11	19	596	79		89	65	100	28	100
	Jul - Dec 11	22	662	69		81	68	97	0	100
	Oct 11 - Mar 12	22	719	78		87	72	100	0	100
	Apr - Sept 12	19	739	88		97	79	100	56	100
	Oct 12 - Mar 13	17	711	85		94	80	100	45	100
	Apr - Sept 13	18	825	83		88	73	98	45	100
	Oct 13 - Mar 14	19	816	81		85	74	100	18	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric Clinical Visits (ART) Scores (%) by Group and Review Period

Percentage of pediatric patients on ART who had at least one clinical visit within 3 months of their last visit during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 4 (n = 4)	Jul - Dec 10	1	2	0		0	0	0	0	0
	Jan - Jun 11	2	62	28		28	14	41	0	55
	Jul - Dec 11	3	65	51		53	27	77	0	100
	Oct 11 - Mar 12	3	62	32		0	0	47	0	95
	Apr - Sept 12	2	66	87		87	83	90	80	93
	Oct 12 - Mar 13	3	76	89		87	83	93	80	100
	Apr - Sept 13	3	80	90		88	86	94	83	100
	Oct 13 - Mar 14	4	91	93		95	88	100	83	100
group 5 (n = 6)	Jul - Dec 11	2	3	0		0	0	0	0	0
	Oct 11 - Mar 12	4	8	56		63	38	81	0	100
	Apr - Sept 12	3	23	72		67	58	83	50	100
	Oct 12 - Mar 13	6	39	89		96	79	100	67	100
	Apr - Sept 13	5	52	93		96	90	100	78	100
	Oct 13 - Mar 14	6	73	92		95	86	100	80	100
group 6 (n = 12)	Apr - Sept 12	6	614	84		80	77	92	70	100
	Oct 12 - Mar 13	7	683	84		82	77	95	60	100
	Apr - Sept 13	9	579	91		100	84	100	64	100
	Oct 13 - Mar 14	9	583	96		100	92	100	81	100
group 7 (n = 18)	Oct 12 - Mar 13	5	7	100		100	100	100	100	100
	Apr - Sept 13	14	44	89		100	100	100	0	100
	Oct 13 - Mar 14	15	113	87		100	71	100	50	100
group 8 (n = 14)	Apr - Sept 13	5	8	100		100	100	100	100	100
	Oct 13 - Mar 14	7	16	100		100	100	100	100	100
group 9 (n = 4)	Oct 13 - Mar 14	1	1	100		100	100	100	100	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric CD4 Monitoring** (Rounds 1-10) Scores (%) by Group and Review Period

Percentage of newly enrolled adult patients (within preceding 6-12 months of review period) who had a CD4 count within 2 months of and between 2-8 months after enrollment

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	15	259	35		33	0	41	0	100
	Jul - Dec 08	15	259	20		10	0	27	0	100
	Jan - Jun 09	14	265	20		17	4	24	0	56
	Jul - Dec 09	15	265	31		16	8	50	0	100
	Jan - Jun 10	14	360	20		9	3	30	0	80
	Jul - Dec 10	15	239	15		5	0	13	0	100
	Jan - Jun 11	17	236	15		0	0	17	0	100
	Jul - Dec 11	16	243	8		6	0	18	0	25
	Oct 11 - Mar 12	14	234	18		11	4	30	0	50
	Apr - Sept 12	14	100	15		11	0	19	0	67
group 2 (n = 6)	Jul - Dec 08	6	33	10		7	0	19	0	25
	Jan - Jun 09	6	54	18		12	1	30	0	50
	Jul - Dec 09	5	129	14		9	5	9	0	50
	Jan - Jun 10	5	125	13		5	4	14	0	40
	Jul - Dec 10	5	113	0		0	0	0	0	2
	Jan - Jun 11	5	110	10		6	0	9	0	33
	Jul - Dec 11	6	125	4		2	0	9	0	12
	Oct 11 - Mar 12	6	128	22		7	0	17	0	100
	Apr - Sept 12	5	96	32		8	0	50	0	100
group 3 (n = 24)	Jul - Dec 09	13	200	13		0	0	27	0	45
	Jan - Jun 10	16	189	10		0	0	19	0	50
	Jul - Dec 10	15	130	12		0	0	15	0	80
	Jan - Jun 11	18	204	11		6	0	20	0	33
	Jul - Dec 11	19	221	14		7	0	22	0	57
	Oct 11 - Mar 12	20	288	13		3	0	19	0	55
	Apr - Sept 12	16	116	16		0	0	19	0	100
group 4 (n = 4)	Jul - Dec 10	1	3	0		0	0	0	0	0
	Jan - Jun 11	3	10	0		0	0	0	0	0
	Jul - Dec 11	3	12	0		0	0	0	0	0
	Oct 11 - Mar 12	3	13	0		0	0	0	0	0
	Apr - Sept 12	2	10	17		17	8	25	0	33
group 5 (n = 6)	Jul - Dec 11	4	24	0		0	0	0	0	0
	Oct 11 - Mar 12	4	23	13		5	0	18	0	43
	Apr - Sept 12	4	25	36		23	9	50	0	100
group 6 (n = 12)	Apr - Sept 12	5	32	20		0	0	0	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.
**As of the Oct 12 - Mar 13 review period, the CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring, measured by the percentage of all patients enrolled prior to the 6-month review period who received the last 2 CD4 tests during the 6-month review period and (2) CD4 at Enrollment, measured by the percentage of patients newly enrolled during the 6-month review period who received a CD4 test at enrollment. Results from the revised CD4 Monitoring indicators are reported separately.

Haiti Pediatric CD4 Monitoring (Rounds 11-13) Scores (%) by Group and Review Period

Percentage of all patients enrolled prior to the 6-month review period who received the last 2 CD4 tests during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Oct 12 - Mar 13	16	484	21		15	8	28	0	100
	Apr - Sept 13	16	514	47		44	37	56	13	100
	Oct 13 - Mar 14	15	459	50		45	37	60	21	92
group 2 (n = 6)	Oct 12 - Mar 13	6	66	15		10	0	23	0	43
	Apr - Sept 13	5	67	55		67	30	76	0	100
	Oct 13 - Mar 14	6	79	60		71	37	76	25	93
group 3 (n = 24)	Oct 12 - Mar 13	16	605	14		5	0	27	0	50
	Apr - Sept 13	17	651	47		45	21	83	0	100
	Oct 13 - Mar 14	17	681	46		45	17	72	0	98
group 4 (n = 4)	Oct 12 - Mar 13	2	84	0		0	0	0	0	0
	Apr - Sept 13	2	77	55		55	32	77	10	100
	Oct 13 - Mar 14	3	82	68		80	53	90	25	100
group 5 (n = 6)	Oct 12 - Mar 13	3	20	7		0	0	11	0	21
	Apr - Sept 13	5	29	70		80	50	88	33	100
	Oct 13 - Mar 14	6	43	58		65	41	81	0	100
group 6 (n = 12)	Oct 12 - Mar 13	6	71	4		0	0	5	0	18
	Apr - Sept 13	8	116	41		38	23	51	0	100
	Oct 13 - Mar 14	9	135	65		67	50	93	19	100
group 7 (n = 18)	Oct 12 - Mar 13	0	0							
	Apr - Sept 13	7	21	7		0	0	0	0	50
	Oct 13 - Mar 14	12	39	38		20	0	75	0	100
group 8 (n = 14)	Apr - Sept 13	1	1	0		0	0	0	0	0
	Oct 13 - Mar 14	6	8	28		0	0	50	0	100
group 9 (n = 4)	Oct 13 - Mar 14	0	0							

Haiti Pediatric CD4 at Enrollment (Rounds 11-13) Scores (%) by Group and Review Period

Percentage of patients newly enrolled during the 6-month review period who received a CD4 test at enrollment

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Oct 12 - Mar 13	4	11	61		71	32	100	0	100
	Apr - Sept 13	7	21	9		0	0	0	0	64
	Oct 13 - Mar 14	4	13	31		13	0	44	0	100
group 2 (n = 6)	Oct 12 - Mar 13	2	2	0		0	0	0	0	0
	Apr - Sept 13	0	0							
	Oct 13 - Mar 14	0	0							
group 3 (n = 24)	Oct 12 - Mar 13	9	13	11		0	0	0	0	100
	Apr - Sept 13	7	28	15		0	0	25	0	58
	Oct 13 - Mar 14	9	30	42		40	0	71	0	100
group 4 (n = 4)	Oct 12 - Mar 13	1	7	0		0	0	0	0	0
	Apr - Sept 13	2	7	58		58	54	63	50	67
	Oct 13 - Mar 14	1	9	44		44	44	44	44	44
group 5 (n = 6)	Oct 12 - Mar 13	1	1	0		0	0	0	0	0
	Apr - Sept 13	3	5	44		33	17	67	0	100
	Oct 13 - Mar 14	0	0							
group 6 (n = 12)	Oct 12 - Mar 13	4	62	18		13	0	31	0	48
	Apr - Sept 13	3	65	42		50	25	63	0	77
	Oct 13 - Mar 14	3	68	80		84	70	92	56	100
group 7 (n = 18)	Oct 12 - Mar 13	0	0							
	Apr - Sept 13	0	0							
	Oct 13 - Mar 14	2	2	0		0	0	0	0	0
group 8 (n = 14)	Apr - Sept 13	1	1	0		0	0	0	0	0
	Oct 13 - Mar 14	0	0							
group 9 (n = 4)	Oct 13 - Mar 14	0	0							

Haiti Pediatric ARV Therapy Scores (%) by Group and Review Period

Percentage of pediatric patients eligible for ART who were enrolled in ART during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	11	244	44		46	20	60	0	100
	Jul - Dec 08	12	227	41		43	16	59	0	100
	Jan - Jun 09	10	221	39		32	26	40	13	100
	Jul - Dec 09	10	222	34		37	16	51	0	75
	Jan - Jun 10	10	185	28		33	13	45	0	52
	Jul - Dec 10	12	188	38		44	14	56	8	67
	Jan - Jun 11	15	172	38		25	24	50	0	100
	Jul - Dec 11	15	193	31		31	17	50	0	69
	Oct 11 - Mar 12	15	194	42		45	29	54	17	75
	Apr - Sept 12	17	208	49		43	33	63	6	100
	Oct 12 - Mar 13	16	133	52		48	36	58	0	100
	Apr - Sept 13	16	156	58		56	45	82	0	100
	Oct 13 - Mar 14	15	106	66		78	55	88	0	100
group 2 (n = 6)	Jul - Dec 08	3	18	42		17	13	58	9	100
	Jan - Jun 09	3	37	24		30	15	36	0	43
	Jul - Dec 09	3	40	30		20	17	39	13	57
	Jan - Jun 10	3	39	53		50	30	75	9	100
	Jul - Dec 10	3	40	30		33	20	42	6	50
	Jan - Jun 11	3	42	47		33	21	67	9	100
	Jul - Dec 11	6	48	51		51	39	65	0	100
	Oct 11 - Mar 12	6	45	42		42	6	69	0	100
	Apr - Sept 12	5	63	50		67	2	82	0	100
	Oct 12 - Mar 13	6	25	75		83	54	100	33	100
	Apr - Sept 13	5	20	81		86	71	100	50	100
	Oct 13 - Mar 14	5	25	80		85	67	100	50	100
group 3 (n = 24)	Jul - Dec 09	12	158	37		37	15	53	0	82
	Jan - Jun 10	13	104	30		33	0	50	0	71
	Jul - Dec 10	13	130	55		50	33	78	0	100
	Jan - Jun 11	16	172	50		48	0	84	0	100
	Jul - Dec 11	22	201	48		55	4	70	0	100
	Oct 11 - Mar 12	21	172	57		56	33	100	0	100
	Apr - Sept 12	12	204	53		49	33	66	0	100
	Oct 12 - Mar 13	12	90	69		74	48	100	25	100
	Apr - Sept 13	17	94	81		100	75	100	0	100
	Oct 13 - Mar 14	17	70	80		100	67	100	0	100
group 4 (n = 4)	Jul - Dec 10	1	1	0		0	0	0	0	0
	Jan - Jun 11	2	5	38		38	19	56	0	75
	Jul - Dec 11	2	4	100		100	100	100	100	100
	Oct 11 - Mar 12	2	5	100		100	100	100	100	100
	Apr - Sept 12	2	3	100		100	100	100	100	100
	Oct 12 - Mar 13	3	5	33		0	0	50	0	100
	Apr - Sept 13	3	10	67		100	50	100	0	100
	Oct 13 - Mar 14	2	5	50		50	25	75	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric ARV Therapy Scores (%) by Group and Review Period

Percentage of pediatric patients eligible for ART who were enrolled in ART during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 5 (n = 6)	Jul - Dec 11	5	20	27		10	0	60	0	67
	Oct 11 - Mar 12	5	26	28		33	8	33	0	67
	Apr - Sept 12	6	43	37		33	1	65	0	93
	Oct 12 - Mar 13	6	27	60		63	40	73	25	100
	Apr - Sept 13	4	22	92		100	92	100	67	100
	Oct 13 - Mar 14	4	20	83		100	83	100	33	100
group 6 (n = 12)	Apr - Sept 12	5	46	23		25	13	28	0	50
	Oct 12 - Mar 13	7	93	25		13	0	40	0	84
	Apr - Sept 13	9	102	56		73	33	80	0	100
	Oct 13 - Mar 14	8	79	64		71	50	97	0	100
group 7 (n = 18)	Oct 12 - Mar 13	6	7	67		100	25	100	0	100
	Apr - Sept 13	9	36	75		100	50	100	33	100
	Oct 13 - Mar 14	12	49	76		92	50	100	33	100
group 8 (n = 14)	Apr - Sept 13	6	11	56		67	8	100	0	100
	Oct 13 - Mar 14	5	12	60		100	0	100	0	100
group 9 (n = 4)	Oct 13 - Mar 14	0	0							

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric ART Adherence Assessment Scores (%) by Group and Review Period

Percentage of pediatric patients on ART who had an adherence assessment during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	8	93	30		4	0	50	0	100
	Jul - Dec 08	12	148	48		58	0	87	0	100
	Jan - Jun 09	11	180	67		97	26	100	0	100
	Jul - Dec 09	11	240	80		98	78	100	9	100
	Jan - Jun 10	11	262	59		67	25	98	0	100
	Jul - Dec 10	11	273	72		100	41	100	0	100
	Jan - Jun 11	15	326	55		71	14	91	0	100
	Jul - Dec 11	14	384	59		73	9	99	0	100
	Oct 11 - Mar 12	15	423	63		91	32	97	2	100
	Apr - Sept 12	15	471	74		91	64	100	2	100
	Oct 12 - Mar 13	14	516	79		91	85	99	1	100
	Apr - Sept 13	16	617	79		95	68	100	1	100
	Oct 13 - Mar 14	15	568	81		92	69	98	31	100
group 2 (n = 6)	Jul - Dec 08	3	25	55		65	33	83	0	100
	Jan - Jun 09	3	20	50		50	25	75	0	100
	Jul - Dec 09	3	41	81		94	72	97	50	100
	Jan - Jun 10	3	47	77		91	70	91	50	91
	Jul - Dec 10	3	48	77		97	65	99	33	100
	Jan - Jun 11	3	44	72		90	58	95	25	100
	Jul - Dec 11	3	48	68		90	51	95	13	100
	Oct 11 - Mar 12	4	58	75		92	69	98	14	100
	Apr - Sept 12	5	69	81		100	95	100	11	100
	Oct 12 - Mar 13	5	89	79		98	96	100	0	100
	Apr - Sept 13	5	95	78		97	83	100	8	100
	Oct 13 - Mar 14	6	116	83		99	95	100	6	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric ART Adherence Assessment Scores (%) by Group and Review Period

Percentage of pediatric patients on ART who had an adherence assessment during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 3 (n = 24)	Jul - Dec 09	10	266	67		77	62	99	0	100
	Jan - Jun 10	10	310	62		82	23	98	0	100
	Jul - Dec 10	10	249	87		100	93	100	0	100
	Jan - Jun 11	18	369	87		100	94	100	0	100
	Jul - Dec 11	19	400	84		100	87	100	0	100
	Oct 11 - Mar 12	20	468	88		100	93	100	0	100
	Apr - Sept 12	18	584	94		100	89	100	71	100
	Oct 12 - Mar 13	11	584	92		100	82	100	75	100
	Apr - Sept 13	18	734	89		100	95	100	23	100
	Oct 13 - Mar 14	17	724	91		100	92	100	0	100
group 4 (n = 4)	Jul - Dec 10	0	0							
	Jan - Jun 11	1	29	0		0	0	0	0	0
	Jul - Dec 11	2	27	0		0	0	0	0	0
	Oct 11 - Mar 12	2	38	49		49	24	73	0	97
	Apr - Sept 12	2	67	96		96	94	98	92	100
	Oct 12 - Mar 13	2	7	75		75	63	88	50	100
	Apr - Sept 13	3	66	43		28	14	64	0	100
	Oct 13 - Mar 14	4	78	50		50	25	75	0	100
group 5 (n = 6)	Jul - Dec 11	1	1	0		0	0	0	0	0
	Oct 11 - Mar 12	3	5	22		0	0	33	0	67
	Apr - Sept 12	2	5	88		88	81	94	75	100
	Oct 12 - Mar 13	6	28	78		100	78	100	0	100
	Apr - Sept 13	5	37	78		100	67	100	25	100
	Oct 13 - Mar 14	6	62	78		90	58	100	38	100
group 6 (n = 12)	Apr - Sept 12	6	488	66		76	49	99	0	100
	Oct 12 - Mar 13	5	68	93		97	95	100	75	100
	Apr - Sept 13	9	493	80		100	75	100	0	100
	Oct 13 - Mar 14	9	491	79		94	80	100	0	100
group 7 (n = 18)	Oct 12 - Mar 13	2	4	67		67	50	83	33	100
	Apr - Sept 13	11	23	65		100	7	100	0	100
	Oct 13 - Mar 14	14	86	71		71	50	100	17	100
group 8 (n = 14)	Apr - Sept 13	2	2	100		100	100	100	100	100
	Oct 13 - Mar 14	7	13	38		0	0	83	0	100
group 9 (n = 4)	Oct 13 - Mar 14	0	0							

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric Cotrimoxazole Preventive Therapy Scores (%) by Group and Review Period

Percentage of pediatric patients (HIV-exposed and HIV-infected) who received cotrimoxazole prophylaxis during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	11	350	61		67	50	75	25	86
	Jul - Dec 08	14	420	72		88	48	96	0	100
	Jan - Jun 09	15	493	74		85	65	98	0	100
	Jul - Dec 09	16	605	79		94	72	100	9	100
	Jan - Jun 10	16	617	68		81	49	100	0	100
	Jul - Dec 10	16	695	80		95	74	100	15	100
	Jan - Jun 11	15	701	78		93	69	97	8	100
	Jul - Dec 11	13	686	96		97	93	100	85	100
	Oct 11 - Mar 12	15	722	89		96	93	98	23	100
	Apr - Sept 12	16	817	89		96	92	100	29	100
	Oct 12 - Mar 13	15	762	83		96	90	99	0	100
	Apr - Sept 13	14	872	92		98	96	100	25	100
	Oct 13 - Mar 14	13	711	94		97	95	100	59	100
group 2 (n = 6)	Jul - Dec 08	5	48	89		88	85	100	75	100
	Jan - Jun 09	6	98	89		97	91	99	50	100
	Jul - Dec 09	5	149	92		94	92	96	75	100
	Jan - Jun 10	5	146	86		93	75	94	67	100
	Jul - Dec 10	5	162	81		74	67	97	67	100
	Jan - Jun 11	5	173	87		100	69	100	65	100
	Jul - Dec 11	5	183	89		100	77	100	67	100
	Oct 11 - Mar 12	5	179	94		96	88	100	84	100
	Apr - Sept 12	6	217	90		100	86	100	57	100
	Oct 12 - Mar 13	6	190	92		100	87	100	68	100
	Apr - Sept 13	5	204	88		100	82	100	57	100
	Oct 13 - Mar 14	6	184	94		100	90	100	75	100
group 3 (n = 24)	Jul - Dec 09	18	450	56		60	30	83	0	100
	Jan - Jun 10	18	423	54		50	36	84	0	100
	Jul - Dec 10	19	474	67		83	38	98	0	100
	Jan - Jun 11	18	542	76		93	64	100	0	100
	Jul - Dec 11	12	573	88		98	94	100	17	100
	Oct 11 - Mar 12	19	697	78		88	61	100	36	100
	Apr - Sept 12	18	908	76		90	63	100	17	100
	Oct 12 - Mar 13	10	741	95		100	99	100	63	100
	Apr - Sept 13	11	760	82		100	91	100	0	100
	Oct 13 - Mar 14	9	662	93		100	99	100	38	100
group 4 (n = 4)	Jul - Dec 10	2	29	57		57	36	79	14	100
	Jan - Jun 11	2	22	64		64	46	82	29	100
	Jul - Dec 11	1	4	100		100	100	100	100	100
	Oct 11 - Mar 12	2	35	67		67	51	84	34	100
	Apr - Sept 12	2	86	65		65	53	78	41	90
	Oct 12 - Mar 13	2	15	95		95	93	98	90	100
	Apr - Sept 13	3	24	98		100	97	100	94	100
	Oct 13 - Mar 14	3	28	100		100	100	100	100	100



*For every review period, CPT data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric Cotrimoxazole Preventive Therapy Scores (%) by Group and Review Period

Percentage of pediatric patients (HIV-exposed and HIV-infected) who received cotrimoxazole prophylaxis during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 5 (n = 6)	Jul - Dec 11	4	22	71		91	62	100	0	100
	Oct 11 - Mar 12	5	26	79		100	94	100	0	100
	Apr - Sept 12	5	48	79		96	50	100	50	100
	Oct 12 - Mar 13	5	57	100		100	100	100	100	100
	Apr - Sept 13	4	43	96		98	94	100	88	100
	Oct 13 - Mar 14	5	66	99		100	100	100	93	100
group 6 (n = 12)	Apr - Sept 12	6	1344	86		87	77	96	71	100
	Oct 12 - Mar 13	6	756	86		93	81	100	48	100
	Apr - Sept 13	8	663	88		98	81	100	50	100
	Oct 13 - Mar 14	8	631	96		100	92	100	86	100
group 7 (n = 18)	Oct 12 - Mar 13	7	16	92		100	90	100	67	100
	Apr - Sept 13	12	58	95		100	98	100	50	100
	Oct 13 - Mar 14	14	119	97		100	100	100	73	100
group 8 (n = 14)	Apr - Sept 13	6	15	96		100	100	100	75	100
	Oct 13 - Mar 14	9	19	100		100	100	100	100	100
group 9 (n = 4)	Oct 13 - Mar 14	0	0							

*For every review period, CPT data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric TB Clinical Screen** Scores (%) by Group and Review Period

Percentage of pediatric patients screened for TB by tuberculin skin test (or by symptoms of cough, fever and weight loss) during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	15	266	17		11	0	23	0	63
	Jul - Dec 08	14	263	26		20	11	30	0	100
	Jan - Jun 09	15	292	25		22	3	35	0	100
	Jul - Dec 09	14	371	12		6	0	16	0	45
	Jan - Jun 10	15	260	18		11	3	23	0	100
	Jul - Dec 10	15	248	22		13	2	19	0	100
	Jan - Jun 11	17	240	85		100	91	100	0	100
	Jul - Dec 11	16	287	86		96	90	100	18	100
	Oct 11 - Mar 12	16	273	87		96	83	100	33	100
	Apr - Sept 12	17	264	91		100	88	100	48	100
	Oct 12 - Mar 13	17	121	91		100	92	100	50	100
	Apr - Sept 13	16	182	87		100	86	100	0	100
	Oct 13 - Mar 14	15	98	96		100	97	100	67	100
group 2 (n = 6)	Jul - Dec 08	6	61	0		0	0	0	0	0
	Jan - Jun 09	5	145	3		2	0	5	0	8
	Jul - Dec 09	5	138	5		0	0	0	0	25
	Jan - Jun 10	5	121	0		0	0	0	0	2
	Jul - Dec 10	5	118	2		0	0	5	0	6
	Jan - Jun 11	6	139	96		100	95	100	85	100
	Jul - Dec 11	6	177	96		98	94	100	85	100
	Oct 11 - Mar 12	5	177	95		99	97	100	80	100
	Apr - Sept 12	4	146	94		97	91	100	82	100
	Oct 12 - Mar 13	5	27	93		100	88	100	77	100
	Apr - Sept 13	5	31	92		100	94	100	67	100
	Oct 13 - Mar 14	4	37	98		100	98	100	91	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**Indicator changed after the Jul - Dec 10 review period. The numerator now includes patients who have been assessed for TB clinical symptoms *in addition* to those who have received a TST.

Haiti Pediatric TB Clinical Screen** Scores (%) by Group and Review Period

Percentage of pediatric patients screened for TB by tuberculin skin test (or by symptoms of cough, fever and weight loss) during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 3 (n = 24)	Jul - Dec 09	16	204	7		0	0	3	0	50
	Jan - Jun 10	15	146	8		0	0	14	0	40
	Jul - Dec 10	14	201	17		18	0	28	0	50
	Jan - Jun 11	17	229	71		96	57	100	0	100
	Jul - Dec 11	20	403	85		100	82	100	0	100
	Oct 11 - Mar 12	21	363	83		100	83	100	0	100
	Apr - Sept 12	21	340	85		100	95	100	0	100
	Oct 12 - Mar 13	15	92	92		100	100	100	0	100
	Apr - Sept 13	16	89	98		100	100	100	83	100
	Oct 13 - Mar 14	17	81	94		100	100	100	0	100
group 4 (n = 4)	Jul - Dec 10	2	4	0		0	0	0	0	0
	Jan - Jun 11	2	10	50		50	25	75	0	100
	Jul - Dec 11	3	19	81		100	71	100	43	100
	Oct 11 - Mar 12	3	17	90		100	86	100	71	100
	Apr - Sept 12	2	11	100		100	100	100	100	100
	Oct 12 - Mar 13	2	8	100		100	100	100	100	100
	Apr - Sept 13	3	10	100		100	100	100	100	100
	Oct 13 - Mar 14	4	15	100		100	100	100	100	100
group 5 (n = 6)	Jul - Dec 11	5	37	95		100	100	100	75	100
	Oct 11 - Mar 12	5	40	97		100	100	100	83	100
	Apr - Sept 12	5	31	98		100	100	100	92	100
	Oct 12 - Mar 13	6	35	97		100	94	100	89	100
	Apr - Sept 13	4	17	100		100	100	100	100	100
	Oct 13 - Mar 14	5	36	93		100	100	100	67	100
group 6 (n = 12)	Apr - Sept 12	6	276	94		100	87	100	78	100
	Oct 12 - Mar 13	7	82	88		100	88	100	43	100
	Apr - Sept 13	9	96	90		100	100	100	33	100
	Oct 13 - Mar 14	8	106	74		89	62	100	0	100
group 7 (n = 18)	Oct 12 - Mar 13	7	13	86		100	100	100	0	100
	Apr - Sept 13	10	28	97		100	100	100	67	100
	Oct 13 - Mar 14	9	34	83		100	67	100	36	100
group 8 (n = 14)	Apr - Sept 13	6	11	92		100	100	100	50	100
	Oct 13 - Mar 14	4	8	92		100	92	100	67	100
group 9 (n = 4)	Oct 13 - Mar 14	0	0							

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

**Indicator changed after the Jul - Dec 10 review period. The numerator now includes patients who have been assessed for TB clinical symptoms *in addition* to those who have received a TST.

Haiti Pediatric Nutrition Evaluation Scores (%) by Group and Review Period

Percentage of pediatric patients who had a nutritional evaluation during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	16	691	54		61	27	77	0	100
	Jul - Dec 08	16	768	51		53	34	68	0	84
	Jan - Jun 09	16	907	56		66	34	76	0	100
	Jul - Dec 09	16	1084	50		57	35	71	0	81
	Jan - Jun 10	16	1013	48		49	25	70	0	88
	Jul - Dec 10	15	1085	49		59	22	76	0	82
	Jan - Jun 11	17	1165	45		50	19	76	0	90
	Jul - Dec 11	16	1276	48		56	36	59	0	82
	Oct 11 - Mar 12	16	1271	48		55	36	63	0	77
	Apr - Sept 12	18	1283	46		49	25	72	0	79
	Oct 12 - Mar 13	17	1129	65		67	53	78	23	93
	Apr - Sept 13	16	1285	68		73	59	85	26	91
	Oct 13 - Mar 14	15	1041	69		71	58	82	33	95
group 2 (n = 6)	Jul - Dec 08	6	130	47		42	33	55	25	82
	Jan - Jun 09	6	254	57		61	46	73	25	76
	Jul - Dec 09	6	327	50		63	23	76	0	85
	Jan - Jun 10	5	328	67		70	66	81	36	82
	Jul - Dec 10	5	344	67		73	67	75	41	80
	Jan - Jun 11	6	385	61		74	59	78	0	86
	Jul - Dec 11	6	453	43		49	47	52	0	63
	Oct 11 - Mar 12	6	463	40		45	39	45	0	67
	Apr - Sept 12	6	501	42		43	35	49	25	60
	Oct 12 - Mar 13	6	341	66		65	58	80	38	86
	Apr - Sept 13	5	340	65		76	52	78	33	86
	Oct 13 - Mar 14	6	329	63		67	50	82	22	90
group 3 (n = 24)	Jul - Dec 09	16	858	32		30	2	42	0	100
	Jan - Jun 10	16	751	26		25	0	43	0	92
	Jul - Dec 10	15	838	27		19	0	46	0	90
	Jan - Jun 11	22	1049	32		24	3	42	0	100
	Jul - Dec 11	24	1660	28		18	0	40	0	94
	Oct 11 - Mar 12	24	1375	28		20	0	48	0	92
	Apr - Sept 12	21	1440	39		41	9	71	0	92
	Oct 12 - Mar 13	17	1132	64		77	40	83	11	100
	Apr - Sept 13	18	1207	56		68	34	83	0	94
	Oct 13 - Mar 14	19	1104	61		71	45	83	0	94
group 4 (n = 4)	Jul - Dec 10	2	12	22		22	17	28	11	33
	Jan - Jun 11	3	64	38		50	25	57	0	63
	Jul - Dec 11	4	87	18		11	0	29	0	50
	Oct 11 - Mar 12	4	105	1		1	0	2	0	3
	Apr - Sept 12	2	106	34		34	19	49	3	64
	Oct 12 - Mar 13	4	112	64		76	53	88	5	100
	Apr - Sept 13	4	110	57		64	45	75	0	100
	Oct 13 - Mar 14	4	125	61		73	46	88	0	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric Nutrition Evaluation Scores (%) by Group and Review Period

Percentage of pediatric patients who had a nutritional evaluation during the 6-month review period

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 5 (n = 6)	Jul - Dec 11	5	68	18		15	14	25	0	36
	Oct 11 - Mar 12	5	79	31		30	29	43	6	46
	Apr - Sept 12	6	83	55		55	48	60	25	92
	Oct 12 - Mar 13	6	86	66		73	63	76	33	82
	Apr - Sept 13	5	79	68		59	58	80	50	92
	Oct 13 - Mar 14	6	139	66		66	58	74	56	77
group 6 (n = 12)	Apr - Sept 12	7	1444	26		30	9	35	0	67
	Oct 12 - Mar 13	9	819	49		51	40	60	0	100
	Apr - Sept 13	10	763	57		61	50	83	0	93
	Oct 13 - Mar 14	9	736	76		75	69	95	33	100
group 7 (n = 18)	Oct 12 - Mar 13	8	27	53		67	30	76	0	100
	Apr - Sept 13	14	95	45		36	4	92	0	100
	Oct 13 - Mar 14	14	129	46		45	19	73	0	100
group 8 (n = 14)	Apr - Sept 13	7	26	39		40	17	50	0	100
	Oct 13 - Mar 14	9	33	56		50	43	83	0	100
group 9 (n = 4)	Oct 13 - Mar 14	1	1	100		100	100	100	100	100

*In 2011, Haiti data were retrospectively stratified into adult and pediatric (<15 years old) data for all but nine clinics. Those nine clinics are not included in the aggregate results for the first six review periods. Beginning in the 7th review period, Jan - Jun 11, all data from all clinics are stratified and included in the aggregate results.

Haiti Pediatric Immunisation Scores (%) by Group and Review Period*

Percentage of pediatric patients (<5 years old) seen during the 6-month review period who have had complete vaccinations for their age

group	review period	# of clinics	# of eligible patients	mean	spread	median	25th percentile	75th percentile	min	max
group 1 (n = 18)	Jan - Jun 08	16	327	0		0	0	0	0	5
	Jul - Dec 08	16	361	2		0	0	1	0	13
	Jan - Jun 09	16	423	2		0	0	1	0	11
	Jul - Dec 09	16	540	50		49	29	65	0	100
	Jan - Jun 10	15	511	43		33	29	58	0	100
	Jul - Dec 10	15	544	39		33	22	65	0	100
	Jan - Jun 11	14	534	47		45	33	55	25	100
	Jul - Dec 11	14	577	41		40	27	51	0	100
	Oct 11 - Mar 12	14	537	40		39	28	49	0	100
	Apr - Sept 12	15	532	49		42	33	51	22	100
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-
	Apr - Sept 13	-	-	-		-	-	-	-	-
group 2 (n = 6)	Jul - Dec 08	6	62	2		0	0	0	0	10
	Jan - Jun 09	6	169	5		1	0	11	0	17
	Jul - Dec 09	5	235	58		50	44	70	41	83
	Jan - Jun 10	5	244	45		34	29	61	25	78
	Jul - Dec 10	5	273	43		36	27	56	25	73
	Jan - Jun 11	5	302	36		26	23	53	19	57
	Jul - Dec 11	5	363	43		43	36	46	34	55
	Oct 11 - Mar 12	5	365	40		37	36	44	33	52
	Apr - Sept 12	6	401	45		38	34	43	19	100
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-
	Apr - Sept 13	-	-	-		-	-	-	-	-
group 3 (n = 24)	Jul - Dec 09	12	460	56		60	43	68	20	100
	Jan - Jun 10	12	373	51		50	35	61	21	100
	Jul - Dec 10	12	425	56		64	30	72	22	100
	Jan - Jun 11	12	446	56		50	42	70	26	100
	Jul - Dec 11	14	693	57		47	38	69	27	100
	Oct 11 - Mar 12	14	692	59		56	38	67	21	100
	Apr - Sept 12	11	766	49		50	31	56	18	100
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-
	Apr - Sept 13	-	-	-		-	-	-	-	-
group 4 (n = 4)	Jul - Dec 10	2	7	83		83	75	92	67	100
	Jan - Jun 11	2	10	83		83	75	92	67	100
	Jul - Dec 11	2	26	8		8	4	12	0	16
	Oct 11 - Mar 12	2	26	6		6	3	9	0	12
	Apr - Sept 12	1	27	22		22	22	22	22	22
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-
	Apr - Sept 13	-	-	-		-	-	-	-	-
group 5 (n = 6)	Jul - Dec 11	5	39	86		100	75	100	54	100
	Oct 11 - Mar 12	5	47	88		100	86	100	55	100
	Apr - Sept 12	5	50	77		100	46	100	40	100
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-
	Apr - Sept 13	-	-	-		-	-	-	-	-
group 6 (n = 12)	Apr - Sept 12	5	119	67		80	75	87	0	92
	Oct 12 - Mar 13	-	-	-		-	-	-	-	-
	Apr - Sept 13	-	-	-		-	-	-	-	-

*Immunisation data captured during Oct 12 - Mar 13, Apr - Sept 13, and Oct 13 - Mar 14 review periods are omitted, pending further validation.

Appendix B: Contributors to previous versions of the report

Special thanks to country based contributors and other HQI staff members who have worked on previous versions of the data report:

HIVQUAL-UGANDA

Zainabu Akol, MD

Charmaine Matovu

John Ssenkusu

CLINIQUAL-MOZAMBIQUE

Ema Chuva, MD

Klaus Sturbeck, MD

Daniel Lee, MPH

Páscoa Wate, MD

Antonio Barros Lourenco

Mauro Sanchez, ScD

António Guilherme Mujovo, MD

Paula Samo Gudo, MD, MPH

HIVQUAL-NAMIBIA

Justice Gweshe, MD

Wilhelmina Kafitha

Naita Nashilongo

Claire Dillavou, MPH

Claudia Mbapaha, RN

Naemi Shoopala, MPH

Johanna Haimene

Tuli Nakanyala

HEALTHQUAL-HAITI

Gabriel Thimothe, MD

Roland Charles, MD

Micheline Louis, RN

Yves-Marie Bernard, MD, MPH

Rachelle Cassagnol, MD, MPH

HEALTHQUAL-NIGERIA

Evelyn Ngige, MD

Ibrahim Dalhatu, MD, MPA, FMCPH

Jerry Gwamna, MBBS, FWACP

Aderemi Azeez, MD

Ahmad Aliyu, MD

Alozie Ananaba, MD

Mukhtar Muhammand, MD

Nasir Sani-Gwarzo, MD

HEALTHQUAL-GUYANA

Curtis LaFleur, MD, MHS

Andrea Lambert, MD

Allister Collins

Darshanand Maraj, MD

Nicholas Persaud

Emily Cumberbatch

Paul Persaud

HIVQUAL-KENYA

Davies Kimanga, MD

Tom Oluoch, PhD

Anthony Waruru, MPhil

Reinhard Kaiser, MD

Ibrahim Mohammed, MD, MPH

Julius Mutiso

Micah Anyona

New York State Department of Health-AIDS Institute-HEALTHQUAL International

Meredith Baumgartner, MPH

Kathleen Clanon, MD

Mahita Mishra

Joan Manuel Monserrate, MPH

Matthew Wetherell

Margaret Palumbo, MPH

Special Acknowledgements

Barbara Aranda-Naranjo, RN, PhD, FAAN

La Mar Hasbrouck, MD, MPH

Elliot Raizes, MD

Seymour Williams, MD, MPH

Andrew Felder, MPA

Michael Insel, MD

Jeremy Konstam

Alanna Mozena

Alvin Thalappillil, MS

Christopher Reisig, MA

Andrew Wei

Adult Performance Measurement Data
by subject area

The following graphs and tables report national-level performance across fourteen technical areas of care provided to adult patients living with HIV/AIDS:

1. Clinical Visits and Retention
2. ARV Therapy
3. CD4/Viral Load Monitoring
4. ART Adherence
5. ART for Pregnant Women (PMTCT)
6. Tuberculosis Prevention and Treatment
7. Cotrimoxazole Preventive Therapy
8. Women's Health
9. Partner Testing
10. Prevention Education
11. Family Planning
12. Nutrition
13. Alcohol Use and Mental Health Screening
14. Vital Signs

Graphs in this section compare longitudinal performance on quality of care indicators between countries. Performance data are reported by round of data collection, with the first round corresponding to the baseline round of data collection for each country.

Because the timing and duration of review periods differ between countries, the rounds do not coincide with dates. For specific information regarding dates and timing of rounds for each country, please refer to the country-specific section of the table below each graph.

I. Clinical Visits and Retention

Total (all clinics) Adult Clinical Visits Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult Clinical Visits Baseline and Most Recent Follow-up Scores (%) by Country

Country	Clinical Visits Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients with at a clinical visit in the last 3 months of the review period (for rounds 1-8, percentage of patients with a clinical visit in each 3-month quarter)	10	Mar - Aug 06 **70**	Jul - Dec 13 **92**
Mozambique[1]	Percentage of patients (ART and pre-ART) with a clinical visit during the first 6 months of the review period	4	Jul 07 - Jun 08 **49**	Jul - Dec 12 **92**
Namibia[2]	Percentage of patients on ART with a clinical visit during the last 3 months of the review period	9	Jan - Jun 08 **79**	Oct 12 - Mar 13 **85**
Haiti	Percentage of patients on ART with a clinical visit within 3 months of their last visit during the review period	13	Jan - Jun 08 **76**	Oct 13 - Mar 14 **80**
Guyana[3]	Percentage of patients (all ages) with at least 2 clinical visits during the review period	4	Jan - Jun 08 **85**	Jan - Jun 12 **79**
Vietnam	Percentage of patients (pre-ART) with a clinical visit in the last 3 months of the review period	4	Jul - Dec 11 **55**	Apr - Sept 13 **75**
Kenya[4]	Percentage of patients on ART with at least 2 clinical visits at least 3 months apart during the review period	4	Jul - Dec 09 **67**	Jul - Dec 11 **73**

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline score reported in the table above corresponds to the second round of data collection, July 2007 - June 2008, which was the first round in which ART and pre-ART patients were combined.

[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.

[3]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.

[4]Because of variation in the group of clinics submitting data in each review period, results from clinics implementing HQ-Kenya are reported only in tabular form instead of in graphs for greater clarity of interpretation.

In addition to measuring performance on clinical visits, HQ-Haiti and HQ-Zimbabwe have added a retention indicator to their HIV quality of care measures. Performance on retention in Haiti for pre-ART patients has remained relatively stable across 3 rounds of data collection. Clinics implementing HQ-Zimbabwe have collected a baseline round of data to measure retention of patients on ART. Data collection for a follow-up round is underway.

Retention

Haiti: Percentage of patients (pre-ART) with at least one visit in the last 6 months, excluding deceased and transferred patients

Zimbabwe: Percentage of patients who visited clinic in the 6 months prior to the review period who had a clinical visit during the review period

Total (all clinics) Haiti Adult Retention Scores (%) by Review Period



Total (all clinics) Adult Retention
Baseline and Most Recent Follow-up Scores (%) by Country

Country	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	3	Oct 12 - Mar 13 **57**	Oct 13 - Mar 14 **58**
Zimbabwe	1	Jan - Jun 13 **71**	N/A

The Uganda HIV Quality of Care Program introduced a new indicator to measure appointment keeping, which complements clinical visits. Performance on the appointment keeping indicator has improved over three rounds of data collection.

Appointment Keeping

Uganda: Percentage of patients who missed their scheduled appointment and did not show up to clinic within seven days after the scheduled appointment date

Total (all clinics) Uganda Adult Appointment Keeping Scores (%) by Review Period



Total (all clinics) Uganda Adult Appointment Keeping
Baseline and Most Recent Follow-up Scores (%)

Country	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	3	Jul - Dec 11 **16**	Jul - Dec 13 **87**

II. ARV Therapy

Total (all clinics) Adult ARV Therapy Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult ARV Therapy Baseline and Most Recent Follow-up Scores (%) by Country

Country	ARV Therapy Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients who are eligible for ART who have initiated ART within the past month (for rounds 1-8, percentage of patients who are eligible and receiving ART during the review period or at time of death)	11	Mar - Aug 06 **76**	Jul - Dec 13 **96**
Mozambique	Percentage of patients eligible for ART who received ART during the review period	5	Jan - Jun 07 **80**	Jul - Dec 12 **85**
Namibia[1]	Percentage of patients eligible for ART who received ART during the review period	9	Jan - Jun 08 **83**	Oct 12 - Mar 13 **92**
Haiti	Percentage of patients eligible for ART who were enrolled on ART during the review period	13	Jan - Jun 08 **45**	Oct 13 - Mar 14 **71**
Guyana[2]	Percentage of patients (all ages) prescribed HAART during the review period	4	Jan - Jun 08 **71**	Jan - Jun 12 **84**
Vietnam	Percentage of patients eligible for ART who initiated ART within 30 days	4	Jul - Dec 11 **58**	Apr - Sept 13 **72**
Kenya[3]	Percentage of patients eligible for ART who received ART during the review period	4	Jul - Dec 09 **86**	Jul - Dec 11 **90**

[1]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.

[2]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.

[3]Because of variation in the group of clinics submitting data in each review period, results from clinics implementing HQ-Kenya are reported only in tabular form instead of in graphs for greater clarity of interpretation.

III. CD4/Viral Load Monitoring

Total (all clinics) Adult CD4 Monitoring Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult CD4 Monitoring Baseline and Most Recent Follow-up Scores (%) by Country

Country	CD4 Monitoring Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients with a CD4 test (percent or count) during the review period	10	Mar - Aug 06 **31**	Jul - Dec 13 **43**
Mozambique[1]	Percentage of patients on ART with a CD4 count test during the review period	4	Jul 07 - Jun 08 **40**	Jul - Dec 12 **89**
Namibia[2]	Percentage of patients on ART with a CD4 count test during the review period	9	Jan - Jun 08 **74**	Oct 12 - Mar 13 **66**
Haiti	Percentage of newly enrolled patients (within 6-12 months prior to the review period) with a CD4 count test within 2 months of enrollment and between 2 and 8 months after enrollment	10	Jan - Jun 08 **31**	Oct 13 - Mar 14 **30**
Guyana[3]	Percentage of patients (all ages) with a CD4 test during the review period	4	Jan - Jun 08 **83**	Jan - Jun 12 **66**
Vietnam	Percentage of patients with a CD4 count test during the review period	4	Jul - Dec 11 **74**	Apr - Sept 13 **75**
Kenya[4]	Percentage of patients with a CD4 count test during the review period	4	Jul - Dec 09 **63**	Jul - Dec 11 **66**
Zimbabwe[5]	Percentage of patients on ART with a CD4 test during the review period	1	Jan - Jun 13 **17**	N/A

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline score reported in the table above corresponds to the second round of data collection, July 2007 - June 2008, which was the first round in which ART and pre-ART patients were combined.
[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.
[3]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.
[4]Because of variation in the group of clinics submitting data in each review period, results from clinics implementing HQ-Kenya are reported only in tabular form instead of in graphs for greater clarity of interpretation.
[5]Clinics implementing HQ-Zimbabwe have collected a baseline round of data. Although data are insufficient to assess whether improvement has occurred, the initial round of data collection identifies opportunities for improvement in the data collection process.

Total (all clinics) Adult CD4 Monitoring (new) and CD4 Test at Enrollment Scores (%) by Country and Round of Data Collection

In 2013, the Haiti CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring (new) and (2) CD4 Test at Enrollment. The HQ-Vietnam program has also developed an indicator to measure CD4 Test at Enrollment.



Total (all clinics) Adult CD4 Monitoring (new) and CD4 Test at Enrollment Baseline and Most Recent Follow-up Scores (%) by Country

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti CD4 Monitoring (new)	Percentage of patients (on ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **18**	Oct 13 - Mar 14 **46**
Haiti CD4 Test at Enrollment	Percentage of patients newly enrolled during the review period who received a CD4 test within 60 days of enrollment, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **62**	Oct 13 - Mar 14 **66**
Vietnam CD4 Test at Enrollment	Percentage of patients newly registered who are tested for CD4 count within 15 days of enrollment (Initial CD4 Count indicator)	4	Jul - Dec 11 **65**	Apr - Sept 13 **79**

Total (all clinics) Uganda Adult Virology Monitoring Baseline Score (%)

Clinics implementing performance measurement under Uganda's HIV Quality of Care Program have collected a baseline round of data to measure performance on virology monitoring. Data collection for a follow-up round is underway.

Country	Virology Monitoring Definition	# of rounds	baseline score (%)	most recent follow-up score (%)
Uganda	Percentage of patients on ART who received a viral load test during the review period	1	Jul - Dec 13 **1**	N/A

IV. ART Adherence

Total (all clinics) Adult ART Adherence Assessment Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult ART Adherence Assessment Baseline and Most Recent Follow-up Scores (%) by Country

Country	ART Adherence Assessment Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients on ART with an adherence assessment in the last 3 months (for rounds 1-8, percentage of patients who had an adherence assessment during the review period or at time of death)	11	Mar - Aug 06 **63**	Jul - Dec 13 **86**
Mozambique	Percentage of patients on ART who had an adherence assessment during the review period	5	Jan - Jun 07 **66**	Jul - Dec 12 **83**
Namibia[1]	Percentage of patients on ART who had an adherence assessment during the review period	9	Jan - Jun 08 **90**	Oct 12 - Mar 13 **98**
Haiti	Percentage of patients on ART who had an adherence assessment (pill count or questionnaire) during the last 3 months of the review period	13	Jan - Jun 08 **29**	Oct 13 - Mar 14 **79**
Guyana[2]	Percentage of patients (all ages) on ART who had an adherence assessment at each clinical visit during the review period	4	Jan - Jun 08 **56**	Jan - Jun 12 **82**
Vietnam	Percentage of patients on ART who had an adherence assessment at the last clinical visit	4	Jul - Dec 11 **97**	Apr - Sept 13 **96**
Kenya[3]	Percentage of patients on ART with an adherence assessment in the last 3 months of the review period	4	Jul - Dec 09 **96**	Jul - Dec 11 **89**
Zimbabwe[4]	Percentage of patients on ART with an adherence assessment at the most recent clinical visit	1	Jan - Jun 13 **55**	N/A

[1]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.
[2]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.
[3]Because of variation in the group of clinics submitting data in each review period, results from clinics implementing HQ-Kenya are reported only in tabular form instead of in graphs for greater clarity of interpretation.
[4]Clinics implementing HQ-Zimbabwe have collected a baseline round of data. Although data are insufficient to assess whether improvement has occurred, the initial round of data collection identifies opportunities for improvement in the data collection process.

Total (all clinics) Haiti Adult Adherence Rate Scores (%) by Review Period

Since 2013, in addition to the ART adherence assessment indicator, clinics implementing HQ-Haiti have collected data to measure performance on adherence rate.



Total (all clinics) Haiti Adult Adherence Rate Baseline and Most Recent Follow-up Scores (%)

Country	Haiti Adherence Rate Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%	3	Oct 12 - Mar 13 **67**	Oct 13 - Mar 14 **72**

Total (all clinics) Vietnam Adult ART Medication Pick-up Scores (%) by Review Period

Clinics implementing HQ-Vietnam have collected data to measure performance on ART medication pick-up.



Total (all clinics) Vietnam Adult ART Medication Pick-up Baseline and Most Recent Follow-up Scores (%)

Country	Vietnam ART Medication Pick-up Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Vietnam	Percentage of patients on ART visiting the health facility to pick up medication as scheduled at the last clinical visit	4	Jul - Dec 11 **68**	Apr - Sept 13 **89**

V. ART for Pregnant Women (PMTCT)

Total (all clinics) Adult ART for Pregnant Women Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult ART for Pregnant Women Baseline and Most Recent Follow-up Scores (%) by Country

Country	ART for Pregnant Women Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of HIV+ pregnant women who were eligible for and received ARV prophylaxis during the review period (eligibility was changed from 28th to 14th week of pregnancy for the 7th round of data collection onward)	13	Jan - Jun 08 **32**	Oct 13 - Mar 14 **91**
Kenya	Percentage of HIV+ pregnant women receiving preventive ART, either HAART or more efficacious short course prophylactic ARV regimens (AZT + sdNVP) during the review period	1	Jul - Dec 11 **90**	N/A
Zimbabwe	Percentage of HIV+ pregnant women with CD4 count < or = 350 or WHO stage 3/4 who initiated ART within one month of eligibility	1	Jan - Jun 13 **41**	N/A

Total (all clinics) Adult ART Eligibility Assessment Baseline Scores (%) by Country

The HQ-Kenya and HQ-Zimbabwe programs developed an ART eligibility assessment indicator for HIV+ pregnant women. Baseline data were collected for these indicators, which were implemented prior to the adoption of Option B+.

Country	ART Eligibility Assessment Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Kenya	Percentage of HIV+ pregnant women assessed for ART eligibility by CD4 count during the review period	1	Jul - Dec 11 **73**	N/A
Zimbabwe	Percentage of HIV+ pregnant women who had a CD4 test performed and received results within one week of diagnosis	1	Jan - Jun 13 **60**	N/A

Total (all clinics) Kenya Adult PMTCT Counseling on Partner Testing Baseline Score (%)

Clinics implementing HQ-Kenya also collected a baseline round of data to measure performance on PMTCT counseling on partner testing.

Indicator	PMTCT Counseling on Partner Testing Definition	# of rounds	baseline score (%)	most recent follow-up score (%)
Counseling on Partner Testing	Percentage of HIV+ pregnant women enrolled in PMTCT who were counseled on partner testing during the review period	1	Jul - Dec 11 **76**	N/A

VI. Tuberculosis Prevention and Treatment

Total (all clinics) Adult TB Clinical Screening Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult TB Clinical Screening Baseline and Most Recent Follow-up Scores (%) by Country

Country	TB Clinical Screening Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients (in general care or on ART) seen in the clinic within the past month who were assessed for active TB at each clinical visit (for rounds 1-8, percentage of patients who were assessed for clinical symptoms of TB during the review period)	11	Mar - Aug 06 **55**	Jul - Dec 13 **94**
Mozambique[1]	Percentage of patients who were screened for TB during the review period	4	Jul 07 - Jun 08 **25**	Jul - Dec 12 **89**
Namibia[2]	Percentage of patients who were screened for signs and symptoms of active TB during the review period	9	Jan - Jun 08 **81**	Oct 12 - Mar 13 **92**
Haiti	Percentage of patients screened for TB by TST or for symptoms of cough, fever and weight loss during the review period (for rounds 1-6, percentage of patients screened for TB done by TST at enrollment)	13	Jan - Jun 08 **29**	Oct 13 - Mar 14 **93**
Guyana[3]	Percentage of patients (all ages) who were screened for TB by TST during the past 12 months	4	Jan - Jun 08 **89**	Jan - Jun 12 **85**
Vietnam	Percentage of patients who were screened for TB at the last clinical visit	4	Jul - Dec 11 **58**	Apr - Sept 13 **72**
Kenya[4]	Percentage of patients screened for TB at each clinical visit during the review period	4	Jul - Dec 09 **51**	Jul - Dec 11 **95**
Zimbabwe[5]	Percentage of patients on ART who had a standard TB screening (all 5 components) performed at their last visit during the review period	1	Jan - Jun 13 **53**	N/A

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline score reported in the table above corresponds to the second round of data collection, July 2007 - June 2008, which was the first round in which ART and pre-ART patients were combined.
[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.
[3]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.
[4]Because of variation in the group of clinics submitting data in each review period, results from clinics implementing HQ-Kenya are reported only in tabular form instead of in graphs for greater clarity of interpretation.
[5]Clinics implementing HQ-Zimbabwe have collected a baseline round of data. Although data are insufficient to assess whether improvement has occurred, the initial round of data collection identifies opportunities for improvement in the data collection process.

Total (all clinics) Adult Isoniazid Prophylactic Therapy Scores (%) by Country and Round of Data Collection

In addition to TB clinical screening, HQ-Namibia and HQ-Haiti have measured performance on prescribing Isoniazid prophylactic therapy (IPT) for tuberculosis. Clinics implementing HQ-Haiti collected baseline data to measure IPT in 2013 and have since collected two follow-up rounds of data.



Total (all clinics) Adult Isoniazid Prophylactic Therapy Baseline and Most Recent Follow-up Scores (%) by Country

Country	Isoniazid Prophylactic Therapy Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months, excluding deceased and transferred patients and those with active TB	3	Oct 12 - Mar 13 **42**	Oct 13 - Mar 14 **52**
Namibia	Percentage of patients with no documented contraindication to IPT and who are not on TB treatment who are currently receiving IPT	9	Jan - Jun 08 **16**	Oct 12 - Mar 13 **25**

Total (all clinics) Uganda Adult TB Diagnostic Evaluation Scores (%) by Review Period

A TB diagnostic evaluation indicator was developed under the HQ-Uganda program. Clinics collecting data under Uganda's national HIV QoC Program continue to collect data to measure performance on TB diagnostic evaluation. In addition, a baseline round of data has been collected from a sample of clinics to measure performance on TB treatment.



Total (all clinics) Uganda Adult TB Diagnostic Evaluation and TB Treatment Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
TB Diagnostic Evaluation	Percentage of patients with signs and symptoms of TB who have been evaluated for TB during the review period using sputum smear and/or CXR or gene Xpert	10	Mar - Aug 06 **23**	Jul - Dec 13 **47**
TB Treatment	Percentage of patients diagnosed with TB who were started on treatment during the review period	1	Jul - Dec 13 **93**	N/A

VII. Cotrimoxazole Preventive Therapy

Total (all clinics) Adult Cotrimoxazole Preventive Therapy Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult Cotrimoxazole Preventive Therapy Baseline and Most Recent Follow-up Scores (%) by Country

Country	Cotrimoxazole Preventive Therapy Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients who have been prescribed cotrimoxazole during the review period and are still receiving it at the end of the review period or at time of death	8	Mar - Aug 06 **88**	Jul - Dec 10 **90**
Mozambique[1]	Percentage of patients eligible for cotrimoxazole who received cotrimoxazole during the last 6 months of the review period	4	Jul 07 - Jun 08 **65**	Jul - Dec 12 **79**
Namibia[2]	Percentage of patients with CD4<300 or WHO stage 3/4 who have been prescribed cotrimoxazole prophylaxis during the review period and are still receiving it at the end of the review period or at time of death or transfer-out	9	Jan - Jun 08 **86**	Oct 12 - Mar 13 **92**
Haiti	Percentage of patients who have received cotrimoxazole prophylaxis during the review period	13	Jan - Jun 08 **62**	Oct 13 - Mar 14 **94**
Guyana[3]	Percentage of HIV+ patients (all ages) receiving cotrimoxazole during the review period (for HIV-exposed infants, percentage of exposed infants starting cotrimoxazole by two months of age)	4	Jan - Jun 08 **78**	Jan - Jun 12 **84**
Vietnam	Percentage of patients who were prescribed cotrimoxazole or dapsone in the last clinical visit	4	Jul - Dec 11 **40**	Apr - Sept 13 **84**
Kenya[4]	Percentage of patients on cotrimoxazole during the review period	4	Jul - Dec 09 **97**	Jul - Dec 11 **98**

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline score reported in the table above corresponds to the second round of data collection, July 2007 - June 2008, which was the first round in which ART and pre-ART patients were combined.
[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.
[3]Data include adult and pediatric patients. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.
[4]Because of variation in the group of clinics submitting data in each review period, results from clinics implementing HQ-Kenya are reported only in tabular form instead of in graphs for greater clarity of interpretation.

VIII. Women's Health

Total (all clinics) Haiti Adult Syphilis Treatment and Cervical Cancer Screening Scores (%) by Review Period

In 2013, clinics implementing HQ-Haiti began data collection for women's health indicators measuring syphilis treatment and cervical cancer screening. Two follow-up rounds of data have since been collected.



Total (all clinics) Haiti Adult Syphilis Treatment and Cervical Cancer Screening Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Syphilis Treatment	Percentage of HIV+ women who tested positive for syphilis who completed treatment during the review period, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **10**	Oct 13 - Mar 14 **41**
Cervical Cancer Screening	Percentage of HIV+ women aged 25-64 years who were screened for cervical cancer (visual inspection of the cervix with acetic acid [VIA] or a cervical cytology) during the review period, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **8**	Oct 13 - Mar 14 **6**

IX. Partner Testing

Total (all clinics) Kenya Adult Counseling on Partner Testing Baseline and Follow-up Scores (%)

The HQ-Kenya program has developed an indicator to measure counseling on partner testing.

Indicator	Counseling on Partner Testing Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Counseling on Partner Testing	Percentage of HIV+ patients who have been counseled about partner testing during the review period	4	Jul - Dec 09 **36**	Jul - Dec 11 **48**

*Because of variation in the group of clinics submitting data in each review period, results from clinics implementing HQ-Kenya are reported only in tabular form instead of in graphs for greater clarity of interpretation.

X. Prevention Education

Total (all clinics) Adult Prevention Education Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult Prevention Education Baseline and Most Recent Follow-up Scores (%) by Country

Country	Prevention Education Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Namibia[1]	Percentage of patients who received prevention education during the last 3 months of the review period	9	Jan - Jun 08 **37**	Oct 12 - Mar 13 **41**
Mozambique[2]	Percentage of patients who received prevention education in the last 6 months of the review period	4	Jul 07 - Jun 08 **66**	Jul - Dec 12 **84**

[1]For the baseline round of data collection, January - June 2007, two separate randomized samples were generated: one for patients on ART and one for pre-ART patients. For subsequent rounds of data collection, patients were not stratified into ART and pre-ART groups. The baseline score reported in the table above corresponds to the second round of data collection, July 2007 - June 2008, which was the first round in which ART and pre-ART patients were combined.

[2]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.

XI. Family Planning

Total (all clinics) Adult Family Planning Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult Family Planning Baseline and Most Recent Follow-up Scores (%) by Country

Country	Family Planning Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of HIV+ women of childbearing age who accepted a family planning method during the review period	13	Jan - Jun 08 **6**	Oct 13 - Mar 14 **51**
Kenya	Percentage of non-pregnant women aged 15-49 years, not already on family planning, who initiated modern contraception during the review period	3	Jul - Dec 10 **30**	Jul - Dec 11 **36**

XII. Nutrition

Total (all clinics) Adult Nutrition Evaluation Scores (%) by Country and Round of Data Collection



Total (all clinics) Adult Nutrition Evaluation Baseline and Most Recent Follow-up Scores (%) by Country

Country	Nutrition Evaluation Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of patients who had a nutritional evaluation during the review period (BMI calculated at enrollment and weight measured at each visit)	13	Jan - Jun 08 **77**	Oct 13 - Mar 14 **86**
Kenya	Percentage of patients who had at least one nutritional assessment (MUAC, BMI or weight for height during the 6-month review period)	2	Jan - Jun 11 **4**	Jul - Dec 11 **18**

Total (all clinics) Kenya Adult Nutritional Counseling Baseline and Follow-up Scores (%)

In addition to measuring performance on nutrition evaluation, clinics implementing HQ-Kenya collected data to measure nutritional counseling.

Indicator	Nutritional Counseling Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Nutritional Counseling	Percentage of patients who received nutritional counseling during the review period	2	Jan - Jun 11 **42**	Jul - Dec 11 **51**

Total (all clinics) Haiti Adult Malnutrition Status Baseline and Follow-up Scores (%)

Since 2013, clinics implementing HQ-Haiti have collected additional data to measure malnutrition status, which is calculated from the number of patients who receive a nutrition evaluation.

Indicator	Malnutrition Status Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Malnutrition Status	Percentage of patients who received a BMI assessment during the last 6 months (excluding deceased and transferred patients) who had a BMI of 16 or lower (severe malnutrition)	3	Oct 12 - Mar 13 **2**	Oct 13 - Mar 14 **2**

Total (all clinics) Namibia Adult Weight Monitoring and Food Security Screening Scores (%) by Round of Data Collection

Clinics implementing HQ-Namibia have collected data to measure performance on weight monitoring as well as food security.



Total (all clinics) Namibia Adult Weight Monitoring and Food Security Screening Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Weight Monitoring	Percentage of patients whose weight has been recorded during the review period	9	Jan - Jun 08 **84**	Oct 12 - Mar 13 **96**
Food Security Screening	Percentage of patients assessed for food security (hunger) during the review period	9	Jan - Jun 08 **24**	Oct 12 - Mar 13 **47**

[1]The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.

XIII. Alcohol Use and Mental Health Screening

Total (all clinics) Namibia Adult Alcohol Screening and Haiti Adult Mental Health Assessment Scores (%) by Round of Data Collection



Total (all clinics) Namibia Adult Alcohol Screening Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Alcohol Screening	Percentage of patients who have been screened for alcohol use during the review period	9	Jan - Jun 08 **24**	Oct 12 - Mar 13 **47**

*The baseline round of data collection reviewed care provided between July - December 2007. However, technical difficulties with electronic data capture resulted in inaccurate results. Data from the second round, January - June 2008 are reported in the table above as the baseline results.

Total (all clinics) Haiti Adult Mental Health Assessment Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Mental Health Assessment	Percentage of patients who received a mental health evaluation during the past 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation, and assessment of sleep and appetite)	3	Oct 12 - Mar 13 **45**	Oct 13 - Mar 14 **53**

XIV. Vital Signs

The HQ-Guyana program has developed general medical care indicators to measure vital signs of temperature, pulse and blood pressure for HIV+ patients aged 16 and older.

HQ-Guyana HIV/AIDS General Medical Care

Temperature: Percentage of patients (ages 16+) with temperature documented at each clinic visit during the six-month review period

Pulse: Percentage of patients (ages 16+) with pulse documented at each clinic visit during the six-month review period

Blood Pressure: Percentage of patients (ages 16+) with blood pressure documented at each clinic visit during the six-month review period

Total (all clinics) Guyana HIV/AIDS General Medical Care Scores (%) by Review Period



Total (all clinics) Guyana Adult General Medical Care Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Temperature	Percentage of patients (ages 16+) with temperature documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **39**	Jan - Jun 12 **86**
Pulse	Percentage of patients (ages 16+) with pulse documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **48**	Jan - Jun 12 **90**
Blood Pressure	Percentage of patients (ages 16+) with blood pressure documented at each clinic visit during the six-month review period	4	Jan - Jun 08 **69**	Jan - Jun 12 **89**

Pediatric Performance Measurement Data
by subject area

The following graphs and tables report national-level performance across twelve technical areas of care provided to pediatric patients living with HIV/AIDS and, in Guyana, HIV-negative children:

1. Clinical Visits and Retention
2. ARV Therapy
3. HIV testing
4. WHO Clinical Staging
5. CD4/Viral Load Monitoring
6. ART Adherence
7. Tuberculosis Prevention and Treatment
8. Cotrimoxazole Preventive Therapy
9. Malaria Prevention and Immunization
10. Disclosure of Status
11. Growth and Nutrition
12. Mental Health

Graphs in this section compare longitudinal performance on quality of care indicators between countries. Performance data are reported by round of data collection, with the first round corresponding to the baseline round of data collection for each country.

Because the timing and duration of review periods differ between countries, the rounds do not coincide with dates. For specific information regarding dates and timing of rounds for each country, please refer to the country-specific section of the table below each graph.

I. Clinical Visits and Retention

Total (all clinics) Pediatric Clinical Visits Scores (%) by Country and Round of Data Collection



Total (all clinics) Pediatric Clinical Visits Baseline and Most Recent Follow-up Scores (%) by Country

Country	Clinical Visits Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients with at least one clinical visit in the last 3 months of the review period (for rounds 1-8, percentage of patients with at least one clinical visit in each 3-month quarter)	10	Apr - Sept 07 **83**	Jul - Dec 13 **92**
Mozambique	Percentage of pre-ART patients in WHO stages 2-4 who had one clinical visit in each month during the last 6 months or in WHO stage 1 (or unknown stage) who had one clinical visit in each 3-month interval. Percentage of ART patients on first year of treatment who had one visit in each month during the last 6 months Percentage of ART patients on treatment for more than a year who had one visit in each 2-month interval	3	Jul 08 - Jun 09 **7**	Jul - Dec 12 **5**
Haiti	Percentage of patients on ART with a clinical visit within 3 months of their last visit during the review period	13	Jan - Jun 08 **69**	Oct 13 - Mar 14 **88**
Guyana[1]	Percentage of HIV-negative patients < 5 years with at least 2 clinical visits during the review period	4	Jan - Jun 08 **67**	Jan - Jun 12 **75**
Kenya[2]	Percentage of patients on ART with at least 2 clinical visits at least 3 months apart during the review period	2	Jan - Jun 11 **74**	Jul - Dec 11 **74**

[1]Guyana Well Child data include HIV-negative patients < 5 years of age. In round 1, data were collected for HIV/AIDS (HIV+ patients of all ages) and Well Child (HIV-negative patients <5 years) indicators together; in round 2, data were collected separately for HIV/AIDS and Well Child indicators.

[2]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

In addition to measuring performance on clinical visits, HQ-Haiti has added a retention indicator to their HIV quality of care measures. Performance on Haiti's retention indicator for pre-ART patients has remained relatively stable across 3 rounds of data collection.

Retention

Haiti: Percentage of patients (pre-ART) with at least one visit in the last 6 months, excluding deceased and transferred patients

Total (all clinics) Haiti Pediatric Retention Scores (%) by Review Period



Total (all clinics) Haiti Pediatric Retention Baseline and Most Recent Follow-up Scores (%)

Country	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	3	Oct 12 - Mar 13 **55**	Oct 13 - Mar 14 **56**

Total (all clinics) Uganda Pediatric Appointment Keeping Baseline Score (%)

The Uganda HIV Quality of Care Program introduced a new appointment keeping indicator, which complements clinical visits. A baseline round of data has been collected to measure performance on pediatric appointment keeping. A follow-up round of data collection is underway.

Country	Appointment Keeping Definition	# of rounds	baseline score (%)	most recent follow-up score (%)
Uganda	Percentage of patients on ART who kept the last scheduled clinical appointment in the last 3 months of the review period	1	Jul - Dec 13 **68**	N/A

II. ARV Therapy

Total (all clinics) Pediatric ARV Therapy Scores (%) by Country and Round of Data Collection



Total (all clinics) Pediatric ARV Therapy Baseline and Most Recent Follow-up Scores (%) by Country

Country	ARV Therapy Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients who were eligible and started on ART during the review period	10	Apr - Sept 07 **26**	Jul - Dec 13 **73**
Mozambique	Percentage of patients eligible for ART receiving ART during the last 6 months of the review period	3	Jul 08 - Jun 09 **59**	Jul - Dec 12 **81**
Haiti	Percentage of patients eligible for ART who were enrolled on ART during the review period	13	Jan - Jun 08 **44**	Oct 13 - Mar 14 **73**
Kenya[1]	Percentage of patients eligible for ART who received ART during the review period	2	Jan - Jun 11 **54**	Jul - Dec 11 **83**
Zimbabwe	Percentage of newly diagnosed HIV+ children (<15 years old by end of review period) who initiated ART within one month of diagnosis	1	Jan - Jun 13 **79**	N/A

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

Total (all clinics) Zimbabwe ART Initiation in HIV+ Infants Baseline Scores (%)

Clinics implementing HQ-Zimbabwe have also collected a baseline round of data measuring ART initiation in HIV+ infants.

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
ART Initiation in HIV+ Infants	Percentage of HIV+ children <12 months of age who have been initiated on ART	1	Jan - Jun 13 **68**	N/A

Total (all clinics) Uganda Infant Referral from PMTCT Baseline and Follow-up Scores (%)

For 7 rounds of performance measurement for pediatric indicators under the HQ-Uganda program, data were collected to measure performance on infant referral from PMTCT to HIV care.

Country	Infant Referral from PMTCT Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of newly HIV-infected or HIV-exposed pediatric patients who were referred for HIV care from PMTCT based on reviews in pediatric clinics	7	Apr - Sept 07 **6**	Jul - Dec 10 **12**

III. HIV Testing

Total (all clinics) Haiti Pediatric Early HIV Detection Scores (%) by Review Period

Since 2013, clinics implementing HQ-Haiti have collected data to measure performance on early HIV detection.



Total (all clinics) Haiti Pediatric Early HIV Detection Baseline and Most Recent Follow-up Scores (%)

Country	Early HIV Detection Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of children exposed to HIV aged 4 weeks to 1 year who have received early screening by PCR during the last 3 months, excluding those out of care	3	Oct 12 - Mar 13 **22**	Oct 13 - Mar 14 **63**

Total (all clinics) Zimbabwe HIV-exposed Infant Management Baseline Score (%)

Clinics implementing HQ-Zimbabwe have collected a baseline round of data measuring performance on HIV-exposed infant management.

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
HIV-exposed Infant Management[1]	Percentage of HIV-exposed infants 12 months of age or younger who had a DBS test performed and received results within one month	1	Jan - Jun 13 **15**	N/A

[1]During the baseline round of data collection, a group of sites misinterpreted the definition of the HIV-exposed infant management (DBS test) indicator. Because of errors in data collection, the mean clinic score reported for this indicator may not reflect actual clinical performance during the first round of data collection.

IV. WHO Clinical Staging

Total (all clinics) Mozambique Pediatric WHO Clinical Staging Scores (%) by Review Period

Clinics implementing CLINIQUAL in Mozambique have collected data to measure performance on WHO clinical staging.



Total (all clinics) Mozambique Pediatric WHO Clinical Staging Baseline and Follow-up Scores (%)

Country	WHO Clinical Staging Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Mozambique	Percentage of HIV+ children for whom a WHO clinical stage was documented at each clinical visit during the review period (for rounds 1-2, percentage of HIV+ children for whom a WHO clinical stage was documented at the last clinical visit)	3	Jul 08 - Jun 09 **69**	Jul - Dec 12 **94**

V. CD4 Monitoring

Total (all clinics) Pediatric CD4 Monitoring Scores (%) by Country and Round of Data Collection



Total (all clinics) Pediatric CD4 Monitoring Baseline and Most Recent Follow-up Scores (%) by Country

Country	CD4 Monitoring Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients with a CD4 test during the review period	10	Apr - Sept 07 **15**	Jul - Dec 13 **35**
Mozambique	Percentage of patients who had a CD4 test in the last 6 months of the review period	3	Jul 08 - Jun 09 **36**	Jul - Dec 12 **46**
Haiti	Percentage of newly enrolled patients (within 6-12 months prior to the review period) with a CD4 count test within 2 months of enrollment and between 2 and 8 months after enrollment	10	Jan - Jun 08 **35**	Oct 13 - Mar 14 **20**
Kenya[1]	Percentage of patients with a CD4 count test during the review period	2	Jan - Jun 11 **54**	Jul - Dec 11 **63**

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

Total (all clinics) Haiti Pediatric CD4 Monitoring (new) and CD4 Test at Enrollment Scores (%) by Review Period

In 2013, the Haiti CD4 Monitoring indicator was revised to be two separate indicators: (1) CD4 Monitoring (new) and (2) CD4 Test at Enrollment.



Total (all clinics) Haiti Pediatric CD4 Monitoring (new) and CD4 Test at Enrollment Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
CD4 Monitoring (new)	Percentage of patients (on ART and pre-ART) enrolled in care for more than 6 months who received 2 CD4 tests in the last 12 months, excluding deceased and transferred patients	3	Oct 12 - Mar 13 **14**	Oct 13 - Mar 14 **49**
CD4 Test at Enrollment	Percentage of patients enrolled during the review period who received a CD4 count within 60 days of enrollment	3	Oct 12 - Mar 13 **20**	Oct 13 - Mar 14 **41**

VI. ART Adherence

Total (all clinics) Pediatric ART Adherence Assessment Scores (%) by Country and Round of Data Collection



Total (all clinics) Pediatric ART Adherence Assessment Baseline and Most Recent Follow-up Scores (%) by Country

Country	ART Adherence Assessment Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients on ART with an adherence assessment in the last 3 months (for rounds 1-8, percentage of patients who had an adherence assessment during the review period or at time of death)	10	Apr - Sept 07 **43**	Jul - Dec 13 **75**
Mozambique	Percentage of patients on ART who had an adherence assessment during the review period	3	Jul 08 - Jun 09 **81**	Jul - Dec 12 **72**
Haiti	Percentage of patients on ART who had an adherence assessment (pill count or questionnaire) during the last 3 months of the review period	13	Jan - Jun 08 **30**	Oct 13 - Mar 14 **76**

Total (all clinics) Haiti Pediatric Adherence Rate Scores (%) by Review Period

Since 2013, in addition measuring performance on ART adherence assessment, clinics implementing HQ-Haiti have collected data to measure performance on adherence rate.



Total (all clinics) Haiti Pediatric Adherence Rate Baseline and Most Recent Follow-up Scores (%)

Country	Haiti Adherence Rate Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of patients enrolled on ART for more than 3 months with a rate of adherence to ART of at least 95%	3	Oct 12 - Mar 13 **63**	Oct 13 - Mar 14 **73**

VII. Tuberculosis Prevention and Treatment

Total (all clinics) Pediatric TB Clinical Screening Scores (%) by Country and Round of Data Collection



Total (all clinics) Pediatric TB Clinical Screening Baseline and Most Recent Follow-up Scores (%) by Country

Country	TB Clinical Screening Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients who have been screened for TB during the last 3 months (for rounds 1-8, percentage of patients who were assessed for clinical symptoms of TB during the review period)	10	Apr - Sept 07 **57**	Jul - Dec 13 **90**
Mozambique	Percentage of patients who were screened for pulmonary TB during the last 6 months of the review period	3	Jul 08 - Jun 09 **34**	Jul - Dec 12 **84**
Haiti	Percentage of patients screened for TB by TST or for symptoms of cough, fever and weight loss during the review period (for rounds 1-6, percentage of patients screened for TB done by TST at enrollment)	13	Jan - Jun 08 **17**	Oct 13 - Mar 14 **91**
Kenya[1]	Percentage of patients screened for TB at each clinical visit during the review period	2	Jan - Jun 11 **82**	Jul - Dec 11 **78**

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

Total (all clinics) Uganda Pediatric Diagnostic Evaluation Scores (%) by Review Period

A TB diagnostic evaluation indicator was developed under the HQ-Uganda program. Clinics collecting data under Uganda's national HIV QoC Program continue to collect data to measure performance on TB diagnostic evaluation. In addition, a baseline round of data has been collected from a sample of clinics to measure performance on TB treatment.



Total (all clinics) Uganda Pediatric TB Diagnostic Evaluation and TB Treatment Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
TB Diagnostic Evaluation	Percentage of patients with signs and symptoms of TB who have been evaluated for TB during the review period using sputum smear and/or CXR or gene Xpert	10	Apr - Sept 07 **8**	Jul - Dec 13 **55**
TB Treatment	Percentage of patients diagnosed with TB who were started on treatment during the review period	1	Jul - Dec 13 **73**	N/A

Total (all clinics) Haiti Pediatric Isoniazid Prophylactic Therapy Scores (%) by Review Period

In addition to TB clinical screening, HQ-Haiti has developed an indicator to measure performance on prescribing Isoniazid prophylactic therapy (IPT) for tuberculosis. Clinics implementing HQ-Haiti collected baseline data for IPT in 2013 and have since collected two follow-up rounds of data.



Total (all clinics) Haiti Pediatric Isoniazid Prophylactic Therapy Baseline and Most Recent Follow-up Scores (%)

Country	Isoniazid Prophylactic Therapy Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of patients enrolled in HIV care during the past 6 months who received INH prophylaxis in the past 6 months, excluding deceased and transferred patients and those with active TB	3	Oct 12 - Mar 13 **23**	Oct 13 - Mar 14 **29**

VIII. Cotrimoxazole Preventive Therapy

Total (all clinics) Pediatric Cotrimoxazole Preventive Therapy Scores (%) by Country and Round of Data Collection



Total (all clinics) Pediatric Cotrimoxazole Preventive Therapy Baseline and Most Recent Follow-up Scores (%) by Country

Country	Cotrimoxazole Preventive Therapy Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients who have been prescribed cotrimoxazole during the review period and are still receiving it at the end of the review period or at time of death	10	Apr - Sept 07 **84**	Jul - Dec 13 **92**
Mozambique	Percentage of patients eligible for cotrimoxazole who received cotrimoxazole during the last 6 months of the review period	3	Jul 08 - Jun 09 **69**	Jul - Dec 12 **73**
Haiti	Percentage of patients who have received cotrimoxazole prophylaxis during the review period	13	Jan - Jun 08 **61**	Oct 13 - Mar 14 **96**
Kenya[1]	Percentage of patients on cotrimoxazole during the review period	2	Jan - Jun 11 **98**	Jul - Dec 11 **97**

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

IX. Malaria Prevention and Immunization

Total (all clinics) Uganda Malaria Prevention and Haiti Immunization Scores (%) by Round of Data Collection

HQ-Uganda and HQ-Haiti have developed pediatric indicators to measure performance on care for disease prevention.

Under the HQ-Uganda program, participating clinics collected data to measure performance on malaria prevention. With the implementation of the HIV QoC program in 2011, the pediatric malaria prevention indicator was discontinued, however mean clinic scores are reported for historical reference.

Clinics implementing HQ-Haiti have collected 13 rounds of data to measure performance on immunization. Immunization data captured during the last three review periods are omitted, pending further validation.



Total (all clinics) Uganda Pediatric Malaria Prevention Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Malaria Prevention	Percentage of children using insecticide-treated material (ITM) during the last 3 months of the review period	7	Apr - Sept 07 **11**	Jul - Dec 10 **30**

Total (all clinics) Haiti Pediatric Immunization Baseline and Most Recent Follow-up Scores (%)

Indicator	Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Immunization	Percentage of patients <5 years old seen during the review period who have had complete vaccinations for their age	10	Jan - Jun 08 **0**	Apr - Sept 12 **53**

X. Disclosure of Status

Total (all clinics) Kenya Pediatric Disclosure of Status Baseline and Follow-up Scores (%)

The HQ-Kenya program has developed a measure for the number of pediatric patients (aged 8-14 years) whose HIV status has been disclosed to them.

Indicator	Disclosure of Status Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Disclosure of Status[1]	Percentage of children aged 8-14 years whose status has been disclosed to them	2	Jan - Jun 11 **56**	Jul - Dec 11 **50**

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

XI. Growth and Nutrition

The CLINIQUAL-Mozambique program has developed pediatric general medical care indicators to measure performance on assessing children's weight, height, weight for height and evaluating psychomotor development.

CLINIQUAL-Mozambique General Medical Care

Weight: Percentage of patients whose weight was documented at each clinical visit during the review period (for rounds 1 and 2, percentage of patients who were weighed during their last clinical visit)

Height: Percentage of patients whose height was documented at each clinical visit during the review period (for rounds 1 and 2, percentage of patients whose height was measured during their last clinical visit)

Weight for Height: Percentage of patients whose weight to height ratio or IMC/age was evaluated at each clinical visit during the review period (for rounds 1 and 2, percentage of children whose weight to height ratio was calculated during their last clinical visit)

Evaluation of Psychomotor Development (PMD): Percentage of patients whose PMD was evaluated at each clinical visit during the review period (for rounds 1 and 2, percentage of patients whose PMD was evaluated during their last clinical visit)

Total (all clinics) Mozambique Pediatric General Medical Care Scores (%) by Review Period



The HQ-Guyana Well Child program (for HIV-negative children <5 years old) has developed growth monitoring indicators to measure performance on assessing children's weight, height/length, head circumference and weight for age, and has also incorporated a developmental milestones assessment indicator.

HEALTHQUAL-Guyana General Medical Well Child Care

Weight: Percentage of children with weight measured at each clinical visit during the review period

Height/Length: Percentage of children with height/length measured at each clinical visit during the review period

Head Circumference: Percentage of children <2 years of age with head circumference measured at each clinical visit during the review period

Weight for Age Plot: Percentage of children with "Weight for Age" plotted on a Growth Chart at each clinical visit during the review period

Developmental Milestones: Percentage of children with developmental milestones assessed at each clinical visit during the review period (as indicated on Clinic Card)

Total (all clinics) Guyana Well Child Growth Monitoring and Developmental Milestones Scores (%) by Review Period



Total (all clinics) Pediatric Nutrition Evaluation Scores (%) by Country and Round of Data Collection



Total (all clinics) Pediatric Nutrition Evaluation Baseline and Most Recent Follow-up Scores (%) by Country

Country	Nutrition Evaluation Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Haiti	Percentage of patients who had a nutritional evaluation during the review period (malnutrition is measured by growth rate)	13	Jan - Jun 08 **54**	Oct 13 - Mar 14 **62**
Kenya[1]	Percentage of patients who had at least one nutritional assessment (MUAC, BMI or weight for height during the 6-month review period)	2	Jan - Jun 11 **18**	Jul - Dec 11 **13**
Uganda	Percentage of patients with MUAC measurement done during the last 3 months of the review period	2	Jul - Dec 12 **26**	Jul - Dec 13 **28**

[1]Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

Total (all clinics) Uganda Pediatric Growth Monitoring Scores (%) by Review Period

Clinics implementing HQ-Uganda collected 7 rounds of data to measure performance on pediatric growth monitoring. Since the implementation of the HIV QoC Program, clinics have collected 2 additional rounds of data for this indicator.



Total (all clinics) Uganda Pediatric Growth Monitoring Baseline and Most Recent Follow-up Scores (%)

Country	Growth Monitoring Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Uganda	Percentage of patients receiving weight-for-age assessments during the last 3 months of the review period	9	Apr - Sept 07 **56**	Jul - Dec 12 **87**

Total (all clinics) Kenya* Pediatric Nutritional Counseling Baseline and Follow-up Scores (%)

In addition to measuring performance on nutrition evaluation, clinics implementing HQ-Kenya collected data on nutritional counseling.

Indicator	Nutritional Counseling Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Nutritional Counseling	Percentage of patients who received nutritional counseling during the review period	2	Jan - Jun 11 **61**	Jul - Dec 11 **67**

*Because of small sample sizes resulting from non-adherence to sampling methodologies, aggregate performance results from all clinics submitting pediatric data are first reported for the second and third rounds of performance measurement.

Total (all clinics) Uganda Pediatric Nutrition Support Baseline Score (%)

In 2013, the Uganda HIV QoC Program collected a baseline round of data to measure performance on nutrition support.

Indicator	Nutrition Support Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Nutrition Support	Percentage of patients assessed in the last 3 months of the review period who had malnutrition and received therapeutic or supplementary feeding support	1	Jul - Dec 13 **64**	N/A

Total (all clinics) Haiti Pediatric Malnutrition Status Baseline and Follow-up Scores (%)

Since 2013, clinics implementing HQ-Haiti have collected additional data to measure malnutrition status, which is calculated from the number of patients who receive a nutrition evaluation.

Indicator	Malnutrition Status Definition	# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
Malnutrition Status	Percentage of patients who received a nutritional assessment during the last 6 months (excluding those out of care) who had weight gain of less than -3 standard deviations or, if 1-5 years, MUAC<12.5 cm or a ratio of AC/HC <0.25 (severe malnutrition)	3	Oct 12 - Mar 13 **12**	Oct 13 - Mar 14 **9**

XII. Mental Health

The HQ-Haiti program has collected 3 rounds of data to measure performance on mental health assessment for pediatric patients.

HEALTHQUAL-Haiti Pediatric Mental Health Assessment

Percentage of patients who received a mental health evaluation during the pat 6 months (assessment elements include cognitive function, screening for depression and anxiety, analysis of psychiatric history, psychosocial evaluation and assessment of sleep and appetite)

Total (all clinics) Haiti Pediatric Mental Health Assessment Scores (%) by Review Period



Total (all clinics) Haiti Pediatric Mental Health Assessment Baseline and Most Recent Follow-up Scores (%)

# of rounds	baseline round and score (%)	most recent follow-up round and score (%)
3	Oct 12 - Mar 13 **3**	Oct 13 - Mar 14 **4**